<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0109211003
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Reblozyl
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LUSPATERCEPT
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        75
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        powder for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        24346.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Patheon Italia S.P.A." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Patheon Italia S.P.A.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Bristol Myers Squibb Pharma EEIG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        QB03XA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Reblozyl is and what it is used for</strong></p><p>Reblozyl contains the active substance luspatercept. It is used for:</p><p>&nbsp;</p><p><strong>Myelodysplastic syndromes</strong></p><p>Myelodysplastic syndromes (MDS) are a collection of many different blood and bone marrow disorders.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Red blood cells become abnormal and do not develop properly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients can get a number of signs and symptoms including a low red blood cell count (anaemia) and may need red blood cell transfusions.</p><p>Reblozyl is used in adults with anaemia caused by MDS, who need red blood cell transfusions.</p><p><s>&nbsp;</s></p><p><strong>Beta‑thalassaemia</strong></p><p>&beta;-thalassaemia is a blood problem that is passed down through genes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It affects the production of haemoglobin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients can get a number of signs and symptoms including a low red blood cell count (anaemia) and may need red blood cell transfusions.</p><p>&nbsp;</p><p>Reblozyl is used to treat anaemia in adults with &beta;‑thalassaemia who may or may not need regular red blood cell transfusions.</p><p>&nbsp;</p><p><strong>How Reblozyl works</strong></p><p>Reblozyl improves your body&rsquo;s ability to make red blood cells. Red blood cells contain haemoglobin, which is a protein that carries oxygen throughout your body. As your body makes more red blood cells, your haemoglobin level increases.</p><p>&nbsp;</p><p><em>For MDS and </em><em>&beta;-thalassaemia </em><em>patients in need of regular blood transfusions</em></p><p>Having Reblozyl can avoid or reduce the need for red blood cell transfusions.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Red blood cell transfusions can cause abnormally high levels of iron in the blood and in different organs of the body. This can be harmful over time.</p><p>&nbsp;</p><p><em>For </em><em>&beta;-thalassaemia </em><em>patients not in need of regular blood transfusions</em></p><p>Having Reblozyl can improve your anaemia by increasing your haemoglobin level.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What you need to know before you are given Reblozyl</strong></p><p><strong>Do not use Reblozyl</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to luspatercept or any of the other ingredients of this medicine (listed in section&nbsp;6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant (see section on Pregnancy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you require treatment for the control of mass producing blood cells outside the bone marrow (extramedullary haemopoiesis masses, EMH masses)</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before being given this medicine if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are a patient with &beta;‑thalassaemia:</p><p>o&nbsp;&nbsp;&nbsp; and you have had your spleen removed. You may have a higher risk of getting a blood clot. Your doctor will talk to you about other possible risk factors that may increase your risk &ndash; these include:</p><p>&sect;&nbsp; hormone replacement therapy or</p><p>&sect;&nbsp; a previous blood clot.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are a patient with MDS:</p><p>o&nbsp;&nbsp;&nbsp; and you have had a stroke or problems with your heart or with blood circulation. You may have a higher risk of getting a blood clot.</p><p>Your doctor may use preventive measures or medicines to reduce the chances of you getting a blood clot.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have severe back pain that does not go away, numbness or weakness or loss of voluntary movement in legs, hands or arms, loss of bowel and bladder control (incontinence). They may be symptoms of EMH masses and compression of spinal cord.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had high blood pressure &ndash; this is because Reblozyl may increase it. Your blood pressure will be checked before you are given Reblozyl and throughout treatment. You will be given Reblozyl only if your blood pressure is under control.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a condition that affects the strength and health of your bones (osteopenia and osteoporosis). You may have a risk of breaking your bones more easily.</p><p>&nbsp;</p><p><strong>Routine tests</strong></p><p>You will have a blood test before each dose of this medicine. This is because your doctor needs to make sure your haemoglobin level is suitable for you to be given treatment.</p><p>&nbsp;</p><p>If you have kidney problems, your doctor may perform additional tests.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>This medicine is not recommended for use in children and adolescents under 18&nbsp;years.</p><p>&nbsp;</p><p><strong>Other medicines and Reblozyl</strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine during pregnancy and for at least 3&nbsp;months before getting pregnant. Reblozyl may cause harm to your unborn baby.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will arrange a pregnancy test before starting treatment and will give you a patient card.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.</p><p><strong>&nbsp;</strong></p><p><strong>Breast-feeding</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not breast‑feed when using this medicine and for 3&nbsp;months after your last dose. It is not known if it passes into the mother&rsquo;s milk.</p><p>&nbsp;</p><p><strong>Contraception</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should use an effective method of contraception during treatment with Reblozyl and for at least 3&nbsp;months after your last dose.</p><p>&nbsp;</p><p>Talk to your doctor about contraceptive methods that may be right for you while you are using this medicine.</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p>If you are a woman, this medicine may cause fertility problems. This could affect your ability to have a baby. Talk to your doctor for advice before using it.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>You may feel tired, dizzy, or faint, while using Reblozyl. If this happens do not drive or use any tools or machines and contact your doctor straight away.</p><p>&nbsp;</p><p><strong>Reblozyl contains sodium</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How Reblozyl is given</strong></p><p>Before you are given this medicine, your doctor will have carried out blood tests and decided if you need Reblozyl.</p><p>&nbsp;</p><p>Reblozyl will be given by an injection under your skin (subcutaneously).</p><p>&nbsp;</p><p><strong>How much will you be given</strong></p><p>The dose is based on how much you weigh &ndash; in kilograms. The injections will be given by a doctor, nurse or other healthcare professional.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended starting dose is 1.0&nbsp;mg for each kilogram of body weight.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This dose should be given once every three weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will check your progress and may change your dose if needed.</p><p>&nbsp;</p><p>Your doctor will monitor your blood pressure while you are using Reblozyl.</p><p>&nbsp;</p><p><em>Myelodysplastic syndromes</em></p><p>The maximum single dose is 1.75&nbsp;mg for each kilogram of body weight.</p><p>&nbsp;</p><p><em>Beta-thalassaemia</em></p><p>The maximum single dose is 1.25&nbsp;mg for each kilogram of body weight.</p><p>&nbsp;</p><p><strong>If you miss a dose</strong></p><p>If you miss an injection of Reblozyl, or an appointment is delayed, you will receive a Reblozyl injection as soon as possible. Then, your dose will continue as prescribed &ndash; with at least 3&nbsp;weeks between doses.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Possible side effects</strong></p><p>Like all medicines, this medicine may cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p><strong>Tell your doctor straight away</strong> if you notice the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in walking or speaking, dizziness, loss of balance and coordination, numbness or paralysis in the face, leg or arm (often on one side of your body), blurred vision. They may all be symptoms of a stroke.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painful swelling and tightness in the leg or arm (blood clots)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe back pain that does not go away, numbness or weakness or loss of voluntary movement in legs, hands or arms, loss of bowel and bladder control (incontinence). They may be symptoms of extramedullary haemopoiesis masses (EMH masses) and compression of spinal cord.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the area around the eyes, the face, lips, mouth, tongue or throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rashes</p><p><strong>&nbsp;</strong></p><p><strong>Other side effects include:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Very common</strong> <strong>side effects</strong> (may affect more than 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in breathing or shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of your legs or hands</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure without symptoms or associated with headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory tract infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu or flu like symptoms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness, headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea, feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; belly pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back, joint or bone pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling tired or weak</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty to sleep or to stay asleep</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in blood test results (increase in liver enzymes, increase in blood creatinine). These may be signs of liver and kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cramps, dizziness, irregular heartbeat, mental confusion. These may be symptoms of too much or not enough of certain minerals in your body (electrolyte abnormalities).</p><p>&nbsp;</p><p><strong>Common side effects</strong>&nbsp;(may affect up to 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting, spinning feeling, feeling confused</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced desire to eat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; belly pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; broken bones caused by trauma</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in your chest</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced muscle strength</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pinpoint, round red/purple spots</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; easy bruising, bleeding from the nose or gums</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intense headache on one side of the head</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart beating too fast (tachycardia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness, burning and pain at the site of injection (injection site reactions) or swelling, itchy skin (injection site erythema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidneys not working properly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; more sweating than usual</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high level of uric acid in the blood (shown in tests)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; not enough fluid in your body (dehydration)</p><p><s>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s>urinary tract infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; foamy urine. This may be a sign of too much protein in your urine (proteinuria and albuminuria).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath while you exercise or when you lie down. This may be a sign of heart failure.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via The National Pharmacovigilance Centre (NPC). By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How to store Reblozyl</strong></p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and the vial after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Unopened vials: Store in a refrigerator (2&deg;C&nbsp;&ndash;&nbsp;8&deg;C). Do not freeze. Store in the original carton in order to protect from light.</p><p>&nbsp;</p><p>After first opening and reconstitution, Reblozyl should be used immediately. If not used immediately, when held in the original carton the reconstituted medicinal product may be stored for up to 8&nbsp;hours at room temperature (&le;&nbsp;25&deg;C) or for up to 24&nbsp;hours at 2&deg;C&nbsp;&ndash;&nbsp;8&deg;C.</p><p>Do not freeze the reconstituted solution.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Contents of the pack and other information</strong><br />&nbsp;</p><p><strong>What Reblozyl contains</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is luspatercept. Each vial contains 25&nbsp;mg or 75&nbsp;mg of luspatercept. After reconstitution, each mL of solution contains 50&nbsp;mg luspatercept.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other excipients are citric acid monohydrate (E330), sodium citrate (E331), polysorbate 80, sucrose, hydrochloric acid (for pH adjustment) and sodium hydroxide (for pH adjustment).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Reblozyl looks like and contents of the pack
Reblozyl is a white to off-white powder for solution for injection. Reblozyl is supplied in glass vials containing 25 mg or 75 mg of luspatercept.
Each pack contains 1 vial.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong><br />Bristol-Myers Squibb Pharma EEIG<br />Dublin 15, D15 T867<br />Ireland<br /><strong>Manufactured by</strong><br />Patheon Italia S.p.A.<br />Italy<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 27 March 2024
This leaflet was approved by SFDA on 26 Nov 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو ريبلوزيل وما هي دواعي استخدامه</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحتوي ريبلوزيل على المادة الفعالة لوسباترسيبت التي تستخدم في علاج:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>متلازمات خلل التنسج النقوي</strong></p><p dir="RTL">متلازمات خلل التنسج النقوي عبارة عن مجموعة من اضطرابات الدم ونخاع العظم العديدة المختلفة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصبح خلايا الدم الحمراء غير طبيعية ولا تتطور بصورة صحيحة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن يصاب المرضى بعدد من العلامات والأعراض مثل انخفاض عدد خلايا الدم الحمراء (فقر الدم) وربما يحتاجون إلى نقل خلايا الدم الحمراء.</p><p dir="RTL">ويستخدم ريبلوزيل في حالات البالغين المصابين بفقر الدم الناجم عن متلازمات خلل التنسج النقوي والذين يحتاجون إلى نقل خلايا الدم الحمراء.</p><p dir="RTL"><s>&nbsp;</s></p><p dir="RTL"><strong>ثلاسيميا</strong>‑<strong>بيتا</strong></p><p dir="RTL">تُعد ثلاسيميا بيتا إحدى مشكلات الدم التي تنتقل عبر الجينات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تؤثر على إنتاج الهيموجلوبين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن يصاب المرضى بعدد من العلامات والأعراض مثل انخفاض عدد خلايا الدم الحمراء (فقر الدم) وربما يحتاجون إلى نقل خلايا الدم الحمراء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ويستخدم ريبلوزيل لعلاج فقر الدم في حالات البالغين المصابين بداء ثلاسيميا‑بيتا والذين قد يحتاجون أو قد لا يحتاجون إلى نقل خلايا الدم الحمراء بانتظام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يعمل ريبلوزيل</strong></p><p dir="RTL">يعمل ريبلوزيل على تحسين قدرة جسدك على إنتاج خلايا الدم الحمراء التي تحتوي على الهيموجلوبين، وهو بروتين يحمل الأكسجين إلى جميع أجزاء الجسم. ومع إنتاج جسدك لمزيد من خلايا الدم الحمراء، ترتفع مستويات الهيموجلوبين لديك.<br /><br />&nbsp;</p><p dir="RTL"><em>لمرضى متلازمة خلل التنسج النقوي وثلاسيميا بيتا الذين يحتاجون إلى نقل الدم بانتظام</em></p><p dir="RTL">يمكن أن يعمل تلقي ريبلوزيل على تفادي أو تقليص الحاجة إلى عمليات نقل خلايا الدم الحمراء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن يؤدي نقل خلايا الدم الحمراء إلى زيادة مستويات الحديد بشكل غير طبيعي في الدم وفي مختلف أعضاء الجسم. وهذا يمكن أن يضر بالمريض مع مرور الوقت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>لمرضى ثلاسيميا بيتا الذين لا يحتاجون إلى نقل الدم بانتظام</em></p><p dir="RTL">يمكن أن يعمل تلقي ريبلوزيل على تحسين وضع فقر الدم لديك عن طريق زيادة مستويات الهيموجلوبين في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما الذي ينبغي أن تعرفه قبل استخدام ريبلوزيل</strong></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">لا يجب استخدام ريبلوزيل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بحساسية لمادة لوسباترسيبت أو لأي من مكونات هذا الدواء الأخرى (المذكورة في القسم 6)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً (راجعي القسم الخاص بالحمل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بحاجة إلى علاج للتحكم في تكوُّن تكتلات خلايا الدم خارج نخاع العظم (تكتلات تكوُّن الدم خارج النقي &quot;تكتلات EMH&quot;)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث مع طبيبك قبل أن يتم إعطاؤك هذا الدواء:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بداء ثلاسيميا‑بيتا:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وتم استئصال طحالك. فقد تصبح أكثر عرضة للإصابة بجلطة دموية. وسيتحدث إليك طبيبك حول عوامل الخطورة المحتملة الأخرى التي قد تؤدي إلى زيادة خطر الإصابة، ومنها:</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج بالهرمونات البديلة، أو</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بجلطة دموية فيما سبق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بمتلازمة خلل التنسج النقوي:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وتعرضت لسكتة دماغية أو مشاكل في القلب أو الدورة الدموية. فقد تكون أكثر عرضة للإصابة بجلطة دموية.</p><p dir="RTL">قد يستخدم طبيبك بعض الأدوية أو الإجراءات الوقائية لتقليل فرص الإصابة بجلطة دموية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ألم شديد في الظهر لا يتوقف، أو خدر أو ضعف أو فقدان القدرة على تحريك الساقين أو اليدين أو الذراعين إرادياً أو فقدان القدرة على التحكم في الأمعاء أو المثانة (السلس). فربما تمثل هذه أعراضاً لتكتلات تكوُّن الدم خارج النقي وانضغاط الحبل الشوكي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت في أي وقت مضى بارتفاع ضغط الدم، لأن ريبلوزيل قد يؤدي إلى زيادة ارتفاعه. لذلك سيتم قياس ضغط الدم لديك قبل تلقي ريبلوزيل وطوال فترة العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لن تتلقى ريبلوزيل إلا إذا كان ضغط الدم لديك تحت السيطرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بحالة مرضية تؤثر على قوة وصحة عظامك (انخفاض كثافة العظام وهشاشة العظام). فربما تكون عرضة لخطر كسر العظام بسهولة أكبر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الفحوصات الروتينية</strong></p><p dir="RTL">ستخضع لإجراء فحص دم قبل تلقي كل جرعة من هذا الدواء، وهذا لأن طبيبك يحتاج إلى التأكد من ملاءمة مستوى الهيموجلوبين لديك لتلقي العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من مشكلات في الكلى، فقد يقوم طبيبك بإجراء فحوصات إضافية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يوصى باستخدام هذا الدواء في حالات الأطفال والمراهقين دون سن 18 عاماً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وريبلوزيل</strong></p><p dir="RTL">أخبر طبيبك إن كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدمي هذا الدواء خلال فترة الحمل ولمدة لا تقل عن 3 أشهر قبل الحمل. فقد يضر ريبلوزيل بجنينك..</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم طبيبك بإجراء اختبار حمل قبل بدء العلاج وسيعطيكِ بطاقة مريض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعتقدين أنكِ قد تكونين حاملاً أو تخططين للحمل، فاطلبي المشورة من طبيبك قبل استخدام هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقومي بإرضاع طفلك رضاعة طبيعية عند استخدام هذا الدواء ولمدة 3 أشهر بعد تلقي آخر جرعة. فمن غير المعروف ما إذا كان ينتقل عبر حليب الثدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موانع الحمل</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عليكِ استخدام وسيلة فعالة لمنع الحمل خلال فترة العلاج بدواء ريبلوزيل ولمدة لا تقل عن 3 أشهر بعد تلقي آخر جرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدثي إلى طبيبك بشأن وسائل منع الحمل التي قد تكون مناسبة لكِ خلال فترة استخدامك لهذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الخصوبة</strong></p><p dir="RTL">إذا كنتِ امرأة، فقد يسبب هذا الدواء مشكلات في الخصوبة لديكِ، مما قد يؤثر على قدرتك على الإنجاب. فاطلبي المشورة من طبيبك قبل استخدامه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">ربما تشعر بالتعب، أو الدوار أو الإغماء خلال فترة استخدام ريبلوزيل. وفي حالة حدوث ذلك، لا تقم بالقيادة أو استخدام أي أدوات أو آلات واتصل فوراً بطبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي ريبلوزيل على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من <strong>1</strong> مليمول من الصوديوم (<strong>23</strong> ملغ) في كل جرعة، أي أنه في الأساس &quot;خال من الصوديوم<strong>&quot;.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يتم استخدام ريبلوزيل</strong></p><p dir="RTL">قبل إعطائك هذا الدواء، سيجري طبيبك فحوصات الدم وسيقرر إذا ما كنت تحتاج لتلقي ريبلوزيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيتم إعطاؤك ريبلوزيل بالحقن تحت الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">تُقدَّر الجرعة حسب وزنك &ndash; بالكيلوجرام. ويتم الحقن بواسطة طبيب أو ممرضة أو غيرهما من أخصائيي الرعاية الصحية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُقدَّر الجرعة الأولية الموصى بها بـ 1.0 ملغ لكل كيلوجرام من وزن الجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب إعطاء هذه الجرعة مرة واحدة كل ثلاثة أسابيع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيتحقق طبيبك من تقدم حالتك وقد يغير جرعتك عند الضرورة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقوم طبيبك بمراقبة ضغط الدم لديك خلال فترة استخدام ريبلوزيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">متلازمات خلل التنسج النقوي</p><p dir="RTL">تُقدَّر أقصى جرعة مفردة بـ 1.75 ملغ لكل كيلوجرام من وزن الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ثلاسيميا بيتا</p><p dir="RTL">تُقدَّر أقصى جرعة مفردة بـ 1.25 ملغ لكل كيلوجرام من وزن الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا فوَّت جرعة</strong></p><p dir="RTL">إذا فوَّت جرعة من ريبلوزيل أو في حالة تأجيل موعد فحصك، فستتلقى حقنة ريبلوزيل في أقرب وقت ممكن. وستستمر في تلقي جرعاتك على النحو الذي وصفه لك الطبييب &ndash; مع ترك ما لا يقل عن 3 أسابيع بين الجرعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن كان لديك أي استفسارات أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الآثار الجانبية المحتملة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب آثاراً جانبية، على الرغم من أنه ليس بالضرورة أن يعاني منها الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الخطيرة</strong></p><p dir="RTL"><strong>أخبر الطبيب أو الصيدلي أيضاً على الفور</strong> إن لاحظت أياً مما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في المشي أو التحدث، دوار، فقدان التوازن وتناسق حركات أجزاء الجسم، خدر أو</p><p dir="RTL">شلل في الوجه، أو الساق أو الذراع (غالباً في أحد جانبي جسمك)، تشوش بالرؤية. قد تكون كل هذه الآثار أعراضاً لسكتة دماغية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم مصحوب بألم وشد في الساق أو الذراع (الجلطات الدموية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد في الظهر لا يتوقف، أو خدر أو ضعف أو فقدان القدرة على تحريك الساقين، أو اليدين أو الذراعين إرادياً أو فقدان القدرة على التحكم في الأمعاء أو المثانة (السلس). فربما تمثل هذه أعراضاً لتكوُّن الدم خارج النقي (EMH) وانضغاط الحبل الشوكي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم المنطقة المحيطة بالعينين، أو الوجه، أو الشفتين، أو الفم، أو اللسان أو الحلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل تحسسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>من الآثار الجانبية الأخرى:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية</strong> <strong>شائعة جداً </strong>(قد تؤثر على أكثر من 1 من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة أو ضيق التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الساقين أو اليدين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم غير المصحوب بأعراض أو المصحوب بصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي العلوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنفلونزا أو أعراض تشبه الإنفلونزا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة، الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال، الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الظهر، أو المفاصل أو العظام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب أو الوهن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم أو البقاء نائماً</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في نتائج اختبارات الدم (زيادة إنزيمات الكبد، زيادة الكرياتينين في الدم). ربما يشير ذلك إلى الإصابة بمشاكل في الكبد والكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات عضلية، دوار، عدم انتظام ضربات القلب، تشوش ذهني. قد تكون هذه أعراض الكميات الكثيرة للغاية أو غير الكافية من بعض المعادن في جسمك (اضطرابات الكهارل).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة</strong> (قد تؤثر على 1 من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء، الدوار، الشعور بالتشوش</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كسور العظام بسبب الصدمات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص قوة العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقاع مستديرة محددة حمراء/أرجوانية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سهولة التكدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الأنف أو اللثة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع شديد في أحد جانبي الرأس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات القلب السريعة للغاية (تسرع القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار، وحرقان وألم في موضع الحقن (تفاعلات موضع الحقن) أو تورم، حكة بالجلد (حمامى موضع الحقن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم عمل الكلى كما ينبغي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرق بقدر أكثر من المعتاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى حمض اليوريك في الدم (حسب ما تظهره الفحوصات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وجود سوائل كافية في الجسم (الجفاف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المسالك البولية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رغوة في البول. ربما يشير ذلك إلى ارتفاع مستوى البروتين في البول (البيلة البروتينية والبيلة الألبومينية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصر النفس أثناء ممارسة التمارين أو عند الاستلقاء. وقد تكون هذه علامة على فشل القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا ظهرت عليك أي أعراض جانبية، فتحدث مع طبيبك أو الممرضة. وذلك يتضمن أي آثار جانبية محتملة غير مذكورة في هذه النشرة. يمكنك أيضاً الإبلاغ عن الآثار الجانبية مباشرةً عبر المركز الوطني للتيقظ والسلامة الدوائية (NPC). بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في تقديم المزيد من المعلومات حول مدى أمان هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيفية تخزين ريبلوزيل</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الموضح على العلبة الكرتونية والقارورة بعد عبارة &quot;تاريخ انتهاء الصلاحية&quot; (EXP). يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">القوارير غير المفتوحة: تُخزن في البراد (في درجة حرارة تتراوح بين 2 - 8 درجة مئوية). لا تجمد هذا الدواء. يحفظ في العلبة الكرتونية الأصلية لحمايته من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد فتح ريبلوزيل للمرة الأولى وتحويله إلى محلول، لا بد من استخدامه على الفور. وفي حالة عدم استخدامه على الفور، يمكن تخزين المحلول في العبوة الأصلية لمدة تصل إلى 8 ساعات في درجة حرارة الغرفة (&le; 25 درجة مئوية) أو حتى 24 ساعة في درجة حرارة 2 - 8 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تجمد المحلول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية في مياه الصرف أو مع النفايات المنزلية. واسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. فإن هذه التدابير ستساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات العبوة ومعلومات أخرى</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>محتويات ريبلوزيل</strong></p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المادة الفعالة هي لوسباتيرسيبت. تحتوي كل قارورة على 25 ملغ أو 75 ملغ من لوسباتيرسيبت. بعد عمل المحلول، يحتوي كل مل من المحلول على 50 ملغ من لوسباتيرسيبت.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السواغات الأخرى هي حمض الستريك أحادي الهيدرات (E330) وسيترات الصوديوم (E331) ومتعدد السوربات 80، وسكروز، وحمض الهيدروكلوريك (لضبط درجة الحموضة) وهيدروكسيد الصوديوم (لضبط درجة الحموضة).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو ريبلوزيل وما هي محتويات العبوة</strong></p><p dir="RTL">ريبلوزيل هو مسحوق أبيض إلى أبيض مائل إلى الصفرة لعمل محلول للحقن. يأتي ريبلوزيل في قوارير زجاجية تحتوي كل منها على 25 ملغ أو 75 ملغ من لوسباتيرسيبت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل عبوة على قارورة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التسويق</strong></p><p dir="RTL">بريستول-مايرز سكويب فارما EEIG</p><p dir="RTL">بلازا 254</p><p dir="RTL">منطقة بلانكاردستاون الصناعية 2</p><p dir="RTL">دبلن 15،&nbsp; D15 T867</p><p dir="RTL">أيرلندا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تم التصنيع بواسطة</strong></p><p dir="RTL">باثيون ايطاليا إس بي إي</p><p dir="RTL">إيطاليا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت اخر مراجعة لهذه النشرة في 27 مارس 2024م.
اعتمدت هذه النشرة من قبل الهيئة العامة للغذاء والدواء بتاريخ 26 مارس 2024م.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Reblozyl 25 mg powder for solution for injection 
Reblozyl 75 mg powder for solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Reblozyl 25 mg powder for solution for injection
Each vial contains 25 mg of luspatercept. After reconstitution, each mL of solution contains 50 mg luspatercept.

Reblozyl 75 mg powder for solution for injection
Each vial contains 75 mg of luspatercept. After reconstitution, each mL of solution contains 50 mg luspatercept.

Luspatercept is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for injection (powder for injection). 
White to off-white lyophilised powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reblozyl is indicated in adults for the treatment of transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) (see section 5.1).</p><p>&nbsp;</p><p>Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion‑dependent and non‑transfusion‑dependent beta-thalassaemia (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reblozyl treatment should be initiated by a physician experienced in treatment of haematological diseases.</p><p>&nbsp;</p><p><u>Posology</u></p><p>Prior to each Reblozyl administration, the haemoglobin (Hb) level of patients should be assessed. In case of a red blood cell (RBC) transfusion occurring prior to dosing, the pre-transfusion Hb level must be considered for dosing purposes.</p><p>&nbsp;</p><p>The recommended starting dose of Reblozyl is 1.0 mg/kg administered once every 3 weeks.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Myelodysplastic</em><em> </em><em>syndromes</em></p><p>The recommended desired Hb concentration range is between 10 g/dL and 12 g/dL. Dose increase for insufficient response is provided below.</p><p>&nbsp;</p><p><strong>Table 1: Dose increase for insufficient response</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Dose at 1&nbsp;mg/kg</strong></p></td><td style="vertical-align:top"><p><strong>Dose increase</strong></p></td></tr><tr><td style="vertical-align:top"><p>If after at least 2 consecutive doses at 1.0&nbsp;mg/kg, a patient:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is not RBC transfusion- free, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; does not reach Hb concentration of &ge;&nbsp;10&nbsp;g/dL and the Hb increase is &lt;&nbsp;1&nbsp;g/dL</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp; Dose should be increased to 1.33&nbsp;mg/kg</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dose at 1.33&nbsp;mg/kg</strong></p></td><td style="vertical-align:top"><p><strong>Dose increase</strong></p></td></tr><tr><td style="vertical-align:top"><p>If after at least 2 consecutive doses at 1.33&nbsp;mg/kg, a patient:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is not RBC transfusion- free, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; does not reach Hb concentration of &ge;&nbsp;10&nbsp;g/dL and the Hb increase is &lt;&nbsp;1&nbsp;g/dL</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp; Dose should be increased to 1.75&nbsp;mg/kg</p></td></tr></tbody></table><p>&nbsp;</p><p>The dose increase should not occur more frequently than every 6 weeks (2 administrations) and should not exceed the maximum dose of 1.75 mg/kg every 3 weeks. The dose should not be increased immediately after a dose delay.</p><p>&nbsp;</p><p>For patients with a pre-dose Hb level of &gt; 9 g/dL and who have not yet achieved transfusion independence, a dose increase may be required at the physician&rsquo;s discretion; the risk of Hb increasing above the target threshold with concomitant transfusion cannot be excluded.</p><p>&nbsp;</p><p>If a patient loses response (i.e. transfusion independence), the dose should be increased by one dose level (see Table&nbsp;2).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Transfusion-dependent </em><em>b</em><em>-thalassaemia</em></p><p>In patients who do not achieve a response, defined as a reduction in RBC transfusion burden of at least a third after &ge; 2 consecutive doses (6 weeks), at the 1.0 mg/kg starting dose, the dose should be increased to 1.25 mg/kg. The dose should not be increased beyond the maximum dose of 1.25 mg/kg every 3 weeks.</p><p>&nbsp;</p><p>If a patient loses response (if the RBC transfusion burden increases again after an initial response) the dose should be increased by one dose level (see Table&nbsp;3).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Non-transfusion-dependent</em><em> </em><em>b</em><em>-thalassaemia</em></p><p>In patients who do not achieve or maintain a response, defined as an increase from baseline in pre‑dose Hb of &ge;1&nbsp;g/dL, after &ge;&nbsp;2 consecutive doses (6&nbsp;weeks) at the same dose level (in absence of transfusions, i.e. at least 3 weeks after the last transfusion), the dose should be increased by one dose level (see Table&nbsp;3). The dose should not exceed the maximum dose of 1.25&nbsp;mg/kg every 3&nbsp;weeks.</p><p><em>&nbsp;</em></p><p><em><u>Increase to next dose level</u></em></p><p>Increase to next dose level based on current dose is provided below.</p><p>&nbsp;</p><p><strong>Table&nbsp;2: Increase to next dose level for MDS</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>Current dose</strong></p></td><td style="vertical-align:top"><p><strong>Increased dose</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>0.8&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>1&nbsp;mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>1&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>1.33&nbsp;mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>1.33&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>1.75&nbsp;mg/kg</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table&nbsp;3: Increase to next dose level for </strong><strong>b</strong><strong>-thalassaemia</strong><strong> </strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>Current dose</strong></p></td><td style="vertical-align:top"><p><strong>Increased dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>0.6&nbsp;mg/kg*</p></td><td style="vertical-align:top"><p>0.8&nbsp;mg/kg</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>0.8&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>1&nbsp;mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>1&nbsp;mg/kg</p></td><td style="vertical-align:top"><p>1.25&nbsp;mg/kg</p></td></tr></tbody></table><p>* Applicable only to non-transfusion-dependent b-thalassaemia.</p><p>&nbsp;</p><p><em><u>Dose</u></em><em><u> reduction and dose delay</u></em></p><p>In case of Hb increase &gt; 2 g/dL within 3 weeks in absence of transfusion compared with the Hb value at previous dose, Reblozyl dose should be reduced by one dose level.</p><p>&nbsp;</p><p>If the Hb is &ge; 12 g/dL in the absence of transfusion for at least 3 weeks, the dose should be delayed until the Hb is &le; 11.0 g/dL. If there is also a concomitant rapid increase in Hb from the Hb value at previous dose (&gt; 2 g/dL within 3 weeks in absence of transfusion), a dose reduction to one step down should be considered after the dose delay.</p><p>&nbsp;</p><p>Dose should not be reduced below 0.8 mg/kg (for MDS or transfusion-dependent b-thalassaemia) and below 0.6&nbsp;mg/kg (for non‑transfusion‑dependent b-thalassaemia).</p><p>&nbsp;</p><p>Reduced dose during treatment with luspatercept are provided below.</p><p>&nbsp;</p><p>Table 4: Reduced dose for MDS</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Current</strong><strong> dose</strong></p></td><td style="vertical-align:top"><p><strong>Reduced dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>1.75 mg/kg</p></td><td style="vertical-align:top"><p>1.33 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>1.33 mg/kg</p></td><td style="vertical-align:top"><p>1 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>1 mg/kg</p></td><td style="vertical-align:top"><p>0.8 mg/kg</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Table</strong><strong> 5: </strong><strong>Reduced dose for &beta;-thalassaemia</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Current</strong><strong> dose</strong></p></td><td style="vertical-align:top"><p><strong>Reduced dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>1.25 mg/kg</p></td><td style="vertical-align:top"><p>1 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>1 mg/kg</p></td><td style="vertical-align:top"><p>0.8 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>0.8 mg/kg</p></td><td style="vertical-align:top"><p>0.6 mg/kg*</p></td></tr></tbody></table><p>* Applicable only to non-transfusion-dependent b-thalassaemia.</p><p>&nbsp;</p><p><em><u>Dose modification due to adverse reactions</u></em></p><p>Instructions on dose interruptions or reductions for luspatercept treatment-related adverse reactions are outlined in Table&nbsp;6.</p><p>&nbsp;</p><p><strong>Table&nbsp;6: Dose modification instructions</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Treatment-related adverse reactions</strong>*</p></td><td style="vertical-align:top"><p><strong>Dose instructions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Grade 2 adverse reactions (see section&nbsp;4.8), including Grade 2 hypertension (see sections&nbsp;4.4 and 4.8)</p></td><td style="vertical-align:top"><p>&bull; Interrupt treatment</p><p>&bull; Restart at previous dose when adverse reaction has improved or returned to baseline</p></td></tr><tr><td style="vertical-align:top"><p>Grade &ge;&nbsp;3 hypertension (see sections&nbsp;4.4 and 4.8)</p></td><td style="vertical-align:top"><p>&bull; Interrupt treatment</p><p>&bull; Restart at reduced dose once the blood pressure is controlled as per dose reduction guidance</p></td></tr><tr><td style="vertical-align:top"><p>Other persistent Grade &ge;&nbsp;3 adverse reactions (see section&nbsp;4.8)</p></td><td style="vertical-align:top"><p>&bull; Interrupt treatment</p><p>&bull; Restart at previous dose or at reduced dose when adverse reaction has improved or returned to baseline as per dose reduction guidance</p></td></tr><tr><td style="vertical-align:top"><p>Extramedullary haemopoiesis (EMH) masses causing serious complications (see sections&nbsp;4.4 and 4.8)</p></td><td style="vertical-align:top"><p>&bull; Discontinue treatment</p></td></tr></tbody></table><p>* Grade 1: mild; Grade 2: moderate; Grade 3: severe; and Grade 4: life-threatening.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Missed</u></em><em><u> </u></em><em><u>doses</u></em></p><p>In case of a missed or delayed scheduled treatment administration, the patient should be administered Reblozyl as soon as possible and dosing continued as prescribed with at least 3 weeks between doses.</p><p>&nbsp;</p><p><em><u>Patients</u></em><em><u> experiencing a loss of response</u></em></p><p>If patients experience a loss of response to Reblozyl, causative factors (e.g. a bleeding event) should be assessed. If typical causes for a loss of haematological response are excluded, dose increase should be considered as described above for the respective indication being treated (see Table&nbsp;2 and Table&nbsp;3).</p><p>&nbsp;</p><p><em><u>Discontinuation</u></em></p><p>Reblozyl should be discontinued if patients do not experience a reduction in transfusion burden (for transfusion-dependent &beta;-thalassaemia patients), or an increase from baseline Hb in the absence of transfusions (for non-transfusion-dependent &beta;-thalassaemia patients), or a decrease in transfusion burden including no increase from baseline Hb (for MDS patients) after 9 weeks of treatment (3&nbsp;doses) at the maximum dose level, if no alternative explanations for response failure are found (e.g. bleeding, surgery, other concomitant illnesses) or if unacceptable toxicity occurs at any time.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>No starting dose adjustment is required for Reblozyl (see section 5.2). Limited data are available in &beta;‑thalassaemia patients &ge;&nbsp;60&nbsp;years of age.</p><p>&nbsp;</p><p><em>Hepatic</em><em> impairment</em></p><p>No starting dose adjustment is required for patients with total bilirubin (BIL) &gt; upper limit of normal (ULN) and/or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &lt; 3 x ULN (see section 5.2).</p><p>&nbsp;</p><p>No specific dose recommendation can be made for patients with ALT or AST &ge; 3 x ULN or liver injury CTCAE Grade &ge; 3 due to lack of data (see section 5.2).</p><p>&nbsp;</p><p><em>Renal</em><em> </em><em>impairment</em></p><p>No starting dose adjustment is required for patients with mild or moderate renal impairment (individual estimated glomerular filtration rate [eGFR] 30 to 89 mL/min).</p><p>&nbsp;</p><p>No specific dose recommendation can be made for patients with severe renal impairment (individual eGFR &lt; 30 mL/min) due to lack of clinical data (see section 5.2). Patients with renal impairment at baseline have been observed to have higher exposure (see section&nbsp;5.2). Consequently, these patients should be closely monitored for adverse reactions and dose adjustment should be managed accordingly (see Table&nbsp;6).</p><p>&nbsp;</p><p><em>Paediatric</em><em> population</em></p><p>There is no relevant use of Reblozyl in the paediatric population for the indication of myelodysplastic syndromes, or in paediatric patients less than 6 years of age in b-thalassaemia. The safety and efficacy of Reblozyl in the paediatric patients aged from 6 years to less than 18 years have not yet been established in b-thalassaemia. For non-clinical data, see section 5.3.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>For subcutaneous use.</p><p>&nbsp;</p><p>After reconstitution, Reblozyl solution should be injected subcutaneously into the upper arm, thigh or abdomen. The exact total dosing volume of the reconstituted solution required for the patient should be calculated and slowly withdrawn from the single-dose vial(s) into a syringe.</p><p>&nbsp;</p><p>The recommended maximum volume of medicinal product per injection site is 1.2 mL. If more than 1.2&nbsp;mL is required, the total volume should be divided into separate similar volume injections and administered across separate sites using the same anatomical location but on opposite sides of the body.</p><p>&nbsp;</p><p>If multiple injections are required, a new syringe and needle must be used for each subcutaneous injection. No more than one dose from a vial should be administered.</p><p>&nbsp;</p><p>If the Reblozyl solution has been refrigerated after reconstitution, it should be removed from the refrigerator 15-30 minutes prior to injection to allow it to reach room temperature. This will allow for a more comfortable injection.</p><p>&nbsp;</p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
•	Pregnancy (see section 4.6).
•	Patients requiring treatment to control the growth of EMH masses (see section 4.4). 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Thromboembolic events</u></p><p>In b‑thalassaemia patients, thromboembolic events (TEEs) were reported in 3.6% (8/223) of patients treated with luspatercept in the double-blind phase of the pivotal study in transfusion‑dependent patients and in 0.7% (1/134) of patients during the open-label phase of the pivotal study in non-transfusion‑dependent patients. Reported TEEs included deep vein thrombosis (DVT), portal vein thrombosis, pulmonary emboli, ischaemic stroke and superficial thrombophlebitis (see section 4.8). All patients with TEEs were splenectomised and had at least one other risk factor for developing TEE (e.g. history of thrombocytosis or concomitant use of hormone replacement therapy). The occurrence of TEE was not correlated with elevated Hb levels. The potential benefit of treatment with luspatercept should be weighed against the potential risk of TEEs in b-thalassaemia patients with a splenectomy and other risk factors for developing TEE. Thromboprophylaxis according to current clinical guidelines should be considered in patients with b-thalassaemia at higher risk.</p><p>&nbsp;</p><p>In MDS patients, TEEs were reported in 3.9% (13/335) of patients treated with luspatercept. Reported TEEs included cerebral ischemia and cerebrovascular accident in 1.2% (4/335) of patients. All TEEs occurred in patients with significant risk factors (atrial fibrillation, stroke or heart failure and peripheral vascular disease) and were not correlated with elevated Hb, platelet levels or hypertension.</p><p>&nbsp;</p><p><u>Extramedullary haemopoiesis masses</u></p><p>In transfusion-dependent b‑thalassaemia patients, extramedullary haemopoiesis (EMH) masses were observed in 3.2% (10/315) of patients treated with luspatercept in the pivotal study and in the long‑term follow-up study. Spinal cord compression symptoms due to EMH masses occurred in 1.9% (6/315) of patients treated with luspatercept (see section 4.8).</p><p>&nbsp;</p><p>In non‑transfusion‑dependent b‑thalassaemia patients, EMH masses were observed in 6.3% (6/96) of patients treated with luspatercept in the pivotal study. Spinal cord compression due to EMH masses occurred in 1.0% (1/96) of patients treated with luspatercept. During the open‑label portion of the study, EMH masses were observed in 2 additional patients for a total of 8/134 (6.0%) of patients (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Patients with EMH masses may experience worsening of these masses and complications during treatment. Signs and symptoms may vary depending on anatomical location. Patients should be monitored at initiation and during treatment for symptoms and signs or complications resulting from the EMH masses, and be treated according to clinical guidelines. Treatment with luspatercept must be discontinued in case of serious complications due to EMH masses.</p><p>&nbsp;</p><p><u>Increased blood pressure</u></p><p>In MDS and b-thalassaemia pivotal studies, patients treated with luspatercept had an average increase in systolic and diastolic blood pressure of up to 5 mmHg from baseline (see section 4.8).</p><p>&nbsp;</p><p>An increased incidence of hypertension was observed in the first 12 months of treatment in non‑transfusion‑dependent b‑thalassaemia patients treated with luspatercept (see section 4.8).</p><p>&nbsp;</p><p>The treatment must be started only if the blood pressure is adequately controlled. Blood pressure should be monitored prior to each luspatercept administration. Luspatercept dose may require adjustment or may be delayed, and patients should be treated for hypertension as per current clinical guidelines (see Table 6 in section&nbsp;4.2). The potential benefit of treatment with Reblozyl should be re‑evaluated in case of persistent hypertension or exacerbations of pre-existing hypertension.</p><p>&nbsp;</p><p><u>Traumatic fracture</u></p><p>In transfusion-dependent b‑thalassaemia patients, traumatic fractures were observed in 0.4% (1/223) of patients treated with luspatercept.</p><p><u>&nbsp;</u></p><p>In non-transfusion-dependent b-thalassaemia patients, traumatic fractures were observed in 8.3% (8/96) of patients treated with luspatercept.&nbsp;Patients should be informed of the risk of traumatic fracture.</p><p><u>&nbsp;</u></p><p><u>Sodium content</u></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No formal clinical interaction studies have been performed. Concurrent use of iron-chelating agents had no effect on luspatercept pharmacokinetics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential / Contraception in females</u></p><p>Women of childbearing potential have to use effective contraception during treatment with Reblozyl and for at least 3 months after the last dose. Prior to starting treatment with Reblozyl, a pregnancy test has to be performed for women of childbearing potential and the patient card has to be provided.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>Treatment with Reblozyl should not be started if the woman is pregnant (see section 4.3). There are no data from the use of Reblozyl in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Reblozyl is contraindicated during pregnancy (see section 4.3). If a patient becomes pregnant, Reblozyl should be discontinued.</p><p><u>&nbsp;</u></p><p><u>Breastfeeding</u></p><p>It is unknown whether luspatercept or its metabolites are excreted in human milk. Luspatercept was detected in the milk of lactating rats (see section 5.3). Because of the unknown adverse effects of luspatercept in newborns/infants, a decision must be made whether to discontinue breast-feeding during therapy with Reblozyl and for 3 months after the last dose or to discontinue Reblozyl therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>The effect of luspatercept on fertility in humans is unknown. Based on findings in animals, luspatercept may compromise female fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reblozyl may have a minor influence on the ability to drive and use machines. The ability to react when performing these tasks may be impaired due to risks of fatigue, vertigo, dizziness or syncope (see section 4.8). Therefore, patients should be advised to exercise caution until they know of any impact on their ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p><em>Myelodysplastic</em><em> </em><em>syndromes</em></p><p>The most frequently reported adverse drug reactions in patients receiving Reblozyl (at least 15% of patients) were fatigue, diarrhoea, nausea, asthenia, dizziness, oedema peripheral and back pain. The most commonly reported Grade&nbsp;&ge;&nbsp;3 adverse drug reactions (at least 2% of patients) included hypertension events (12.5%), syncope (3.6%), dyspnoea (2.7%), fatigue (2.4%) and thrombocytopenia (2.4%). The most commonly reported serious adverse drug reactions (at least 1% of patients) were urinary tract infection (1.8%), dyspnoea (1.5%) and back pain (1.2%).</p><p>&nbsp;</p><p>Asthenia, fatigue, nausea, diarrhoea, hypertension, dyspnoea, dizziness and headache occurred more frequently during the first 3 months of treatment.</p><p>&nbsp;</p><p>Treatment discontinuation due to an adverse event occurred in 10.1% of patients treated with luspatercept. The most common reason for discontinuation in the luspatercept treatment arm was progression of underlying MDS.</p><p>&nbsp;</p><p>Dose delays due to pre-dose Hb &ge;12.0 g/dL occurred in 24.3% of luspatercept treated patients.</p><p>&nbsp;</p><p><em>Transfusion-dependent &beta;-</em><em>thalassaemia</em></p><p>The most frequently reported adverse drug reactions in patients receiving Reblozyl (at least 15% of patients) were headache, bone pain and arthralgia. The most commonly reported Grade &ge; 3 adverse drug reaction was hyperuricaemia. The most serious adverse reactions reported included thromboembolic events of deep vein thrombosis, ischaemic stroke portal vein thrombosis and pulmonary embolism (see section 4.4).</p><p>&nbsp;</p><p>Bone pain, asthenia, fatigue, dizziness and headache occurred more frequently during the first 3 months of treatment.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="_x0000_s1028"
 style='position:absolute;left:0;text-align:left;margin-left:256.45pt;
 margin-top:32.7pt;width:2.65pt;height:.6pt;z-index:-57616;
 mso-position-horizontal-relative:page' coordorigin="5129,654" coordsize="53,12">
 <v:shape id="_x0000_s1029" style='position:absolute;left:5129;top:654;width:53;
  height:12' coordorigin="5129,654" coordsize="53,12" path="m5129,660r53,e"
  filled="f" strokecolor="#b5082e" strokeweight=".7pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="5" height="2" src="file:///C:/Users/aldawoom/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:group
 id="_x0000_s1030" style='position:absolute;left:0;text-align:left;
 margin-left:318.6pt;margin-top:32.7pt;width:2.8pt;height:.6pt;z-index:-57592;
 mso-position-horizontal-relative:page' coordorigin="6372,654" coordsize="56,12">
 <v:shape id="_x0000_s1031" style='position:absolute;left:6372;top:654;width:56;
  height:12' coordorigin="6372,654" coordsize="56,12" path="m6372,660r55,e"
  filled="f" strokecolor="#b5082e" strokeweight=".7pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="5" height="2" src="file:///C:/Users/aldawoom/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:group
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:35.75pt;margin-top:25.65pt;width:.1pt;height:12.6pt;z-index:1096;
 mso-position-horizontal-relative:page' coordorigin="715,513" coordsize="2,252">
 <v:shape id="_x0000_s1027" style='position:absolute;left:715;top:513;width:2;
  height:252' coordorigin="715,513" coordsize="0,252" path="m715,513r,252e"
  filled="f" strokeweight=".82pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="2" height="19" src="file:///C:/Users/aldawoom/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" />Treatment discontinuation due to an adverse reaction occurred in 2.6% of patients treated with luspatercept. The adverse reactions leading to treatment discontinuation in the luspatercept treatment arm were arthralgia, back pain, bone pain and headache.</p><p>&nbsp;</p><p><em>Non-transfusion-dependent </em><em>b-</em><em>thalassaemia</em></p><p>The most frequently reported adverse drug reactions in patients receiving Reblozyl (at least 15% of patients) were bone pain, headache, arthralgia, back pain, prehypertension and hypertension. The most commonly reported Grade&nbsp;&ge;&nbsp;3 and most serious adverse reaction (at least 2% of patients) reported<strong> </strong>was traumatic fracture. Spinal cord compression due to EMH masses occurred in 1% of patients.</p><p>&nbsp;</p><p>Bone pain, back pain, upper respiratory tract infection, arthralgia, headache and prehypertension occurred more frequently during the first 3&nbsp;months of treatment.</p><p><s>&nbsp;</s></p><p>The majority of adverse drug reactions were non-serious and did not require discontinuation. Treatment discontinuation due to an adverse reaction occurred in 3.1% of patients treated with luspatercept. Adverse reactions leading to treatment discontinuation were spinal cord compression, extramedullary haemopoiesis and arthralgia.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>The highest frequency for each adverse reaction that was observed and reported in patients in the pivotal studies in MDS, b-thalassaemia and the long-term follow-up study is shown in Table 7 below. The adverse reactions are listed below by body system organ class and preferred term. Frequencies are defined as: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (frequency cannot be estimated from the available data).</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td colspan="4" style="vertical-align:top"><p>Table 7: Adverse drug reactions (ADRs) in patients treated with Reblozyl for MDS and / or</p><p>b-thalassaemia in the four pivotal studies</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>System</strong><strong> </strong><strong>organ </strong><strong>class</strong></p></td><td style="vertical-align:top"><p><strong>Preferred</strong><strong> </strong><strong>term</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p><p><strong>(all</strong><strong> </strong><strong>grades)</strong><strong> </strong><strong>for</strong><strong> </strong><strong>MDS</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p><p><strong>(all</strong><strong> </strong><strong>grades)</strong><strong> </strong><strong>for</strong></p><p><strong>b-</strong><strong>thalassaemia</strong></p></td><td><p>&nbsp;</p></td></tr></thead><tbody><tr><td rowspan="5" style="vertical-align:top"><p><strong>Infections</strong><strong> and infestations</strong></p></td><td style="vertical-align:top"><p>bronchitis</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common<sup>a</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>urinary tract infection</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common<sup>a</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>respiratory tract infection</p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>upper respiratory tract infection</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very common<sup>a</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>influenza</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>extramedullary haemopoiesis<sup> VI</sup></p></td><td style="vertical-align:top"><p>Not known<sup> VII</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>thrombocytopenia</p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune</strong><strong> system disorders</strong></p></td><td style="vertical-align:top"><p>hypersensitivity<sup> I, VI</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Metabolism</strong><strong> </strong><strong>and nutrition</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>hyperuricaemia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>dehydration</p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>decreased appetite</p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>electrolyte imbalance<sup>IX</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>insomnia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very common<sup>b</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>anxiety</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>irritability</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>confusional state</p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>Nervous</strong><strong> system disorders</strong></p></td><td style="vertical-align:top"><p>dizziness</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>migraine</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common<sup>b</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>spinal cord compression<sup>VI</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>syncope/presyncope</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common<sup>a</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear</strong><strong> and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>vertigo/vertigo positional</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common<sup>a</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Cardiac disorders </strong></p></td><td style="vertical-align:top"><p>atrial fibrillation</p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>cardiac failure</p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Vascular</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p>prehypertension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common<sup>b</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>hypertension<sup>II, VI</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>tachycardia</p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>thromboembolic events<sup> IV, VI</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Respiratory,</strong><strong> thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>cough</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>epistaxis</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common<sup>b</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>dyspnoea<sup>VIII</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Gastrointestinal</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>abdominal pain</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very common<sup>b</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>abdominal discomfort</p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>diarrhoea</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common<sup>a</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>nausea</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>hyperhidrosis</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>Musculoskeletal</strong><strong> </strong><strong>and connective</strong><strong> </strong><strong>tissue</strong><strong> disorders</strong></p></td><td style="vertical-align:top"><p>back pain</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>arthralgia<sup>VI</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>bone pain<sup>VI</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>myalgia</p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>muscular weakness</p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>proteinuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common<sup>b</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>albuminuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common<sup>b</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>kidney injury<sup>X</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p><strong>General</strong><strong> </strong><strong>disorders</strong><strong> and administration site conditions</strong></p></td><td style="vertical-align:top"><p>non-cardiac chest pain</p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>influenza-like illness</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>fatigue</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common<sup>a</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>asthenia</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>injection site reactions<sup> III, VI</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>oedema peripheral</p></td><td style="vertical-align:top"><p>Very common</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>alanine aminotransferase increased</p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Common<sup>V</sup></p></td></tr><tr><td style="vertical-align:top"><p>aspartate aminotransferase increased</p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Very common<sup>V</sup></p></td></tr><tr><td style="vertical-align:top"><p>blood bilirubin increased</p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Very common<sup>V</sup></p></td></tr><tr><td style="vertical-align:top"><p>gamma-glutamyltransferase increased</p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="vertical-align:top"><p>traumatic fracture<sup>VI</sup></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Common<sup>b</sup></p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>The four pivotal studies are ACE-536-MDS-001(ESA-refractory or -intolerant MDS), ACE-536-MDS-002 (MDS), ACE-536-B-THAL-001 (transfusion‑dependent b-thalassaemia) and ACE-536-B-THAL-002 (non‑transfusion‑dependent b-thalassaemia).</p><p><sup>I</sup> Hypersensitivity includes eyelid oedema, drug hypersensitivity, swelling face, periorbital oedema, face oedema, angioedema, lip swelling, drug eruption.</p><p><sup>II</sup> Hypertension includes essential hypertension, hypertension and hypertensive crisis.</p><p><sup>III</sup> Injection site reactions include injection site erythema, injection site pruritus, injection site swelling and injection site rash.</p><p><sup>IV</sup> TEEs include deep vein thrombosis, portal vein thrombosis, ischaemic stroke and pulmonary embolism.</p><p><sup>V</sup> Frequency is based on laboratory values of any grade.</p><p><sup>VI</sup><sup> </sup>See section&nbsp;4.8 Description of selected adverse reactions.</p><p><sup>VII </sup>Reported only in post-marketing.</p><p><sup>VIII </sup>Dyspnoea includes dyspnoea exertional for ACE-536-MDS-002.</p><p><sup>IX </sup>Electrolyte imbalance includes bone, calcium, magnesium and phosphorus metabolism disorders and electrolyte and fluid balance conditions.</p><p><sup>X</sup> ADR includes similar/grouped terms.</p><p><sup>a </sup>ADRs observed in transfusion-dependent &beta;‑thalassaemia study ACE-536-B-THAL-001.</p><p><sup>b </sup>ADRs observed in non-transfusion-dependent &beta;-thalassaemia study ACE-536-B-THAL-002.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Bone</em><em> pain</em></p><p>Bone pain was reported in 2.4% of MDS patients treated with luspatercept with all events being Grade 1-2.</p><p>&nbsp;</p><p>Bone pain was reported in 19.7% of transfusion-dependent &beta;-thalassaemia patients treated with luspatercept (placebo 8.3%) with most events (41/44) being Grade 1-2, and 3 events Grade 3. One of the 44 events was serious, and 1 event led to treatment discontinuation. Bone pain was most common in the first 3 months (16.6%) compared to months 4-6 (3.7%).</p><p>&nbsp;</p><p>Bone pain was reported in 36.5% of non-transfusion-dependent &beta;‑thalassaemia patients treated with luspatercept (placebo 6.1%) with most events (32/35) being Grade&nbsp;1-2, and 3&nbsp;events Grade&nbsp;3. No patient discontinued due to bone pain.</p><p>&nbsp;</p><p><em>Arthralgia</em></p><p>Arthralgia was reported in 7.2% of MDS patients treated with luspatercept with 0.6% being &ge; Grade 3.</p><p>&nbsp;</p><p>Arthralgia was reported in 19.3% of transfusion-dependent &beta;-thalassaemia patients treated with luspatercept (placebo 11.9%) and led to treatment discontinuation in 2 patients (0.9%).</p><p>&nbsp;</p><p>Arthralgia was reported in 29.2% of non-transfusion-dependent &beta;‑thalassaemia patients treated with luspatercept (placebo 14.3%) with most events (26/28) being Grade 1-2, and 2 events Grade 3. Arthralgia led to treatment discontinuation in 1&nbsp;patient (1.0%).</p><p>&nbsp;</p><p><em>Hypertension</em></p><p>MDS and &beta;-thalassaemia patients treated with luspatercept had an average increase in systolic and diastolic blood pressure of up to 5 mmHg from baseline not observed in patients receiving placebo.</p><p>&nbsp;</p><p>Hypertension events were reported in 12.5% of MDS patients treated with luspatercept (placebo 9.2%). Grade 3 hypertension events were reported in 25/335 patients (7.5%) treated with luspatercept (placebo 3.9%).</p><p>&nbsp;</p><p>Hypertension was reported in 19.8% of non‑transfusion‑dependent &beta;-thalassaemia patients treated with luspatercept (placebo 2.0%). Most events (16/19) were Grade 1-2 with 3&nbsp;events Grade 3 (3.1%) in patients treated with luspatercept (placebo 0.0%). An increased incidence of hypertension was observed over time in the first 8-12&nbsp;months in non‑transfusion-dependent b-thalassaemia patients treated with luspatercept. See section 4.4.</p><p>&nbsp;</p><p>Hypertension was reported in 8.1% of transfusion-dependent &beta;‑thalassaemia patients treated with luspatercept (placebo 2.8%). See section 4.4. Grade&nbsp;3 events were reported in 4&nbsp;patients (1.8%) treated with luspatercept (placebo 0.0%).</p><p>&nbsp;</p><p><em>Hypersensitivity</em></p><p>Hypersensitivity-type reactions included eyelid oedema, drug hypersensitivity, swelling face, periorbital oedema, face oedema, angioedema, lip swelling, drug eruption.</p><p>&nbsp;</p><p>Hypersensitivity-type reactions were reported in 4.6% of MDS patients (placebo 2.6%) with all events being Grade 1-2 in patients treated with luspatercept.</p><p>&nbsp;</p><p>Face oedema occurred in 3.1% of non-transfusion-dependent &beta;-thalassaemia patients (placebo 0.0%).</p><p>&nbsp;</p><p>Hypersensitivity-type reactions were reported in 4.5% of transfusion-dependent &beta;-thalassaemia patients treated with luspatercept (placebo 1.8%) with all events being Grade 1-2. Hypersensitivity led to treatment discontinuation in 1 patient (0.4%).</p><p>&nbsp;</p><p><em>Injection</em><em> </em><em>site</em><em> reactions</em></p><p>Injection site reactions included injection site erythema, injection site pruritus, injection site swelling and injection site rash.</p><p>&nbsp;</p><p>Injection site reactions were reported in 3.6% of MDS patients.</p><p>&nbsp;</p><p>Injection site reactions were reported in 2.2% of transfusion‑dependent &beta;-thalassaemia patients (placebo 1.8%) with all events Grade 1 and none leading to discontinuation.</p><p>&nbsp;</p><p>Injection site reactions were reported in 5.2% of non-transfusion-dependent &beta;-thalassaemia patients (placebo 0.0%) with all events Grade 1 and none leading to discontinuation.</p><p>&nbsp;</p><p><em>Thromboembolic</em><em> events</em></p><p>TEEs included deep vein thrombosis, portal vein thrombosis, ischaemic stroke and pulmonary embolism.</p><p>&nbsp;</p><p>TEEs were reported in 3.9% of MDS patients (placebo 3.9%). Reported TEEs included cerebral ischemia and cerebrovascular accident in 1.2% of patients. All TEEs occurred in patients with significant risk factors (atrial fibrillation, stroke or heart failure and peripheral vascular disease) and were not correlated with elevated Hb, platelet levels or hypertension. See section 4.4.</p><p>&nbsp;</p><p>TEEs occurred in 3.6% of transfusion-dependent &beta;-thalassaemia patients receiving luspatercept (placebo 0.9%).</p><p>&nbsp;</p><p>TEE (superficial thrombophlebitis) occurred in 0.7% of patients in the open-label phase of the pivotal study in non-transfusion‑dependent &beta;-thalassaemia.</p><p>&nbsp;</p><p>All TEEs events were reported in patients who had undergone splenectomy and had at least one other risk factor. See section 4.4.</p><p>&nbsp;</p><p><em>Extramedullary haemopoiesis masses</em></p><p>EMH masses occurred in 10/315 (3.2%) transfusion-dependent &beta;‑thalassaemia patients receiving luspatercept (placebo 0.0%). Five events were Grade 1-2, 4 events were Grade 3, and 1 event was Grade 4. Three patients discontinued due to EMH masses. See section&nbsp;4.4.</p><p>&nbsp;</p><p>EMH masses occurred in 6/96 (6.3%) non-transfusion-dependent &beta;‑thalassaemia patients receiving luspatercept (placebo 2.0%). Most (5/6) were Grade 2 and 1 was Grade 1. One patient discontinued due to EMH masses. During the open-label portion of the study, EMH masses were observed in 2 additional patients for a total of 8/134 (6.0%) of patients. Most (7/8) were Grade 1-2 and manageable with standard clinical practice. In 6/8 patients, luspatercept was continued after onset of event. See section&nbsp;4.4.</p><p>&nbsp;</p><p>EMH masses may also occur after extended treatment with luspatercept (i.e. after 96 weeks).</p><p>&nbsp;</p><p><em>Spinal cord compression</em></p><p>Spinal cord compression or symptoms due to EMH masses occurred in 6/315 (1.9%) transfusion‑dependent b-thalassaemia patients receiving luspatercept (placebo 0.0%). Four patients discontinued treatment due to Grade &ge;&nbsp;3 symptoms of spinal cord compression.</p><p><em>&nbsp;</em></p><p>Spinal cord compression due to EMH masses occurred in 1/96 (1.0%) non‑transfusion‑dependent b-thalassaemia patient with a history of EMH masses receiving luspatercept (placebo 0.0%). This patient discontinued treatment due to Grade&nbsp;4 spinal cord compression. See section 4.4.</p><p>&nbsp;</p><p><em>Traumatic fracture</em></p><p>Traumatic fracture occurred in 1 (0.4%) transfusion-dependent b-thalassaemia patient receiving luspatercept (placebo 0.0%).</p><p>&nbsp;</p><p>Traumatic fracture occurred in 8 (8.3%) non-transfusion-dependent b-thalassaemia patients receiving luspatercept (placebo 2.0%) with Grade&nbsp;&ge;&nbsp;3 events reported for 4&nbsp;patients (4.2%) treated with luspatercept and in 1&nbsp;patient (2.0%) receiving placebo.</p><p>&nbsp;</p><p><em>Immunogenicity</em></p><p>In clinical studies in MDS, an analysis of 395 MDS patients who were treated with luspatercept and who were evaluable for the presence of anti-luspatercept antibodies showed that 36 (9.1%) patients tested positive for treatment-emergent anti-luspatercept antibodies, including 18 (4.6%) patients who had neutralising antibodies against luspatercept.</p><p>&nbsp;</p><p>In clinical studies in transfusion‑dependent and non-transfusion‑dependent b-thalassaemia, an analysis of 380 b-thalassaemia patients who were treated with luspatercept and who were evaluable for the presence of anti-luspatercept antibodies showed that 7 (1.84%) patients tested positive for treatment emergent anti-luspatercept antibodies, including 5 (1.3%) patients who had neutralising antibodies against luspatercept.</p><p>&nbsp;</p><p>Luspatercept serum concentration tended to decrease in the presence of anti-luspatercept antibodies. There were no severe systemic hypersensitivity reactions reported for patients with anti-luspatercept antibodies. There was no association between hypersensitivity type reactions or injection site reactions and presence of anti-luspatercept antibodies. Patients with treatment-emergent anti-luspatercept antibodies were more likely to report a serious treatment-emergent adverse event (69.4% [25/36] for anti-luspatercept antibodies-positive patients <em>vs</em>. 45.7% [164/359] for anti-luspatercept antibodies-negative patients) or a Grade 3 or 4 treatment-emergent adverse event (77.8% [28/36] for anti-luspatercept antibodies-positive patients <em>vs</em>. 56.8% [204/359] for anti-luspatercept antibodies-negative patients) compared to patients without anti-luspatercept antibodies in the TD MDS pool.</p><p>&nbsp;</p><p><u>Other special population</u></p><p><u>&nbsp;</u></p><p><em><u>MDS patients without ring sideroblast (RS-)</u></em></p><p>RS- patients are more likely to experience serious adverse events, Grade 5 treatment‑emergent adverse events, adverse events leading to drug discontinuation or dose reduction compared to patients with ring sideroblasts (RS+). In ACE‑536-MDS-002 study, RS- patients showed higher incidence of some adverse reactions compared to RS+ patients in both treatment arms. When comparing RS subgroups in the luspatercept arm, asthenia, nausea, vomiting, dyspnoea, cough, thromboembolic events, alanine aminotransferase increased, aspartate aminotransferase increased, and thrombocytopenia occurred more frequently in the RS- subgroup.</p><p>&nbsp;</p><p><em><u>MDS patients with mutational status SF3B1 non-mutated</u></em></p><p>Patients with mutational status SF3B1 non-mutated are more likely to experience Grade 3 or 4 treatment‑emergent adverse events, serious adverse events, Grade 5 treatment‑emergent adverse events, adverse events leading to drug discontinuation, dose reduction as well as dose interruption compared to patients with mutational status SF3B1 mutated. Known luspatercept adverse reactions with a frequency &ge; 3% higher in the non-mutated SF3B1 luspatercept arm subgroup included vomiting, dyspnoea, and hypertension.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia:<br /><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:428.4pt;
 height:40.35pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>Please report adverse drug events to:</p><p>The National Pharmacovigilance Centre (NPC):</p><p>o&nbsp;&nbsp; SFDA Call Center: 19999</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp; Website: <u>https://ade.sfda.gov.sa</u></p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose with luspatercept may cause an increase of Hb values above the desired level. In the event of an overdose, treatment with luspatercept should be delayed until Hb is &le; 11 g/dL.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antianaemic preparations, other antianaemic preparations, ATC code: B03XA06.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Luspatercept, an erythroid maturation agent, is a recombinant fusion protein that binds selected transforming growth factor-&beta; (TGF-&beta;) superfamily ligands. By binding to specific endogenous ligands (e.g. GDF-11, activin B) luspatercept inhibits Smad2/3 signalling, resulting in erythroid maturation through expansion and differentiation of late-stage erythroid precursors (normoblasts) in the bone marrow, thereby restoring effective erythropoiesis. Smad2/3 signalling is abnormally high in disease models characterised by ineffective erythropoiesis, i.e. MDS and &beta;-thalassaemia, and in the bone marrow of MDS patients.</p><p>&nbsp;</p><p><u>Somatic mutations in MDS patients</u></p><p>Luspatercept demonstrated clinical benefit and favourability over epoetin alfa across multiple genomic mutations that are frequently observed in lower-risk MDS with the exception of CBL gene mutations.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em>Myelodysplastic</em><em> </em><em>syndromes</em></p><p>The efficacy and safety of luspatercept were evaluated in a Phase&nbsp;3 multicentre, randomised, open-label, active controlled study COMMANDS (ACE-536-MDS-002) comparing luspatercept <em>versus</em> epoetin alfa in patients with anaemia due to International Prognostic Scoring System-Revised (IPSS‑R) very low-, low- or intermediate-risk MDS or with myelodysplastic/&nbsp;myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN RS-T) in ESA na&iuml;ve patients (with endogenous sEPO levels of &lt; 500 U/L) who require red blood cell transfusions. For eligibility, patients were required to have had 2 to 6 RBC units/8 weeks confirmed for a minimum of 8 weeks immediately preceding randomization. Patients with deletion 5q (del5q) MDS were excluded from the study.</p><p>&nbsp;</p><p>Patients were treated for at least 24 weeks, unless the patient experienced unacceptable toxicities, withdrew the consent or met any other treatment discontinuation criteria. The treatment was continued beyond week 24 in case of clinical benefit (defined as a transfusion reduction of &ge; 2 pRBC units/8 weeks compared with baseline) and absence of disease progression. Based on the outcome of these assessments, patients either were discontinued from treatment and entered into the Post-Treatment Follow-up Period or continued open-label treatment (with luspatercept or epoetin alfa) as long as the above criteria continued to be met or until the patient experienced unacceptable toxicities, withdrew consent, or met any other discontinuation criteria.</p><p>&nbsp;</p><p>A total of 363 patients were randomized to receive subcutaneously luspatercept (N=182) or epoetin alfa (N=181) at 1.0 mg/kg every 3&nbsp;weeks or at 450 U/kg every week, respectively. Randomization was stratified by RBC transfusion burden, RS status, and endogenous serum erythropoietin (sEPO) level at baseline. Two dose level increases were allowed for luspatercept (to 1.33 mg/kg and to 1.75 mg/kg). Doses were held and subsequently reduced for adverse reactions, reduced if the haemoglobin increased by &ge; 2 g/dL from the prior cycle, and held if the pre‑dose haemoglobin was &ge; 12 g/dL. All patients received best supportive care, which included RBC transfusions, use of antibiotic, antiviral and antifungal therapy, and nutritional support as needed. BSC for this study excluded the use of ESAs outside of the study treatment. The key baseline disease characteristics in MDS patients in ACE-536-MDS-002 are shown in Table&nbsp;8.</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:98%"><thead><tr><td colspan="3"><p>Table&nbsp;8: Baseline demographics and disease characteristics of MDS patients in ACE‑536‑MDS-002</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Luspatercept</p><p>(N=182)</p></td><td><p>Epoetin alfa</p><p>(N=181)</p></td></tr></thead><tbody><tr><td colspan="3"><p>Demographics</p></td></tr><tr><td style="vertical-align:top"><p><strong>Age<sup>a</sup> (years)</strong></p><p>Median (min, max)</p></td><td><p>&nbsp;</p><p>74 (46, 93)</p></td><td><p>&nbsp;</p><p>74 (31, 91)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Age categories, n (%)</strong></p><p>&le;64&nbsp;years</p><p>65-74&nbsp;years</p><p>&ge;75</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>27 (14.8)</p><p>68 (37.4)</p><p>87 (47.8)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>25 (13.8)</p><p>66 (36.5)</p><p>90 (49.7)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Sex, n (%)</strong></p><p>Male</p><p>Female</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>109 (59.9)</p><p>73 (40.1)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>92 (50.8)</p><p>89 (49.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Race, n (%)</strong></p><p>Asian</p><p>Black</p><p>White</p><p>Not collected or reported</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>19 (10.4)</p><p>2 (1.1)</p><p>146 (80.2)</p><p>15 (8.2)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>25 (13.8)</p><p>0</p><p>143 (79)</p><p>13 (7.2)</p></td></tr><tr><td colspan="3"><p>Disease Characteristics</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Hb</strong> <strong>(g/dL), n (%)<sup>b</sup></strong></p><p>Median (min, max)</p></td><td><p>&nbsp;</p><p>7.80 (4.7, 9.2)</p></td><td><p>&nbsp;</p><p>7.80 (4.5, 10.2)</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Time since original MDS diagnosis (months)<sup>c</sup></strong></p><p>Median</p></td><td><p>&nbsp;</p><p>7.97</p></td><td><p>&nbsp;</p><p>5.13</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Serum EPO (U/L) </strong><strong>categories,</strong><strong> n (%)<sup>d</sup></strong></p><p>&le;200</p><p>&gt;200</p><p>Median serum EPO</p></td><td style="vertical-align:bottom"><p>145 (79.7)</p><p>37 (20.3)</p><p>77.245</p></td><td style="vertical-align:bottom"><p>144 (79.6)</p><p>37 (20.4)</p><p>85.370</p></td></tr><tr><td style="vertical-align:top"><p><strong>Serum ferritin (&micro;g/L)</strong></p><p>Median (min, max)</p></td><td style="vertical-align:bottom"><p>623.00</p><p>(12.4, 3170.0)</p></td><td style="vertical-align:bottom"><p>650.00</p><p>(39.4, 6960.5)</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Baseline transfusion burden / 8 weeks<sup>e</sup> (pRBC units), n (%)</strong></p><p>&lt;4 units</p><p>&ge;4 units</p></td><td style="vertical-align:bottom"><p>&nbsp;</p><p>118 (64.8)</p><p>64 (35.2)</p></td><td style="vertical-align:bottom"><p>111 (61.3)</p><p>70 (38.7)</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>MDS Classification WHO 2016 at baseline, n (%)</strong></p><p>MDS-SLD</p><p>MDS-MLD</p><p>MDS-RS-SLD</p><p>MDS-RS-MLD</p><p>MDS/MPN-RS-T</p><p>Missing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:bottom"><p>1 (0.5)</p><p>50 (27.5)</p><p>2 (1.1)</p><p>127 (69.8)</p><p>2 (1.1)</p><p>0</p></td><td style="vertical-align:bottom"><p>4 (2.2)</p><p>47 (26.0)</p><p>6 (3.3)</p><p>118 (65.2)</p><p>5 (2.8)</p><p>1 (0.6)</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>IPSS-R classification risk category, n (%)</strong></p><p>Very low</p><p>Low</p><p>Intermediate</p><p>Other / missing</p></td><td style="vertical-align:bottom"><p>16 (8.8)</p><p>130 (71.4)</p><p>34 (18.7)</p><p>2 (1.1)</p></td><td style="vertical-align:bottom"><p>17 (9.4)</p><p>133 (73.5)</p><p>29 (16.0)</p><p>2 (1.1)</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Ring sideroblast status (per WHO criteria), n (%)</strong></p><p>RS+</p><p>RS-</p><p>Missing</p></td><td style="vertical-align:bottom"><p>133 (73.1)</p><p>49 (26.9)</p><p>0</p></td><td style="vertical-align:bottom"><p>130 (71.8)</p><p>50 (27.6)</p><p>1 (0.6)</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>SF3B1 mutation status, n (%)</strong></p><p>Mutated</p><p>Non-mutated</p><p>Missing</p></td><td style="vertical-align:bottom"><p>114 (62.6)</p><p>65 (35.7)</p><p>3 (1.6)</p></td><td style="vertical-align:bottom"><p>101 (55.8)</p><p>72 (39.8)</p><p>8 (4.4)</p></td></tr></tbody></table><p>Hb = haemoglobin; IPSSR=International Prognostic Scoring System-Revised; MDS-SLD=MDS with single lineage dysplasia; MDS-MLD=MDS with multilineage dysplasia; MDS-RS-SLD=MDS with ring sideroblasts with single lineage dysplasia; MDS-RS-MLD= MDS with ring sideroblasts with multilineage dysplasia; MDS/MPN-RS-T= myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis; RS+=with ring sideroblasts; RS-= without ring sideroblasts; SF3B1= Splicing Factor 3B Subunit 1A MDS mutation</p><p><sup>a </sup>Age was calculated based on the informed consent signing date.</p><p><sup>b </sup>After applying the 14/3-day rule (only Hb values that are measured at least 14 days after a transfusion may be used unless there is another transfusion within 3 days after the Hb assessment. If a transfusion within 3 days after the Hb assessment occurs, that Hb value will be used despite being &lt; 14 days after the previous transfusion), the baseline Hb value (efficacy) is defined as the lowest Hb value from the central, or local laboratory, or pre-transfusion Hb from transfusion records that is within the 35 days prior to the first dose of study drug, if it was available.</p><p><sup>c</sup><sup> </sup>The number of months from the date of original diagnosis to the date of informed consent.</p><p><sup>d</sup> Baseline EPO was defined as the highest EPO value within the 35&nbsp;days preceding the first dose of study drug.</p><p><sup>e </sup>Collected over 8&nbsp;weeks prior to randomisation.</p><p>The efficacy results are summarised below.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:624px"><thead><tr><td colspan="4" style="vertical-align:top"><p><strong>Table&nbsp;9: Efficacy results in MDS patients in ACE‑536‑MDS-002</strong></p></td></tr><tr><td style="vertical-align:top"><p>Endpoint</p></td><td colspan="2" style="vertical-align:top"><p><strong>Luspatercept<br />(N=182)</strong></p></td><td style="vertical-align:top"><p><strong>Epoetin alfa<br />(N=181)</strong></p></td></tr></thead><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong><em>Primary endpoint</em></strong></p></td></tr><tr><td colspan="4"><p>&middot; <strong>RBC-TI for 12 weeks with associated concurrent mean Hb increase of &ge; 1.5 g/dL</strong></p><p><strong>(Weeks 1-24)</strong></p></td></tr><tr><td><p>Number of responders (response rate %)</p><p>(95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>110 (60.4)</p><p>(52.9, 67.6)</p></td><td style="vertical-align:top"><p>63 (34.8)</p><p>(27.9, 42.2)</p></td></tr><tr><td><p>Common Risk Difference (95% CI)<sup>a</sup></p></td><td colspan="3" style="vertical-align:top"><p>25.4 (15.8, 35.0)</p></td></tr><tr><td><p>p-value</p></td><td colspan="3" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td><p>Odds Ratio (95% CI)<sup>a</sup></p></td><td colspan="3" style="vertical-align:top"><p>3.1 (2.0, 4.8)</p></td></tr><tr><td colspan="4"><p><strong><em>Secondary endpoints</em></strong></p></td></tr><tr><td colspan="4"><p>&middot; <strong>HI-E per IWG &ge;8 weeks (Weeks 1-24)</strong><sup>b</sup></p></td></tr><tr><td><p>Number of responders (response rate %)</p><p>(95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>135 (74.2)</p><p>(67.2, 80.4)</p></td><td style="vertical-align:top"><p>96 (53.0)</p><p>(45.5, 60.5)</p></td></tr><tr><td><p>Common Risk Difference (95% CI)<sup>a</sup></p></td><td colspan="3" style="vertical-align:top"><p>21.5 (12.2, 30.7)</p></td></tr><tr><td><p>p-value</p></td><td colspan="3" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td><p>Odds Ratio (95% CI)<sup>a</sup></p></td><td colspan="3" style="vertical-align:top"><p>2.8 (1.8, 4.5)</p></td></tr><tr><td colspan="4"><p>&middot; <strong>RBC-TI for 24 weeks (Weeks 1-24)</strong></p></td></tr><tr><td><p>Number of responders (response rate %)</p><p>(95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>87 (47.8)</p><p>(40.4, 55.3)</p></td><td style="vertical-align:top"><p>56 (30.9)</p><p>(24.3, 38.2)</p></td></tr><tr><td><p>Common Risk Difference (95% CI)<sup>a</sup></p></td><td colspan="3" style="vertical-align:top"><p>16.3 (7.1, 25.4)</p></td></tr><tr><td><p>p-value</p></td><td colspan="3" style="vertical-align:top"><p>0.0003</p></td></tr><tr><td><p>Odds Ratio (95% CI)<sup>a</sup></p></td><td colspan="3" style="vertical-align:top"><p>2.3 (1.4, 3.7)</p></td></tr><tr><td><p>&middot; <strong>RBC-TI for &ge;24 weeks (Weeks 1-48)</strong></p></td><td style="vertical-align:top"><p>163</p></td><td colspan="2" style="vertical-align:top"><p>167</p></td></tr><tr><td><p>Number of responders (response rate %)</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>99 (60.7)</p><p>(52.8, 68.3)</p></td><td colspan="2" style="vertical-align:top"><p>66 (39.5)</p><p>(32.1, 47.4)</p></td></tr><tr><td><p>Common Risk Difference (95% CI)<sup>a</sup></p></td><td colspan="3" style="vertical-align:top"><p>20.7 (10.8, 30.6)</p></td></tr><tr><td><p>p-value</p></td><td colspan="3" style="vertical-align:top"><p>p &lt;0.0001<sup>c</sup></p></td></tr><tr><td><p>Odds Ratio (95% CI)<sup>a</sup></p></td><td colspan="3" style="vertical-align:top"><p>2.6 (1.6, 4.3)</p></td></tr></tbody></table><p>EOT = End of treatment<sup>. </sup>Hb=haemoglobin; NE = Not Estimable; RBC = red blood transfusion</p><p><sup>a</sup><sup> </sup>Based on CMH test stratified by baseline RBC transfusion burden (&lt; 4, &ge; 4 pRBC units), RS status (RS+, RS-) and sEPO level (&le; 200, &gt; 200 U/L). 1-sided p-value is presented.</p><p><sup>b </sup>HI‑E = haematological improvement &ndash; erythroid. The proportion of patients meeting the HI‑E criteria as per International Working Group (IWG) 2006 criteria sustained over a consecutive 56-day period during the indicated treatment period. For patients with baseline RBC transfusion burden of &ge;&nbsp;4&nbsp;units/8&nbsp;weeks, HI‑E was defined as a reduction in RBC transfusion of at least 4&nbsp;units/8&nbsp;weeks. For patients with baseline RBC transfusion burden of &lt;&nbsp;4&nbsp;units/8&nbsp;weeks, HI-E was defined as a mean increase in Hb of &ge;&nbsp;1.5&nbsp;g/dL for 8&nbsp;weeks in the absence of RBC transfusions.</p><p><sup>c </sup>Nominal p-value</p><p>The treatment effect of luspatercept on RBC-TI &ge;12 weeks and Hb increase of &ge;1.5 g/dL was higher than epoetin alfa across all clinically relevant baseline demographic and most disease characteristic subgroups, except in patients without ring sideroblasts, where the treatment effect of luspatercept was comparable to epoetin alfa.</p><p><u>&nbsp;</u></p><p><em>Myelodysplastic syndromes in ESA-refractory or ‑intolerant patients</em></p><p>The efficacy and safety of luspatercept were evaluated in a Phase 3 multicentre, randomised, double-blind, placebo-controlled study MEDALIST (ACE-536-MDS-001) in adult patients with anaemia requiring RBC transfusions (&ge; 2 units/8 weeks) due to IPSS-R very low-, low- or intermediate-risk MDS who have ring sideroblasts (&ge; 15%). Patients with del5q MDS or without ring sideroblasts (RS-) were not included in the study. Patients were required to have either received prior treatment with an ESA with inadequate response, to be ineligible for ESAs (determined to be unlikely to respond to ESA treatment with serum erythropoietin (EPO) &gt; 200 U/L), or intolerant to ESA treatment.</p><p>&nbsp;</p><p>Patients in both arms were treated for 24 weeks, then continued treatment if they had demonstrated clinical benefit and absence of disease progression. The study was unblinded for analyses when all patients had at least received 48 weeks of treatment or discontinued treatment.</p><p>&nbsp;</p><p>A total of 229 patients were randomised to receive luspatercept 1.0 mg/kg (N=153) or placebo (N=76) subcutaneously every 3 weeks. A total of 128 (83.7%) and 68 (89.5%) patients receiving luspatercept and placebo respectively completed 24 weeks of treatment. A total of 78 (51%) and 12 (15.8%) patients receiving luspatercept and placebo respectively completed 48 weeks of treatment. Dose titration up to 1.75 mg/kg was allowed. Dose could be delayed or reduced depending upon Hb level. All patients were eligible to receive best supportive care (BSC), which included RBC transfusions, iron-chelating agents, use of antibiotic, antiviral and antifungal therapy, and nutritional support, as needed. The key baseline disease characteristics in patients with MDS in study ACE-536-MDS-001 are shown in Table 10.</p><p>Table 10: Baseline demographics and disease characteristics of MDS patients with &lt;5% marrow blasts in study ACE-536-MDS-001</p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Luspatercept</strong><strong> </strong><strong>(N=153)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong><strong> </strong><strong>(N=76)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Demographics</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Age</strong><strong>a </strong><strong>(years)</strong></p><p>Median (min, max)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>71 (40, 95)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>72 (26, 91)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Age categories, n (%)</strong></p><p>&lt;64 years</p><p>65-74 years</p><p>&ge;75</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>29 (19.0)</p><p>72 (47.1)</p><p>52 (34.0)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>16 (21.1)</p><p>29 (38.2)</p><p>31 (40.8)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Sex, n (%) </strong>Male Female</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>94 (61.4)</p><p>59 (38.6)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>50 (65.8)</p><p>26 (34.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Race, n (%)</strong></p><p>Black White</p><p>Not collected or reported Other</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>1 (0.7)</p><p>107 (69.9)</p><p>44 (28.8)</p><p>1 (0.7)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>0 (0.0)</p><p>51 (67.1)</p><p>24 (31.6)</p><p>1 (1.3)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Disease characteristics</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Serum EPO (U/L) categories </strong>b<strong>, n (%)</strong></p><p>&lt; 200</p><p>200 to 500</p><p>&gt; 500</p><p>Missing</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>88 (57.5)</p><p>43 (28.1)</p><p>21 (13.7)</p><p>1 (0.7)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>50 (65.8)</p><p>15 (19.7)</p><p>11 (14.5)</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Serum ferritin (&micro;g/L)</strong></p><p>Median (min, max)</p></td><td style="vertical-align:top"><p>1089.2</p><p>(64, 5968)</p></td><td style="vertical-align:top"><p>1122.1</p><p>(165, 5849)</p></td></tr><tr><td style="vertical-align:top"><p><strong>IPSS-R classification risk category, n (%)</strong></p><p>Very low</p><p>Low</p><p>Intermediate</p><p>Other</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>18 (11.8)</p><p>109 (71.2)</p><p>25 (16.3)</p><p>1 (0.7)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>6 (7.9)</p><p>57 (75.0)</p><p>13 (17.1)</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline RBC transfusion burden/ 8 weeks</strong><strong>c</strong><strong>,</strong><strong> </strong><strong>n (%)</strong></p><p>&ge; 6 units</p><p>&ge; 6 and &lt; 8 units</p><p>&ge; 8 and &lt; 12 units</p><p>&ge; 12 units</p><p>&lt; 6 units</p><p>&ge; 4 and &lt; 6 units</p><p>&lt; 4 units</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>66 (43.1)</p><p>35 (22.9)</p><p>24 (15.7)</p><p>7 (4.6)</p><p>87 (56.9)</p><p>41 (26.8)</p><p>46 (30.1)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>33 (43.4)</p><p>15 (20.2)</p><p>17 (22.4)</p><p>1 (1.3)</p><p>43 (56.6)</p><p>23 (30.3)</p><p>20 (26.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hb</strong><strong>d</strong><strong>&nbsp;</strong><strong>(g/dL)</strong></p><p>Median (min, max)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>7.6 (6, 10)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>7.6 (5, 9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>SF3B1, n (%)</strong></p><p>Mutated</p><p>Unmutated</p><p>Missing</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>149 (92.2)</p><p>12 (7.8)</p><p>0</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>65 (85.5)</p><p>10 (13.2)</p><p>1 (1.3)</p></td></tr></thead></table><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="_x0000_s1026"
 style='position:absolute;margin-left:432.45pt;margin-top:618.9pt;width:.1pt;
 height:26.1pt;z-index:-55544;mso-position-horizontal-relative:page;
 mso-position-vertical-relative:page' coordorigin="8649,12378" coordsize="2,522">
 <v:shape id="_x0000_s1027" style='position:absolute;left:8649;top:12378;
  width:2;height:522' coordorigin="8649,12378" coordsize="0,522" path="m8649,12378r,522e"
  filled="f" strokeweight=".58pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page" anchory="page"/>
</v:group><![endif]--><img width="2" height="37" src="file:///C:/Users/aldawoom/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:group
 id="_x0000_s1028" style='position:absolute;margin-left:432.45pt;margin-top:685.85pt;
 width:.1pt;height:26.1pt;z-index:-54520;mso-position-horizontal-relative:page;
 mso-position-vertical-relative:page' coordorigin="8649,13717" coordsize="2,522">
 <v:shape id="_x0000_s1029" style='position:absolute;left:8649;top:13717;
  width:2;height:522' coordorigin="8649,13717" coordsize="0,522" path="m8649,13717r,522e"
  filled="f" strokeweight=".58pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page" anchory="page"/>
</v:group><![endif]--><img width="2" height="36" src="file:///C:/Users/aldawoom/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p>EPO=erythropoietin; Hb=haemoglobin; IPSS-R=International Prognostic Scoring System-Revised</p><p>a Age was calculated based on the informed consent signing date.</p><p>b Baseline EPO was defined as the highest EPO value within 35 days of the first dose of study drug.</p><p>c Collected over 16 weeks prior to randomisation.</p><p>d Baseline Hb was defined as the last value measured on or before the date of the first dose of investigational product (IP). After applying the 14/3-day rule, baseline Hb was defined as the lowest Hb value that was within 35 days on or prior to the first dose of IP.</p><p>&nbsp;</p><p>The efficacy results are summarised below.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:710px"><thead><tr><td colspan="7" style="vertical-align:top"><p><strong>Table 11: Efficacy results in patients with MDS in study ACE-536-MDS-001</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Luspatercept</strong><strong> </strong><strong>(N=153)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Placebo</strong><strong> </strong><strong>(N=76)</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr></thead><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong><em>Primary</em></strong><strong><em> </em></strong><strong><em>endpoint</em></strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&middot; <strong>RBC-TI</strong><strong> </strong><strong>&ge; 8 weeks (Weeks 1-24)</strong></p><p>Number of responders (response rate %)</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>58 (37.9)</p></td><td colspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>10 (13.2)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&middot; Common risk difference on response rate (95% CI)</p></td><td colspan="5" style="vertical-align:top"><p>24.56 (14.48, 34.64)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Odds ratio (95% CI)a</p></td><td colspan="5" style="vertical-align:top"><p>5.065 (2.278, 11.259)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>p-valuea</p></td><td colspan="5" style="vertical-align:top"><p>&lt; 0.0001</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong><em>Secondary</em></strong><strong><em> </em></strong><strong><em>endpoints</em></strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&middot; RBC-TI &ge; 12 weeks (Weeks 1-24)</p><p>Number of responders (response rate %)</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>43 (28.1)</p></td><td colspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>6 (7.9)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&middot; Common risk difference on response rate (95% CI)</p></td><td colspan="5" style="vertical-align:top"><p>20.00 (10.92, 29.08)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Odds ratio (95% CI)a</p></td><td colspan="5" style="vertical-align:top"><p>5.071 (2.002, 12.844)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>p-valuea</p></td><td colspan="5" style="vertical-align:top"><p>0.0002</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&middot; RBC-TI &ge; 12 weeks (Weeks 1-48)</p><p>Number of responders (response rate %)b</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>51 (33.3)</p></td><td colspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>9 (11.8)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&middot; Common risk difference on response rate (95% CI)</p></td><td colspan="5" style="vertical-align:top"><p>21.37 (11.23, 31.51)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Odds ratio (95% CI)a</p></td><td colspan="5" style="vertical-align:top"><p>4.045 (1.827, 8.956)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>p-valuea</p></td><td colspan="5" style="vertical-align:top"><p>0.0003</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Transfusion event frequency</strong><strong>c</strong></p><p>&middot;&nbsp; Weeks 1-24</p><p>Interval transfusion rate (95% CI)</p></td><td colspan="4" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>6.26 (5.56, 7.05)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>9.20 (7.98, 10.60)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Relative risk <em>vs. </em>placebo</p></td><td colspan="6" style="vertical-align:top"><p>0.68 (0.58, 0.80)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>&middot; <strong>Weeks 25-48</strong></p><p>Interval transfusion rate (95% CI)</p></td><td colspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>6.27 (5.47, 7.19)</p></td><td colspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>8.72 (7.40, 10.28)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>Relative risk <em>vs. </em>placebo</p></td><td colspan="6" style="vertical-align:top"><p>0.72 (0.60, 0.86)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>RBC Transfusion units</strong><strong>c</strong></p><p>&middot; <strong>Weeks 1-24</strong></p><p>Baseline transfusion burden <strong>&lt;</strong>6 units/8 weeks LS Mean (SE)</p><p>95% CI for LS mean</p></td><td colspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>7.2 (0.58)</p><p>6.0, 8.3</p></td><td colspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>12.8 (0.82)</p><p>11.1, 14.4</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>LS mean difference (SE) (luspatercept <em>vs. </em>placebo) 95% CI for LS mean difference</p></td><td colspan="5" style="vertical-align:top"><p>-5.6 (1.01)</p><p>-7.6, -3.6</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Baseline transfusion burden <strong>&ge;</strong>6 units/8 weeks LS Mean (SE)</p><p>95% CI for LS mean</p></td><td colspan="4" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>18.9 (0.93)</p><p>17.1, 20.8</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>23.7 (1.32)</p><p>21.1, 26.4</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>LS mean difference (SE) (luspatercept <em>vs. </em>placebo) 95% CI for LS mean difference</p></td><td colspan="5" style="vertical-align:top"><p>-4.8 (1.62)</p><p>-8.0, -1.6</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&middot; <strong>Weeks 25-48</strong></p><p>Baseline transfusion burden <strong>&lt;</strong>6 units/8 weeks LS Mean (SE)</p><p>95% CI for LS mean</p></td><td colspan="4" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>7.5 (0.57)</p><p>6.3, 8.6</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>11.8 (0.82)</p><p>10.1, 13.4</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>LS mean difference (SE) (luspatercept <em>vs. </em>placebo) 95% CI for LS mean difference</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td colspan="5" style="vertical-align:top"><p>-4.3 (1.00)</p><p>-6.3, -2.3</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Baseline transfusion burden <strong>&ge;</strong>6 units/8 weeks LS Mean (SE)</p><p>95% CI for LS mean</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>19.6 (1.13)</p><p>17.4, 21.9</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p><p>22.9 (1.60)</p><p>19.7, 26.0</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>LS mean difference (SE) (luspatercept <em>vs. </em>placebo) 95% CI for LS mean difference</p></td><td colspan="5" style="vertical-align:top"><p>-3.3 (1.96)</p><p>-7.1, 0.6</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>RBC-TI: RBC Transfusion Independent; CI: confidence interval; CMH = Cochran-Mantel-Haenszel;</p><p>a CMH test stratified for average baseline transfusion burden (&ge; 6 units <em>vs.</em> &lt; 6 units per 8 weeks), and baseline IPSS-R score (very low or low <em>vs.</em> intermediate).</p><p>b After the Week 25 disease assessment visit, patients who were no longer deriving benefit discontinued therapy; few placebo patients contributed data for evaluation at the later timepoint compared with luspatercept (N=12 <em>vs.</em> N=78 respectively).</p><p>c Post-hoc analysis using baseline imputation.</p><p>&nbsp;</p><p>A treatment effect in favour of luspatercept over placebo was observed in most subgroups analysed using transfusion independence &ge; 12 weeks (during week 1 to week 24), including patients with high baseline endogenous EPO level (200-500 U/L) (23.3% <em>vs.</em> 0%, explorative analysis).</p><p>&nbsp;</p><p>Only limited data are available for the group with transfusion burden of &ge; 8 units/8 weeks. Safety and efficacy have not been established in patients with a transfusion burden of &gt; 12 units/8 weeks.</p><p>&nbsp;</p><p><em><u>Exploratory</u></em><em><u> </u></em><em><u>findings</u></em></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 12: Exploratory efficacy results in patients with MDS in study ACE-536-MDS-001</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Luspatercept</strong><strong> </strong><strong>(N=153)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong><strong> </strong><strong>(N=76)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>mHI-E</strong><strong>a</strong></p><p>&middot; <strong>Weeks</strong><strong> </strong><strong>1-24</strong></p><p>Number of responders (response rate %)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>81 (52.9)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>9 (11.8)</p></td></tr><tr><td style="vertical-align:top"><p>(95% CI)</p></td><td style="vertical-align:top"><p>(44.72, 61.05)</p></td><td style="vertical-align:top"><p>(5.56, 21.29)</p></td></tr><tr><td style="vertical-align:top"><p>RBC transfusion reduction of 4 units/8 weeks, n (%)</p></td><td style="vertical-align:top"><p>52/107 (48.6)</p></td><td style="vertical-align:top"><p>8/56 (14.3)</p></td></tr><tr><td style="vertical-align:top"><p>Mean Hb increase of &ge; 1.5 g/dL for 8 weeks, n (%)</p></td><td style="vertical-align:top"><p>29/46 (63.0)</p></td><td style="vertical-align:top"><p>1/20 (5.0)</p></td></tr><tr><td style="vertical-align:top"><p>&middot; <strong>Weeks</strong><strong> </strong><strong>1-48</strong></p><p>Number of responders (response rate %)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>90 (58.8)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>13 (17.1)</p></td></tr><tr><td style="vertical-align:top"><p>(95% CI)</p></td><td style="vertical-align:top"><p>(50.59, 66.71)</p></td><td style="vertical-align:top"><p>(9.43, 27.47)</p></td></tr><tr><td style="vertical-align:top"><p>RBC transfusion reduction of 4 units/8 weeks, n (%)</p></td><td style="vertical-align:top"><p>58/107 (54.2)</p></td><td style="vertical-align:top"><p>12/56 (21.4)</p></td></tr><tr><td style="vertical-align:top"><p>Mean Hb increase of &ge; 1.5 g/dL for 8 weeks, n (%)</p></td><td style="vertical-align:top"><p>32/46 (69.6)</p></td><td style="vertical-align:top"><p>1/20 (5.0)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Mean change from baseline in mean serum ferritin with imputation by baseline (ITT population)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean change from baseline in mean serum ferritin averaged over Weeks 9 through 24 (&mu;g/L)b</p><p>LS Mean (SE)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>9.9 (47.09)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>190.0 (60.30)</p></td></tr><tr><td style="vertical-align:top"><p>95% CI for LS Mean</p></td><td style="vertical-align:top"><p>-82.9, 102.7</p></td><td style="vertical-align:top"><p>71.2, 308.8</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Treatment comparison (luspatercept <em>vs.</em> placebo)<sup>c </sup></p></td></tr><tr><td style="vertical-align:top"><p>LS mean difference (SE)</p></td><td colspan="2" style="vertical-align:top"><p>-180.1 (65.81)</p></td></tr><tr><td style="vertical-align:top"><p>95% CI for LS mean difference</p></td><td colspan="2" style="vertical-align:top"><p>-309.8, -50.4</p></td></tr></tbody></table><p>Hb=haemoglobin</p><p>a mHI-E = modified haematological improvement &ndash; erythroid. The proportion of patients meeting the HI-E criteria as per International Working Group (IWG) 2006 criteria sustained over a consecutive 56-day period during the indicated treatment period. For patients with baseline RBC transfusion burden of &ge; 4 units/8 weeks, mHI-E was defined as a reduction in RBC transfusion of at least 4 units/8 weeks. For patients with baseline RBC transfusion burden of &lt; 4 units/8 weeks, mHI-E was defined as a mean increase in Hb of &ge; 1.5 g/dL for 8 weeks in the absence of RBC transfusions.</p><p>b If a patient did not have a serum ferritin value within the designated postbaseline interval, the serum ferritin is imputed from the baseline value.</p><p>c Analysis of covariance was used to compare the treatment difference between groups (including nominal p-value), with the change in serum ferritin as the dependent variable, treatment group (2 levels) as a factor, and baseline serum ferritin value as covariates, stratified by average baseline RBC transfusion requirement (&ge; 6 units <em>vs. </em>&lt; 6 units of RBC per 8 weeks), and baseline IPSS-R (very low or low <em>vs.</em><em> </em>intermediate).</p><p>&nbsp;</p><p>The median duration of the longest RBC Transfusion Independent (RBC-TI) period among responders in the luspatercept treatment arm was 30.6 weeks.</p><p>&nbsp;</p><p>A total of 62.1% (36/58) of the luspatercept responders who achieved RBC-TI &ge; 8 weeks from Weeks 1-24 had 2 or more episodes of RBC-TI at the time of analysis.</p><p>&nbsp;</p><p><em>Transfusion‑dependent </em><em>b-</em><em>thalassaemia</em></p><p>The efficacy and safety of luspatercept were evaluated in a Phase 3 multicentre, randomised, double-blind, placebo-controlled study BELIEVE (ACE-536-B-THAL-001) in adult patients with transfusion‑dependent b‑thalassaemia&ndash;associated anaemia who require RBC transfusions (6-20 RBC units/24 weeks) with no transfusion-free period &gt; 35 days during that period.</p><p>&nbsp;</p><p>Patients in both the luspatercept and placebo arms were treated for at least 48 and up to 96 weeks. After unblinding, placebo patients were able to cross-over to luspatercept.</p><p>&nbsp;</p><p>A total of 336 adult patients were randomised to receive luspatercept 1.0 mg/kg (N=224) or placebo (N=112) subcutaneously every 3 weeks. Dose titration to 1.25 mg/kg was allowed. Dose could be delayed or reduced depending upon Hb level. All patients were eligible to receive BSC, which included RBC transfusions, iron-chelating agents, use of antibiotic, antiviral and antifungal therapy, and nutritional support, as needed. The study excluded patients with Hb S/&beta;-thalassaemia or alpha (&alpha;)-thalassaemia or who had major organ damage (liver disease, heart disease, lung disease, renal insufficiency). Patients with recent DVT or stroke or recent use of ESA, immunosuppressant or hydroxyurea therapy were also excluded. The key baseline disease characteristics in patients with b-thalassaemia in study ACE-536-B-THAL-001 are shown in Table 13.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td colspan="3" style="vertical-align:top"><p>Table 13: Baseline demographics and disease characteristics of patients with transfusion‑dependent<em> </em>b‑thalassaemia in study ACE-536-B-THAL-001</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Luspatercept</strong><strong> </strong><strong>(N=224)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo (N=112)</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Demographics</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Age (years)</strong></p><p>Median (min, max)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>30.0 (18, 66)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>30.0 (18, 59)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Age categories, n (%)</strong></p><p>&le; 32</p><p>&gt; 32 to &le; 50</p><p>&gt; 50</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>129 (57.6)</p><p>78 (34.8)</p><p>17 (7.6)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>63 (56.3)</p><p>44 (39.3)</p><p>5 (4.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Sex, n (%) </strong>Male Female</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>92 (41.1)</p><p>132 (58.9)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>49 (43.8)</p><p>63 (56.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Race, n (%)</strong></p><p>Asian Black White</p><p>Not collected or reported Other</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>81 (36.2)</p><p>1 (0.4)</p><p>122 (54.5)</p><p>5 (2.2)</p><p>15 (6.7)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>36 (32.1)</p><p>0</p><p>60 (53.6)</p><p>5 (4.5)</p><p>11 (9.8)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Disease characteristics</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Pretransfusion Hb threshold</strong><strong>a</strong><strong>, 12-week run-in (g/dL)</strong></p><p>Median (min, max)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>9.30 (4.6, 11.4)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>9.14 (6.2, 11.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline transfusion burden 12 weeks</strong></p><p>Median (min, max)</p><p>(units/12 weeks) (Week -12 to Day 1)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>6.12 (3.0, 14.0)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>6.27 (3.0, 12.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&beta;-thalassaemia</strong><strong> </strong><strong>gene mutation grouping, n (%)</strong></p><p>&beta;0/&beta;0</p><p>Non-&beta;0/&beta;0 Missingb</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>68 (30.4)</p><p>155 (69.2)</p><p>1 (0.4)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>35 (31.3)</p><p>77 (68.8)</p><p>0</p></td></tr></tbody></table><p>&nbsp;</p><p>aThe 12-week pretransfusion threshold was defined as the mean of all documented pretransfusions Hb values for a patient during the 12 weeks prior to Cycle 1 Day 1.</p><p>b &quot;Missing&quot; category includes patients in the population who had no result for the parameter listed.</p><p>&nbsp;</p><p>The study was unblinded for analyses when all patients had at least received 48 weeks of treatment or discontinued treatment.</p><p>&nbsp;</p><p>The efficacy results are summarised below.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 14: Efficacy results in patients with transfusion dependent </strong><strong></strong><strong> thalassaemia in study ACE-536-B-THAL-001</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Luspatercept</strong></p><p><strong>(N=224)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=112)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Primary endpoint</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&ge; 33% reduction from baseline in RBC transfusion burden with a reduction of at least 2 units for</strong></p><p><strong>12 consecutive weeks compared to the 12-week interval prior to treatment</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Weeks</strong><strong> </strong><strong>13-24</strong></p></td><td style="vertical-align:top"><p>47 (21.0)</p></td><td style="vertical-align:top"><p>5 (4.5)</p></td></tr><tr><td style="vertical-align:top"><p>Difference in proportions (95% CI)a</p></td><td colspan="2" style="vertical-align:top"><p>16.5 (10.0, 23.1)</p></td></tr><tr><td style="vertical-align:top"><p>p-valueb</p></td><td colspan="2" style="vertical-align:top"><p>&lt; 0.0001</p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Secondary endpoints</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Weeks</strong><strong> </strong><strong>37-48</strong></p></td><td style="vertical-align:top"><p>44 (19.6)</p></td><td style="vertical-align:top"><p>4 (3.6)</p></td></tr><tr><td style="vertical-align:top"><p>Difference in proportions (95% CI)a</p></td><td colspan="2" style="vertical-align:top"><p>16.1 (9.8, 22.3)</p></td></tr><tr><td style="vertical-align:top"><p>p-valueb</p></td><td colspan="2" style="vertical-align:top"><p>&lt; 0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>&ge; 50% reduction from baseline in RBC transfusion burden with a reduction of at least 2 units for</strong></p><p><strong>12 consecutive weeks compared to the 12-week interval prior to treatment</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Weeks</strong><strong> </strong><strong>13-24</strong></p></td><td style="vertical-align:top"><p>16 (7.1)</p></td><td style="vertical-align:top"><p>2 (1.8)</p></td></tr><tr><td style="vertical-align:top"><p>Difference in proportions (95% CI)a</p></td><td colspan="2" style="vertical-align:top"><p>5.4 (1.2, 9.5)</p></td></tr><tr><td style="vertical-align:top"><p>p-valueb</p></td><td colspan="2" style="vertical-align:top"><p>0.0402</p></td></tr><tr><td style="vertical-align:top"><p><strong>Weeks</strong><strong> </strong><strong>37-48</strong></p></td><td style="vertical-align:top"><p>23 (10.3)</p></td><td style="vertical-align:top"><p>1 (0.9)</p></td></tr><tr><td style="vertical-align:top"><p>Difference in proportions (95% CI)a</p></td><td colspan="2" style="vertical-align:top"><p>9.4 (5.0, 13.7)</p></td></tr><tr><td style="vertical-align:top"><p>p-valueb</p></td><td colspan="2" style="vertical-align:top"><p>0.0017</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>CI: confidence interval.</p><p>a Difference in proportions (luspatercept + BSC &ndash; placebo + BSC) and 95% CIs estimated from the unconditional exact test.</p><p>b P-value from the Cochran Mantel-Haenszel test stratified by the geographical region.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Exploratory</u></em><em><u> </u></em><em><u>findings</u></em></p><p><em>&nbsp;</em></p><p>Table 15: Exploratory efficacy results in patients with transfusion‑dependent<em> </em>b‑thalassaemia in study ACE-536-B-THAL-001</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Luspatercept</strong></p><p><strong>(N=224)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=112)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>&ge; 33% reduction from baseline in RBC transfusion burden with a reduction of at least 2 units for</strong><strong> 12 consecutive weeks compared to the 12-week interval prior to treatment</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Any</strong><strong> consecutive 12 weeks*</strong></p></td><td style="vertical-align:top"><p>173 (77.2)</p></td><td style="vertical-align:top"><p>39 (34.8)</p></td></tr><tr><td style="vertical-align:top"><p>Difference in proportions (95% CI)a</p></td><td colspan="2" style="vertical-align:top"><p>42.4 (31.5, 52.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Any</strong><strong> consecutive 24 weeks*</strong></p></td><td style="vertical-align:top"><p>116 (51.8)</p></td><td style="vertical-align:top"><p>3 (2.7)</p></td></tr><tr><td style="vertical-align:top"><p>Difference in proportions (95% CI)a</p></td><td colspan="2" style="vertical-align:top"><p>49.1 (41.3, 56.2)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>&ge; 50% reduction from baseline in RBC transfusion burden with a reduction of at least 2 units for</strong><strong> 12 consecutive weeks compared to the 12-week interval prior to treatment</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Any</strong><strong> consecutive 12 weeks*</strong></p></td><td style="vertical-align:top"><p>112 (50.0)</p></td><td style="vertical-align:top"><p>9 (8.0)</p></td></tr><tr><td style="vertical-align:top"><p>Difference in proportions (95% CI)a</p></td><td colspan="2" style="vertical-align:top"><p>42.0 (32.7, 49.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Any</strong><strong> consecutive 24 weeks*</strong></p></td><td style="vertical-align:top"><p>53 (23.7)</p></td><td style="vertical-align:top"><p>1 (0.9)</p></td></tr><tr><td style="vertical-align:top"><p>Difference in proportions (95% CI)a</p></td><td colspan="2" style="vertical-align:top"><p>22.8 (16.5, 29.1)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Least</strong><strong> </strong><strong>square</strong><strong> </strong><strong>(LS)</strong><strong> </strong><strong>mean change from baseline in transfusion burden (RBC units/48 weeks)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Weeks</strong><strong> </strong><strong>1 to Week 48</strong></p><p>LS mean</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>-4.69</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>+1.17</p></td></tr><tr><td style="vertical-align:top"><p>LS mean of difference (luspatercept-placebo) (95% CI)b</p></td><td colspan="2" style="vertical-align:top"><p>-5.86</p><p>(-7.04, -4.68)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Weeks</strong><strong> </strong><strong>49 to Week 96</strong></p><p>LS mean</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>-5.43</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>+1.80</p></td></tr><tr><td style="vertical-align:top"><p>LS mean of difference (luspatercept-placebo) (95% CI)b</p></td><td colspan="2" style="vertical-align:top"><p>-7.23</p><p>(-13.84, -0.62)</p></td></tr></tbody></table><p>ANCOVA = analysis of covariance; CI: confidence interval.</p><p>a Difference in proportions (luspatercept + BSC &ndash; placebo + BSC) and 95% CIs estimated from the unconditional exact test.</p><p>b Estimates are based on ANCOVA model with geographical regions and baseline transfusion burden as covariates.</p><p>* Placebo patients are assessed up to prior to crossing over to luspatercept. For the rolling analyses at any consecutive 12 / 24 weeks, luspatercept treatment arm does not include placebo patients who crossed over to luspatercept.</p><p>&nbsp;</p><p>A reduction in mean serum ferritin levels was observed from baseline in the luspatercept arm compared to an increase in the placebo arm at Week 48 -235.56 &mu;g/L <em>vs. </em>+107.03 &mu;g/L which resulted in a least square mean treatment difference of -342.59 &micro;g/L (95% CI: -498.30, -186.87).</p><p>&nbsp;</p><p>A total of 85% (147/173) of luspatercept responders who achieved at least a 33% reduction in transfusion burden during any consecutive 12-week interval achieved 2 or more episodes of response at the time of analysis.</p><p>&nbsp;</p><p><em>Non-transfusion‑dependent </em><em>b</em><em>-thalassaemia</em></p><p>The efficacy and safety of luspatercept were evaluated in a Phase&nbsp;2 multicentre, randomised, double‑blind, placebo-controlled study BEYOND (ACE-536-B-THAL-002) in adult patients with non-transfusion‑dependent b-thalassaemia‑associated anaemia (Hb&nbsp;concentration&nbsp;&le;&nbsp;10&nbsp;g/dL).</p><p>&nbsp;</p><p>A total of 145 adult patients receiving RBC transfusions (0-5&nbsp;RBC units in the 24-week period prior to randomization), with a baseline Hb level &le;&nbsp;10.0&nbsp;g/dL (defined as average of at least 2 Hb measurements &ge;&nbsp;1 week apart within 4 weeks prior to randomization) were randomized to receive luspatercept (N=96) or placebo (N=49) subcutaneously every 3&nbsp;weeks. Patients were stratified at randomization based on their baseline Hb level and their non‑transfusion‑dependent &beta;‑thalassaemia (NTDT) patient‑reported outcome (PRO; NTDT‑PRO) Tiredness/Weakness (T/W) weekly domain score. Dose titration to 1.25&nbsp;mg/kg was allowed. Dose could be delayed or reduced depending upon Hb level. Overall, 53% of luspatercept patients (N=51) and 92% of patients on placebo (N=45) had their dose increased to 1.25 mg/kg within the 48-week treatment period. Among patients receiving luspatercept, 96% were exposed for 6 months or longer and 86% were exposed for 12 months or longer. A total of 89 (92.7%) patients receiving luspatercept and 35 (71.4%) patients receiving placebo completed 48&nbsp;weeks of treatment.</p><p>&nbsp;</p><p>All patients were eligible to receive BSC, which included RBC transfusions, iron-chelating agents, use of antibiotic, antiviral, and antifungal therapy, and nutritional support, as needed. Concurrent treatment for anemia with blood transfusions was allowed, at the discretion of the physician, for low haemoglobin levels, symptoms associated with anemia (e.g. haemodynamic or pulmonary compromise requiring treatment) or comorbidities. The study excluded patients with Hb S/&beta;‑thalassaemia or alpha (&alpha;)‑thalassaemia or who had major organ damage (liver disease, heart disease, lung disease, renal insufficiency), active hepatitis C or B, or HIV. Patients with recent DVT or stroke or recent use of ESA, immunosuppressant or hydroxyurea therapy, or on chronic anticoagulant or uncontrolled hypertension were also excluded. Only a limited number of patients with comorbidities associated with underlying anemia such as pulmonary hypertension, liver and kidney disease and diabetes were included in the study. The key baseline disease characteristics in the Intention‑To‑Treat (ITT) population with non‑transfusion‑dependent<em> </em>b‑thalassaemia in study ACE‑536‑B‑THAL‑002 are shown in Table&nbsp;16.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:98%"><thead><tr><td colspan="3" style="vertical-align:bottom"><p>Table&nbsp;16: Baseline demographics and disease characteristics of patients with non-transfusion-dependent b-thalassaemia in study ACE‑536‑B‑THAL‑002</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>ITT population</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>Luspatercept<br />(N=96)</strong></p></td><td style="vertical-align:bottom"><p>Placebo<br />(N=49)</p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p>Demographics</p></td></tr><tr><td style="vertical-align:top"><p>Age (years)</p><p>Median (min, max)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>39.5 (18, 71)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>41 (19, 66)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Sex, n (%)</strong></p><p>Male</p><p>Female</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>40 (41.7)</p><p>56 (58.3)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>23 (46.9)</p><p>26 (53.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Race, n (%)</strong></p><p>Asian</p><p>White</p><p>Other</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>31 (32.3)</p><p>59 (61.5)</p><p>6 (6.3)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>13 (26.5)</p><p>28 (57.1)</p><p>8 (16.3)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Disease characteristics</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>&beta;</strong><strong>-thalassaemia diagnosis, n (%)</strong></p><p>&beta;-thalassaemia</p><p>HbE/&beta;-thalassaemia</p><p>&beta;-thalassaemia combined with &alpha;‑thalassaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>63 (65.6)</p><p>28 (29.2)</p><p>5 (5.2)</p></td><td><p>&nbsp;</p><p>34 (69.4)</p><p>11 (22.4)</p><p>4 (8.2)</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Baseline Hb level</strong><strong><sup>a</sup></strong><strong> (g/dL)</strong></p><p>Median (min, max)</p></td><td style="vertical-align:bottom"><p>8.2 (5.3, 10.1)</p></td><td style="vertical-align:bottom"><p>8.1 (5.7, 10.1)</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Patients with mean baseline Hb level</strong><strong><sup>a</sup></strong><strong> category (g/dL), n (%)</strong></p><p>&lt;&nbsp;8.5</p></td><td style="vertical-align:bottom"><p>55 (57.3)</p></td><td style="vertical-align:bottom"><p>29 (59.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline NTDT‑PRO T/W domain score</strong><strong><sup>b</sup></strong><strong>, n (%)</strong></p><p>Median (min, max)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>4.3 (0, 9.5)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>4.1 (0.4, 9.5)</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Baseline NTDT-PRO T/W domain score</strong><strong><sup>b</sup></strong></p><p><strong>category, n (%)</strong></p><p>&ge;&nbsp;3</p></td><td style="vertical-align:bottom"><p>66 (68.8)</p></td><td style="vertical-align:bottom"><p>35 (71.4)</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Baseline transfusion burden (units/24&nbsp;weeks)</strong></p><p>Median (min, max)</p></td><td style="vertical-align:bottom"><p>0 (0, 4)</p></td><td style="vertical-align:bottom"><p>0 (0, 4)</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Splenectomy, n (%)</strong></p><p>Yes</p></td><td style="vertical-align:bottom"><p>&nbsp;</p><p>34 (35.4)</p></td><td style="vertical-align:bottom"><p>26 (53.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>MRI LIC (mg/g dw)</strong><strong><sup>c</sup></strong><strong>, n</strong></p><p>Median (min, max)</p></td><td style="vertical-align:top"><p>95</p><p>3.9 (0.8, 39.9)</p></td><td style="vertical-align:top"><p>47</p><p>4.1 (0.7, 28.7)</p></td></tr><tr><td style="vertical-align:top"><p><strong>MRI spleen volume (cm<sup>3</sup>), n</strong></p><p>Median (min, max)</p></td><td style="vertical-align:top"><p>60</p><p>879.9</p><p>(276.1, 2419.0)</p></td><td style="vertical-align:top"><p>22</p><p>1077.0</p><p>(276.5, 2243.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline use of ICT, n (%)</strong></p></td><td style="vertical-align:top"><p>28 (29.2)</p></td><td style="vertical-align:top"><p>16 (32.7)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline serum ferritin (</strong><strong>&mu;</strong><strong>g/L)d</strong></p><p>Median (min, max)</p></td><td style="vertical-align:top"><p>456.5 (30.0, 3528.0)</p></td><td style="vertical-align:top"><p>360.0 (40.0, 2265.0)</p></td></tr></tbody></table><p>Hb = haemoglobin; HbE = haemoglobin E; ICT = Iron Chelation Therapy; LIC = liver iron concentration; max = maximum; min = minimum; MRI = magnetic resonance imaging; NTDT-PRO T/W = non-transfusion-dependent &beta;-thalassaemia patient-reported outcome tiredness and weakness domain score;</p><p><sup>a</sup> Mean of at least 2&nbsp;Hb values by the central laboratory during the 28-day screening period.</p><p><sup>b</sup> Baseline defined as the average of non-missing NTDT-PRO T/W domain score over 7 days before Dose 1 Day 1.</p><p><sup>c</sup> The value of LIC was either the value collected from the electronic Case Report Form (eCRF) or the value derived from T2*, R2*, or R2 parameter depending on which techniques and software were used for MRI LIC acquisition.</p><p><sup>d</sup> Baseline mean serum ferritin was calculated during the 24 weeks on or prior to Dose 1 Day 1. Baseline ICT was calculated during the 24 weeks on or prior to Dose 1 Day 1.</p><p>&nbsp;</p><p>The efficacy results are summarised below.</p><p>&nbsp;</p><p><strong>Table&nbsp;17: Efficacy results in patients with non-transfusion‑dependent<em> </em></strong><strong>b-</strong><strong>thalassaemia in study ACE‑536‑B‑THAL‑002</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>ITT population </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:bottom"><p><strong>Luspatercept</strong><br /><strong>(N=96)</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo<br />(N=49)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Primary endpoint</em></strong></p><p><strong>&nbsp;Increase from baseline &ge;1.0 g/dL in mean Hb over continuous 12-week interval (in absence of transfusions)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp; <strong>Weeks 13-24</strong></p><p>Response rate<sup>a</sup>, n</p><p>[(%) (95% CI)]<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>74</p><p>[(77.1) (67.4, 85.0)]</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.0</p><p>[(0.0) (0.0, 7.3)]</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>c</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt; 0.0001</p></td></tr></tbody></table><p>CI = confidence interval; Hb = haemoglobin</p><p><sup>a </sup>Defined as number of patients with &ge; 1.0 g/dL Hb increase in the absence of RBC transfusion compared to baseline (i.e. the average of &ge;2 Hb measurements at &ge; 1 week apart within 4 weeks before Dose 1 Day 1).</p><p><sup>b</sup> The 95% CI for response rate (%) was estimated from the Clopper-Pearson exact test.</p><p><sup>c</sup> The odds ratio (luspatercept <em>vs.</em> placebo) with 95% CI and p-value were estimated from the CMH test stratified by baseline Hb category (&lt;8.5 <em>vs.</em> &ge; 8.5 g/dL) and baseline NTDT-PRO T/W domain score category (&ge; 3 <em>vs.</em> &lt; 3) defined at randomization as covariates.</p><p>Note: Patients with missing Hb at Weeks 13‑24 were classified as non-responders in the analysis.</p><p>&nbsp;</p><p>A total of 77.1% of luspatercept treated patients achieved an increase from baseline &ge;&nbsp;1.0 g/dL in mean Hb over continuous 12-week interval (in absence of transfusions) (Weeks 13-24). This effect was maintained in the 57.3% of patients who reached Week 144 of treatment.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p><em>Myelodysplastic</em><em> </em><em>syndromes</em></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Reblozyl in all subsets of the paediatric population in myelodysplastic syndromes (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p><p><em>b</em><em>-thalassaemia</em></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Reblozyl in one or more subsets of paediatric population older than 6 years of age in b-thalassaemia (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>In healthy volunteers and patients, luspatercept is slowly absorbed following subcutaneous administration,&nbsp;with&nbsp;the Cmax in serum often observed approximately 7 days post-dose across all dose levels. Population pharmacokinetic (PK) analysis suggests that the absorption of luspatercept into the circulation is linear over the range of studied doses, and the absorption is not significantly affected by the subcutaneous injection location (upper arm, thigh or abdomen). Interindividual variability in AUC was approximately 37% in b-thalassaemia and MDS patients.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>At the recommended doses, the geometric mean apparent volume of distribution was 9.57 L for MDS patients and 7.26 L for b-thalassaemia patients. The small volume of distribution indicates that luspatercept is confined primarily in extracellular fluids, consistent with its large molecular mass.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Luspatercept is expected to be catabolised into amino acids by general protein degradation process.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Luspatercept is not expected to be excreted into urine due to its large molecular mass that is above the glomerular filtration size exclusion threshold. At the recommended doses, the geometric mean apparent total clearance was 0.47 L/day for MDS patients and 0.44 L/day for &beta;-thalassaemia. The geometric mean half-lives in serum were approximately 14 days for MDS patients and 11 days for b-thalassaemia patients.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p>The increase of luspatercept Cmax and AUC in serum is approximately proportional to increases in dose from 0.125 to 1.75 mg/kg. Luspatercept clearance was independent of dose or time.</p><p>&nbsp;</p><p>When administered every three weeks, luspatercept serum concentration reaches the steady state after 3 doses, with an accumulation ratio of approximately 1.5.</p><p>&nbsp;</p><p><u>Hb response</u></p><p>In patients who received &lt; 4 units of RBC transfusion within 8 weeks prior to the study, Hb increased within 7 days of treatment initiation and the increase correlated with the time to reach luspatercept Cmax.&nbsp;The greatest mean Hb increase was observed after the first dose, with additional smaller increases observed after subsequent doses. Hb levels returned to baseline value approximately 6 to 8 weeks from the last dose (0.6 to 1.75 mg/kg). Increasing luspatercept serum exposure (AUC) was associated with a greater Hb increase in patients with ESA refractory or -intolerant MDS or b‑thalassaemia.</p><p>&nbsp;</p><p>In non-transfusion-dependent &beta;‑thalassaemia patients who had a baseline transfusion burden of 0 to 5&nbsp;units within 24&nbsp;weeks, increasing luspatercept serum exposure (time-averaged AUC) was associated with a greater probability of achieving a Hb increase (&ge;&nbsp;1&nbsp;g/dL or &ge;&nbsp;1.5&nbsp;g/dL) and a longer duration of such Hb increases. The luspatercept serum concentration achieving 50% of the maximum stimulatory effect on Hb production was estimated to be 7.6&nbsp;&mu;g/mL.</p><p><u>&nbsp;</u></p><p><u>Special</u><u> </u><u>populations</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>Population PK analysis for luspatercept included patients with ages ranging from 18 to 95 years old, with a median age of 72 years for MDS patients and of 33 years for b-thalassaemia patients. No clinically significant difference in AUC or clearance was found across age groups in MDS patients (&lt; 65, 65-74, and &ge; 75 years) or in b‑thalassaemia patients (18 to 71&nbsp;years).</p><p>&nbsp;</p><p><em>Hepatic</em><em> impairment</em></p><p>Population PK analysis for luspatercept included patients with normal hepatic function (BIL, ALT, and AST &le; ULN; N=373), mild hepatic impairment (BIL &gt; 1 &ndash; 1.5 x ULN, and ALT or AST &gt; ULN; N=216), moderate hepatic impairment (BIL &gt; 1.5 &ndash; 3 x ULN, any ALT or AST; N=189), or severe hepatic impairment (BIL &gt; 3 x ULN, any ALT or AST; N=74) as defined by the National Cancer Institute criteria of hepatic dysfunction. Effects of hepatic function categories, elevated liver enzymes (ALT or AST, up to 3 x ULN) and elevated total BIL (4 &ndash; 246 mmol/L) on luspatercept clearance were not observed. No clinically significant difference in mean steady state Cmax&nbsp;and AUC was found across hepatic function groups. PK data are insufficient for patients with liver enzymes (ALT or AST) &ge; 3 x ULN. No PK data are available for patients with liver cirrhosis (Child-Pugh Classes A, B and C) as no dedicated study was performed.</p><p>&nbsp;</p><p><em>Renal</em><em> </em><em>impairment</em></p><p>Population PK analysis for luspatercept included patients with normal renal function (individual eGFR &ge; 90 mL/min; N=471), mild renal impairment (individual eGFR 60 to 89 mL/min; N=278), or moderate renal impairment (individual eGFR 30 to 59 mL/min; N=93) as defined by Modification of Diet in Renal Disease (MDRD) formula. Luspatercept steady-state serum exposure (AUC) was&nbsp;24% to 41% higher in patients with mild to moderate renal impairment than in patients with normal renal&nbsp;function.&nbsp;PK data are insufficient&nbsp;for patients with severe renal impairment (individual eGFR &lt; 30&nbsp;mL/min) or end-stage kidney disease.</p><p>&nbsp;</p><p><u>Other intrinsic factors</u></p><p>The following population characteristics have no clinically significant effect on luspatercept AUC or clearance: sex and race (Asian <em>vs.</em> White).</p><p>&nbsp;</p><p>The following baseline disease characteristics had no clinically significant effect on luspatercept clearance: serum erythropoietin level (2.4 &ndash; 2920 U/L), RBC transfusion burden (0 &ndash; 43 units/24 weeks), MDS ring sideroblasts, &beta;-thalassaemia genotype (&beta;0/&beta;0 <em>vs.</em> non-&beta;0/&beta;0) and splenectomy.</p><p>&nbsp;</p><p>The volume of distribution and clearance of luspatercept increased with increase of body weight (33 &ndash; 124 kg), supporting the body weight-based dosing regimen.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Single and repeat-dose toxicity</u></p><p>Following repeated administration of luspatercept in rats, toxicities included: membranoproliferative glomerulonephritis; congestion, necrosis and/or mineralisation of the adrenal glands; hepatocellular vacuolation and necrosis; mineralisation of the glandular stomach; and decreased heart and lung weights with no associated histology findings. A clinical observation of swollen hindlimbs/feet was noted in several studies in rats and rabbits (including juvenile and reproductive toxicity studies). In one juvenile rat, this correlated histopathologically with new bone formation, fibrosis, and inflammation. Membranoproliferative glomerulonephritis was also seen in monkeys. Additional toxicities in monkeys included: vascular degeneration and inflammatory infiltrates in the choroid plexus.</p><p>&nbsp;</p><p>For the 6-month toxicity study, the longest duration study in monkeys, the no-observed-adverse-effect level (NOAEL) was 0.3 mg/kg (0.3-fold of clinical exposure at 1.75 mg/kg every 3 weeks). A NOAEL was not identified in rats and the lowest-observed-adverse-effect-level (LOAEL) in the rat 3-month study was 1 mg/kg (0.9-fold of clinical exposure at 1.75 mg/kg every 3 weeks).</p><p><u>&nbsp;</u></p><p><u>Carcinogenesis and mutagenesis</u></p><p>Neither carcinogenicity nor mutagenicity studies with luspatercept have been conducted. Haematological malignancies were observed in 3 out of 44 rats examined in the highest dose group (10 mg/kg) in the definitive juvenile toxicity study. The occurrence of these tumours in young animals is unusual and the relationship to luspatercept therapy cannot be ruled out. At the 10 mg/kg dose, at which tumours were observed, the exposure represents an exposure multiple of approximately 4 times the estimated exposure at a clinical dose of 1.75 mg/kg every three weeks.</p><p>&nbsp;</p><p>No other proliferative or pre-neoplastic lesions, attributable to luspatercept, have been observed in any species in other non-clinical safety studies conducted with luspatercept, including the 6-month study in monkeys.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>In a fertility study in rats, administration of luspatercept to females at doses higher than the currently recommended highest human dose reduced the average number of corpora lutea, implantations and viable embryos. No such effects were observed when exposure in animals was at 1.5 times the clinical exposure. Effects on fertility in female rats were reversible after a 14-week recovery period.</p><p>&nbsp;</p><p>Administration of luspatercept to male rats at doses higher than the currently recommended highest human dose had no adverse effect on male reproductive organs or on their ability to mate and produce viable embryos. The highest dose tested in male rats yielded an exposure approximately 7 times the clinical exposure.</p><p>&nbsp;</p><p><u>Embryo-foetal development (EFD)</u></p><p>Embryo-foetal developmental toxicology studies (range-finding and definitive studies) were conducted in pregnant rats and rabbits. In the definitive studies, doses of up to 30 mg/kg or 40 mg/kg every week were administered twice during the period of organogenesis. Luspatercept was a selective developmental toxicant (dam not affected; foetus affected) in the rat and a maternal and foetal developmental toxicant (doe and foetus affected) in the rabbit. Embryofoetal effects were seen in both species and included reductions in numbers of live foetuses and foetal body weights, increases in resorptions, post-implantation loss and skeletal variations and, in rabbit foetuses, malformations of the ribs and vertebrae. In both species, effects of luspatercept were observed in the EFD studies at the lowest dose tested, 5 mg/kg, which corresponds to an estimated exposure in rats and rabbits of approximately 2.7 and 5.5 times greater, respectively, than the estimated clinical exposure.</p><p>&nbsp;</p><p><u>Pre- and post-natal development</u></p><p>In a pre- and post-natal development study, with dose levels of 3, 10, or 30 mg/kg administered once every 2 weeks from gestational day (GD) 6 through post-natal day (PND) 20, adverse findings at all doses consisted of lower F1 pup body weights in both sexes at birth, throughout lactation, and post weaning (PND 28); lower body weights during the early premating period (Weeks 1 and 2) in the F1 females&nbsp;(adverse&nbsp;only at the 30 mg/kg/dose) and lower body weights in F1 males&nbsp;during the premating, pairing and post-mating periods; and microscopic kidney findings in F1 pups. Additionally, non-adverse findings included delayed male sexual maturation at the 10 and 30 mg/kg/dose. The delay in growth and the adverse kidney findings, in the F1 generation,&nbsp;precluded the determination of a NOAEL for F1 general&nbsp;and&nbsp;developmental&nbsp;toxicity.&nbsp;However, there was no effect on behavioural indices, fertility or reproductive parameters at any dose level in either sex, therefore the NOAEL for behavioural&nbsp;assessments,&nbsp;fertility&nbsp;and reproductive function in the F1 animals&nbsp;was considered to be the 30 mg/kg/dose. Luspatercept is transferred through the placenta of pregnant rats and rabbits and is excreted into the milk of lactating rats.</p><p>&nbsp;</p><p><u>Juvenile toxicity</u></p><p>In a study in juvenile rats, luspatercept was administered from postnatal day (PND) 7 to PND 91 at 0, 1, 3, or 10 mg/kg. Many of the findings seen in repeat-dose toxicity studies in adult rats were repeated in the juvenile rats. These findings included glomerulonephritis in the kidney, haemorrhage/congestion, necrosis and mineralization of the adrenal gland, mucosal mineralization in the stomach, lower heart weights, and swollen hindlimbs/feet. Luspatercept-related findings unique to juvenile rats included tubular atrophy/hypoplasia of the kidney inner medulla, delays in the mean age of sexual maturation in males, effects on reproductive performance (lower mating indices), and non- adverse decreases in bone mineral density in both male and female rats. The effects on reproductive performance were observed after a greater than 3-month recovery period, suggesting a permanent effect. Although reversibility of the tubular atrophy/hypoplasia was not examined, these effects are also considered to be irreversible. Adverse effects on the kidney and reproductive system were observed at clinically relevant exposure levels and seen at the lowest dose tested and, thus, a NOAEL was not established. In addition, haematological malignancies were observed in 3 out of 44 rats examined in the highest dose group (10 mg/kg). These findings are all considered potential risks in paediatric patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Citric acid monohydrate (E330)</p><p>Sodium citrate (E331) Polysorbate 80</p><p>Sucrose</p><p>Hydrochloric acid (for pH adjustment)</p><p>Sodium hydroxide (for pH adjustment)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial 5 years.

After reconstitution
When stored in the original container, chemical and physical in-use stability of the reconstituted medicinal product has been demonstrated for up to 8 hours at room temperature (≤ 25°C) or for up to 24 hours at 2°C - 8°C.

From a microbiological point of view, the medicinal product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2°C - 8°C.

Do not freeze the reconstituted solution.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C - 8&deg;C). Do not freeze.</p><p>Store in the original carton in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Reblozyl 25 mg powder for solution for injection</u></p><p>3 mL Type I glass vial with a hydrophobic inner coating closed with a bromobutyl rubber stopper and aluminium seal with yellow polypropylene flip-off cap.</p><p>&nbsp;</p><p><u>Reblozyl 75 mg powder for solution for injection</u></p><p>3 mL Type I glass vial with a hydrophobic inner coating closed with a bromobutyl rubber stopper and aluminium seal with orange polypropylene flip-off cap.</p><p>&nbsp;</p><p>Pack size: 1 vial</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reblozyl must be reconstituted gently prior to administration. Aggressive shaking should be avoided.</p><p><u>Reconstitution of the product</u></p><p>Reblozyl is supplied as a lyophilised powder for reconstitution before use. Only water for injections (WFI) should be used when reconstituting Reblozyl.</p><p>&nbsp;</p><p>The appropriate number of Reblozyl vials should be reconstituted to achieve the desired dose. A syringe with appropriate graduations must be used for reconstitution to ensure accurate dosage.</p><p>&nbsp;</p><p><u>The following steps should be followed for reconstitution:</u></p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the coloured cap from the vial and wipe the top with an alcohol wipe.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Reblozyl 25 mg powder for solution for injection</u></p><p>Add 0.68 mL WFI into the vial by means of a syringe with appropriate graduations with a needle directing the flow onto the lyophilised powder. Allow to stand for one minute. Each 25 mg single-dose vial will deliver at least 0.5 mL of 50 mg/mL luspatercept.</p><p>&nbsp;</p><p><u>Reblozyl 75 mg powder for solution for injection</u></p><p>Add 1.6 mL WFI into the vial by means of a syringe with appropriate graduations with a needle directing the flow onto the lyophilised powder. Allow to stand for one minute. Each 75 mg single-dose vial will deliver at least 1.5 mL of 50 mg/mL luspatercept.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discard the needle and syringe used for reconstitution. Do not use them for subcutaneous injection.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently swirl the vial in a circular motion for 30 seconds. Stop swirling and let the vial sit in an upright position for 30 seconds.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inspect the vial for undissolved powder in the solution. If undissolved powder is observed, repeat step 4 until the powder is completely dissolved.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Invert the vial and gently swirl in an inverted position for 30 seconds. Bring the vial back to the upright position and let it sit for 30 seconds.</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Repeat step 6 seven more times to ensure complete reconstitution of material on the sides of the vial.</p><p>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visually inspect the reconstituted solution prior to administration. When properly mixed, Reblozyl reconstituted solution is a colourless to slightly yellow, clear to slightly opalescent solution which is free of visible foreign particulate matter. Do not use if undissolved product or foreign particulate matter is observed.</p><p>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the reconstituted solution is not used immediately, see section 6.3 for storage conditions.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bristol-Myers Squibb Pharma EEIG Plaza 254
Blanchardstown Corporate Park 2 Dublin 15, D15 T867
Ireland

MARKETING AUTHORISATION NUMBERS
Reblozyl 25mg: 0109211004
Reblozyl 75mg: 0109211003

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2024
Approved by SFDA on 26 Nov 2024

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="data:image/jpg; base64,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&#x2B;xsCJLikrliIhiJu0BHf/IS&#x2B;GH2kKNvyAX27h&#x2B;v5Dm3uHC2QBpJTAtwEuZERwAc8P6h2cx72EcfQb7gR34ELt9irsWU&#x2B;4GV6Bv1LCiErj0QByk5ZErXLD7F8sgSJe/3EXm&#x2B;/csQN3dgZt6&#x2B;0lSu3HF7j3RfcCT6rclVFFa8tTt6stko2gRw0BFTFvM49xEbfY15URpw7fQBMbBsTG42coCS&#x2B;48rjfcXm/0L7oDMMNObv7Goa&#x2B;REnyBEo4LDm4id0IlAVPuyekclkQluwJbuSDUf0yK6dwJ5bSXYsQrx7wTe8fQBEXFx5eEGrxAEhNCFyvsPmVQtwIlNxEWKlO4t/kBH7sXLAXeQIX2QD/qwDzdxvsL7MWjf2AXF3shfZxAcLYBtx9RzvBfLFvqLz5pAil7MVLuitd0TgCOlKwi8xwaj&#x2B;oENgZjkJFaStyIgCRyI5ZUo3RfL/TAzBXsVpq0D5ATYXG02FuAIm0W3P5BpiAJC7BLsVejFp/MCNeghdiw4EQBIXAbbLFifIAGrhooEgbFiWI7AZ/rYst7FjgJPhkEUq4LC7j6AFD3ZIvcvMJiG7yUSCNS/kW0CL2IDXoVT8haQvYCRBRDgIgjuRqWahCJKMOn1YVKdmjUepfLG5BjyIsLg00I9SbjMW5&#x2B;Yj1fyZYXYRewGfL/lcJJ7mkrQIII0luvsTdQoNQiNARq0JfYjpspRri4iLgZ8qngsL0&#x2B;hWpspEXkCQp2&#x2B;4i7geVJFs7JAS3KnsPkWEI9AMuQlw0WOB5WBIUXQt39mI8ziS1duEBJv8x8g1zEFfdgI9CeXsitpPfYiXHID3RYe8fYRay&#x2B;QhxKAiU2bgfaTV9pHP&#x2B;YESs4fzEKNytcX9x6NASO5Y9fYbIOGpAJ3tb5EiZZeVBLcAIi6J5Zumyq3JfkBEqpuxKfqW6EW2Alpv2Ir2NOzRIhWQEhcPYkW2&#x2B;ZqJFSW6AiRUn3CXEhXhwAd7fmIUyWI2XyD9V9gI0neOdhaS78iPkAlPsZ&#x2B;RYX9MsLmwGfZBUptMt/uElxACFP8i72mIHqImzAPsrB&#x2B;u/oWERgS&#x2B;yD9yx2EXsBIezEtXkRwhDiwF9iVK0MQ&#x2B;GN7ANldB7bfYvl9A99gEtuOxGpuV9oEcQBl09i0rmfuVqLsQoAkRyVJja1ygSLyGu5RuBl0zaN2PKlMJFgNeoESpXH2KoHMtCCBPdPcTe4c7DcApuX1RN7FATI43EcD2AnzCTCmS3KJCfH2JCi38jXqOAMwtm5LBbBEEvIi8LYtuwanYDLTl3XsVbwiwuABLIKYuWLhIgkJ8IQk7FS7CCjPlhbB73NJQIgSMwk5hfQNJOVBVZbBzF0BIaUE32&#x2B;6NNWlCG7MDLvuVKbyVLlsLsQIvJd&#x2B;QwgI32H&#x2B;Et&#x2B;4WwEcchLiSxeQUSGuLkdrtmoHAGb7fkPLuypdyqwESEFgQQRuERruaaD7AYdLS2CpfyNQ9&#x2B;REL&#x2B;ABTO/I43&#x2B;5RE7oQM&#x2B;xbtFi8j0QyBlqdkaSuIQGfLaGuCeVbwbjuAM&#x2B;WbfxJCN&#x2B;XuSOyAz5XshCiTUciO1QgTa8D92z&#x2B;gavcqUL&#x2B;AEiePsRpf5GntCH8EBmOEhSvUqSiy&#x2B;5UodgF43DsUARqeESGv8AQtvcRcAnLJfd2LHCKkQZa7MkLubgRwBlJzZlW0pBgoP0I0uEW4SXBNhPLxBPJff7mn&#x2B;Qfdr6gZXZv3LDSb7lgrUgcm/BHtc0RyznEbT2e24hxsVpMiQARwI2/kWwE8q5EFAEu7NB2NbkAm4fqywEBI7CH3LAU8sCeW0IJWsyiOACiIQQAAjZY4aEASH2JeditX/iI5/gAVnv8gInkJfYBCSv9RBRYCeqQ4t&#x2B;RWGpAy4TlIq23EdvoPKuUgJFoZflwEuGWLbATiIHuixIjuBmGrL7j0ZqyJ68gSGtmxs5n0L8hFwEOdkTmJLASjkCeie/oFHsVtSLJRAEi4W8fwLEBeYCWn&#x2B;Ij0K1ezI&#x2B;FIBruLp25Lz6dmLRK&#x2B;gEXpHoLcFXeAlbtIGUlN/qVq3cvaURUxeAEW7fIcxBWnFncQ4AdouS744LH9MLdsA1bf5EUwWO/PA2uwJD7e44iSpJ8j6bARIm3&#x2B;ZYhwy7ASy9fQtkpT4DhuCr2AnMLuRpbMrHzAkIR3Kto9RF78gT0iwhbstoSHIE8t7MKeF9C7PbcNARCP8AUQ/mITe23ACOAkpshx&#x2B;clXcCPckdium1n9SxygM&#x2B;33LF/mHs0lPcsEEidhEwVRuRNO6AQ4DTi5YvtYf1uUSFvyH7FiNkHvDQEXZ7TckLeTW7mRfncCc2Qa4LHLHv2IJEsbchIRFMPYdQfoH6hw7lW8x9CbCLYRtcrQe159wJFuPUX52Ep/zD9vmQR72Dtu&#x2B;S7WC&#x2B;4EdmIaC2geVr&#x2B;JAhdxHqWG1CZIaewEsILsGo3AkINFiXYP1AzF5EJFEcwBIvIVJfYsegGYUQhHdcmon&#x2B;Ia7AZj0CVywGpAlxHCRQBPWCRL7Go9SJcoBdKBFoL6gCNPhj2RXPcAEI7lSkNeoGXMFaA2AlkHG&#x2B;xQ1AEv7QVKAIABlERZsDLU7iOxrmxIAjSmRfgo9gJH9SIUQWw9ACUAQVqEBCbbIoYGYcwn9iw0yqRF5AjurCO1iwInYCKeAlz9SwEA&#x2B;YLzccbgQRHBSQBPZC&#x2B;6KIIIo&#x2B;ovMMsLlFS7ASBBY4F0USPUexYj5Dm6Agi9wwiCJFBUm7FDcj3LEbBRzYgkciC7XgNcR9wJCYiCu7HyAghrgsPkWs5AkMQasyQ3wOoiQa4ZUuwYEgRKkvuWLjqM7Fa5kPy8iEBC8SEuF2K7ICcuC23I77fkX2AjS3QgsKB7L7gSzESVqbIReGBF7ByiqHuhPb6EEhdxFwkuWGoQEDRXvsAJEoQXew3uBAai0iIUeo7iR3IXyldO/8wMwH6li0IPewD0aIWOzEWkBtZkLu7DZyUGoERsxDixUmnf5kzkSO4ulM7l93x2EPlFgTmRE8i9JVuQSOPURzsWLWDUXS5Ai3ETBY9SJ&#x2B;g6Ak3sIgWnYq/hYmBA4m7L5fQNOJGBkvzESglexRN&#x2B;BD2gvMiIVkBIBWmi&#x2B;jQGR8ixOwixBGu4hFSc/mFHBRILbkRNk7B/1cgb8ELC5LEuF8yjMegKnG4gCIMR6F53IFuUI2bLtz9iWgA0tyQahpi0OwEfuQ0k4mSWAkEixqNkFuBIDVrl2EAckw5gJBpthJvY5wXqTa5dnDY32QE9Ruy73CvugC9At7hrlDgBxYRBVZ33IwIxuWysPcAybXRX6sJLkCQw/QsRyOdgIn6BFS/wAxAEe8wIksW3D4YEhAvl9PkRrv9AAEQV7yBAiw4kgAAWAm/JUpC7QX1AnoH6FuF2AggrmbDdgRr1EMvGxLgORHcsLf7CHugJFybTbYrUACNhzwWLfmIXcAkAX2AhN7lEASIuhfbco9gI5Dh8lAD1DUiPURyBGo2Q22LAaARaAp3Yi8CEmA5EBKdi2AkTyAWAMwleRs9ywSO4Df6lj1AARzAgqX&#x2B;hPZASI5LACvsAEQI5K33AgLFpIBLj1jcJWiCoCJJuexYjYJINARbQiwWI3kgDckcyWA53QAkTuWHEiAAQ&#x2B;QACOxUNv5gRwSL7moIA5I1wWLwh8iSAS5ZYYgCQSHMlgQBIDtwVqBHJOwjVw72LuIkbCRe25Hfg0Sy3MRPK3yGuWV9xD7gSVt/EPtH1Kkt5F1uBnaLqxYjgeu4f8AEBCeyDUKy5D3vuF82BEp9haCtWEXAi2uxd7yV3sEnABR/OxF3jYtoj7BzEfxAnuI7D5D7ATcFDlKGgJDiYKLxLZUm7pgZLDLfaSP2i9wCmRHcJP/AEKp3Ajc2/iX9mbfYJTZMW&#x2B;qAj7/AFECIV0VJTuBLpCFul7ldlKfsFZWAiU2TCtx9yw27oRN0gETySWt&#x2B;UXsheboCRe4drbe5f2oHo19AJHoISs2VqH8&#x2B;xVZgZhNCCw&#x2B;H9iQt/yAR6CJX8itJ2nm45uBEu/3EFanftwEu31AkKdwkpiS&#x2B;WVKCfdkEh8PYT3ZX6P3FNL3KJvdi&#x2B;xqfcjUrf7ECLyIfKuGrC0QBN9g&#x2B;6K4mwiLJARL1ERwVK1185ERuxtIjKkojt2HrH1KlfcdAtuyej&#x2B;RXIallGfVhKeCxNkgl6EEdtxD7FiEI9PYdxIllXaBvuWY4sBIiwU7Nyi8x69hbaQJDVmIm4jslIalwuPUA0pj7C3Fx7BSAagW4/IbJJdixyx1ESi637Bq1r&#x2B;4skXmG/qBGm1&#x2B;6HGxflIUJEEtECLyWEtkif1JdsCR35Kl&#x2B;ZUu4iOSQIl3Qc8osdw4f&#x2B;gEc8lvNxvuhyIDiWvqItDgc3LyXuI7e424FhzJIEV7l5mPmIlQWCjL9g0phsqXItNiCRLuh7FSQhvgCQ1LT9xEuSvfgjVwCT5RYtAXcNNvcAyReUyv1CHUSGg1G7NQRwrgZSvtJb/6hqOwa4HQG2lsEp4LC7iIuNxNueS7KZEMq2sMieqRH6mrO5I7sZEgTD2LtYNSoAJd/lAXYRAjggk2gPtJqLkalyURb2Q53&#x2B;Ul2QjuQSE/8ix3L8gUTy9yL2g1AIM&#x2B;XjYu1ipCO4yMxe25Ye3BWR9oLAiU7oR2&#x2B;pYvdjmIGwiXM7CLxuX3QajZDoJxdbljloLsIuQTyp3XzFoktgu0WAUzHzsR3UplSiwa9QI1MiODUepIjkCJceohSVw9gBOLJlSS2LsPQDPKqkRbexY9PoONwI6UrC8ljnuNgJ6N/IKJksLckJu31A21w2I7la9RCW1znCHwhDlx&#x2B;QmLMKXdAEnAWysItDUFccASJahh9/4Br09wncBHcObwF7C6AkQ9wky7u/2RI7AWO79yRvD&#x2B;xVLcpl23AlufyJC2hF5iFsJm4EfqPRlt/Mi9gFuxYQURYLf27gFdWfykeXhhTO4cTcCX4HMMt43&#x2B;YiVZAS/KDUuOStLeSOXaPoAiwi0li8yRJ8AIvBPc1D7Dy&#x2B;oE3uxxt9y3ifyG10rAS6UB3LEO4/pARJu&#x2B;4jg1EbkSe6fyAi9tx7lTu7CJ3YE3iQ13YidxaYfzAJTyEo5Rd/qSz2AJPsIRUo5Dh/stMDN9hsaaTuTa38AEdiL07lUqw52AnzFo/wAi&#x2B;zEXSgB7iLwg0kPcCQytQ7XENcCIQBK1mVbXQiXOwbe0AR9uwSadi83YcwA2siFewb7gTkLsixCDh9gI1Aj1K7ciF7ARJWuEufoHNiu1pAjS/wBSxFhK&#x2B;QajYCQ9g/UNtKEVpgSPQPsWPUJPYDJUhxdlTjncCJJqwhPcqXyDadwJHMli&#x2B;0CbWHsBI4EWLEKENmBItcu8R9ApXMCLygI12Q&#x2B;ZWmnLDtsBIU22kRZPuVd0EpuwI1A4tsWHEl33QGd/r2Hl4NQnuIi8EGbrdjdyWPmIAkBL6FaELYCNPuhDFiq&#x2B;wESbsI7/AHNL&#x2B;rkaUkkSO7EFbm8iI3RiMxIjsacfvJk4Aj9CTa35FEcgT2DXZlabQ9wI43C7zuIdy8gRJREDgR2HIE2cBwW0/MPcBC3RGvWYLzPcR&#x2B;YEjn8gt4geq/MsPv8AQCbL1kNBr0LCkCbWSG1wpb7BX7gGk9uwuWHuFLQEVuAky3Ym8Igl1PcRKgsc9icz&#x2B;ZQi6XqVJQLqYEd3BMiNWidi22jfYOd&#x2B;42uUGryvzJ6Ir9Bd3TIJDjb2HZNcF3n3HzKJtyIbVypTugpm5BN7wVudvqItuIYD0ETcsCAMwWOfQP1C3uAjlsR6BJdigRr3D3KyewCIQG7LvuBN7dg9ywTe5Ai2wX/SF5ouItYokcwiynyVzwR2uwELcPe32DvaCgTnYe&#x2B;4a9h8gLfgfIABFtyc7oseggCRLkCGVWsQTmHyWAWORkSA1yI7lajkdBm4ff8AIrVyOdpKEdl7B9ipdhBOgjfZi3JY4AEtIj1&#x2B;xY9CQ3K4KFyiLAgRBI7WKLgI9QBuAiQXmSDIR3ALAEYt3EbXEQAAgqgdRIBUn2I&#x2B;0gIEeo9GW20ASBYtpDT4W4EixL7FHuAuIKo5IQBHoLcFKJAjkblXcgjQgvuh7gQJcFYUdywJHKEGoXBORsJAahlgR3IJAKyFBAoUbTuQSAy/INxa3yAkd0ItJXsIlTHuO4gK3YjQAD0ACEixyPQjT5AsEjkvISfCAiXbkFVtw7gS4hCC87gSAW3cQ9o5AkPcNFW45gCCJuWy45HzAkArnkjcgSI2LCAACOSwPmQSBHJdrpjYokJCC27EaII1IXuUqVpkDUXkRba5USEt&#x2B;DYB0qCbymysPuAiHPAU9iP0VoKncBs77ktMiJ52e4UJuFsAUv8AzKqm3BFvsVp7MCXdmEmlDK95CvdoCTw2PWCk/pAW0xBN7l57khJOwCHH8BxsGu7LLAnqxtuHC2Hl7ANnFmE4sw1aXv6F/rcCXmyQuphliGH6gSGnsNluivu0IuBI48v0EKbiL7fUrd9wIublttsPkX3Ay9rsKl8o1YnIEi3y3Kw7u3AUcAHEeaAlumxdMSk4/iBNnv8AUNTa6kNpWn5C725ARbbYf1BXuFPYBFrEibMsJOPoTmyAsTdj3QmSgS0hqH/EXQ/a2YEnmOdxZuIkrptYm8wgDULYQVK8sRyBI7hp7lnsHKSSQEtw7C/b5lab3C3ANWsGk7piEx6oCeqC7qEWJciLeUCWEc&#x2B;hWuP4C3ICYI16&#x2B;5bJ7BL0AnKgc&#x2B;pp7E5uAvtAaXI2JN5j5gJ9Lh35LabkiwBR8wt5/iVKHsFe4ESezLD7F9USOyAcQyO7gsTIjvyBLbcCbx3RqCejYE9PzChfPuX2Qv3AQpsglaX8wkuwSmGwDtYesC4amwC87hSFPMliQJE7iLXKIAEa4KyQAiwhbh&#x2B;5QJDbkRJX2HsgM7WQdtiu4iVDAkNW5Hsix6j1bIEcJhRwGkHbbggnHISlbe5WlG4fZEEiZhfYjX&#x2B;Zrj&#x2B;ZHb5epBLDcrX9QEkBmBsafouQ1YDIgRG5YYE&#x2B;ZJ7o0kuSACb7FAEgL3KIAR6gfIANiWjcofZgRew33HqWOQI1N0Gi7AgzEqNyw44GxV7ARptwNixaESAC7i0l&#x2B;QSkDMRcquWOBHqAuIHyAAqp7hQEnIEh9g0nYrs7sNXHcQF32QSHYSCR2NcE3EByBD3BADsIAAMsWt3IUEAtwAED3L7iRIjkD5FhoCQCxyvqNgI7F4lAvllK4GQVqCQQCpQx7iXxA7hwSCveGwkMCQILEbF8s7ATm4Ti6K55J2EASPUrsXeZXuMDJY4kRDDXyAKQ01csRtYJWlDIlu31D7MNKbcliFPqIE4FtxzdBwlCkCbF&#x2B;QhCL3Re4PcluxY5m4SlbEgQNOYLHYRGxOwjLz8hISc7FB&#x2B;oixeyYa7kEdrSFewgt1aQIp4kRz/EvzkWiEwIlexCuU5TLV/SAzBdntYQ0ohhS&#x2B;QFnyIjaSvb&#x2B;AiFJRH9BzAh9ypOeBsC9PzJF0IjcscgSF3BXTKJHMECErfcsWnt2ENTfYNWhAG7&#x2B;VL7kUtl5hhTMATawjv9iqHZjaGUIcTH2F5crkK79AQPUjSasVKLiG93uBGg0ywlwGpKD2vaBC3iSxayHFkTIkNPde7I9/crTS3&#x2B;YbXYCS&#x2B;WVcp7hL/UX2/MBvuyXfJb7NiLJfmBIa2D9EI7Fj33AiTn&#x2B;Y2cQVLgR2&#x2B;gE3u0Lp7FjlINSrARxG4iUV2cEVgCUlcJhTEkiADUIDiwqUWIEW4Hq/oPYLsBVtPfuNlZL&#x2B;Qd1v8AIRNy9BI&#x2B;g8r4Zfbv3FkrsCQ9/UMsen1DXMEEduPZhud/sV2sIavBRFA9x6FsuPmQT3ETcQt2mEnvIEUt2Kny2OboNqZdIHIr7k5LHEkdzYEdkE5EuJSC2kBEXkN&#x2B;hYHrIEdhZ3THrP3KgHJI4KAI9oEIpHICOIESv5l9ESJ5Abf5hd7hqSgSL7/IPeEpENbIPvAEuphCpOpf5FhFSW4E9xeS25HyAcwxHJN3MFAfMQGp5I03yAiLJBFW1xbuAgQuwFgEdh7gNxuBIW42LsRqQEdg1FkvYvqRpTMAInsIuX5EgCwPckW/kWJ3QEaEdkXbgPbcAIgMNdwBOZTKSFwAYS9OSpABcATDABAAI9BCCFgABbAQAKAHyHyAgAixbYL2FuQJD7BqStKJD3Ay05mA0n9DUcIkICQ0VS7gAFYRwi77EgAHcNdxEgEgiw&#x2B;wXZICPcM01aWRgSBBY7hpASJVw0VLieBCbtsBIi8CCreIF1swIPYsdvyHEAHbYjtuUm/IBx2FmBACLbBdiuOCRG4AAROwBXsAWJVgI/YNFa7EsQT1ETsUEkS&#x2B;5eNgCSI9w57/AGKLdiCQt4&#x2B;44&#x2B;Q9xHAEhRCDv/kV3XyESojYDO1hBYi8BgSFvI&#x2B;Q32H8QCU/5Bq0wF/ENWi4EsPUveWITAgZYYiboCAqTiYF4sBI7gqUqwRAaIVx3DUcFEdrj5Bq4aa4IECIHsNiZCLli9g442HuUH3GyiUP6UC&#x2B;4E9B8yjZ3RA34ERt9h8hNrdyhEMNyFPDHuiC32khWrxBHd3RRbwlb2J6CysXfi4EvHcnsaUzKU&#x2B;pI4IJBfTuOB6NFBR9w7uxYUw5Jtt85IJdAsP7XHpBQ2HoGn2F/f5E6hPEi&#x2B;yQ3cFSUzHyKDt6DZuH7kV90VROwDbf8xstyq7EMgmzjv6CO6ET/ELsBNuC03Ed0GpduwgS6sVTvL&#x2B;SEzuiJPuBbRG19w204Fp3HLKG780iG/oIU&#x2B;oajb5kB7BWewUcokxvyMi2dp4Hlcu3HAmbtlUsZEh/5BqVYKZRXbZARebYll/oVWcMu72&#x2B;Y9RG5iA0v8y3YaQEc8/ITa9vUPkStoAcRIsroe6Gz2AQtxEbFh9xCdwJaIgK7uV&#x2B;nzCSe4EXYR&#x2B;ZVf6B34AkW24H7SuV34twGQTmN/QNwri0Ftv9ZAkXmA1y0Fa3oGodgCUiys&#x2B;RL3&#x2B;YXZfMBFoaQtPpPBV7j5ASPURKK0puFd3QEsuAl/lYrXpuItAEW&#x2B;yksNCCtegEiWSFNi2dxsrATyvkKdx5Wnv9ypRyBP8AFK&#x2B;hfL24DVoYXcoitfYrXEewd&#x2B;A4IC9RMcBFXqBNlLEegaa2EbN/UBN5Q4W4&#x2B;YnuwDS2HlcWEXmwl7fUBE3Yhq7YUjazAXdx8xsFOysBFewdtmW&#x2B;4UvdAS31KuyQSCulIDe7RKk3c07Ea5II0pSCTsypJXQaL0EUxEiJZfKEo52AiXK&#x2B;gfYsSIh2RBmI9CxeILAtSUZSTUssX2EtWgb/ALJBYvYXf&#x2B;QXr8g7FEqQ/wAUJl3dw79vYgk9voL7fmIl2cF43AkMW3kuzlslm9k/YCLa5eb/AJCEnYO1vQBbh/UVbQWEw1K3AoHuLq5sAwWCQAEdyxaGxEXmwEjy2Ezsywudx5eQIN9iww2k/cCJPkFcJ2IAF5/gCpSBBBYhiOP4ASBBd3FgBGmhEFDQEa9QXm7H7K5AjljcsCJ2YEC3ksXJEXAX2F9ir0JxcAX5jawtAE3dxFy&#x2B;4niQICxy/sFKcAEmxATchriPmBHcF3AEgekF5&#x2B;Yj1AJSSJL/AFuObqQJCRbwIX2EdwI1IjksORYCJFi9mPn9gly2Au3cl3waTtEepIbWwELHIibiG&#x2B;AGxPYv0ENboBHA42G3BYeyAyWIEf6ltAEgNBCOX9ACtewRV7EW9gL67diOVsgneXYrvd/UCRCnuEuSrsTgBHM&#x2B;waa4LC55DulYCfP2HugitARKd2W/9IJFSAi&#x2B;waWxVtyOZAkQ5J8voVxs&#x2B;4W/qBNt1wWEo/iFdlhO0ARrki2uVhJ7WARLlIRPy5E87ld1dz8gMuUo/gI7laS9iNQAgReGGkipWlsCK9hCkrfL&#x2B;gu7sCNQErFdoSkRDtIEhp7jbcsP0HOwEW&#x2B;4&#x2B;YX&#x2B;pZV7MCO0QGE4dhHcgkBqBHoWGBAXZ3I0YyAEAgb3J7KSiOwEaew2Yj0D2AbEcfzkrtsH6dgI9rj5CyUSF24AQ5shDpuW6tIldgIrqWxfeRt&#x2B;yEo4AnyEJ2L6QLegBuxGmXiUgnF45IIt4Y9SwtpDSW6&#x2B;YEgO9y3fIUPgDLux6lhLgsSpYEUpyVrZhWcwRpp3J0FiePYjS7O5U7jkBxYekbCX8u4iX&#x2B;RRG4cAsNTDJZDcGnBQ787B2W2xBEl3HFi8TPsR&#x2B;gBz9hx7Cf6ZXsvTgvQI54Imu2wu7RfuVev5gEITWwbadvoF3IEWmQvcc7BQ9kUImHIU&#x2B;WJDcv0C7r7EBXsxM7je0bFjgCORDgqUCNoQEShbiN2yx3EdwJfiRDiGEpcl9V8wDdrbhtPke/zHG0AHMwSeJD3lbje6&#x2B;ogG72Ft4ESt0w72YCE7yN&#x2B;BE8e4SSsAXEFSTul8mE5Y&#x2B;YCE3KGzY4lj2YC/f7Eal7FiLCIV2JEvMpFu7kcx&#x2B;8EnMQMC22Ah9xFrjoD9QnxA3UNBAN3uFfkQmGkybhEOEiezLaZSC2sAd2I7ja4m9wH5lRORbsAcBuOA3AiSg9/QcyGPcgbKwF1/oLbpDYFAjuWPQcgS38w1O&#x2B;whrYASJ3RVxYJQVIoiQfcohognNvuI4koSACCxaYG&#x2B;4E&#x2B;QK47kcTsAZIiyKPWQEcgDiQFpkMEi4BNzAl7fmI7i79AESPQexYfJBItYb7l9CNFFfqANwJF&#x2B;PoV3HI&#x2B;QEVmIvsVCEQQsQNhtuBPQWmCzYexQ9wEpEdyBvcFtBCgACAAAD2HyHzJKd1&#x2B;QDiZEFJDkA0osw1O6DXYICpQSzUyV3WwXuXInz&#x2B;wfaR6/kH6kDbdi7Vx6oWdgBGmtog1Av3AkLaBFg1O4a7OAFtvqPkIS4LFwC2RX8tg1CQtGxsA7KCF/qCpTx9AJ8yw0hZ33EJ2SAnMsMvy&#x2B;w9gI01dhJz&#x2B;RY7/Mn7uwBwv9BbsJa3&#x2B;gXr9AF3aAt4Q23&#x2B;ZWoAibnYTcsQ5gRPf2ALlC8Q38hsm0yRCuwAV7FW1uOQ2vUCbOfyFiuIUIjlgLMb3CKk7zsASW7Ju9ixe0WDXEgElsyIrtNx67gT3sWyiRPHoGruwCOxIjcuy3DSnkBA2cQh7P2Kl3Am265JP2KnwRTFmBQ1aIEbW&#x2B;gv8AMBaLXCuJ8qQd2BLR/kV9pEW243CtF/oBI4RfT&#x2B;kE&#x2B;IsN&#x2B;foBFcqX&#x2B;Y5vYrtdgT2f1F0toG6h/wCQf37gSFO1uS33ncOVt9htuAagJ8sNKJf1C7NAN3H0Ft39A7v&#x2B;IS7AL8COwunsP&#x2B;oAlK80kiHsa5hqSP8A6WBUl/wkjiIL6ifUA7r3I7epfceUCQ/pwF2Q4hrnYu/IE2tASezXuX0EdwEcfwJ&#x2B;03sVtbIQouBI5lBJbxJYbtAabd2Anh/MRcKOw9rgIch7D2DumkBGp3C9UXh2I7XgC32kXiX9Q4j0F2pAQo3CTV4LE2ZE27gJvuSfqXaWvyC2mQI04K&#x2B;7f2E8oIBE2YF0hxDAWfASi4v3EMArr&#x2B;Q2Ww34E8OAHv8AmPV79x6SWYuwMva5UtnAhNQIUSu4E3UBrayLv/oGrAT&#x2B;rjfdhqf4iO0E6Al2RCx&#x2B;fYPa5Bm7BXK/yFuUTsD9yFlq6J8yBtuyRHJYkWAkfswF&#x2B;YbhQJn/ACAj3n7FVwot/EX7fQC77om9mhL5QTW8gRrkRyiw2xG1rAS09xaHYb/xCnZgLK7RUrhr2NUYWJiSsOiqprfyqSdBm/8AqiP0&#x2B;h&#x2B;nC0zO4jhYDS71W/M56On8euHiY9K7wpJmB45uUEz9OrY3SPTVOHX1H1Flcn&#x2B;I4o/Ws1Rh&#x2B;ZxsvM7/ACJh9W&#x2B;HeBiU0vqPT6XXal4mZpSq9m3AyOBKUFG/8DzVWladnaVjZdpKpSqsJ2Z&#x2B;XH6fzFEvAxFWvWzESPHuYiNxEXbOTFy2YwKvLjYVS7yjjlp3fBQ9u3JLRsJaW/3LvZECO/3LEbIiaks27AI/pCeyG/CA6CO7/wAw187FbG65Akyw94ksXvIiVcCJNqbk39TUKBEuQJH1Cp4L5XwJ9QJDWwauXgQpAm&#x2B;4uuSrv&#x2B;QvAB9kuA5V0LbwPVoBtsXdkiFcvIESvuHt&#x2B;QY9/oAtshHA5sgQVDjcACQIjZFn0EFyI54&#x2B;oTlWZWuSQ4uQS8dytDZXSCSKJHDDXp9jUdyezIEevAlN&#x2B;49ilE3vBUoJzsXawCO4gSIb4AjSYUlZCBF7BKEN7FAi3uLK6ZWRe4BPhFSG4j0KJsrMQ&#x2B;SxyNiCNR8hFt/qIuN7QA3e8lmOCQWAJ6h34KBAgniCxcR6gS5YESAAAgYCAAiBYMbciYksAA3LmBPqAgt4mSD3HQPmWxLMvAEvwHBd&#x2B;BIEBWSCB8wAUBHoPUqXoBITECOAASDGwsQEionNhdAAAUIA4AAu10RAAIuABPkUQCAi2ZLFmeQJ6AAAAvcvoBGJ5A9wA9QIAichQl7FHqAjhAQ&#x2B;wACENyqO4EaJC2K9iMBxG5UkT5FuAfqAABHJSOy3Aclm4ZG4UgbaiZCtsWpLmCWW7NgOIHPYNvbgRAFj0F04gRfYTaZAOdl8yRKtuLq0hLsAaldiNyVW3pFtgJ6tiJDUK6LspT9gHpcJW2I3G5Vb9qPoA9Ei3kWJwBVL/gRwv9S2W31DiIAl43LEuyEcIJNqNgD9iRwtwkuCr3AzDjYqcqGypOSPtMANwnyywyK2wBNRsVWuiKeO4jeAL6Ien0YttI422AifqX0TDXbkSgJs4gX27blXb6XEKI7gRN/cqhbCF9ic7bAJZYm8fIWVwvQBD2sPSBvdD1aARPIs7p8dhCb3G/PyAcNwH2j6iYtsLSAc&#x2B;g9ICfYTFvsAb9NxE8iw9EAakbqwQSgA99iPsa9yQ&#x2B;4E9lcsPeQg1f8AyAjadmWVMJlJHAEuosWZENWTF2oAcbhNNC3YQt4AexRFxAET4QvMepXtuTm4D3CfqXmEITuBHvsX5k5ktgJs9xCnkvI92BA/QschRuAc8Ej6FsnI9wJ6Bx2TCKBHa0fMTezLCZAL7B7EU8luBNnuEre43clgCQxEIsWD9AIkuxSwyPcCbD5FJ7gOZ5gJLaAvcoEWxQkkhAAk3hPYpKfcB8vcReVBbx6kSQCFyI2/gWOQl6gTkQ&#x2B;8lI1eTGRI9CR2WxWpt6DZTOxBImwaf8htwCBvuSIE9y7gRrsGipS4RujLY&#x2B;Ipw8KqrvCA4wlY/VhaRnMRS6FSo/xM5v7EWHR58xnKaEt3wTMDx7RHPH5H79Pr6YzuPVlshq&#x2B;XzWLQprw8LMU1NLvCL1HjZzQtFx9R6f6WxNVzOFROFkcHHw8OvFfZVYjVK&#x2B;bROYfhw8DGr/cw6n7I58LSc/iqfwlT61M9F1Dxw6l0XpKnq3xGyGn9C4VeZWXpy2q4eLnMw622lTTThKmmup8eSqtM8jmPHrpHoXQlq3X2r6hRgVuac5mNK/CT9KcOluuOyhsZke3Yeh1J&#x2B;XMZmilvZI8R1N1n4b9Faxkem&#x2B;pupcPD1LUlV&#x2B;oZCnzV42YhftOiihOppcs/VrGa8MOs8plVrmoafiqvy4&#x2B;TWPmFhYtLatVTdVUv6HiNX8Aei9a6lyHWGHnc9RntNT/UcxiZhZmrCT3VFWYpxHhzs3RDa5JmR7DoPUPR&#x2B;t49eR0vMU1Y&#x2B;HSqsTL4&#x2B;DXh4lKezdOIk19DzFNGHSvLRSkl2Pn7qH4V/GHr3xPXUvVPiPgZbQMli&#x2B;bT9Ho1jUcz&#x2B;PUn&#x2B;ziY6eLh01d/JSlSmv8AFudydM9KdR6NjrH1brjHzuHTQqaMjhZLBwcCiOVFLxPrWxiB55IoS9S8&#x2B;WSD1zXvCzo/qDqfB60zOTxcDV8vl6sDC1DKZirDxFhu7pcOGpvdM8HmfCTWNFpz9fSPU&#x2B;Z8udfnxMHPZjEzFVdfKVWYqxaMNelOGke/BuLAfO3V3RXin0PVm&#x2B;uMlrep6M8Ga8xmHrGLm8PGSSinDy1EYaduMCWe2eDPjl4h9SaHXqniL0Pj6dgJqnJ1YmXxaMfGp5xMX8XDwsPCninzN3vGx260qlD25PA9XeGnR3XWbyee6n0t5jF0/EeJk6lmMSj8OpreKakm/cuw5Ml4hdG5tYeFjdRZDAxsWPLl8TPYTqbey/Zqal&#x2B;jPI4ul6dmv72nDUvnDe56nqXgvo2eTrzOZecpw8X8XAwNQwlmqaak/MoWO66aWuGkoOvNY0T4ksnqeP1xoODqeUzGWrroo0P9ZwMbLZrDplUNpYlFNPms7U&#x2B;ZbXgYHcePoGJTfL4yaiyqPyY&#x2B;RzWBfFwaku8WOvOj/it0CrTK6uusxh06hgry5rTNN0/Eqx8DEUeal0&#x2B;ZupKf30lTye9aD4y&#x2B;H&#x2B;uaLg67i65habhY7ijD1TFowa1fZp1W&#x2B;o3HIu4secryWnZ/DpxaPI1UppxMNq67zyj82Y6fv5svjfKsZHjNrFUHNjafm8u3&#x2B;JgOFvVSpRwq5QJF7F9SW7jARwypQSFNkUgCOQPkA9ibFDvwURdmi7E23DILvwRqblQEiLt9A1NikhzYCge4EACxwibbjoJuWFtAgJSASQ9ipck23AJQB8hAFIVkAWSgDcIoAcggRyLIeogoQgL7Fhq/0JuINikABLgRyWPUCRALvsg0lyBBBSewD0HIGzuABYgcgSL2ESOSwomQJAG3JXIEAd&#x2B;C27gQFVrhxwA9whbgKOwE5HqWwvuASm3IibJFTa3f3EWkCbbBqB6RAai0ewE2EFidhtYCQILTHcJAEg4T2&#x2B;ocyEu4D23CHskE4ASnv8w7WE/UNtq/AE9gXbYbcALTccRPIV7ISA35HuLPYRfcBEK4C7cFjeCCQ42G/AcTCQT5KFu5ILx/mRexACuVppwT3AQGUgACPQAAX3JebgBPBV6sK3ACHySCuZiB6P5gFvCKlckrdyWX32AjTW6IX2&#x2B;YdwIX3ERx7gBBNtyy4IBW5IhzIAu6kdh/TAEYfoOBYB7AC/YB8wPkAALbYnADawewAG6mk5SEPdEczcttzYEj0fyHEwIuJTAXixbveTN&#x2B;xQLCTiBwFMyGAlNBBSl6hMAtrolSNIjAj23YmbBrzcCIAbveCytp&#x2B;5FHCLD7gLboNpr0YsS10/qBUGv&#x2B;Ub3QiACUvcJPYpIi0AO6j3YtMCV3&#x2B;g/xbAGl2JMF5gICRA2UwX1G4ETUT2L8xtLaCdrccAL8P5BXCcuxY7gRIu6CgQwDU8kfYrXYNJgSzs0NtyuyEICJWv8AYQ9oLAaAk9nyF3f5Cb7MIBupLJInuhIARD2&#x2B;gm&#x2B;5QEXA&#x2B;QAMBzwIYBpiAFCAQIX1LbgP0QEDuILN7gSBBYCX&#x2B;YEEQPmXYCesAtyc2AcgBAAFBYi8/YCeshlajggCJtsI9AvQQAiUCxaQBCXnY01aUSH3AAIqjsBIEcMtnwIS3X3AjCSbKTmQCTZXT&#x2B;Qtx9xC2Abbh3VkGp3EqAG622JvuWU7tBpxK2AQRor33G6smwIlLLHI7XEJPf7AEpEJi6sHAESsIaNJWI1awEdgH7yVe4EhAV1UUKaqkkleWbowMfFf93g1P2RJmBgl3c/RRpeoVptYCp/66kvyOfD0LEanGzKXpSjCaoHjyN3PMYei5KiHWqq3M/tP&#x2B;RzYeTyuDU6sPL0JvdqknMPCUYGZxknhYNbT7Kxy4ej5/Ed8JUrvVUjze1oHqTmkeMwun63fGzCX/SjOp4OkaBpuLq2orGrwcvQ68X8LBrxKvKt4ow06qn6JM8r6CJUWJmR1XpXxI9K9S6XmNX8J/DzXOqcPKVunMfqGDgZbEwqtoqw81i4eKnv/AIHMWk/XmvG/Xul9LwurfEPojJaPoWJTQ6s5Vr1NONlp4xcLHw8KPaiqtzZJnvGq9IdK67irF1rpzI5upK1WZytNbX1R19rnwl&#x2B;F2s9VPrPG0jJ4&#x2B;fpdP6r/AGnpuFmcDJ0py/wcFpUU1PfztOqfoNh7r091h0r1/wBPYWr6Hq&#x2B;I8pnKFVg1vz5fEqT2aVSpqU&#x2B;x194ufCppXiVhtY3Wes/q/m870vEzqrw8xV/z4uNRi100&#x2B;lDpR&#x2B;3N/DXXiajTn8v4m6lThLDpp/s5ZDK4GXlNNVf91w8HElJR/tI9Dznh/wCEurdE9R5rXs14kavn8LM4KoWk4uK3k8Fpy66KcSqvEpqfP7ceg27DqHp3wI8fuhNIxNG8N8bSekchl6avMshVksv&#x2B;NH&#x2B;OrFWUxZ93QmeV8NfE3xUq0Z5PG8S9F1bUMpjfhY&#x2B;Dk9PxdXpxWm1fMZWunyO13VhUQ/8ACd&#x2B;YmFh41DwsWhVU1KKqWrNHgaPCvw6wMavMZDo7IZTExKnViV5LB/Adbd228OJllyPWepvG7QOkOm6NT8Y&#x2B;lc3pmnV/h0ZjUMxlqMTLKutqlJ0eZ4iUveqhK9zyHUXg94deIeBkNTwMPHyeFRXTi0VaLjvKPHpatTXVhpVOl2tKPLU&#x2B;FXhvTqVOtV9E6bi52hp0ZvMZWnFxaYcqK602vqefVKptSoXYg9UyHgV4NadqeFruV8L9CWoYNarw9Rq03DqzFNSUeb8Vp1zHMye100&#x2B;SlJJJLZIsSHFCuQI5JE8mMHHwMfF/Awceiutb0U1JtfI/X/Z2c/DeKsGYUqmbsGHAPU9b0HqvqnqXO4&#x2B;Sp0XLaK8vi1UPD1muv8WpJx51RTSqXS1dNVvg5NW8QtI6f1GjTauotF1HM1b5HK49f6w438tFCxG4Xocv0NzOO7n/AJa7zcuN3sDtuzhz2oZDTMnXn9RzmHgYGFQ6sTFxa1TTSlu22fmy/Xfh3r&#x2B;ewemNVwHg5vNU&#x2B;fL5LUcnVS8SEm48y3XZwzg6m8EehuqtWy&#x2B;tZjTspiVZZzgZbHy1OJl1VN6nhryqqr1qmBFFMT/UzHuKbVNNURezTHo/T0x1HoPV2n06rouqYdeWrrdOHi4k0Ku&#x2B;68yUrs1Z8HmqtHxPL5sLGpq9j0jrHovxAxs7gaV03i6fp2l&#x2B;SMzncjpWHXmVZJLCpf7NH/U/N7H4K&#x2B;r854fYOX6H6cyvUus6q15sPLVU5eqpr/ixcWttYdL7u/ZHJ9BFf2J93l5y5v5Wm5GbdXXt4R5ztH77PfcXAx8Fxi4TXGxxuHuvqePynX2raJ06tU8RtHwshVh0ebN4n63grCwl71Yk1R3hT2PJaH1L0l1Vp2Dqmm5ylYeYX9z&#x2B;LOHVV6qmqH9jhqt10742a9Vm5TGcbdMxvH5vA9W&#x2B;G/RfXNWTr6n0SjMPIZhY&#x2B;Uarqo/DxFz&#x2B;y1Ps5R4zqHwm0vVMJ4GHhZXMYNX7VeX1fCxM5R5lt5aMTE/Dph/8rPfMXR6r1YGIql2Z&#x2B;bFy2Ywn/eYTXqYZw4nUerZjqvw/yuY61zXTHUudzWUSoWWx9dy&#x2B;BkKcJNJ1U0YNSpVKV5qo80I/Xp/jhj6VrNGD1jr/AE/i5bPYSel5XRcXFzOZqrhuqmp00&#x2B;WI2dtmdmzD2&#x2B;x4frDoPpbrzRMXp7qTT3i5XGj8SjCxq8JuGnvQ04ttMMuR4rpTxr6E6py&#x2B;JjV6g9LxMPHqwnltZdOXxamuaaaqpdLlNPs0exrA0rU8CnMZd4WJRV&#x2B;5i4Naafs1udZdU/DDkM/1ZoXVHTGvvJ4ei1VP9Rx8F4tOLNPlUNuKGu7pqbhHqmF0L8RHTXUPUGVWsaxjZXGzCzOi57KZuijDo/ZX9z5Kaa0lKu3hLd77jEDvHMaDS15srixbar&#x2B;Z&#x2B;PH03OYF68Jtd6bnUPT/AMUnW3TGoadofjbo&#x2B;kdO5jFoqqzmDquPiYNdOHSr14WJTTXh479E6X3jY7I6K8evDfxAx3gdOajnaqFSms5mtHzOXy9f/RjYuHTRX/8AS2N4H7/K6X&#x2B;0o90EjzsafqFCxKK8PGpTcVU1yvsflxtBw3fBxXT6VAeMEn6sbSc5gUut0KpLfyM/K05AFvEE&#x2B;Qbm7QAANPksAACCxYkFd9yABzcvEhveRsEcsCPVliXcCbu4Rd0yNTfgAk9hHYX5YXv7gI5asIcbP1HEC&#x2B;yYEBfuLNgT2KlK3DSQe0fQoW3QvyFLu2F/UkEhcMvMpFXqhu4Q7CbXEcCeF8glaeB1D/mRCx3e4atYCFXciKr/AOY6ir6ElQWObfQKPT3AjcgNc7EAF2IVS9gASnYK5XMQmBOLhpyVXc7kcQA&#x2B;Yh7uQuFJX77bCBIh2EWkO6s/kGBEWwS5HouAC4CgX3G3zAK9ytPePoGrQ0R7fMBYsQvkJT4Jabr5kF3W1hH&#x2B;YYan1KEXu19SNJuxYWy/MhAhvgXmO4qLK/1KDtuhwS&#x2B;yRXKV2QS8bjf6BbQIXMFBTwhYL&#x2B;HcqS3QEba4Dl3ZduSTe9uxA9lPqHO73HMwJncBMsRe42e31LMLcALbonuVqAD2lksyzwSYAWX&#x2B;oT9huPSACcXgK8oerK77ARqLTwEp2EWmw49tgAhi6csiAqXZB79xNixCiLgSEuS2mJ5C7qPoJgBakj7QGvqPV/YCu&#x2B;1xbn5j0QdnuBO8oKZLPNRNu6&#x2B;QBzO&#x2B;wZeZgNKLICehIgsi6vAD1DUIL2LCdgJ7IblUIjs4AgLNobFmtwDjhBBL&#x2B;pHoAagPaGXZS0RrmAHG3zHyHFpuFMSuNgHqQsX&#x2B;fBANtw4F09g3xAlrdGwG839iNdiufuNwqOzUiflYQ5mRN4SCFrlhcBzIU9/uBL9vYr7zAgb7gXkOGyXG&#x2B;wFhEZUryPUAAOQJ8wkldFFu4EsmUQLAGRuCtN3TF&#x2B;AJHcXmUhBQJd7j1LAhARwtxC3LZgCRD2DtcMtmAvx8wAAG4DhoC2I0ABNt9ihpPcAGuwZYSsQB6kn0LuSLAHLuuCrb&#x2B;QJC7AWLyEEpL7bARgrTd19CRCAAFnugG0qPqNnAaaQc2a/IB7Ehl9ET3AvuGFvuvqPWQHoPdi6YmwBhw3dhxIhpgSCu4hpX5HuvqA2cMc2HYnqBU7ci25fX8iRe72AXbEW3EdxsoAe/3CT3RY7EXABKXdBq92VRFxCgCPaJEOCz/mIjkCX2ZX3gkS&#x2B;RspAs&#x2B;hOYLu7L2EJXTAihIvIaixJ7ANlLEcW9gr7FhRF/SWBI5fJYbtYRPApc3j3AKA5YvxdCzvICErp8EsWFzyFO1SjsA2qgO25WvT6CGlvIE8rYSvHraD45/wD2qGJ4W&#x2B;NHU3hl4x&#x2B;HVOf0/Seoc1lMpqeiYjoxqMGjEqpoVeFiPy4jhKWqqfY&#x2B;mPBb4rfhy8csHDw/DbxD07FzdVF9LzNX6vm6e6/CxIqaXdSvUyuW7tuMzGzuNbwHi2gtRdu2p5JiJiqN4xO/WOnvw9xw8DHxaZw8GqrtC3OXC0vO4l3QqP8Aqf8AI8qqVwVnBNcuneOo0OXOJmbcqlHNRo&#x2B;SpTVVNVfeav5H64J6mM1TI48LJ5XBUYWXoXqqTkhJQrF4uxJBLiYdxcR6gE13CchOQ55YB9g95bEBb3YB9k/oWfUj9xM7AX5k5sL9h8wCsW8k&#x2B;RZvAFTvc48zmMLKYFWZzFXlw6VNVUWRuYUn6cHVcfD/AGcRKpewHqHUPiv0p05h&#x2B;fPLO3q8tCeSrw/O4mKXiKlVfJsvSHiXkeo8HEz&#x2B;s6Pi6Fk6E3TmdXzeXw3Wu/lWI6qf/qSPZM/0/wBHa5mnn89oeVWcdHlWceVoeLSuyrabR4HWvCLLvDrzvTtWBiZqmpvLfrapqhxs68SjF8q/6aUbFP8ALzTjG/i3aJ0dVHLMTE&#x2B;M/v45ew6Rm&#x2B;k&#x2B;rtMrxunupcHN4VX7P63p&#x2B;ZorSfpUpR6z1t4JZ3qGicj1dm8PDpo/2dVVeJiYj5XmrxPJSn6UL3PUs30d4gZfqXBp6hxtV1DEVS/Vspp2ezOBkKHNvO6aqJ/K&#x2B;x7o&#x2B;qesulqP7W8Qur&#x2B;l9K07ComrK4WHiYmK&#x2B;y89eIr&#x2B;nlZyck2qom3V&#x2B;/n&#x2B;Tl&#x2B;iqsVxNmuJz7//AO/lD1PIdF634W5fFegZHL6MmvNnM/lNOwcWvE7OrGxvIp35q9jfTvjP1dS1l8ll6tRyyq82Y1fXc2sCminny0YOXXmt8vU966X8WemOrMHEzNFFeWy6h4OLm3RTVjUv/EqE3VSn/wAyT9Dmx&#x2B;mPD3rrPYOvKnBzuLlcT9ivCzNTppqXDpTh&#x2B;zRlN3r9NTn9/vuzqv7zGpt5nx/e/wCvucGneJ3Q/VGYw9Hy6zGoV1/v14GkZjFy6a74v4fkV&#x2B;7PNajpWn6tlv7OwMfDwlSv2qMPBw6oXby1UtL6H49U6W1vVKMXJ1dXY2Ry1SjCp0vK4eHiU09nXWq/qlSeqZTpXVOl8nmsp4f9OaziZmqtt5nUc9gYNOPWv8VeK6asWpesNnBFNFX2Zx&#x2B;/c1YotVb0VYnz/wAziPi11X4Z9b5zPYeR0fqbN5TSa01mqdIwsthZrGnjzuilYdPrTNXZo8XjZ/W&#x2B;jM1g9CeGvRWuZjN&#x2B;Tz/3mcwaMrgOUvNj4qTbfMLzVM8zkuseqfDnpqrPeJ&#x2B;vaZi4zq81TxM6sOmif93QlQ6q3xO77HlumPE/pTrHRnmtU/DyCxk0svm8xQqq6e/lTlJq8VJP0ObN2I3iKqY/LPuxlsc9&#x2B;mnemKqY8Okz47YmXj854nar0DoWBmPEzG0tZuqpU4lGUzb82I24Sw8NU1VVObfyPMYPU/QnU2Qw8zqzydDxUpy2oVYTrp7KpS0j9ekaP0stPeL0dlNNw09sXL5aiqmfXyxP1PC9UeGeL1JkfwureqtTzmXpq81WnadhYeBhYv8Ay1JLzVL0dUPlHFE2pnfaf32/8uCJ09VW/wBWc/vEf&#x2B;Wdb8E&#x2B;heotcy3U9On5TEry1M5XBxsvTiZehv8AxrDUUur/AJnJ4jrPo3xKzWfp0zRdRy2n6ZVS/wBYz2maXhVZxt/4cJVfs0etVXm9uT83Umo9XdPYWW0LpDMZfQcOry04WJr2r5fC/CoUWwsDDTVdv&#x2B;JqPU9myfiNXlMlRRqGe0fM4mFhr8avC1nD89dSV4p8qpTniUcn9amInOfDu5onU0RTVExVHaJ3x8nq2Z6uzfh5g5XojpfLdTatqn4XmwNPqpy1VWJf9/Fxap8lM7ttPse2ZDrjXtH6d/tXxB0LDyVWHR581i05rBpwcJf9VWJPzhexdF656B661GrRcTKVU52heavK57JtW2lVw6K/lUz8fUngR0V1Jr&#x2B;V6gzWnZXEeTc5fJZnKUV5eiqZ8/kUTV6uY4RJm3M4uRifHx&#x2B;DGqqzM8t6nlnrM43n9Y2/e/R5vROpekuq9MwtZ03OUrAx/wDZYmInh&#x2B;ZcNeaJT4ezP14miuJy&#x2B;MmuzPQOtuiPEjOZpaLoWdyWmaR5P&#x2B;8Z3TtHw6s23/w4VLmmh/8ANVPouT8me6uXhVlMl0X06up9X1Suj/uul4WXwK8XFjevFxK/3KW3eptbwjH6CK/sTvPby85YfylNyI&#x2B;iqzM9vCPOdo/e&#x2B;HYGLlM1gua8JpdzjaTUNT3TPw6H1t1ZlenKdT686SqyONRQ6808PNYCwcFetVWLeFzCP39O9V9HdbaatX0PPU4uXrqaoxlS6FXFpplLzLs1KfDOGq3XS16rNymJnGYjbMbx&#x2B;cPF6z0d0xryxHqeiZbExcTBqwnmFhJYtNL3VNa/ap&#x2B;TOrfED4QemtX8Osfo3orVP1LH8qWVzGoZfDx6qby5xVQsZvtV52167HeeJo7qvl8VP0qPzY2TzGC/7zCcd4MHE6W0HwK8Zen8zkMDp3xQo03K4NdH9o11YeXx68xhpQ6KVTlcJpuF&#x2B;3VVU97M7a0rJZrIZf8AAzeq4&#x2B;cqmViZimhVJdv2KUj9NSezQiYAm12Zx8vgZleXGw1UbYjlgfixdCy9S/uq6qX63PyY&#x2B;j5zBXmppVa/5dzzPJfmB65Xh14b8uJhtPs1Bk9ixcHCxqfLi0Kpdmj8mPoOWxG3gVOh9t0XI8RvuIP1Y2i57BbdNKrUT&#x2B;yz89eFi4bjEodL9UBnc09lcyl3KnAFSc2InAXaQ77AP6UCfX7hMQ5gBt&#x2B;1Zli15Hl7onIDa8COJClqRFhsCKoX&#x2B;ZEu/LLxcYEtzwiu26XoTbjYb7IBZiF/IqfCQ/P2AEa7Bx3LEu/HICPT6kfsX5iIcARuLeuwScbF9PS4YB7h3sif1sVJsCRDhFctQFHZliHYCRs54EuNivcWnuBmORDkr3iBbttzAGd9ix2G92iqXcCKbfyL/WxIjcOJ33IKlLkQo2&#x2B;5IbRVMlD3ENL5CbTsIAlm9xtOw52EMB6B3u9wpHNiA9txHccWYAvrIibIc7TAX8Cg0&#x2B;OPQO4Uu7Gzt&#x2B;ZAcci&#x2B;/qHEbbBSrAI49Ql6BTukGlt29QIvYXVg/TsW8AR&#x2B;m4u1Ys9n7SGm1cBCiGSxYvYO3HsBEmnZl53gm7gW3KLPP3JPMi&#x2B;yYTcwQFa8j0LKJzYAlI4uHfYsQtgIlNrl2ckhfzLNkAjhDZhzEfcKG7ICbbwOLCG7tlcq4Ej8i7vYesXD9AI2&#x2B;fzFpsw5DUqQG5Y5gnCLuoe4ET4ZeN93aCe9JfRv5ASGvZFtu2JpvHJNuLgVev5hwtkHO5Gu4FbTJz/Mrnv8hs7AJm29uA7uwUbbj344YDmGtxe8l&#x2B;ZIh/5AHK2XJHdyWW9yNXkAti&#x2B;mw9/zHqn9QD3lC8zH0LMWI77ASIdhBbK7kkQ/QA/csQFE7hw9gCUqZ9hCS2F3uIXIEj/MRx9iudouS7AK7uVbfMkN2gqvyBYVoRfcbg2AEcgARqQ16GmiNdgJDTdrBd&#x2B;ChXAIAARprYLuUbAFZl9mQbgNmI4Fg/8AUA9hIt2DQDce4CACCj2YEjmRBbTItEcgRAqXckAGk9wxHqAEARcWQCAWO6YSXIEi4utiz2D3lAQtiF3cJgI7fkI9Cq3BNmAd3C/MKdkGIbAjSBYlWEPcCQ9yxZSIkJATbgqdMxuXi6&#x2B;UCFNvqBGuOSOJsVudu3cQAjsI3IW64At3eSRO5VeA1F0BH6CHyWOUySvUBHd8iBLmz3Kmp3QBJPZrYP17hW2EcRaQJEj1S45NQ5sSG7QBJWz59Q3Ysc/YkQ/zASuRPI3CiQLDbu7iq38BteRHZAFDUx9wne6Gz3K3ZgRxG&#x2B;4drpFlqWkLcgSFHzsPdoLaWLKyANrsGr32EKJYe29&#x2B;wC8T9CWK5dmwkojuAvyiJKG3criBfdJAS8lV24ZXySJd52AKzlssNepIhlVuADvuSJ4Zd7wJbAkXvISS2Vwk5n8h8oQBNR8iz3kKfQeiAJdyN&#x2B;Wl90X0bET&#x2B;zAH8gfjLydOQ&#x2B;KjrzBjfqLHr/wDun5v4nW2XxcbLYtOYy2NVh4lFSqoxMOqKqWtmmtjt34/8i9P&#x2B;L7rbCShV5/CxF/8AVl8Or&#x2B;J06n6ne2t7VPpD9L8Iri5wmxV40Uf9sPqj4IPjf&#x2B;IzSPFXQfC/Wuu8fW9E1HMVYNeX1qcfEwl5Kqk6MVvzq6Vm2o2SP6J6N4t6TmksLVsCvLVveun9qn&#x2B;aP5B/C3mast8Q/R&#x2B;LQ1P9t4NLns3D/M/prMtydRr6KabsYjrD5L/EHR6bS8VtzZoinmpzOIxmczv6u7sjqeQ1PCWPkM3h4tD/AMVFSZznR&#x2B;Sz&#x2B;d03G/HyGbxMGv8A4sOuD2fRfFzV8k1haxl6czR/x0/s1/yZovBOyPWAmpPC6N1905rflowc8sLEf&#x2B;6xv2XPbszzPmVSmmpNcQBVHCKZV9zSAjSj2K9rgb8AT0Ye4mLyw3aIAP3HmX&#x2B;YmxJncYFn5iYZl4uGtqvkjP4q2/DbnllxI5G13MufcxViVTZJfcy6quan7F5Vw5XUuWT8bDd1XK9LnG6qXDa&#x2B;pfNyZRSN/j0t8x/0s3h55YLmnGdPumjhlu8k83DHLA8lgavU6Yritd0y5HJ9PZXGrzGR0zK5fFxavNiYlGXppqqfdtK54uqiipzEPutzSxsenZqr3sycsx0XeI2XXuic31JksXJ6v1hqawcVNVYOmVUZeaXx50vOrdqkeuU9I6/ofTtWg&#x2B;GfSWY09YdsHE1XVlgYb71v8HzV1P38rfc9owdUxMFwq6qe6q2P1rVcHMYTwM5gU10VKKrSmvZmVN2umMdnNRqLlEcvbw7fph6VieImoeFnT/k676k07UM3S/3f19vFxG/8NGHRhOqPdv1Z7L014k6Rr2lYOd1LDpyOLjJP9TxcejErXafI2jyukZDpvT6Pw9J03K5ZPenBwaaPyR&#x2B;/y0xani0Frrt1R9nf99i5cs1x9nfxzj9OkPH5Dp7p/IU14&#x2B;jaPlMvVjN1VYmDlaaXU3y4SbPEa14eah1TlsTI691xqNOXxFFWX0ynDy1LXZ1Kl1/So9n8q5f2ENbP5mEV1UzmHHTdrpqzE7vA6D4d6P01p2FpGi5/OZfLYL/YwcHGVC&#x2B;flpUnnaKPw8OmhVVOFCdTlmt9xwY1VTVOZY1V1VzmqXj9f6W6c6oyyyvUWh5bOUUuaKcxgqp0Pum7p&#x2B;qN6RomQ0TJrI5JYrw6f3fxsevEa&#x2B;dbbP2Od0BzVYxnY56&#x2B;XlzsKlKypQtM9woE2lkYjUM/LntE0rUk1ntPwsXzKKnVRd&#x2B;kn605F5v9hmYWJmOj0jrPwL6P6vzeXzOcyGXrwcrFWFp2PllVlq6&#x2B;Kq6F5XXHZ1R6HiOuuluvdOymX0jojQ&#x2B;nMCiuFmNS/sB1LK0K37GFTW6q6&#x2B;ysrXfB2cT/AKkc1N&#x2B;5TjO8R4tmjV3qcRM5iO09HVGH1NkfBzp3Devdaa3ncTMY7VLxtCxsTMZrFf8AgopcxL2VKSXoez9E9d9Ya1pVep9TeH2eyDqxP&#x2B;7Zd&#x2B;WrFeHxVWpVNL9E3Hc9m1DQtI1XEox89kMOvEw5/Cxoiuid/LUr0/JnrPXXg7pvW&#x2B;Qw9Jq6h1LI5Z4qqzaymcxFXj0L/B53VNCfLVzPntXPtRvPWf8AERj9&#x2B;DP6XT3ftxiZnef8RGP34PLaP1N0l1Zi4&#x2B;BpOfwsbGytfkzWHhVp1YNf/DV5W0n6H6sXR6pf4GLPozxvTvhP4ddLaVRo2idIZLAy&#x2B;G5popwt33c7vu92edymRymn4FOVyOWowsOi1OHQoS&#x2B;Rw18mfq9PNrXPoub&#x2B;nnHm8Ti5PMYD/vMJ&#x2B;6VjjjiDz0J2mTixcjlsa9WEp7owcbw4P3Y2jVb4OIt9mfmxcnmMFxVhP3SA4i3JtugBZkzXhYWIvLXhp&#x2B;6KAPyY&#x2B;jZTFl0J0N/8J&#x2B;PG0XN4c1YbVal7bweXZH9APX8TAxsGry4mE6XHK4MxbY9iaTTpqpTTV01ucGNpWSxn5nheV96LFyPCK0NhNxD/ADP3Y&#x2B;h41F8CtV&#x2B;jUH5MTLZjB/2mDVT6tEGC3m6Jbkt5v2LAm38bFj0D3kNUxbuBPcsOdhHP8RtxsAibOQ9x9o9Sc97kFUpwhfdCZ3QSRQ23G0ci09g3D2kBbYOH3CYUKzAbbfmG1AflkQp2IEvmPmE&#x2B;VuLQHfkAmtxZcCLw/qRQijX1JEhu8tC7SjcBDiIY5kQ2IkA05b&#x2B;gdregvyw2t4IF/UjvuW26CTbkBdchRFwk09g1LsA2bJNpL6/kTi4Fu7wS74ZZ/wCHkkT/AKAFDt2L/wBMbjZyx6lCL3U/Mnr6l4kJOJggi7oWW6Lt6iHEzyATtf5juwN/oATCmdvsGokKJiwFT7BqURtFlrdgRO/mD7FlvuRbT6gTkrn&#x2B;Ui8DZxADa6G939g5tb5Dd2f0AjXLDs7or2jkW4&#x2B;gEb/IX2TKr2IqZ/gBVfdXHrA57FTAkzsGuFvwKk4kJevID3&#x2B;4e2wU9/kJaUgFtYbWkRD2F27gVpcojUPYt39SNLm4ANwIlir1X0AWf1uSE9ipPsgAlwriP2oj6ji4qnhgRdhzYoc&#x2B;bYBPLDa3TDUKfoRXcwAt2L8ibcllAJkO3f1CdtvoFtvIDb94JoNcSRWYGk&#x2B;Sbu/0DvePsH7cgJlC1/UWjcTuwL6Nk2hFbtDI7R/EA2o7ku3bcJQ4aL6yAduQk&#x2B;GRehd3t9wHlTF4DSiZDlWARwHG4bc/zHNgJbl8D1/gVQ3clKh3AbbI02T1guwGn7Ec7FVw/f7GwIWAlfcbKwBCOwTgejAgRfkGoYBNcbEDUDewC3BRNtw1YCReY3Gzug7bMeoFZG1bcL1L6yBONh8y3gKAIVLmQnzHzLKAkRYJXL7kAQ1uJ&#x2B;ouufuW3KAjXqONwtyfICwu4aU2IixbcBEO/wBgpfqFsWyUpgIuRxexZ5QhTYCK7sJcD58D&#x2B;QBJzYKwhtXKkldASJvBfQjQvNgEz/mErbBzx9hEOWgDSCmGl&#x2B;ZWlu2/cibTlMAu0FhXX8QiqbICQ&#x2B;7DsrMOdmhK2Aj9QG5uLT2ARG4Ti6RUu7C/4oAbKPuPkIbuybWTAvqxblkhMvsgClhp8hd0xF7oB6Ni0Qwo4Ybh7AWycuSX3ll9WS8RtIAKlR39gr7PfcqSnYCRNmSO/e5pr1EreQJ90JfcveWRRvAFgkJ7u5eRM7gLOWmPdBR25ChXkBF9hF5CfHoW2wGXzAidyx2Ycw7gIU7EhR27FjuLJR/EBzJN3cRzHAW0JxHcBG38xedxZ7F3cpgEuZF9vQb&#x2B;gjmHsAW2xFG5V7D5gReiCnn7Fj0DSYBi6sNosP3kAbvP0ChPcbcDfj7gfys/SX5J5P4xupXH&#x2B;2wMnie//dsNfwOhof8AofSH6VXJPKfFtm8ZKP1jQsniS&#x2B;X5aqf/AEnzgvU7ux/Zp9H6M9nqufgemn8FPwh7d4BZp5Lxu6SzUr9nqHKXfri0r&#x2B;J/URyndn8q/C3GWW8S&#x2B;nsx5o/D1zKVT2jGoZ/VR3cq1jruJR9el89/iRTjV6er8NXxj/I9tyuFci39i/vHWvmqQ4lQo7HlNF6y6j0RqnJ6jW8NP/ZYn7VP32&#x2B;R4twuPsHZKEB2Do3i/kcZrD1rIVYL2eLhftU/Tdfc9r03W9K1fC/G07P4eNT/AMlW3uuDpN&#x2B;ty/ruc09VZvJ5ivDxKKW6asOppljcd6SnsZqxKKXetL0bOrtG8WNfyCpw9SpozeHz5rVfVbntuh&#x2B;JHTesRhvM/q&#x2B;I/wDd46j77GUUrh7E8anilv5QT8Wt2hL5ycdGIsRKuipNPlOStxcy5TDTxKnbzP1hGf2Zh393JHvdibxBYjCw15oUjzNoj/hcf1cuEVubNknjYezG7AKUI7Be3Ah7L6gE7XX1LutgHD4B0Ti5UPRD0QEXZhUJOaG6fZiBLJhWqcXFp3U&#x2B;qP05fVsfChLEd/8ADUfkmGVpVLy1KUY8qYzLzGX1vDajFoh90fqwczgY6nDxE59T1ylVUKMOqPTg1h5jEw7107c0sxmkw9ls/cX2c3PDZXV8ahpLEVSXFW5&#x2B;3A1fArUYidL78GOMI/ZfjYLs0Zw8bDxV5qK1UvRmuO/yAe35hRNn9w9roNWgAnNmgoas9vQKNk/cejQF5uRNJMTGwU7P5gWYUT9CT24DncJ3AN8RA7i3NhC33ALdX9w16F3exE5cegCFdsLb37BT3JXiYeHS68StUrltgceLk8tiy68JT3Vj82No6a82Di/Jnr/Vfjx4PdF47yPUXiJpeBmVS3&#x2B;p0ZqnEx6o3jDomp/Q9CXxx&#x2B;Gmv4ONi&#x2B;HOmY&#x2B;s04NTpqzWbzuX07AprTjyurNYlFava1D3OejS6i5GaaZx49vzblrQa29TzUW5x44xH5zs7SxslmcG9eG47q6OG2x6n4deMXif1Ho&#x2B;NrHXHgjmdMpeYVGSwdM1bL5141Df7/mpqppiL2Z7Zp/WfQfUGs4vTmU1/JV6pgYarzOnUZqh4&#x2B;Cn/wAVNLbRhXaromYnt4Yn4OK7pr1qqYmM464mJj84zBvZoPaT9&#x2B;Lo1FS82XxrRs0flx8jm8BxVhOO6UnG4HGNyReH9ygA1KhhxJN&#x2B;QPz4&#x2B;l5TMOaqPL60WPy4&#x2B;iVpurAxU&#x2B;yqPJNv7hgeCxsrmMu/73CavvBxtN7nsMLscOPp2Ux5dWEk&#x2B;XTZgeEj&#x2B;kJlbnkMXQ6l/wDa&#x2B;Mt9qz8uNkM5gx58KZcfs3A4bNQyOJg1E8e5lrgAndWLs5SJtv2LvuUWb7kd7Cewl9vcBdMW7uREqwfrBAhTAtMJC&#x2B;y&#x2B;xdgJPy9iJLkrXsN1EgHM7D2j3F3PsFKALZpMu&#x2B;0kS7sTwAv8xxYJ2G5Qs3LQ2Ww9JFk4RAi2/sWF2Jsy&#x2B;gBbiPsLLYT3AjTV18x7lsiRPsvUA/RBvhF32I1yA9EGlwvqFvfkJWAbK&#x2B;wjv&#x2B;ZYSUMm/b1uAd1a/wAxLW4v3LbZgEPRsbfImylMBbv8xxLEdmH3XcA/Yvq2Td7ewb5gA4nct3vHoSbwg7W&#x2B;gF3u1cNhbEhKyAfMRZrYqT5QiAJupUCEnIU77WCs4n5AEo4K5QEtQBLvgrhsNWuyTDAKdklvYOJuLO6Chu4EjgtPsS3JZ4a&#x2B;gCXOxd1ZE2smX2cgLTEEs/puWbx&#x2B;bJDVmgEvZjZiP&#x2B;Id7W9ACnfcReGxHYWb/hABQvSBHL7Da7ZVEfMBZEcp/MqXqIn6ASLQ4knJr3Jz2Aj7xyVIRa32K4AkL7j0XBYcfMkdwE2ldhduPyCu4DhKPqAfvMi7uWIYUdgJsvzFLW0h9&#x2B;whbr/UB6FuSG1fkKFu/uA4uGu49U9xZ7PkB&#x2B;0rBrzXgeg&#x2B;oFtMNkstx2h7hptQAbmeRyWEvmSbWAJcsRf59hb0Y7w9wCXIbUfMJeyI1bYDkpT8kOOAocdiqHzwSHsbAWF1wL9hPoAsrwLq/cP5/MttrAT3DjvsIW8la/ZmQM&#x2B;rCK52SEJAF6oPsPUW7gHKskRNrct5gl2BbDff5E9UWP6gBMzLInL39yruRQ3dAVdoF9hP9QFvADaxVEWEp2T&#x2B;hEAhpCHF/wAyq9go3Ak&#x2B;gcbhpLdhw1MATiSqd0hEoX7AN&#x2B;/zKojbkJx9BtdgJc9wlDvIcbInoBfmSIDbC/r0AWHNkJuVOeQDl/xHNvqFN2tp2EPYCRxMh7QWOBdO4ByleGFdE3sHfdAVruJlTH&#x2B;Yd/cTeU&#x2B;QDUuUxffkRKuvmI7L5ARrj&#x2B;JU7bCHOxX3Am6&#x2B;XImXMBbQi7AR&#x2B;sCF2&#x2B;hdmNkBEkmFwty8C02&#x2B;gB2UQR&#x2B;qsX2Q&#x2B;UgTbZCI42RbLZCyUoCJWmfsXe5JjcrUXYBd4DU2DcLcQlsBJj5sqCXzG2wCXu2GvWCkvMAFa7EPvcto3I43bAKYJaXYszdAAmW9yehfcAkS88FYAkQC3AE9/ox8ywnwPcCJPaBzctiegC8FgicqzKAjsSG7MouA53I94koYEXoVEhexUlwAhP2Edix2E7x&#x2B;QH81/wBLtkf1f4l9PzqX&#x2B;36Xy794xsZHyuq/Q&#x2B;v/ANMZkHg&#x2B;NPS&#x2B;o&#x2B;W2P026J7unHrf/AKj4/Z3Wn3sUv0D7LV83s/p/&#x2B;PwmYeR6WzjyXUun5tVNPCz2FXKd1FaZ/WPDqVeFRWuaU/sfyPyeI8HOYWLSr0YlNS&#x2B;TP616PjrM6RlczS01iZbDqT96UzR4lH2Z9Xjf4kU76ar/AJ//AFfoa24ZE9&#x2B;Q7&#x2B;oT4OrfMFnmbCXNgvb6EtD7AVxsvucebvlsSb/sP8jajkxmJeDWk96X8rFp6rHVwUy6F7clVlYmG6ng01OzgQc0MnktH6r17Qqk9P1Cumlf7upzS/kz2vQ/GGitrB1/IxP&#x2B;9wNl8mehuPQLeJKbO6tJ6g0XW8P8TTNQw8XvSnDXutz9jUcHRmFjYuBiLGy&#x2B;JVRXS5VVFTTR7Fonih1JpUYWbrpzmEuMa1X1/mTdHaERxdeovu2euaL4n9N6tGDmcZ5TFf8Agx9m/wDq2PYcLEw8alYuDiKql7OlyBpu0pcFU7JkUtD2Km44m6LF5Y&#x2B;QmxBWRuLwH3&#x2B;ocRcRsG1x8g54HyAr9SesFJ7MBE&#x2B;hURNu0cl8vEDoYwDa0FhvgeVTEk2GaqVVui0vGoUYeJPpUipKG1e/BVRVMKmPVsxmRcPPVYNdNNU0N/4k7M/dgatmcO1bVS9dzx7yyrr82JVKT/ZSVkcqhmE47Gzy2FqmXxIVTdLnk/Sqqa1Kqs&#x2B;TwKdtzkw8xi4TnDxGvYiPN&#x2B;35i543B1bFptjUKpd1Y/XgallMVx5/K&#x2B;1QHO23uiQ&#x2B;HcJruV2vYCWeyKm3D5IkvKeqeLWoeMumaBVmfBvprRNTz1KbeBrGoYmAvl5aGqn6N0&#x2B;5lRTNdURn82du3N2uKYmIz4ziPze2OFZnDntS0/TMF5nUc9g4GHSpdeNiKlL5s&#x2B;ZtR8Uev9ZyL0Tx98YupfDHVMZPDopynTuBgZB18eXOVLHpqX/8Sh&#x2B;iOtfETq/w/wCjc3kNK6oyOndfYFeLVh5qrVNbwNS1LUPMn5astg05itUy428ri0bHY2uG1V1Ymr8o6&#x2B;kziPyl3djgdy5VyzVv5RM59JnET7pl9VZ74nfBXBz9WkaL1jRrmdw/9pk&#x2B;nMviaji0PtUsvTX5fnB6H178ZvXOhanVo3Rnwodd6jXTSqq83ndNqwMBUf8AGnh04tb9vLPofPPwZeIOV6B&#x2B;I7Xemsr4aaZ0fg6thp5PKdR49eTx8Ff4KKKcWp&#x2B;ZudknxHY921nwS8fv/bXqniLm/EanWMXLVV4&#x2B;n6JqmNqOBp2DTVdOnNV4TwbJTCUWSbsbc6DTWL0017xjMZnr&#x2B;XT3y7KeD6DR6ubd3eOWKo5p65/47R6zOHk/ED4qvFfqXD0vSfDvxm6ay2sajqNGWxuntP0LEpzuWTnzed5utVUxzV&#x2B;ElseD&#x2B;LbpHw86Op0vWfE/4tetf1jEqpxMbQrZ3CzTTXmoWHhfh00Tt&#x2B;1Y9VzHhPgdGdQV&#x2B;J/xJ&#x2B;C&#x2B;n6tndbz1TyeqZTrDEqyuTtNNWL5KacJUKyl1y&#x2B;x6VjeAWneMPjDldE8XeoOnuksvnav/AHNjdI5TAzWFmsLf9rGw8ZuiqP8AFWmvXg3rVnT0VxVRVimnOZiKZmfTGc49HcaXS6K1cprt18tFETMzTTRM1eUTGZmKfOnPd7j1T8THhZpnU2hZbobwEzHQ&#x2B;HmlTl8x1bqfTNGBj4&#x2B;E7TQqMOuW&#x2B;/7W57r4eeEfi70P1Rj4XSfTHQWpdMavg1Y9fUuuaVgZjUFTUpbxaP7jErm9odme257N&#x2B;CPgn4WLwo6O8c9Q6h1LJVeevK5F5fVtQrScwsOrDxacOP8ApUHo3ir0p4BeKHQWL4g6L4pdL5jXXlVgZt9f6/iYeYy3fDpowMTDpwmrqFhxPscUXKa4xTTMUztmYmc&#x2B;E74x&#x2B;cx5NWm9Rcpim3RNNEzjNUTVnwnE4x5bzHk8ZpXiV1Lp/UGc6a8O&#x2B;pehPEDO6TjPEynSml9BPKUYLUuacR4lCoqUcee5y9LfEth6N1XmeqfiW0jpbpHLZ/Cqw890vkels3Tqeai1P4ldWHDXCaqhyzrL4cPBHpenxP0jrXQ9D1bL6ZpFdeJqGv6vjUYum42LQpTy9dFFLqpbT/eng7XzukfEV8VetYfinlVks1oGgZvFw9M03p3Wq9LzuJG1X4mJRXQ5t290bF63YpqmmemN52ic&#x2B;HhvjymPFu6mxo7d2aKscuPrVTimYmc4iNuXeYz0iY65e79J/Fdo/WWv0ap4Ca/q&#x2B;b0jIZF4S6RXTn4VFGKv8WJmcaqmiinayqlHYWJ8Umc8O&#x2B;nNJ1Hxy6QxdOr1PHdNec0/Ewq8llKG7PFx3i&#x2B;VbrZu585dYfADrHizpOd8WOr6dR6KzeHgYjxdFozeLrGczjpVqqsWrGipvaEoPXPCfr/NdE/DJrnQ2heEma6hzWQzVS1anqh05TJ4eG6ppTp/WKa6nZfsxc1atHo79MfRTnExE9Mxn8WYif1z4uur4ZwvVURNiebExFUbRMZ/HExTO/fE52jL7q6K8VvCnxTy&#x2B;Lm&#x2B;h&#x2B;rtP1TCwK1Ti4&#x2B;SxlVQm&#x2B;PMrP5Nnm8XSKX&#x2B;1l8ZNdn/ADPjHp34P894peG&#x2B;keKGXyOmaXm81lacRabpGp0aVp2VcSqsTD/V8X8Vqyfmbk7B0LxH8R/Abwg1rrPrrrrL65n9IwFRl6Mtr2Bm8k4SVKWFg4GDVQ7xDb23Otu6C3nFqvM5xieuXSanhFjm5dNd5qs8vLPXOcdY67&#x2B;Ue99CY2RzOC/28Jx3VzhdLW6Pn7we/SV9FdY6ZksfrfpTVNNwqqFTqPUGPkFl9OwcS1lXViVt/NnfPh54leHXjHolXUfh9reHqWSWI6P1vBwa6aKmv&#x2B;F1UpVe6lGrf0mp00/1KZj4Ou1fDddoZn6aiYiO/b836GoZHMXPIYuj074OJxtUfmxsjmMG9WG47q5rNFwb/wAUUmJiYeFS6sWtUpK7qcHidR6&#x2B;6R0tRmtawqqk/wBzCfnf/wCCB5aO48q2SPSdT8btLwqXh6VpGNjNO1WNUqF/Fnr&#x2B;peMHVud81GVrwctTx&#x2B;Fhy/qwO0czk8pi0OrHppX/ADNwev6zrnSOkqpYuv4SrX&#x2B;6pfnf0pOr9Q17WtVrdeo6pj4s/wCGvFcfTY/Ko7AdrabqOV1bK057IV1VYdTapqdLUw45Oe54roinydM5anZOlv6tnlnE2AimNir0Q3uIly9iipN7/UkzcT6D3qICs7MNvn8hZqO4fq/qAe9ybWNcfxJyA9RCj0E&#x2B;hZKJAa5b&#x2B;ZZU/wAhbzSyBxbkjm9&#x2B;S7hN2TAl1NvoEknP2FlxyF3gBMu31DshC2/Ib3jcA7lS7EbgWV4Ab/5CLQJi/cL1fsBZ9COHuRK25V3YCYmEi8T6Eh&#x2B;t&#x2B;wjhwAakTxPzDUqJCcbAJn91wVLhIb&#x2B;oSi0cAJ5HsHPAX0ANLb0Itp4LvDImleAEBRuJc7C/LgBzM/JBy&#x2B;4/ZLEbAS&#x2B;3cqnsI7BKOAHo2SHElvMD&#x2B;mBPb7DZy2V2JwBduBtwHbgJpqAG9oJuon6FQW4EV7zuRqFv8jSnsIU&#x2B;wEhcF9BCmdiWtcB/SLNpn7hJzv8AUcyAvEEe0Jlakkf1ABNRd3ETYP8AMNp2bAP7dw7c8F4/kR22ANegdqpj7iydh6/YC8b/AEG3Ei0JDi7Ac2ENCYVgm7gRdmXiR/SC3AO/H3I94ZfmGpvAB9iTBY7kduwFvsRudkIbdhEWARf5dx6JxfuL3DYD2Q&#x2B;XA2j6yw/pIBbzI9YCUuWKfVgTexX/AF6C39IvNpsBJ5gTzAi0SvkEvRQBXEbktteQne9x&#x2B;125AKOydw1cK4V1cBbdJDdSlYqup/iFSnyBv1QhbsK6sW/&#x2B;psDOzDclcTuNtgJLWw3cFXdr5i38pAWX7P0JMexZvKcibASJX8RF7QVPhj37gPm/kNltv2DVpYX9ICTN2w12EPb1LE8fYCR6iLygvpBWpsBI7iy37hpchL&#x2B;pALexYUBJMt&#x2B;4GXG4lplb9PckdgKo2bExtwSOxVa7VgHqhO6aDbmUPWfuAaSHlc3Yhp2j5iIu0AtEt/IXCtC5HNufQA0lyGnwipQIlQBOA/3YbQidwk4SAOETf/Mr9PoIXIBTsN3H1DXLYtPPowC7QN7q/wAhKfBVEygI4V5&#x2B;qJdb/QvqgpVp27ANiw1ZD7fMNJsCQ29iwpsISVxLakA0&#x2B;y2I5mFPqWdiQ52AJyrFvt9iSmv8ygEoGw3Up7hzNwD7yIn&#x2B;QcNyJSAT3LYKNgBGpewiLspL9wDv/oWCKOCwBGu4D9x6AE&#x2B;Sv2JxsN3YC77iFvBPRFiAERsT5FDAkdhE2Zd&#x2B;AgHMgbD3AX5AACeBHqHHIXuAswBcBFhEbAAF7gD5AAHuAAgF9GgJHcFfoRb3AvsxM7kRUryB8Cfpmsp5esuhc8l&#x2B;/pmdon2xMJ/&#x2B;o&#x2B;KZsfdX6Z/It4fQOoxs9Qw5/wDvD/gfCctbHcaXexD7t7HVc3s7Y/8Ad/3S3RaqT&#x2B;sXQuPTmuitIzNNfmWJpmXqVUbzh0uT&#x2B;Tba77H9U/BbHWa8Hulswmv2&#x2B;nsm7f8AyaTV4lH1aZed/iLTnT6erwmr4R/h7LfuGv8AQNC/J1L5WPaPoO7ZN7l5Al&#x2B;DFaToaa4uckPgy4l2LHUflwKm8vRUrTSuCpszlpeXov8A4TRzQz7nqXZkU8Fh79igttw3O4mVLD9wG&#x2B;7P26T1HrWh1&#x2B;fS9RxMNTeiZpfydj8S2Et2f5BHvOjeMdS8uFr&#x2B;nT3xcD&#x2B;NL/me3aP1ToOuUJ6dqOHXV/4bcVL5O50xElorxMKpYmHW6WnKacMmDDvVQ0GrnVGieJPUukRh4mZWZw1/gx7v67/me36L4raBqapws&#x2B;qspiOz896Z91/GCm72iP6Qi9jjy2ay2cw1mMrmKMSipfs1UVJp/Q2qqJ8qd&#x2B;yMZkW4iWVKtuFhvbd2L&#x2B;FiP9nzpfKScyJD7ksruEcn4FNX71TfzNU4dNP7tCXsTmMuNKdqW/dGlRiWhJe5yQpuHTOxjzEywsOq3mr5vBVhUbVUzbm5Yiq5U73JmURL7FhLj7hNKyQfZPcgnlLtCkboPs2AjYTz/EluSt3uBZc/MEVm0wr7MDlwc3j5f/Z4rS7cH6sDWWn5cfD43pPwcXDmbAeawc7lse1GKm&#x2B;3JyxClM8BLV0c2FqGawVbEldmB5TOZHJ6hlq8rn8ph4&#x2B;DXT5a8LGoVVNS7NPc6R8Wf0dvwz&#x2B;KWLVqeB0i&#x2B;n9Sb81Of6frWA1VO7w4dDfyn1O5cHWsOr9nHoj1R&#x2B;vCzGFjKcLFT&#x2B;Zy2r96xVm3VMejZ02s1Wjr5rFc0z5T&#x2B;8vlPqn4XfG/wn6MzGh&#x2B;GPhn4adc0vB8izWu6H&#x2B;HqFdKe1bqrdGK4581Pseq/DXmOs&#x2B;isPMdBeMPippfRGLqOYfm6b1zpbH/AAqVL/YwMTMYryzp9KUz7Zbmx&#x2B;LX&#x2B;m&#x2B;nuqdOxNI6l0TKahlcWlrFy2cy9OLRUvWmpNG9TxKuq3NFymJz32z&#x2B;uY/SPV2tPHbtdmq1foieaczVERnPpMTT&#x2B;UR6vSPE/o3xF1jw8y&#x2B;j&#x2B;CnVWlZHMUOmr8WrL4VOFj4a3pUYddNE91S4PlP4mdI8KPCjqTQtQ8ePh16beYzmPT5qukddxaM3i1qpTXiUrAwsLEpdpTh3d&#x2B;30J4hfA/0H1BpOPkPDTrnqfoSrGqdf4XTWtY2FlfPw3gebypTFqfKdb534bfE3wwyf9o9a&#x2B;CeneNOZymHGS1XUOo8ZZqhLZPL5nz4a96KpfY2NFdsW52r8dvsz/wDLMR&#x2B;re4TqNHZmJi7nedv7dU5/HzRTj1mfKHX3inhZbws6v0zx18OPEXRemcLP6fRg4PSuHkcDL6nTgNKVh1fh49NVW12l2M5H4etU8U/E3N5vxZ600vM42raYsxk8HqfJ5zUc7lcGP9oqsvTlsKn2cx&#x2B;fium/GbXOq/GHVMTrrwYxtF6qWQeW6V6fzOl5anCy8KzpxM08NUuZuk5iE3seE8Kukfi&#x2B;6i&#x2B;JLD0zxU0/qjS/17Drws7nHlMKmirL/wDBRiql4b4SdL7HbRTXRROaopqinrtnHWIjxiPHfL0kW71qzOblNFdNH2sxzTHWIjbeI71b5l37V0/03oXgLgdDeFPhf0r4i6JksR4ebzPUGaWVpw6k4qxFRmKIq8t9sRO1jxmk/Dp4I9HdM5bxY6kzmUoyGBh1PH0vw96fqxcGpc0Y9WHXj1YqV1NVSR73o3wmeHmS6Z1LSuhPBRZDVKMV1ZXUOr8fDzmFi4jv&#x2B;LRS6sZJS5/cpZ5On4KukNaxdJ1nqGvA0/PZfCVOsYOg4FOXwNQt&#x2B;7ifhU4U09k0dV/NWqc4uTETO/jP6zHvjDzn/UdPbmrF6qImqZmfvTnx&#x2B;tNMZ8YiPOHzD1P8RngJ191DVhaBmtRoy2hUPE0zJ6pqWF0/lqWlHloeUwni4jtMVVI7F6C8QF4&#x2B;dF5bA656I13TMfHxFh6c89ktZzWj5mhO1VVWBjf33ecTyJn0H0H8MHw&#x2B;&#x2B;EuNn870l0JkcktSX/fsPFxKsTCxF28mJVVSl6I85/208L&#x2B;iMktM0vHyWWwcL93LafhJU0&#x2B;1NChGF7iOnxEWqZ26TM/uP8uPV8b0M0xTp7dUYxiZqxMeO0Zjeevi&#x2B;b9X&#x2B;Dvxg8VvEPE0fxU1eqrprTdOpp0KrQ4yOVqxOFVhPExqml3rTk7I6K&#x2B;D/LYfSeUyfiDhdO5rWMu1TiajT0zkcd14S/wftZeiPeG&#x2B;zPa9W&#x2B;ITTsOaNF0TFxnNq8atUJ/SWes6v42dbaiqqctmMHKUN2WDhy183JqXOI6m5TFOYiI8I/fXu6y9xrXXaIozERGMYjH7z38XuXRfw&#x2B;eEnhjm8fUOlNGenUY9EZjJ4GcxaMnW3u/wPN&#x2B;Gn7Un7st1D4S&#x2B;HmUq0/QqNMyGF5nU8tpmWopXme/7OGoOm9Q17W9XqdWp6rmMeeMTFbX02Px1Q3Y1K7ly5OapmXXXL9&#x2B;9OblUz6y7Z1b4gtIwU6NH0fGx2tqsapUL&#x2B;J6xq/jf1nqKqoyuJg5Shu34VEtfNnprvLnYm7MHE/ZqOu61q&#x2B;I69S1THx23MYmI2l8j8n/SJhy&#x2B;Qn/TAjjdcCCtTt2LErb6gZjsiGrbkqTmwHZXSFKp6cyij/dJ2PJ/PY/B0zS6dAyij/8Ad6bfI/fzMfMBaNy7IkOIQe4F3tHI59w1chRW5RH7hJRMlcTL&#x2B;4CfoS&#x2B;35F24&#x2B;xHMRBBbQlI7zIid6bjiQETZiCTwxLiJ&#x2B;YFdgvR&#x2B;5E7XZfRsA1PBLJR/EqaXIi/me4ElJ2QVla4b&#x2B;Ui7hQAsoXJU&#x2B;0kam87hpbgFtDYhbiL2LebICLvIXLgb1WQ3AnNrFTvz7C&#x2B;5XPDuAhNySXEC0fISlwBbNbj1Jv2CYFnuxPp7EvMC74AKA3H&#x2B;Zdtib8e8AVxHuRztJUvQi9eO4F3Ef5iE97lShbgR7XG2xeSTx9QHzFmE&#x2B;A5kAkk4FnYOYgjb5QFe4StawjuFe4Ce7G4VtxMbsBF7hRtOwYlAHdWHF0NrvgRACL&#x2B;ol7EidkW27n5gG42I36lhzuTd78AVWvAa4lhbykGuGAvEwS63LEbjf0AjfYQu/uXe5JjZgHN2/mLTYcxJdwIoasHKf8ywuR8wIuCv0DCYBLgL/Uu5N7gTiwU/MvrPJFul6AJh&#x2B;4drepWpdxvwBLvd7F9&#x2B;5PWPuEmtwEzuPUQp2&#x2B;chXtACE&#x2B;CpJ/xEegiQEJqBaJDFQCOURReA5VkWNgJtuh80WJVgrANv3kS6lstkIn/QCJt3RVHeRHYcSBtbbPYq7enIdPYjXJsBKiEJ8wi9xtcoP1CSW9y3IiA3G/YQ&#x2B;4hRsywu3yAlkElBd7/cOeAI7BpxD7iJmEH5uPyAJNKCcw0WG9x6tgNuBCcwyqVYXmAJC7e4tNg25KkAfefcRMfaR6B/mBJUyw1sLdw92wo25TaKla6JD2QWwQjzbBJzEFXZP6kXoA3twO8vYvq/kPZbgLkT5L8xyAUbvkd7kvs0WFEoCWd2IU/zL8&#x2B;RAESXoWOXz3Fw3D3Akr09Cw1sHDF4uAngQlsPcoE5sIW8l3G4CCO9mVgCQxzf8xFxPoAlN72DhWY5EPeQIp4K3CExz7hSBfUBD5gIIlCg0lcJICJJbIFUdiXVmAI1YoAkXks2kRzA9gJcTwW4StAE9S83EcCOAF&#x2B;WNuAHsAIvcttxuASQAABlJHAAFhdiAORsEACUB2CuWyAivsywLvgiXdgVJ3sLRDD9ScgXZE&#x2B;QfaQ1wmBZ7BwPkGuyAguUNgRIsKETctpA&#x2B;Lv0zGU/E8PujNQVN8PWcxhJ/wDVhUv/ANJ/P2&#x2B;z/I/ov&#x2B;mLyP43gZ05qCp/2PVNNLt/xZfF/wD0T&#x2B;dCTtY7nRf7eH2v2JrzwCiPCavjkcXsf1C&#x2B;GvNPO&#x2B;APR&#x2B;PVWm309lVK9MNL&#x2B;B/LxylZTbsf00&#x2B;EXO0574bOj8ZVTGkU4dl/wt0/wODicf0qZ83XfxCjPDrM/j&#x2B;Uuxm4ckupvuV&#x2B;jIu0c9jpXyUf/Miw5J7CXugK&#x2B;xKvcT32DjYR1H48t/8Aa9Kk0ZwVVTh&#x2B;SpbVNfc0bDknqLsJgL3EsIvBJHNx7BOyyuEFYTYgFaiJI/YrG4EtNzdFnsYNUtp2JPQfr0rWtV0vN11adqGJhQk4pqt81zse3aH4t57LRhazlKcannEwv2ao9tn9j0fBa/WK1F/JTP3OdehxVdUl2/o3WXTuuUqnJ5&#x2B;hYj/3WI/LV9Hv8jyqSalOToxSqpVo5R5nRevupNDjDw868bDX&#x2B;7x/2l8nujFHbf1E33PUtF8WdIzkYWr4FWWr/wCL96n6q6PZsnqGS1DC/WMlmqMWh/4qK00BzzPAknmgvql7gG7wJSVvzJKnctluAtuIUWFldDfgBLdkhLD/AKQ9Y&#x2B;wCL3Fu3uIbsGAhrgfMXkb72ATew2czuFvPZCU919QE2t9Av6sLxuNgFkrFVTpvS2nw0ZfKkVOdwP04OqZrC3q81K7n68DWcCuFip0vvweFzOfyWRp/EzmcwsKlbuutI8LqPiZ0hp0r&#x2B;0XjVU/4cCnzffYD36jEwsRebDqVS9GVW/gdS53xyqw6mtG0dppWrx8SPsv5nhdT8XeudSTpWq/gUv8Aw4FCX3csDtzqvpfoXqfL00da6BpeewsN&#x2B;ahajlsPEppfdedOD8Wa8SfDzpnL05PL6hl/LhU&#x2B;XDwMnRKpS4SpsjpDO6vqmpV&#x2B;fUNQxsarl4uI6vzZwS4mS81UxjLKaqpp5ZnZ2rq3xCZPDTp0XRK8S1qsevyr6KT1fV/GjrjUZpwc5h5Wl7LAw7/VyepKdmw2yMX6s/resaq3XqOqY&#x2B;O//MxWz8ydPBmO7KuyYFnsG33gPu0R&#x2B;4Fn1iSTuTfdBtbP6gG27jYs2vsLRdAS/YqUzA4uW7twAEd/qE/UNrsAlJwZe0ssw9jLYHamh0fh6NlaY2wKbfI/U7OOTiyVH4eSwqEtsNL7HL6UoCtCY2YjuxxcCNxt8w3ezFp7dw/T8wK4ja3uFL4IVRsBHLagqSiIEcIR7/UoJOLgO7gOYj7EEaXLEWsP/p9w1HIC0fyEtiLJxxsH2aAriJClrb2JHdlW9wEhK/8AEQ2wvSAEXi30F13EWiQ/eQG3H3ERZMON38hvuBGoTkOWVRAaXIESS3YbcXGz9QgFt9wt5THv&#x2B;RfSoCcbF4ge4i9mBNkrhXLxYJt2ARPNhzISC9tgHGw&#x2B;QgekgPkXZkcC&#x2B;0&#x2B;wFJC4ExyAH9XCkfUXkA0yTF&#x2B;PUt0NgExwJb2/Inl5fzLDTAK24sxEK4cQAfa4ajiAkuGI9QDTYvEwNg5dl8wHMhLs/cNTZpCbQgHMSHdxAv8AILawEe92Xf8AzE2JvdICtykyPv27lSvbtYcxO4E3qgbbdi2X1CvuBJ4lljifmgygB8w57k9gH1DaDlbfQR3QB3ESI5Kp5AQ&#x2B;1hHoF6hv0AjvsNiuYImgEN3Ql8i2wqXMAEyJ8/0i3d4t7jZ2QBtciVwtgvV/Ie4BPuNnsPb52DmLgOdgp2F2xs5kAk9x/TG&#x2B;6&#x2B;Y2ukBFCs/Yu9oJM87he8AHLUSE23dfIQnz6DYDmJBXe4lvdmyJfgF2sS0ALRZC4jgjdtiC/Mc2QTnkXiSgtoE32EETU/kQWJtyR2syrb0HrAEunZBeghzCf2K4vyUNuA78/IXV2uBalWsAmX/ENetg&#x2B;8hEF&#x2B;ZH6hQ3H1Fmiqc7EutlcvMtfUW3u/QiIkmWE/UQhD7cAGo5sOZC3ljiwBqbMQ4tcb7oOxVPkLtXY2cfQTciF3ui3IvQoAIDYASO6RRcCRN2hHZBKNygAIvCDSi4BbCSRD2LEooeoQBAEdxAgAIjYKRuBEON5KR3sBQJAFkQ5uQewVY5Y3IX0QEEPsLF4lBEStuEpKkFMgSIC9QI5AWLPdkRWAIytyAqfICwiVcIJL/IvsTncoBPuF6ckdipTwA9iFSDnlARXASkscJgPSAu49WxFgFkLLcNB9wFouPUK2zJ6sBC3LvA324LfZALeUT3Qmf8xKd18gI7kL8iAXZ7CL2ci/LK1x9APlj9Lnk/x/hhymZ8v/2v1Tlan6Th41P8T&#x2B;aS2hH9Rf0qen/rXwh6nmWp/V9WyOJ7f3vl/wDUfy2VXH0O40P9j3vsXsLVngkx4Vz8Ily&#x2B;zP6P/BBm1mfhg6Wrl/sYOPRf/lzGIj&#x2B;bs8H9EP0f&#x2B;aqzHww6NTU/9lm85RSp2X49T/icfEo/oR6uL29pzweifCuPhU7rTmzQ33QTlfPge50b5ETG6&#x2B;cku7wWGuBF7gRK8Dd7l2RHO8Afjwm3TV6YlSX1ZrkmCv37/wC8qt8ynPHRn3Vdh/Uk&#x2B;RexQaX&#x2B;QXoVJKxLT/kEgckK97kASWHMESKpXADfctLuTeC0vuwLhL/vVba/3dP51HOl63OHBX/ea5VvJT&#x2B;dRzJSog4auqSK5b/zkWnn3FpMUKbI5slqWf0zF/H0/N4mDWrzh1NT/M4eYT9yT2YHt2i&#x2B;LWr5SMLV8tTmaFb8Sn9mv&#x2B;T&#x2B;x7bonXnTet&#x2B;XDwc/&#x2B;FiP/dY/7Lnt2fyOpU2uCzN0B3lS1VT505XcN9jqHRusuodDdNOS1Cp4dL/2WL&#x2B;1THa&#x2B;x7bovi5kMw1ha3kqsB/&#x2B;JhftU/TdAe4u9l9hxL&#x2B;x&#x2B;bT9U07VMJY&#x2B;m53DxqXzRUm0foVTVgNKymRd/wChE0n6lSgAr/IsKIQ4kjqUwAb9RK&#x2B;p&#x2B;XPa1penU&#x2B;fPahg4S3/vMRI8HqPir0lkW6cDM4mYqWywaHH1dgPZZU3ZZTdjrvUfGnPVzTpWkUYc7V49cv6I8DqPX/Vup2xtYrop/wCHBXkX2uB23nNU03TqPPnc/hYS74mIkeD1HxV6RyNXlws3XmKlxgUN/fY6pxcXGx63iY&#x2B;LVXU96q6pf3MtxuwPedS8aszVNOl6PTR2rx65f0X8zwGpeJHV&#x2B;pTTVqlWFTV/gwaVT99zwbSV2RgcmYzebzdfnzWYrxG&#x2B;a6239zj35LdW/IN92AtwyNzvuHbdCePQC34LzfsS&#x2B;zD7dgEqfmQ16MnuAs9/mEm&#x2B;1xFpnYIA7Lm4mLSV7R9zOzlcAJatIUb7BzPyKoiWATXCCtZMtolC0xACX2KlBmFvH1Kp3gAyOfn6FdyTNpAjdiUJ4mLTQuaoDRvKLzZ3Cp74lK&#x2B;4WOrtrBhYNCn/AApbehqIcvsShfs0p8JF5gIbX&#x2B;g3AfogJPpwG&#x2B;4iePoJsocgW0wG3vAjYW4AbqIDmLCEFvAC0XQtzG4S2DULcAm9hHYD0AjXdMQ9vkV&#x2B;ghPj7AIkfIN92IWwBwrNC8iJEQ5ALaz&#x2B;xOZ&#x2B;5oi3AnFuexVuFC2QQC&#x2B;35iFESFLvsPRgErXQ9ApixX6gSJV3uC&#x2B;xJ7AWzuROORsTmJQDiZKk/sFumhxABN8j3Y3HzAXFkh6wN7gObSLKwlJTI2ATsLrYNXERcCReS72D2CYCXzyONgnP&#x2B;oTcWQBPmR8hF9w/RAH7DkBPvAFiCQuxVHAkCN&#x2B;vuJD9wtrP2kBuoHNh7Dde4D0Qm4Xb&#x2B;I5uASkjgsOGmHMARWvNi7qUytSSQHNhMvuNrhQgKHdR3I3bcNwgHMQGpInyiqe2wCd4CfDY2swuwFbtJJtIv2F3sBU5EzsRD3AXmwuEv6kc3QD0gnljt7mncjmfyAejC9Al2Y4utwG/AlbvkbkalWQBx2Lug95S&#x2B;Y2uAandBw1DL7EbaUpANuYD/MbuFcRwAi9yW2LbZkd1uA2Qb9A&#x2B;5G7WA5lHcpFbku&#x2B;5swE&#x2B;ofeByIlXAicvcN/0xHBWgqJR/MsRsGp3DXcCNTYIrJD2CC3dgpm&#x2B;wdywgI7bsNN7li5IcR2ICa2kNubId3v8g&#x2B;zKEPdfcNWuyFj&#x2B;mQLiGFtdFixRPYbFhxYRYCWSG&#x2B;6LEAgnuwpi49Wh8iqRBVPYmxUrXAR3DQgBEv7FW0gEBAKygAA45JuUqgDBEL8CE&#x2B;B8ygQFtBGUBwJEhVtwhAknsEUewlcv6ABYjLwQYUYHzCXZEQJN9ixeBHIBbgKmNipXuBC25Q2uGlyoAJrke43G1mAhkL6R7EKBVYkrsCAFMwi/MPeeSg/UQFs2F2RAew9ExFi8XAjT5HNkWLT&#x2B;RNwHpHyEKdxNuPaCxH0AijsHe0QVRuwpe6&#x2B;wEgWa7F3tuI3/ACAjc8lc8ESlR/ENdkAXMiJ2CaKl7WAiSSiS8Xj8xPDHZICTLuVrmQk4iNhbv9QIm1sIm/oW3KDngAr2gQ04Q4j8x80B0P8ApLcn&#x2B;ufBr1Xy8J5PEjtGawv5n8n1Eyj&#x2B;u/x&#x2B;ZF6h8H/XOE1Pk0qnEVv&#x2B;DFw6v4H8iF5WlHJ2/D97M&#x2B;r6z7BV/wDpVyn8c/8AbSbcH9AP0cWYeY&#x2B;HLDwnXP4OtZqlKNp8tUfc&#x2B;ANlv9j7w/Rl5v8AWPAbUMvP&#x2B;x6jxlHacLCf8ScRj/T&#x2B;&#x2B;Gz7cRzcD9Kqfm&#x2B;i07FT7E92WezOhfHVdrk9UJDcqyARYPeIDbjYlrwB&#x2B;TBpq82JL/3tX5mr/fkmFT5cTGolP&#x2B;8n6pMsS5k54Z9zgegi4t2KKoSj1I57sTDE23QD0bIVLuhPZALvj2HpHJeZI1FghfYqhsnvJVbgDWE4zNX/AMunderOdXOHChZhu/7qi3qzm9/zOGpJIS7k9XyV7TI8ziyMURfmG0FLiRzZgVS5DcbiFEC4FkJkjn8gn6AcuWzeZyWKsfJ5ivCrW1WHW0z2XR/FXX8glhanh0ZvDX&#x2B;J/s1x7o9WT5NK/AHaGmeJ3Smew5zOc/VKkpqWZ/ZS&#x2B;exwan4s9M5NNZTExMzVwsKiF7y4OrNbbWk5ipO6wqoh&#x2B;jMYTnCplv8AdQ7ssfVy911Lxm1fGTo03TMLC482LX539FB4HP8AXHVmpprMazi00v8AwYX7C&#x2B;x4p3cwTmWwxaxMTExa/Pi4lVdXLqcmU23EjiJ&#x2B;gU7gVWYTvAns/uSfVganuyNz/mE53Fo2Aj4HMSr&#x2B;hWvUyrcAXa7/ADJ8uOBxLXsWbTwBI/1C7l43&#x2B;gj/AEALm9iNX2&#x2B;hVvfcjUKYAKG4n7Fj5EnuXm4FXYm3IvsL9gHyuNmGuUOIYD3Fm7CLQwomF&#x2B;QFW0thpvYJLkJrZICO9uRDL2ZGpfuAut0J8z9&#x2B;BZKPzEzx8gI0tjm0zD82rZalrfHoVvdHCv4n7NCw/NrWUXfMUf8A2SCx1dop/wCZVxcju32ngsX/AHggLh9g73&#x2B;gE34HqkWJ/wAwuzAWTSFk9/ZDZXEWutgG2/cfKA04hfMPaJAQuFuLiOI22HsAurjgQJ4ARwI4JG7S&#x2B;ReAE2uLiP6Ym4CEggygRKORyPQsJAR9xyVw7ACTD2DQcNCzXcALwG7By7pgNuSTHATUyhdcT8gAsmWSezsBYETyAoiwB33CstgocQAFneQ&#x2B;5YAEXoxLFiL1fuBbK8BvsEu/IalbALx7bkU8l5mSJbNgL8sTCt3C2mfuWwBb7ie6HzL7ARxwFE7BXLEcgNgoI7BtpAOBccMvsBLMK&#x2B;xSKLgG&#x2B;EG5TK/VETkB7MKRxYoAzd7mpc7EfogJtdlbiA16Dd2YDdu5IaV1sGnuWXywC7kvxH1K&#x2B;8knvwBY4E3tcnBVDAN8fwLxBJ/piVMp/cBvdBzH&#x2B;Yv2&#x2B;4vNwHpDKT2HqBdyewn0Im3ZMC7JwJcBu0i7UoAogNBNvixfQCL3E&#x2B;q2G&#x2B;44sAbiydyOYlsr2hsi3jZgWX2&#x2B;5LRDLEDZQA22HMQHvsPcCObwyNcGokjV7fRgczXDA3ewNlRj3HoAghtui7XgjAP0Q2FxwA33EAvy&#x2B;oEGymCw9mJtEAN7kakAKOYglRfmNgIl&#x2B;03O49WWI4J8wi8f5gBerCnoC&#x2B;xHZhBvuAGgHuBxcLYBadxdMBSBbQONyBpQgE3D9wOLEgH7iQChJN9ypCEtgqWDsX5jYIF4uQBVe8QQq33FvUIgtwWCRcAFHIZbwFE53EQ7kK9wEsm1i7/MdwIIQi8FvyO4egS7BONhxEEQi3yLHCYvEoj7fQoQtp&#x2B;5X5b2JNoG9of1AK5VvHYl27iH2ATa7CTZWp4&#x2B;wv6EEaELuPlASW8AElxI4n8iqeI&#x2B;o9/zAj7IbX/iWHENkvEfQornuGkyeo23ZBWoCkidhPoUF6dhDmEVJtWf0CbnuQLLdbBbX/MjfMFV/wCQBRv/ABCaSuvuLLcREy4LsonbcLtAW20hxe7IhDdv4Ee/yL6yVKIQEtKXqP8ADYsepLv/AEAXVQs2PYXVpAOJ4E8oNK8j1kBDd5Dl7hd0uQk43A61&#x2B;MXJ/wBofCx19lWm2&#x2B;ls3Ul/04bq/gfxvpq7M/tP8RmS/tL4futsl5ZeJ0pqFKUf/k9Z/FeGltwdtw6fqVQ&#x2B;oewVf&#x2B;jvU/ij4f8AhtVKD7f/AEXOa/E8Kuosm3/s9eVUf9WDQv8A0nw8faH6K3MKrpXq7Kp/uahlqo96K1/A5OIxnSz7nbe2P1uA3PKafjD6ulccCJ3QlTZ7FV78QedfGUTsk0WZW/AU/Mj2hAFHHJH2K/ZfMO10wPzUx&#x2B;PjWj9pf/Yori07ET/v8Zf8yf2Qnjuc8Mx&#x2B;iCK1L3&#x2B;ZOYKQMcBrmB6JAIX1CTiVIcK3oFK2Aqc8jZ2JdXjYsw5CJtyVb2QtOz9glvYDeEv7&#x2B;W3Hk/icytadjgw/Ks1E3/Dtb1Odevc4akkmUHEwI5LBiiQoshF7lS9QwJzsIL7ACOOA054KlAAbFViNNWEtMD8&#x2B;ty9IzEP/AHNX5Mxh2wqX/wAq/I1rX/wnM&#x2B;mBV&#x2B;TM4dqFfhGP3mc/249f8NT3G5GoK494MmBfaAtrD5CzUAGIfYR6iewEaacth2uvqVTPsPl9wI5b3JM3kszZsewDdcD3YSYae4FiN&#x2B;1x/wA0kXyfcv8ALuBI4VhL5LzZSR1Whp/MAtpX1C9PoE5cC&#x2B;/1AqshxdhbXXzESoYEmdvkJ5b9w7SLt2AJzaC8ySyci02Aq9RHIj1HzAfwJfdrYr23M&#x2B;ZLZAXn19yWTsyVV&#x2B;W9Thdz1rqrxi8M&#x2B;iU6upOtMhl6qf8AdLHVeI//AKaZf2OO7etWaea5VER5zhz6fTanVXOSxRNVXhETM/lD2aTyPSlPn6iylH/nL8mepdA&#x2B;I3R/ifoj6h6M1X9ay9OK8PFTodNVFavDTvtD&#x2B;Z7j0UvN1LlJ/wCN/wD2LLbuW7tEV0TmJ6TCXrF7TXptXqZpqp2mJjEx6xLshXq29i3spF5ItjNwq2mGEklCEpXAWe42LKJad/uAKtiTeEVOeAAt/qFcARW3Y&#x2B;ZYvuRAX1Jt/ASLAIfIsrhfkF6gHDCdthzdhegBtSN1Zhq8D5AFvsUk3EgVqVcBsc3AkJl2uRwtw9twDkSkPcPswCV7/kObobbxuTfaQHzChli9hvcB6iBZX&#x2B;Q4kCgnG5WA2SlkcxYX7CzAO3AsmHYJxYB6wNrCYC/MBFxHBYuRpAEJSu3sFIcfQBPI5uh8hebL7gW2xLSUX7ARj2AtIC7GxdluAI/UOpL/ACEkdK3UAV&#x2B;pbdiJShbafYA2ix2I7IoEsJ42AnkAxZ3f5lY&#x2B;QEaXYR6lAE5iB6sX/wAh6yAtMiBZCO3zAcb/AEI7KWjULaCPvYBsFM3Aj0AJ7KQ3DiBf1DfdAPUe9gvQL2AOGxCHEbCLzICJf8S3ItrsuwBkvz3KrhgRTyRlavuNnYCS&#x2B;xZlSGlsOYgBC2gIN/0wmAlDkpLtyBzdyehr1a4I243NkNvkFHMB9kyy6XC&#x2B;jCjiIJM3f5F9CdoAgLyIgCe5WlMoRLuOYTCFgn3&#x2B;g&#x2B;ROAK2R77AbodFP6uAC9gG90JEJ7gFPYWLAjsBFuNiuZJvsQB7hAIRJE03Ye5eAA9AvccAX5h&#x2B;5IK47jAgKl6&#x2B;xH2QUCidpBYvAE2BZtfYNDAjvwSPQ0kiQEPYbWksWkjGFW8WQJHd&#x2B;5eJQBr1EXsPnb2G6swiekF9SC&#x2B;4VYewew33DlbiAj8hfcWd23PYWiwwHJN&#x2B;CtXmBvwUOdgr/AEFhxZEQESxAQBTz9SwuWRK&#x2B;wtF0PMPRP7j0Q3UFt3AXiUhNSFlsRpSBX3Exv9yTxG4vt2GBVe442FoloPtH0AR9UN1cTPI9AHuhN7k4lsXuA4LNpj7hS7CLbb8hSzu/kJlbD2QmGyIN2EW2F94LMfQoWm/G4U8klfzK3F4IJM8FtyT52LvsyiStwpdywoFpmCAiWXMll7MAFM7kbh3D2hjiZAO38QphCYWxYW8cAJtdhu233J7FA8F4m5P&#x2B;0fDjqDTqlKzGiZrDa98KpH8QXCqa5Tg/uhrmAs1oucytSlYmVxKY96Wv4n8Ms9hvLZ/GwGv3MWql/Js7Xhs7VR6Po/sFV9TUU/8AH/7MK9j6/wD0VWYXn60yvm4yVfl/&#x2B;/I&#x2B;P0&#x2B;zPq79FfmnT1d1dk/ParTctXHtiVqfubGvjOlq/fd6L2qjm4Bej0/7ofaPqnJ8vfGP8fmt/DP4w6X4e9PdJ5TUsCrJ4ea1j9axKqa/LXVUlRhtOKWlTMud1Y&#x2B;oZS2Z8EfpU/BrVc14y6H4mYOXr/s/UtKWVzWYpVqMbCqqaT7N0VKP&#x2B;lnV8Lo01eqxfj6uJfH9Hp7mr1NNm3GaqpxEecvpzxc&#x2B;LTo/oP4ZafiJ0Ly5vA1HK4b0bLV1Q8XHxNsOrt5WqvN/0s&#x2B;UvB79K94oZLrbDp8XtLyGd0LNZiMarI5b8PFydFT/AHqY/fS7O77njutdIx9S&#x2B;Anpbp7M04uHk8v1lmqcvd/tL8OqpO&#x2B;/7VVZ8v6zpOY0TP1ZHMpWvTUtql3O74ZouH3rdduqMzmevXHbDuNf7P63htmbt2ImnmmnMb4mJxj/AA/td0/ruk9UaHlOo9Bz&#x2B;HmclnsvRj5XMYVU04mHUpTXyP11LdpnyV&#x2B;iX8ZMz1b4W6r4Sa1nXiZjpzNLF0/zO6yuL/hU8U1qr/7tH1t5YR5zWaerSamq1Pb4dnn6o5Zw/K0qc1XSld0qp/l/ANPbsXNP8LGw8VxFT8tT/L&#x2B;vUVJ&#x2B;hx0zsygdrNgihFUzsZiSPn8h&#x2B;QatOwAS2xDiEhDmwNhj8huEo2&#x2B;4FvefoEp9uA4uWlRz7gKP/tulJ/7t8eqOemFscFErN02/3dX5o/QnwmcNTGVBF7lRihcMAB8ierK0TcCyCF5AFsQAfm1pxpGafbAq/IzhNvDp/wCnuXW4Wj5p/wDkVfkTBT/DpvwifeZz/bj1n5NKXuIvZiJ3uVepWCVOwst2HGwlT2AJdhMJj1HsATfBJSUJoqcsk2Aeqf3CTe/zK134HsgJFosV&#x2B;iIp7e0F5AbserJ/EsQAankjlv8AMr3JCv7ALNJwVKbpkajdyE1NgG3HuJUXdvUPeCw1IEs1b5h8jaxVH0AkPfkWb32PSvEL4g/Crw0zdWmdR9S0vOUJefJ5XDeLiUyrJpWXzOp&#x2B;rfj2wqfNgdD9E1VcLMajjR8/LTP3Z1Wr41wzRzNNy5GY7RvP6PR8M9kvaHi1MVafT1cs9Kp&#x2B;rHrEzjPuy&#x2B;jqVFoPHa/1f0r0tl3mepOocnksNL97M5imj82fEHid8bHiFiZCrO9TeI2Do&#x2B;Srqqopw8lGGqmrulNTU3HEnWXSvjFo3izns7jaVqmdztWTqp/GzWbVX7fmmI8znj03Ol1HtTV9DNzT2Kppj707R&#x2B;mfi9dof4b0zqqNPrtZRRcq6UU/WqnbPfHbviYfcnV3xmeDnTjrwdLzmZ1bGo2pyeE1Q3/11QvodX9W/Hh1pn1Vg9H9LZPT6HKpxszW8av3iyX3Og8zmstlMGrMZvMUYWHRS6q8TErSppS3bbPVeqPG3w76W0ijWMTW8PN04uI6MLCyLWJVU1vabe7sefr47x7iFXLZzGdsUx895/V7qz7E&#x2B;xXA7f0mrxViM5uVfKMR&#x2B;ku2eq/G/wAVetnVT1B1rna8KvfAwcX8PD/&#x2B;5pg9WqrqrrdddTqbu23MnXviB445HQeiNP6h6XwFms3rTVOm4GLS/m6kt4do7tHpWj&#x2B;IXjPmPFLQulOucWvILGx6a8TLYWHTQsXDcu8bqzXyNWjhXEdbbqvXasY5vtTvPL1xG87Tt6u0ve0nAeDX6NJprczzTRH9OmOSOfHLmdojMbx5P6PfAPl/w/DzW8z/AMes&#x2B;WI7YVH8z6P6Co8/U&#x2B;A09lU//wAFnz/8CeW/C8IM7mIj8XXMWbdsPCR9CeHtPm6jVXbAqf5H0PgdPLwizHl/5fCPbWvn9qtXP4sflEQ7B539gvb7BRuJO2eXT9lxJdybqxU33AsLsRwrlD9QI2xZ&#x2B;/oRw1Yqst/mATLNycD5cgVbE9w3YJNSmAiBfcC2&#x2B;4BWuOYG6EKAE&#x2B;v1EzwwtxCpugF&#x2B;Q4kWd0HM2YD0cjZQw5SgN8MBzEi3LEylYQlsgLHqRC4cbt7ARu8W9ZLL7Ee0wVNu0QAfaQ0u5Y5AEatAnksdiOGA&#x2B;gvEsW&#x2B;SH0ABNDZhd2Bb9hASGwEi0CE&#x2B;5WiL3AQxf7hPlsvoAagXWwkkTugAj0F4hBJMB7WDlq5YI1DsBUS6foGuBN7dgL7k9YAmbgPYT3RSTPyAO2xP5l9xEKAEcJhqdxE7oey4AKI2kpPdlAjneReILuSfQA4m7FuEPkIW6AseoHO4AEtJfYjQC2wvuhZL&#x2B;Q4swD2v8wGpVhezswEt7MWmYECWnADZx3EXFt5HH8gE2iBEqEFG4XqgG27L6kVigEuYEeoIuwCJZfkE/UnICPXcXEvfgTNvqAandD1&#x2B;o37eoTAc2CmFFw12QuufmBbO6ClckDXqBzu1kI7oW&#x2B;od&#x2B;xshCblDZXX0F3v9g4QVPYPcqp7Brv2Aj95FtvuI5gu3JRNnawsLiJIELuQq79tw0oQC0XFyxxBLu64KGzj8yPsX3J8wF9wr8jezK01dgNhC5IVtxCEgrXIXgi9iAgF7lj1CJAhyVoRedgqJXhFiHYewsl/Bl6hAukVbbcEhRIC7dycSW3f5CO4EhBSXgbDYJn1HshHqN0RDYL3C9g24iChtcNXswoVoQYVEJcwWLbhv1JsAe8SFGzW42X8Sg1e4tuLBtE3BeiDVvYWmyHcuEJfDDE8tB7TAU92WY2&#x2B;pJgt4/mQSbBbxIcRMBJt2QBXvP1DV7MqTT3Ec/mEPQNSFKQ/jsFPb7COCx6h7BEXm7fUKXsFe0BtcAItdokp8FhsjuBZtebC742I16cl3iVYBM3cejCtsvYOf4Fd7xYoitwOb/cXaC&#x2B;ZJwCaQs3cLexZtZAJ4jgm3AVg4XP1ALYrJTtZBei&#x2B;QC02/IONvQqadvzC9EFSew2uHvC&#x2B;aEcKPqEX1FWwm1rkUtbIYFvyRVWv9StLeRs5IF&#x2B;xOZgqT3EQodwM/tbt&#x2B;xqLWDvaPcekAR2UoNrjkb7cFe9mgMY1LxMGuh80NP6H8Oeucp&#x2B;oda6xkoj8HVMxRHaMWpH9yHZQ&#x2B;x/EzxyyT03xq6u090x&#x2B;B1Nn8NL2zFaOz4b9qqPR772Erxev0&#x2B;VPzeqy1c&#x2B;nv0XGc8vix1DknH97oCq3/AOHGo/8A0j5hafCPoz9GNmXg&#x2B;Pufy0/7XpzGsvTFwmbmsjOlqeu9oo5&#x2B;CX48vhMPvZJHX3i/4g/DtmMPE8NfF/qPRq3j001YmnZ3GTqSm1Ti9D7Ox7L4o9aZbw58N9e68zVKqp0jScfNeVtLzOihtL5tR8z&#x2B;Remdb651x17qfU3U&#x2B;oV5nO6ni142NjYlct1OqYvwk7L0Oq0Ogq1Nqu7nEU/F8s4Bo6Ndxa1ZrrmiJnGY6xPbHvw/oh8Wvhd0nrfwl15bwty&#x2B;WeQ0HGw8/kqMlUq6HhKVW007/s11VP2P549e6X&#x2B;vaR&#x2B;tUUziZd&#x2B;bb/Dyd&#x2B;fC58RuoeFHUK6S6rzeLm&#x2B;k9WnL6lkcWt1U4KrXleJSntvdLdHivib&#x2B;GnXvCTXsw9Py2Jm&#x2B;nNSVWJpGp4SdVFWFWm1S2tqkvqlJtaOurS34iZ75/wAvqWl4ZVotLqOC6yvm&#x2B;kzXbqn7094/5U1Ynzzlz/oktXzWU&#x2B;I/UdMw2/ws501jfi0p2/ZxcKpP&#x2B;HzP6QNNuGj4Y/RJeCWv5DXdd8Ztc03EwMpVk1kNLrxcN0/jN1qrEqplbLy0qfVn3MpOPjldFfEJ5e0RD4xd&#x2B;2xj4NOPh1YOIv2alc/NTi15b&#x2B;5zkpr93Ee1S/mftu7h0qpRUpT3TOpicMInD88bOlz6yRrl2GJpyVXnyuNVhPlJTS/kZ/FxsBeXN4DVr4lCmn&#x2B;aOSKssoxLXpEMd/XuxRXh4q82HWql3TkrUOUixIkRaBEXK4e5I7oolmpuE4NOF8yK&#x2B;wBW3C7L8x6K4UTZhFpf/eaHz5KvzRzq1zgw5WYocx&#x2B;xUpfuj9Ck4akkm3sUAxQFgW20AQbMrUbkfsBObl5Jd3sOLAUcQT3Ku4H5tb/&#x2B;DZqP/Aq/Izg2wqf&#x2B;lGtah6RmU&#x2B;cGr8iYf&#x2B;zV&#x2B;Cd2c/249Z&#x2B;TSG4E8FYI&#x2B;0iEoD9BvZAF3XYQePzvVvS2m6hh6TqPU2n4Gbxf9nlcbOUUYlXtS3LPIK&#x2B;zTtumWYmOoQI4&#x2B;pSckCLRA2D2/wAxPdgIl7QSZ3t2K94/gFHCAJdxZLcfyDtb8wEd9iXUSWOGS24DdfMsJfxG3BYasBI5kkJn4cr1Z0vn9dxumMj1DksfUcvR58xkcHNUVYuFTKU1UJzSpa3XJ6t8RnjbpPw8eE2peJ&#x2B;p6c85&#x2B;pqijL5NYnk/Hxq6lTTT5ocXctxsjOm3crriiI3nosRMy6/&#x2B;IDxy8QejPir8MvB/pnVMLL6T1HVXiavS8uqq8VKpqmlVb0q14&#x2B;p5z4c&#x2B;g/FjpvX&#x2B;o&#x2B;rPE/M5inF1LHqeHgY2aWJS4rqadNNLappS2dm1XDX7KOk&#x2B;tepOoevvjd8Cuo&#x2B;qtEw9Pz&#x2B;e6Y/XsfI4dbqpwPO8xWqJcNtJKdr8H2HnK/w8ljYiUxhVPb0Z2Gqn&#x2B;W09FERH1qd59Kp7s/CH84PFbXups3g691DptLzerYuJj4uAqqfM8XFbbSjm7Pm3xFzvj5h4mSy/WWu42Bi6pi&#x2B;TLaZlcyqW7pXpw9lLSu5PpvPVJ5zGr2Txam2&#x2B;Ls6V6Rf/ALXPHrO9WYyeJpmgr8PJqpfsutNql/N&#x2B;ar6HxzgepizN29XRTMUxNU1TGZz0iIntmX6L9seHzq6dLpbN6umu5MUU0U1YpxG9ddUR15advDo8J43aVk&#x2B;kdN6R6Gx8niZzBymFXmM7h4VTVWNU3T5nKupfmue5/Dn1p0d1HlM9pfT3R&#x2B;Bo&#x2B;Pl3RVi4eBX5/wAWhylU6ndtOd&#x2B;5&#x2B;rrjxy6B6G6rz2j65ouLiZ7L5ahUY&#x2B;Hg01PFTp8yol7K/wBzwXwu9N5/GzWteIebyf6vg6liujJ4SUKPM66mvS6S9mbd6qu9wGqdRRNOMTTVnauaquaduk7T5&#x2B;51ekotaX22t06G7TcirNNdEURm3TboiiPrzvG8dIxmfF4fUens54m&#x2B;OXUPTeqdQ5zDyGUy2JW8LCx3FqaEqUrpKYb9j1nozpLp/NeDHVfU2byFGJmsrjYeHlcapucP9qmY95udu9H&#x2B;F2u6V4n9RdaahmMGjL6pRiYeWpw6prSqaip8cbHkejfBfpfpTpHNdG5ivEz&#x2B;VzuYpxs2sxC89SiFC4/ZVjOrjVjT2ot0V7RFrEU&#x2B;W9e/j2cVHsfrNfqKr921EVVTqczX&#x2B;Pa1tvOI3mMRt16um&#x2B;osj1LpHSfQnWWladi5nCyWXdSoWE6qacRYrrUxtKiPY8n01rXWHXHxC6Nq3Vel/qeLTgfiYWSSa/BwVRU1M3u5d&#x2B;52B4p9B&#x2B;IuayWQyXhTrtGmZTK0eSvIYdf4VLvNNSaX29Dm8IfBfXen9ex&#x2B;quptTr1jX89T5FVhUupUUvim0tuEttlYyq4rpZ4fVcq5eeYrimIzzRzT0ntHXMz37MKPZriVvjduxR9JFqmqzXXM8sW5&#x2B;jpiMxOeaZnEREYjHWekPv8A&#x2B;CjC/B8D8HEe&#x2B;LqeYq&#x2B;6p/gd&#x2B;eHFLq1&#x2B;qpcZer80dQ/DP0Tq/Qfg5peia9gVYObr/EzGNgV0w8P8St1KlrulErudxeGFKq1fHr/4cH83/kex4XbqtcNs0VRiYppz&#x2B;T5R7S37ep9oNVdtzmmblWJjpMZl7xtuFsHLcSIbub7oxFvwiJ9xN4Au9mibuGg7ykJANcoindorupIlNmgK73G14JEOV9S8WQDiwUxdltwS6dkAjsF9BN4f1LvdAIjkMACb7MP3KI7ASICmNi2REtkAgQkOblXuBIX&#x2B;TKABLDcoAm3JYQAAP1Ai4EbXImVKKTa0gPYsEjhh7ACjYL3AAe5AKwvQIAPmF7Es7MPsAH8QmVATnbgL3D9wu0gV9voRxygX3QEc7SBcX7yAv3C/piBCWwDcQXdEUAHC3HaGJ4n6CQG3In0GzlhANrBKxVe6CjgAIkE33sAdlshE8j2YlgV9yPuHHLAFHrJF6i/CATz&#x2B;QakQIcfzAkWUrksRsgi&#x2B;4CPQk8FAEfcJFI&#x2B;wD2QXaPuJTugmBbAjksgHHIJDkNvgAtxwOCzwBH3j5hvlh&#x2B;iC9gEX/wAy7bEV9y&#x2B;oEiNxPMQLzaBvwAtuEudhHawQHOnKgQ4iSUq8GoSfeTaVHtLKpS/kPRC7ViCTe8CCr3G12AULYj9I9CwoDUjKM1Fu1YJKZkJKJe5VN5Qvww/aUF6MHYtsiXaK0LRCYRN7L6EZdhbuFLiGg7sNehAcpEixWoiNxb&#x2B;ZUNrC4hiLbDAkKSy1aRu7E52Kq7CPQfIceiMUH6hO0BbB7FU9xNoCfcJ/IgiTjcqvd/UqmrkJLdsImxQ&#x2B;5Hv&#x2B;YUa/4UI&#x2B;xYsRtCEEpkNz/qIh2LfbgqpDXIcN7&#x2B;4bS2YVryRBiLwi7qGx5XwVUgbL1Ef1IlMiDtbjsG737cl4sTdzIFj9kez&#x2B;hJUW&#x2B;pdrsvRSHE/xIyy3YOWrASHOxeLsnr6GrK0&#x2B;xBF7MfIqUdxMWX5BEvDuIkRP&#x2B;IsXu4KDhyoI52&#x2B;pXPH3JEsgKVcswS65uWG9/oBHO8XHyDjzSx6oqqvUjUOxfWYDiCRsJKTn8xEuxXK9yX3qgBEcBMRe7LNpQE4mA0&#x2B;1itW/mI5QRIUWLsgN1sFSG7iOPyLyPVouUTazHr9C7cBSnDIotvQP6Dn5BuwRH27BKFcrmNuNhHp7BUnlbi7/AIlVhAQjgLcK/uItYKB&#x2B;rEdvzEkQXogtmLjcA3Ngtv5BNxZESaUq4Bbw/wAz&#x2B;MPxW5L&#x2B;z/iY69ysR5erM80o741T/if2fUM/jt8cmT/Ufi469y/lidfxK4/6qaav4nY8Nn&#x2B;pV6Pbew9WNddj8Pzh1Vwd9/o3s48t8SuBg3jH0XNUOPamr/0nQZ3V&#x2B;j7zKwPii0Sl1x&#x2B;Llc3Ql3f4Fbj7HZarfT1ej3PGo5&#x2B;EX4/BV8H2P8bWHj4nwqdcrLJupaFiNpf8Pmpb&#x2B;0n8ldF1CrTNSwc8v8FX7S9Ofsf2a8XOkf8At74XdQ9FqhVVapouZy1Cf/FXh1U0/do/jDncpmdPzeLkM3hOjFwMR4eJRVvTUnDT&#x2B;Zn7OzRXp7lufH4x/wCHxvSXa7FyLlE4qpmJj1jo7Oy&#x2B;Yw81gUZjBqmmulOlrlM/oB8DfXuD4reAOX0LqPCw81j6HjPIY9OYpVarw0k8NtOf8L8v/wBJ/MnpjrGvRl&#x2B;qZymrEwP8Plu6fY&#x2B;0f0VfiFldW6w6r6QyeJiVUV6dg5uGopTprdH1/bX9QafE9Des25nG0b5fS/aLjnC&#x2B;PezUV80U3qJieXvnpOPLEzPxfYusYtPTfS2dzOkZPBw1ksji4mBg00qmhOmhtKFEKUfPPgT&#x2B;k48F/EnGwtD8QaKultUrao82aq82Vrq9MX/D/wDUl7n0X1BgUZjp/PZbEU04mTxaXad6Gj4k&#x2B;Dv4OfBf4kfhrxsx1jpGLldYyvUGcy&#x2B;HrGQxfLjUpeVpVJp01pTs0aGjt6OvT11X87TG8dYzn/D5ZTFON33Dp2pZDVsph6hpedwsxgYtPmw8bArVVNa7pqzP0Hxz8PtPiX8EHxEZP4cevtfxNU6O6tdT6Z1HEXlpwswtkk2/I3al0zDbTW59jb8GrqtPGnrjlnmpmMxPjCVRgM1e3zNOxGvc1mLhryOC8R4mEvJXzVTafdcnEv1zAqazGGq6eK8Pf5o/W0pKkZRVLKKpflw8TCxVOFWn7Fajg5MfJ4GP&#x2B;1UnTUtq6XDRw1YOcwOVjU/SpfwZnFUSsTEtMkTuZoxsLEqdCqaqW9LUM06bmWRG&#x2B;EWZ5D2/gLWj5FRaX5cxRPNLX5H6FG75PzzT&#x2B;Ph/tQ4cLufoTf8Aw/c4aklQPkDFANyAAdrBsB7AZv5di8WkrXoJAAbWAH5tZ/8AhWY83/g1fkSn9xKeBrMvSsxP/g1fkKf3V7E&#x2B;8zn&#x2B;3HrPyV9xzuFMOx1T8YXxMZP4X/Cqrq3A0&#x2B;jO6vn8x&#x2B;q6Nk8RxRViult11/8ALSlLSu7Lk5bVqu/ci3RGZljETM4drReJk&#x2B;R/0jHxsa14VVLwS8KNReW1rM4CxNZ1PDS82Twql&#x2B;zh4b4rqV2/8KiLuV6z8EPxzeO/ir435forxOzeUz&#x2B;lax&#x2B;JRg14WUpwnlcZUuulUtXqps1Dni50D49adl/ELxj6n6u1XM5h5nO6zmKnVViT5aVW6aadtlTSkl6HcaXRW9JrcanE4jO2&#x2B;/n6O&#x2B;4X7OcU4pXMWaOkRVvOMxMzEYz13ifydS5nVdTz&#x2B;eq1PP6hjY2Zrr89eYxMVvEqqmfM6m5meT&#x2B;hv6Ln4hOpPFDoHVPDfrTU8XO53pp4VWSzePX5sSvK4kqmmpu7dNVLU9mj&#x2B;fPUGgY&#x2B;g5pYVdfnoqU0Vpb&#x2B;h9k/oeuj85/afWXXtdFSy6wMtkMKriqturErXukqP/ujvOLxZvcMqr8MY/Noa3S3tHdqs3qeWqnrD7mG1y25cE81LW8R3R4d16kc9g4ewm2wH5tV1jSNCyFeq65qmXyeWw/9pmM1jU4dFPvVU0kcmTzeVz&#x2B;VwtQyGYoxsHHw1Xg4uFUqqa6WpVSa3TR88fpSsWvC&#x2B;E/OUUYtVPn13JKpU1R5l5qnH2&#x2B;x5bVvi68Evhv8JektM6&#x2B;17Er1LG6cyNeHpOn4X4uP&#x2B;G8Cj9tqYpXu1PBu0aOu5p6a7eZmZmMekR/llFOY2d7UtzdfY&#x2B;f/AIM/HjxF8avEHxMynW&#x2B;pYOJlOntdoyek5fBy6oWDhrEx07q9Taoplvse&#x2B;eAPxQ&#x2B;EPxIZLM5rw21zErx8lDzen5zBeFj4NL2qdN003KlN3Ohv0d&#x2B;tab0tmvGzrLW8ZYWTyXUleNmcV28tGG8zXU4e1jltaeaNPeiun60cvWN95WI&#x2B;rL6h698Seg/C/RK&#x2B;pPEDqrJ6VkqHDxs3i&#x2B;XzPslvU/RI8T4Z/EB4MeMmLj5Xwz8Q9O1fHy9KqxsvgYsYlFL58tUOPVKD5e8G/A7UP0gPVuo/EZ4/ajn10tTncXK9KdPZfHeEvwaKmm21sls2r1VKq6hHrvj/AOBWlfBJ8SPh94oeCmNmMvpmr6osvjafj49WJ5a/PTTiUKp3dFdGJs5hqe0c9HD9LNU2Jrn6XH/tzjOF5aemd3aviJ8UPxjdSdf6z4f/AA/fDi68vpeo42TWv6rRX&#x2B;Di&#x2B;St0vEpdbw8OLSr1bcnVfhFqXxj&#x2B;MfxdZPw98R/FnMY2X6VzuDn&#x2B;p8vpGaVGSwFhVKtZepYSpprqqqihq/N35WfUfxgeP&#x2B;D8Png5nOo8j/ea3qD/AFHp7K0pOrEzVaaprVPKo/efslyeP&#x2B;Cn4fcXwL8Kac11LS8XqjqPE/tDqPNYt8R41c1LCb/5FU5/5nU&#x2B;S29RbtaOq5FumM7U95me85nw&#x2B;JE4pzh0d4jYNXwwfpJdG6&#x2B;dX4Ghde0fhZqt/s0KvEjCxJe1sVYdf/1HuXx2YuN4teMnhh8MOS81eFqesrVdappuqcthSlKi68v429rI8j&#x2B;k68LMbrT4f117pGG1qXSGeoz2FiUL9pYLaoxI9ppr/wDoPR/gK1jXfiT8e&#x2B;ofiY6tyboej6Bk9FyFLrlLFeGvxak&#x2B;8U1Ven4xz26or01GsnrRTNM&#x2B;vSn4/ovWObwee8WsLAxP0nvhtp&#x2B;Bl/LRk&#x2B;ksR00xZKM5H0Pp7qDGeX6fz2YSvh5LFqSXpQ2fOvVvSXU&#x2B;r/pNeneq8toOar0rTOjHTmdQWBU8HDqqpzKVLr2TmpW3vPMn0F1ksd9HaustQ6sT&#x2B;zMf8OlK7f4dUL6nU8RqiLFvHaj5yzsxzX6Inxj4v5v9a5PXtU6azuR6czGHh5zM4VWHhYuLU0qPNZ1WvKUx6weJ8JPDfB8MelFon61Tj5jFxXi5rHpUKqp2SXokl9z23K5POZ7MLK5PK4uLitwsPCodVTfsj3zpL4X/ABn6uVONl&#x2B;ksTJ4FUP8AH1CpYSh8w7v6Hw7Tzrb&#x2B;nnTWaZmJmJnEZmZjpnyh&#x2B;rtd/wBG0Wtp4hq7lNFVNM00zVVERETOZxE9523642dQar4Y&#x2B;H&#x2B;u6y&#x2B;odZ6Wy2YzlUebGxk3MKFK22POYODhZbBpwMvg04dFFMU0UKFSuyPpLpD4CsKl043XPWjqi7y&#x2B;m4UfLz1/yO1ekvhq8G&#x2B;j1TXkejcvmMalR&#x2B;Pn5xqn6xVZfJHd2PZvjWsppi9PLTHTmnOI8ojPyeO1n8QvZLhddc6Sjnrq3maKYpiZ86pxn1xL4z6Z8PeuOscVYPS/S2ezrqdqsHLt0r3q2X1OzukPgj8U9b8uN1Jmsno&#x2B;FVepYmJ&#x2B;LiL/AOmm33PrbLZTLZLApy2Sy2HhYdKinDw6FSku0I25k7zTex&#x2B;it73q5qny2j5z&#x2B;rxnEf4q8Y1GadJaptx4z9ar9cR&#x2B;kumOkPgf8MNE8uP1NqGc1fEpcuiur8LDf/003&#x2B;52d0x4edC9G4NOF0v0pkMl5VCrwcuvPHrU7v6nmbpWDUo9DpuGaDR/2bcR543/ADnd4XiHH&#x2B;NcVn/VX6qo8M4j/wCMYj9DbZ7HtXhZhp5vN4l7YdC&#x2B;7PVrTB7d4W0Q83iLnyL8zedO9uqU2YsrIc3EeoCxQhutgG4AAkRsLSW5AHzCCsUABcMA54IlHJbyEA&#x2B;QAASJEoSgJPdF24HyABJwGNyu4EahgMQ&#x2B;wAFjsHOzAm4A5AAKxPkBSMo9AIwrbl2uOLgAkBbcAOQSb7gUD5D5gGuxOfQsdiR6gUK423AAch9h7gSbTBV3FgACVtgAEAc7gAB8wAfdESkrHuBBFrFAADYT6AJlTBEPUQALtcJCAI55ERt8g/cPuwHog/ccjuALyRehQJHYXi/5FW5G2gK2S4UvgJudgDngO90NxHoA33Qa/MNJbBLhAUekAkxzuAsxxAbC7ABC2Cmbi/IBLuI7CeZsVeoADYm4BhegCmEAliyDnYTcD9EJcCO5QzaVIRYvIBES8C7v6lfqT2YUjlh7x/EeyE3Ab83gQo2Qe8sW/eCFluNiNPn5hTwiqSld88hu0ldg1w/mBmzd7BKJuWHEJhWQ7A05n8g5mU/sXdwZSkBd7BKV&#x2B;Y9Nir3CJ6fkGny9zV4gm7Co/YfkV73&#x2B;ohPgCOwVlDCTdyqeQJKDcOBPoNluAhMK95K3N5HG2wCZFl2&#x2B;ZLsrlboBdkVlcqb3b9iP33CKly2OPYQvn2YvwxCjsrqxHK2F2rja3YiHr/As08ki0hLh8lVU1wg32TCHewQcbr6sT3Udg4m7Ew7iFJQdnsOLL5ocQmAaTW4W&#x2B;4hO0fMb2&#x2B;hEWr1M88l2/ixH0ALtDK1BEVTsxuu8CUbfYS1v9h7ifX6hEjmfmE4UP5iz524H7xeqq4mY&#x2B;YSa3SG1h6QRE2vBSxaGRdhkF3Ys7tDm6HyLgPdi3C&#x2B;4UO4ScXkKWkbKLBK28&#x2B;o2Q6iW5K4SG63CaVkEPQtibbli0BSIEJhIqQEJxsX5h&#x2B;xES/cRHH2DVoG9hhRuzS&#x2B;wVwxHMgHPAiVYREhqXdBBUx8g9p7CHG4SlXAX5G62HpBSCXmR8gr39RxcKbXD7x9A494G3IQts2J5XI9EwrWQEUT87n8j/wBI1kP7P&#x2B;M3rWmI/FzOWxf/ALrK4TP647bqx/KP9KLk1lPjL6hrdMfj5PJYi9f&#x2B;74dP8DsOGz/Xn0/w9f7F1cvFKo8aJ&#x2B;NL59ix2v8AA7m3kvil6Ur8ySrzGPhuefNl8RHU6Ox/hGx3lviU6NxUt9Zop34aqX8Ttb8Zs1ek/B9D4lEV8OvR&#x2B;Cr4S/p59j&#x2B;XP6RfwFzfg74&#x2B;Z7qDI5KqnRup8WvP5HGpoiijFqc4uFPdVOY7VI/qK9kei/EH4B9FfEX4d5noLrHA8s/3mQz2Gv7zKYyT8tdL&#x2B;zXKOk4Xrf5HVRVV9mdpfEKKuWX8dN17n2H&#x2B;h60XNY/ij1X1B5H&#x2B;DgaFh4FVUWdVeKqkvpQzrfxA/RwfE50d1VVoei9GVa3k6sV05XUshi0/h4lM2dSbmj1TPt/4GvhfzHwz&#x2B;FmJp3UNWFXr2sY1OZ1R4V6cOFFGEnyqVPzbPR8X1&#x2B;mq0E00VRM1eDlrqjldz5qhYmWxcN/4sNr7Hxv&#x2B;jl&#x2B;Izwg6B6d1vwe6260y2latidVZrHyi1B/hYWNRV5aUliP9nzTS/wBltPtJ9lunzUtPmk&#x2B;Bfhs&#x2B;DHww&#x2B;Jrpvr7E6jzWayWs6b1pmsHJanlMS6od1TVQ5TUz9Wef0FNirS3YvTMU/V3jt1cVOMTl2j&#x2B;kv6n6bw9P8Oc1pmsZfE1XL9aYOPk3gYtNVdOGv3mov5ZVHzg&#x2B;gfErxu8KvBzI5bO&#x2B;JfWmS0mnNPy5dZjE/axO8UqW13Z8JfCH8GWN11486vpHiP1e2/DrXMOjNaPiOqqvM001v8OqlzCw6nTxeIPd/FTwmp&#x2B;MD9INrXhx1fq2ZwdA6V0fCVWFl8RU1R5KG6aG5SbrxW57I3Lmk0szRYmvNNuJqmceMxjDLlp6ZfaPTXVPTnWWi4HUPSut5XUMjmKfNg5rKYyxKK16NHTXgV4x9edRfFj4neEHUOqrMaTobwMxpGFXQvPgrEVPmpVW7p/a2e0nXng50xr3wN/E5p/gpi9SZjP9Cdd4df8AYmJnHfKZ2mWqG9k3am0ebzK0o5vDzrXpTwy/SAeLmu9aa/ldN09aBlcXEzOaxFTTMYEe921C3NanSU0Rcin60TTmmcfiiPz7MeXq&#x2B;srDjc8L0L4jdEeJeiU9Q9B9UZLVcnU4/GyWYVapfaqL0v0Z1T4qeN/XXQnxl9A&#x2B;FenZnCq0HqjSsZZ7AxcJOpYtH4jVdFW6dqU&#x2B;I&#x2B;p11vT3Llc0dJiJnfy3YxEzLvBiADgRjFy&#x2B;Dj/7XDTjZ8o4KsrmcGp1YOJ56OaK9/kz9QLFUwsTMPxrHw3X&#x2B;FiUuiv/AIalE/zOSmh9jmxMOjFXkxKFUuzR&#x2B;erI4iXlyubqw1/wteb8zPmhcxKU1LEz6pSth4bdXo21C&#x2B;x&#x2B;pU2g4snk6Mph&#x2B;Smp1VNzXXU7t9zliNjCqcykr6jgMcdyIfIEnuJW4FQCsJQCAAA4ACuB&#x2B;bWLaVmf/kVfkSi&#x2B;HS0&#x2B;C6z/APCczH/gVfkTC/2dPsT7zOfsR6z8lSUQfNf6Sj4ePELx06B0DO&#x2B;HOm15/M6HqWJXmMhhNKuvCxaaaXXTLUul0q3KbPpU6n&#x2B;JH4tug/h6wKNHzTWodQ5vAeLk9HwsWGqE4/ExKr&#x2B;SmduXFu5taO5etaiK7UZmHNo7N3Uaqi1ap5qqpiIjx8nUPwHfB/1l4f8AVeH4k&#x2B;Iui1aWshl68PSNOxK6fxK66l5asWtJuEqW4m7dU7I6b&#x2B;LrwW6g8JfFzVMzi6bi/wBj6rm683pmbpw26HTXU6nht7KqltqN4h8nleq/j4&#x2B;I3qLPfrWndS5bSMJVTRl9PyVEJcJutVN/U7L&#x2B;G341s54jdQ5Xwr&#x2B;IDTtP1LB1HGWHktRxsrRCxX&#x2B;7TiUteWG7KqFd3Nyf5mmubtW&#x2B;er65bse0/CdTVxK7RRXRyxTNuiZjlpp6cuY7b956y&#x2B;WdC8Fuv/HLP4HSnh/05j53NV5iicammMLL0txVXiV7U0pX/mfe2k9JaX8C3wialjdKZPC1HOdP6XXns3XjN0053N1eXzVVRdUzCS4SSO3tI6f0Lp7KPI6DouUyWC6peHlMvTh0t7TFKXY61&#x2B;OBR8JfXf7TX/uOq6t/jpMY1lepqt2J&#x2B;xzRt6vnHtBxmnjnEf5im3yRiIxnOcd56PmbQvFP9Jl8VOl06/4eZfC0DQM6qlgZ3KUYWVwqqZabpxMR1YlV01NPY9a8V/Dv41/gxo0zxp1rxlxdXytWoYeHnacHV8fGw/xGm/w8WjFSVVNSpdMr7WPqf4Hdd0Hpr4OOjtR1/WcrkcvTp&#x2B;LVXj5vMU4dK/v8RzNTR0/8afjPo/xXa9oXwn&#x2B;AOZw9dxs3q&#x2B;Fmda1TKp14GWoolfvq0U&#x2B;Z1VVbWS3Z2dm/XOsm1Tbpi3EzE7do8ZdPEzzYxs&#x2B;hvEL4kOi/CnwIynjj1o3hYGc03L4&#x2B;UyOFUniZnGxcNV04NHd3d&#x2B;Em2fL/AFX8a3x6aZpX/tup8FsHTOia8SmujAzeQdSWC3&#x2B;y6q5pxEqk1&#x2B;35Utvnx/Gz4hdDdD/Er4deGniDls3j9HdDaPgZrHyOBhKqrNYnlaoUNpVL&#x2B;6w6b2h1dz2HrL4wPH34mumNR8O/An4UtRzOkatk8TJ4uo6vQ1hrDrpanzPyYdLi6mpxY49PpKLVqmubcVRVvM1TiIjO0R543Smnvhz/AByeL&#x2B;leN/wA6N4naFgVYODq2u5R42Xqql4OJT&#x2B;LTXQ3zFdLU&#x2B;x7F8I3wW9Caj4dZPxW8e&#x2B;n8LqXqTqLKYWaq/tfDeJTk8B4aWFhU0u0qjyy/ZLY6e8bvBzxC8Af0dOR6D8SsrgYGo1df0Zj8DBzKxlRh1YeI0vNTaZpex9d&#x2B;E3jr4Ta34G6N4g0dcaVlNNwtIwVmasxnaKP1aqmhU1UVJuU001G5hqKq7Gi5NPP1Zrq3jw2xGf30ScxTt4vmjo/w30j4b/0nWm9G&#x2B;HuF&#x2B;q6Nr2kYmJ&#x2B;o4db8uFRXg4lTw/VLEwVUvRnqvg7VqeJ8JXxDajp3mWLjaw1iKnjD89Trh8/s1M7L&#x2B;GrN4/xQ/Gt1N8UWQy2LR0309kXpmg4&#x2B;JQ1&#x2B;sVvD8ian/lddb7eelH7P0a/Rtes&#x2B;GviNp3VXTuPRkNb6lxqHTmsCqmnM4FeE6avLKXmV913Ni9em3bmqveqmLefXOfgymcdfJ2H&#x2B;j36g0HXfhK6XwdEzWHVVp&#x2B;Di5fP4dNV8PGWLU6lUuG00/8A6jrH4hNfyPxO/GZ0N4JdF5nDz2m9FZt6p1Jm8CqaMOumuiqqhVLlKimn/qrjg8Hmv0W3ir011Pncr4V/EDVpPTuexH&#x2B;JhebHox/w&#x2B;KKlh1KnEhNqW0fRfw1fC34e/DP0vi6N0tTiZzUc81Vq&#x2B;s5tL8bNVdrfu0Jy1Su923c07lzRae7Xft181VWcRjpnvPoxnlicxL4z8a/it/8Aah8X&#x2B;X620nw9zXVukdHV1YHS&#x2B;i4Pm8mLmaal/wB5rVNNTada8yXKoo9TvLwg8RP0hXjD4n6FrXVfQuT6R6Nws/Rianlnl6MPFx8BS3T/AHjqxG3ZWVJ9H9M9AdC9GUPC6T6P0zTaW26v1PJ0Ybqb3baUs8u1NjivcQsVW4ot2o2jETO/6dM&#x2B;aTVGMRDoH4s/jK8FPD/o/qzwxxNWo1Pqh5GrI0aDTl66vPi4&#x2B;FFPmaXl8qVabvPG55z4E/BfOeCHw46PoGuZNYOq6k6tR1PDaiqivFh00P1poVCfqmexYPws&#x2B;AGD4h5nxXxPDHT8fqDNZr9ZxdRzfnxqljSn&#x2B;JTTW3TS5SukdgJcI1ruosxpos2onfE1Z8cdvJJmMYhFHEfUNJ/suGnumX0Ef5GkxeO0vpPpjQ8evM6N05ksriYtTqxK8vlaaKqm&#x2B;W0jyCS80r8yV42Fh4lOHXjU01V/u01VXft3NLfcxpooojFMYZ13Ll2rmrmZnz3EosNmG6aafPU0kldtngMTxY8McLrijw0xOvtJ/wC0FdDro0dZ6h5hpKX&#x2B;xMq143MmDz7UKyHpcKGrbFdwJawvvJbLYkcoCP5XPc/C&#x2B;iclmcTvipfb/M9MneT3fwvpjScw/wD8o/8ASgPZouUm12yqEAHyHsGAuB6ML1AbgcF2YEsBEgAOA7iVACAu5HuW3AAezEhoCfw4LMj1JsAttBVtYbkvyBZ7AcXADYeshACz6h7/AMxMkAs8kcEc8FhAH6j1HrAQAFIwEcjYNwSOGwE&#x2B;pZRObBqbeUA7l5I9oK2BPUo2ACABIAATfYA/QXAAchW4AANiX3D2sJW4D3BONvqUALdyNwIb3AoC9bgAH6jYc7gNwS7tIu&#x2B;AF&#x2B;CoiXqW4BSAAAYc8BAT1QuVBOdmAAEoAAEBIQSjksCwAcgAGmBzsSy/iAbWwtwxbhBIBce4W8Fi8gABwA3C2sSIVh6AVOR8xsF3Aj2gPfkKVyOL9rgRz/IuzloerCUsD9KuikpupkvMNmyJ7lbkNNBxukBCNfkUlnyVSJVykiFBfZDsBLSWAREEJTf6lYhBYTjcJJF2RPUoO2yEKLoRCHzIg5gjkvqG0WBFbkR&#x2B;QUOb3FNn/kRZFZWY9WLJ2&#x2B;RYcyUTa3p3Ep3ngsuY/gRzOwES7Isy4kKJafYt2p4HcR/IcFuS3eSBfuWSd2mLtXn2KF1f8g1cey5ENqWMIfIewqfdBSkFS2yRd7SIcyIhwwJHmv8AxHefmVtJ2Qi7UgSFN2J2ZYS3fA4sBJ/zLtwLxImFDQBzHp7ibxAdiWW46i2Y5hIWiY9kIncgTfcbOPyCvefdIsr7lEm9y8Q2NlAt39wEc/QiU/xKGhCEKLqSTC/mFP8AIQgDlXj7i0zIURtcKOXIVVcLeG/kF7D2IhZC/AXcJ3gql&#x2B;wbfBbj2ESJ7sNd0GrhT3Eh7Ml7pfYNe4ae/wBiQEze&#x2B;/YJ2/kIff3LDSui9AVyonoti/MdEABK4CnqOYEgCbuVuPmXcAR2RXZWHI2J0AcWC9iWkIoG&#x2B;w2YAiG1xMbsKf8AMhyLq7C3giLyRy&#x2B;Sv1GwEXqHK2Hoy37AZam5/Lv9LZkv1T4tsXMRH6z07k8SY7fiU/8ApP6ix2P5ofpisn&#x2B;B8Suj5yI/H6SwPrTj45vcP/3Hueo9kauXi8edM/KXydTVa57x8NmaeT8f&#x2B;jceUo6kyil&#x2B;uKl/E9G9YPZvBfM1ZTxg6VzOG70dRZKpfLHoO6uRm3MeT6ZqoirS3I8aZ&#x2B;D&#x2B;r1VtkP59xS5TuVX9Dx74WUtpWki2ll9EIauAifmdLfCN4Idc&#x2B;Cev&#x2B;IeV6qyuAsprfVNeo6RmMvjKqnFwcTzOHzS1ZNNL5ndXuDlovV0W6qI6VYz7t1zth8v&#x2B;NOJR8OnxxdJ&#x2B;MmA1g6J19lv7E1&#x2B;8UrMKFh4jtE/7O74pqOrPHLwL8S&#x2B;r/j96jyXhf16&#x2B;ndezug4Or6PmK8SuinNeSjDorwnVTt&#x2B;63s1&#x2B;yfWvxJ&#x2B;Auj/EZ4XZjw91PVKshjfrGHmdP1DDwlXVlsehzTUl6qaX6VM6c&#x2B;LHw08WOiumOifiT6WdGodX&#x2B;HuXpwtd/VFV5dQynl8uLVdJtWbaiyxKnwdxotVTM0YmIrmJo3/On/DOmXQHxBeMXxUaTj9JdJfER0M8DP8ATPVGX1DTuosPBhY/kqhp1UzRXNnKjbY8542eBma&#x2B;I79IjqPh/l9TrymQzmmZXO6jmsNftLL05fDbhcttpKeWdsZj9Jd8NniDltD6U17pDN5qnWc3g5fVspqeSoeDklW0nW25VaVTWy2uY0rXNL6T/SpZzSsV04VGr9GYeWyqe3npwqKqUvlhvv8Ay3Kb2otRM/RclUUVY8OsbwyiZiOmHpuveFHUX6NrxW0TxS6L6jz2qdAazm6ch1DlMy15su6tnV5bNpTVTVG9LT3PffiazOXxfjr8EdWy2LTVhZjDzCw8SlyqqXMNe/m&#x2B;52f8bPSuR6t&#x2B;FfrTTM7h0OrA0ivN4DrceTEwWsSlqeZpj5nzS&#x2B;p8z1P1R8LHV2exvxMbEy7ymLW5lvDqw8KX6239zX09yrV0xer&#x2B;1iqmZ8fqzMfOEiebd91T9ip&#x2B;p8V/Gd8R3xA9V/EDT8Nvw2ZnO4GZ0/BoqzlWmwsXHxqqFW06n&#x2B;7RTS6Z92ez/Cl8W3jFpHiZR8Nnxa6LiZHXsfDX9i6pj4Kw3mav/Dq8v7NfmhxXTu007s0J4ZfjTxdiYzjOO&#x2B;PHDHknGX1aD8i17RXrFfT39q5f9ew8JYteU/Gp/EVDbSq8szFnc/W4mTrpiY6sBxyhBCkADcJ2AQIAQEf8QnIuv4BvuBQRfQoAsQQXAbsC4A/PrMf2TmFP&#x2B;5qn6Ew7UU/9JdZh6VmZ/wDBq/IlH7ifoifeZz/bj1n5PB&#x2B;J3XeleGHh7rPiDrb/AO7aPp2LmsSn/j8tMqn5uF8z&#x2B;RXWni51P4k&#x2B;Kue8Uess28bO6jm6sTHSf7OHhuyw6VxTTTCS9D&#x2B;h36TvWs9pHwm6ngZLE8qz2q5PLZj1w3ieZr60I/mI4ix63gGmt1aau5VG8zj3NnR3q9NdpvW5xVTMTHrG7s/Bx8HMYNOZwK1XRUppqRMXWcLp906vXmVhVYFSrwm9/NTdR62Oucnq2pZBeXJ53Ew1zSqrfQ/ToWm6v1p1Lkensq8XMZrUM3h5bApX7VTqrqVKj6m3HC8VZqq&#x2B;q&#x2B;m3f4hxOkxRY/qY7z9X18Z9P1f2W8PuoP8AtZ0FovU7pqT1DScvmWq1DmvDpqv9Tr3468X8L4SOuak2p0hKz74uGv4nZnS&#x2B;jU9OdM6d09SqEshkMHLr8OmKf2KFTZcK2x1h8eKxK/hJ62wcFN116ZhqmmlS6n&#x2B;PhWXqeS0/L/O0Y6c0fF8ozmrL5Y&#x2B;HX9HT1H47&#x2B;E&#x2B;i&#x2B;IHWfjZmMppWcydVemaVlcGvFeDT5qkqW66lTQpTcUp79zm&#x2B;C7rZ/Bp8RusfD74x6Nlsp/auZpwctrleCqaqar/hVed/7nEUeiq35Pqn4JMlmch8KPROTzmUqwMSnR068LEodNSmup3T2mU/meM&#x2B;K34MejPikelaln9bxdF1XS8TyrVMrl1XiYuBMvCabWzunw57nbV8R&#x2B;k1FyxqJ/pzMxtHTE7Tt1Z8&#x2B;ZmJ6OjfjzwNc8Cviy6S&#x2B;KDE6VWsaHVlsLAzuFi4NNeGsTDdVNWHNSapqdFSqpb/AMSfY8v19&#x2B;kc1Dxh0yjwr&#x2B;FHw&#x2B;1nMdSazhvAozeYwFT&#x2B;oU1KHiUqltSk/wB9tU0xLnY&#x2B;o9F8PdIy/h9kvDzqzE/7R5bK5KjL4&#x2B;NreDRi1ZryqFVWohv1g5ej/Dbw98PsGrL9C9E6VpFFbmtafkcPCdT9XSk382asa7S/R0xct81VG0TnETHbMMeaMbw6M8cvhT8XPFT4VelfBDNdbYGqa/p&#x2B;o5bMavrOrY1UVKnDxVVDSbr8vnVCm7Sls9Z//ZI&#x2B;EOLr9GdxPELXMLTXTS8fSsDyRVXClLEd1TM7ptTufWcQLf8AEcFHEtZbp5aKsbzO3mkV1RGzwnh54ddG&#x2B;FXSOU6G6C0PB0/TMlRGDl8JTL5qqbvVU3dt3Z5rCwsPBoWHg4aopW1NKhI0RdjRqqqqnMzmWKtkhzMDb5ss9yCOb8BKNioKEgB4fozr3o/xCyudz/RmvYOoYOn6li5DN4uCn5cPM4TSxMOWlLpbhtWmx5TAzeVzdNVeUzGHi001umqrDrVSTTurcnyb4C&#x2B;NVfgL8HHWPi/ltEw9UrwfErVFhZarG/CpxasbUacFOqpJ7eabJ7QB9bNXh/I6y8WviS0Dwm8ZOj/DHqHEyGTyfUeS1DNZ7WdRz9ODh5PDy2GqleppTVVUld8PdnivjX8Q&#x2B;s/D3wMy2u9Ea9i6XqWc6l0nJfrOAqXUsPGzWHTiUJtNKaXUp&#x2B;51v4t&#x2B;Avhp1B&#x2B;kW6Lx&#x2B;punVreHrXS&#x2B;p5/UcnrNTzOXpxMFYWHhOjCrmmhLeErtzfgO0OpV4SdXfFB0Lq&#x2B;J1PqePruX6Wz2f0DI5Our9QxsrX5KK8zW1Z1ftKmlXnzTFk14PrXxp&#x2B;IjxL6r1/pX4T9E6deV6WxqspqvUHUzxasLM56mlVVZXLU4bUumfLVXVZNwpg4NZymTyv6QrRclpuQowqNO8Hc2sDDwaEqcKl52imlUpWpiGrLZweJ&#x2B;BnxX6C6P&#x2B;DbH636q6gy2XxdJ1TVMx1RiY2IliUZp5rFrqVabl1NOiO9kB6l4xfED1h48fAVh9XU5JaH1PidZ5HRc/gYFVSowc9h57Dor8t5dDcOHNm0fr&#x2B;Ij4a/Dbwh1Pwl6z6X0yqnqqrxQ0vLaj1FXjVVZrUHjOt41WLU3d1Omey9jwlXhp1vV8HXSrzPT&#x2B;beodY&#x2B;MOS1/H07AydVVWUwMxn3jJVU70qnDppqbdlN2fQ3xDeEfUvitrPQGPoOPlsPB6a65yus6nVmMR0t4GDh4i8tEJzU6qqVFlvcDsmZdkF7C26Xsh7AHbcesbB9pDAjXDPfPDXD8mh11R&#x2B;9mG5&#x2B;SR6I9tzsDw9p8vTlLjfFqf3A85PH8Cr1Ip4KtrgAAwEXkTwJAFW9yBehZ7AQsBwmLq4EDEXI5YCSkXsWefzARyBPAARO5Ha8lc8CLgPZD0A2AAm6sVbXAB&#x2B;4KncCSGBcB6jkBACyo2IAEi/cDewAhSRe4B&#x2B;lRdiQmiwuQCsoA4I2AVi&#x2B;4AD3AJN4Aos0PmOQAJbcqAAAA2TmQ72K1OzAkzYS52HIh8gLpjmJDXoPVgVRsgSLWEvmwDcvyMttqxYAL0C9CpE2&#x2B;YFQiAFuAYTsGJ7ANwR&#x2B;hQEE5sXgfICb7MqJ7lQACErIALAD0ABj0D7AJJ6fcu4m4EY5uvmXYmykC3A53CACxZ5/IgAchpbjbcCTfYfICEA2D&#x2B;pedhAEvwVIQVO4H6EVb3XuEosmWOxtCOHsQrfdk5vsFTkmxY9ANw33ARYAgL7ksAFx8gIC49xCQgIkIu&#x2B;45DXBBJXYnCsHDRVDfsVUhN33ERv8AMu/JLJSAW7ESp3LzsLTuA9yOXv2K7bIWAO9/qFGysRwnITtuJFDjdC82IlMkhFbRFFhMuPtIcrm/oyqNfmE55gsSg4e/JRLsRf8AyEtMqcMBeSTK79y73uIW8EE5LCXJJjfgs8AHHf3EOZRJ4RZ2TG4m2zkvMEVkVd5uEQijdMqT5EKLhe5u59Bu5uIcxAa9QHsWGu0k2cyy73AJrgO3A9mPQGSQuxHa8lbiwRH2ncQk5RV2j5k/dVkMqJrdl9hNxdWQQi0MqdpZJvHYRO6IpfkO38RPYTH&#x2B;pQe3oUl3Ivx8yIrI54FxcKbMjTd19yzwWF2LhEvO4&#x2B;YbY9BgHe08FkLsABL8lcRJG4d2QPb5FgiuW8lAAJogATA3EKewTEWsAhaA/REieCgR&#x2B;gTW8/cKbouwVGm0IjgvBKlb5gNtizwRu4lxde9yIcQOZkb2TG3IBn86f0z&#x2B;RWF4wdI6i6Y/F6dxKJ7&#x2B;XHqf/qP6L/M&#x2B;AP01&#x2B;SVHUPQGpKn9/JZ/Db9qsF/xNzQf7qPe9B7L1cvGbfnFXwl8OcweV6Cx1leuNGzLSjD1XL1OXG2JS/keJ815k/To&#x2B;P8Aq&#x2B;rZXMKqHRmaKp7RUjv6ozEw&#x2B;q14qomH9e6YVFLa4lFfocWRxVjZHBxpT82DRUr90jo7rv43emvCTxb6i8N&#x2B;vum9RzWHpWPlcXCzGh6fXj1ZfI4uXorqzGOl&#x2B;7TTiOumVwpix4yer4VMYl3unvH5i/8Aofj0LW9K6l0fK9Q6FnsPNZLO4FGNlMzg1eanFw6kmqk1w0z9lMgVexEUgFJVTTXS6a6U6WodL2Zb9xYDq/LfBr8NeS6&#x2B;p8S8n4W5HD1TDx/xqKqHUsKnE/4lhz5Zm&#x2B;250R8YnwzePWv/ABMUfEB4VZNqnSNBw83kczhV01VPN5Zur8GqmZ/bplKzT2PsZ/wDUqGbtjX6izd55nm2xvvsyiuYl8J&#x2B;PX6SvpPxM&#x2B;HLUvD/AE/pXP5PqnWMp&#x2B;o6jl8XDX4OBMLEdLmXZNJWam&#x2B;xx6r0nqXQmmfCxp&#x2B;r4Lw8xRqLqxaalDp/FxsHESfrFaPp/qT4L/hu6t6/XiVrXhtla9UeOsbFeG3RhY2JM&#x2B;avDT8tTm8tXPTfjR8L&#x2B;t&#x2B;rOvvCfqfozpjMZ7KdO9W4eJqdWVo836tg1YmDFbSv5V5XL2R2dnV6OaqbVmnlieaZzPeaZjEM4mnOIeq/DfpGXw/0ini7mdRwKXmcLK4VeVeJT&#x2B;0qa3h/tU/KF8z2X9JL4Z0a/wCCVPi7odH4Wv8AQ&#x2B;dwdRyGcwlFaw/xKVXTPZfs1/8A0ep674/aivhj&#x2B;Njpv4htQ81HTXWGQ/sbqDMf4cvi0wqa6vksOr2oqOz/AI0etumNJ&#x2B;E/q3V8zqGWxcvqOi1ZfJVLETWNXixTR5f&#x2B;LebdpOKqq5/N2L1HSYpj8tphN&#x2B;aJdW&#x2B;LXw59c/FnoPSXxTeDPilVonUWN0vlfLlv2sLDxalNbX4lDmhquqqmGmrHpnT/AMdnxJ/DFr&#x2B;B0D8W3hzj5vCrp/7vqWHTTRi4lChOumumcPGXeId7ne/wRalg9L/Bl0nrfVObWWy2V0jFx8XGx64VGCsXEqTb7eWD5j0nL9QfpJfi2r1nPYeNhdDdN1KKW4pWXpqtR/14tSl9l7Gzp5puVXLV&#x2B;mJtW879432iJWN8xPSH3Vo3iT0Prmr4XTmS6jyv9p4mRws5TptePSsd4OJT5qa1Tu1HKtZnnImyPln4yspg&#x2B;DvxDeD/AI56VhvL5LL6itC1OqhxSsvVHkpb7KirF&#x2B;h9MdS9QZHpfprPdT6lXGW0/J4mZxnP&#x2B;Cil1P7I6W9Yppot10bxVH6xOMMJiNsPUPG74g&#x2B;kfAbN9OYfWWUzFWX6i1X&#x2B;z8LMZdJ/gYrS8rqXNLb34Pc8trWkZ3UMfScnqeBi5rKql5nL0YqdeEqv3fMt1PqfFfxk&#x2B;P3Q3xEeDvh54j9C/rdOXwPEDCy&#x2B;Zw8zhOirBxVQqnTP7rcQ002d69M&#x2B;GHWHTnxSZ7rrL5DFr03WcDzV5vDaWHTQsK9NfLqeI6YXahO/G1XoqKNPTNf1asVbecTG35LNOId0zAUHUniX8W/Snhn4jVdCajoOax8LL0UPOZzAqU4dVSVSSpe9mpvye9dDeKfQniNklnOkuosvmbTVgqtLEo9KqXdHnrXEdFfv1WaLkTVTOJjvn5&#x2B;52ep4FxjR6OjVXrNUW64iYqxmMT0zjpnzw9gvFhwWbSrhbbG66lF7yUesiE9wCDc7j5CeIABQPYAfm1m2lZhv/wAGr8hR/s6X3Q1n/wCE5h/&#x2B;TV&#x2B;Qof8AdqOyJ95nP9uPWfk6i&#x2B;Onwt1Lxc&#x2B;GXqLp3RcvVjZ7KYeHn8ng0O&#x2B;JVg1ed0&#x2B;7p8y9z&#x2B;T1VLpqdNSaa3TWx/b&#x2B;z3SfofNvjh&#x2B;jI8E/FzqTH6v6e1fPdMZ7N4zxM7RkKKcTAxq25qq/Dq/dqd9mlfY9BwfilrSUTau9JnMSyt1xTtL&#x2B;aTj/ADPsn9GL8Jmsan1Pg/ER13pOJgadkFV/2cwceh0vM4zUfjpP/BSm4fLc8HcHhH&#x2B;i58A/DzVMPW&#x2B;rM7neqcfBq82Fgaglh5dObN0UfvNerj0PpPLZbLZLAoymTy9GFhYVKpwsLDpSpopWySWyNjiXG7dy1Nqx36z5eS13ImMQ212Zx5jL4GbwHls1gUYuHVHmw8SlVUuHKs/U5LMjPMdHCQlSqaVCWyXASS&#x2B;gXsX1kCJtu4tBMPEw8ahYuDiU10ttKqipNW9Ua&#x2B;YCF2DHJ614veJXTXhH4bat4h9V63g6fk9PylVSzOYny/iNRh02Tc1VulK27A8Zl/iI8Kc94uPwN0rXsXO9RYdFdWby&#x2B;TyeJiYWU8tDrjFxVT5KKmlaluWe8eWLnyd&#x2B;j98cvD3RfhxzvU&#x2B;u9La3kP1HJ5rXerOrNR0t4eVzuYxMeuqpYWM749STS29EzXiJ8QXxxaX4Zv4ptC6O6ZyXRmUopzv/AGRzeFiYmp4unNr&#x2B;&#x2B;xMWVTRW6WqvLTst5uB9VZjN5XKU&#x2B;bN5rDwqWn&#x2B;1iVpbKXv2Vz8XSvV3THXGi0dSdHa9ltTyGJiV0YecyeKq8Ouqit0VpVKzipNW5TPmL4rMFfEF4q&#x2B;A2h6LqGPlNM6xy&#x2B;o4&#x2B;dqwcXyYjyNeVwcXFoTWzqw/NRP/ADuD6Z6H6F6Q8Nul8p0V0J0/l9M0nI4fkymSy1Hlow022/m222&#x2B;WwOpOq/Hbx78QPEHW&#x2B;gfhe6I0HN5bpbO4eT1/qHqXNYlGDVmmlVVl8vRh/v1UUteaptJNwfn8Z8fXfHjx50/4W8tr&#x2B;b03QtP0Ja31zjaZmKsHGzVFeJ&#x2B;HgZOmulqqimpquqppy0kjrn4kPBzxr&#x2B;E3F6q&#x2B;JjwB8c8TLabqOt06nq/Rmp5WnEwc1j4uJTTXTh1OZqqbSSSVUWnt&#x2B;7rHxU1P4avjBzfjP4jdB6zjdN9f9Gafl8PPaTp9eZryWdwKZeXqoo5bb&#x2B;qjkD9vhB4aab8MPxy4nhH4aahnaOlequiMXV8XSM1m68enKZnBx1R56XW20qpfPPsdYZzNYeX/AEXuravncVOjN&#x2B;I&#x2B;Lj5iuP3af7bTqd/Shv2PoHwB6a618TvFvX/io696YzWhUahpNGjdHaNqWG6czgafTU8SvHxqH&#x2B;5Xi138vFKXc8j4P/CppHTvwwf/AKuPi3&#x2B;q63lc3i5uvU/1aquiiv8AGzVeOlS7VJ0&#x2B;an9q10B6D8eniv0Zr/TfQnhl03rOX1HO6z1zouarWSxliLL5VZmny4tflf7KqqdNNM737HkviU03xt6X&#x2B;Kzojxn8JvCHM9XYGD01ntIzeBg5vDwKMvXiYlNVNdddX7tP8rX37J8I/hS8BfBLQF090N4fZRYf6zh5ivMajOaxq8bD/wBnW68XzNOmX5YhKbQdiOlRDQHW2X8HupsX4p34&#x2B;5zUcpRkKehqdFw8lTVU8b8Z5n8aup28vkhJK8t8WPG4nwNfDJj&#x2B;Iua8Tc34c0Y2fzecpzmYy1ecxf1OvMpz&#x2B;M8uqvw6qpvdNeh22X0AipppXkopSSskhBX7EAjvb04G959xC7Bpq8gFZhbJSN1MfQXd5Au52H0HT5emcH1qq/8AsmdeLZfxOxui15enMsnzQ392B5VtXjgLtAcvYbbgUNtLYfMASY4vwE&#x2B;43G1tgLd7AfIALcAIAObiAAJEOSx6iWVT2kCJDgT6i0ACclDAX4AAEkth7ie4BFldvkRAB8gLsAArgXAfIAMAna4FwAAF92ADQDAMCOwajgAHsAAewuCNxuA9i8ySU7ITYC7cElzEFAAAWkBPcWA3ADgQWybTQEAHO4C&#x2B;6IUAT&#x2B;Q9d7lCUcgPSCWK4Vwo4AIAMATmYLIQCO5eSJQADDv8xC7h2AAQWAIxxZAbMAty2IAKiANWAD2DEgI7Ei8sojmAECeAPcAG&#x2B;QPkAkl9yiL7AJUgL1AC0huBAAbDaUiR2Dl2A/YreojlyX0DXc2lRolktitOZkNJra5EZh9hafyK4gm9i9VH2JyWyF1/qAbjYklaXDIIAXA2GwegUBl42CIHYewibCFRr8hFyuewa4Alr2EXv/qV&#x2B;iJbcB6yJtYRcvI9URbSHBfcjCo1edy8wSzd1Bd&#x2B;LjAj9rFandj1IqVxyAumioj9WF3HYNroPkR3Yu7ICRb/ADLDTmQ53/MqUoZQaXYOVsPWBMhUcTPcJWsHM27F27R3ARKsRP8AyZdnJHuEVXsg7EdNI3tIU9hu&#x2B;REKE0PQAoiWW1rkUPZFhTAEdlZiytAUO8D1&#x2B;4gKp3T2LPqTZX59S7qQCt8hK4HtsEET57jbjcsPclnu/oFH/wAJbbC0wL7OCIOxHvJfcOGXopeE0I9PYfP3ERyTohz&#x2B;YuPdBv6lD0TCUq7HEFYjdYS/CKRht8oIO7jkIKRPHYKfIpLzv7FnuOiHyJ7fkF2YhbuwU5nhi0ywqYdg1I2O62kjaVkJXcO24Bb2Cc8oi9O/YvMoIpObFUCERTfZj1IrcFswhyRvuUnqQHbYW4YSHIB&#x2B;oslfkQEr8APcMvyH9WAnJ8Lfpr8nOi9Aah5f3czn8Nt&#x2B;tOC/4H3TM/5nxZ&#x2B;mlyDxPCro7U1T/suocXDn/qwG/wD0G3of91S7r2eq5eM2p85&#x2B;Ev52r3ZrDxHRXTUnDTJuiOZuj0eH1rq/rz0ljrNdKaXmqak1i6dg1Jy&#x2B;aKXzc6k8OstpGJ8anidkM3gYWJjZvpfQ8SqmqlNvC8uPQ17TB2X4TZmjOeFvTebojy4ug5SpO95wae58&#x2B;&#x2B;J2jeLeS&#x2B;N/XeufBJZXH1/TvDzT66dF1HGqw8vqmVqzOYpxMN1L92tVKl0VbTTGzZ4uuMVS&#x2B;HXIxcqjzl6vlPErxW6R6Rw/hd8ENay&#x2B;m6u/FrUun9K1LHoVdOR02hPOKE1fy4eIqF2VMHb3QPxC9T&#x2B;HWn9TdHfE1j5erXOjtPw9RzOqaTl2sLUdMrq8qzVGG70umpVU10qYj1g6p0bw18RPCTp7pr4i/GrTcvk9Yfivjaz1Ll8Gvz0aflM9hVZS9S4o82G29kr8HvXxGaZp/VvxO9O9D5LMU1YnU/hp1Bp&#x2B;eopipPAqpw6sKppceeYn5GLB9C5PN5bUMphZ/JY1OJg4&#x2B;GsTBrpf71DUp/Rr6nJ6QfHD8bursfqj4fNSyWqY&#x2B;Dlcpo1D6sw6KmqaqcbEwtPpVaTXmX4vmd7J0yd&#x2B;6R8RGlvr3xE0Hq6jKaZonQf6l&#x2B;PrWNj&#x2B;Wmt42B&#x2B;LXTUtl5V5bp38yUdw7JbVN6rdpEnR3WPjN051x4t&#x2B;DvUnhZ17RqGi61qmq5XNYmnZyp4OZX6m61RiUpw3TVQnFSlNHeMywD7hShHoVIAW3KkIPaIA9T8a/B3o/wAd/DzP&#x2B;HPW2V8&#x2B;VzlE4eNRSvxMvir93Fob2qT&#x2B;0rk&#x2B;J9R/Rj/ExqHUWU6F1LxMwM70llc0ngZnH1DEawsGbunAcpVRaFaeYP6BtdiOnsb2l4jqdHTNNudp8e0&#x2B;MMqa5p6PiP8ASN&#x2B;I2Z8I&#x2B;gOlPhH8P8R5LIZrS8F5zNYlXlVWXoq/Doob4TqpdVR9E/B94N9D&#x2B;Cngpp3T3R2qZTUcTNULManqmUrprpzOPVSvM1VTvStkuyP3&#x2B;PPwu&#x2B;DvxGafRlvEfpx15zAwnh5PVMrifh5jLq7imrZqXMNNeh8t658JfxifCDqmL1V8NHXeZ6i0WirzYmlJTi&#x2B;RcVYFU04nvRf0N6i5Y1mjixFfJVnM56VT6somKqcO/f0g3QOL198LWv1ZOip5vRPw9Vyjo3peDVNbX/8ADdZ6X8Qfj5Tnf0cOB13hZt/rfU2hZTIOtWdWNiJUY3/2GId89MPN&#x2B;J3g5kV1rpX4GY17p6hatk6sN0&#x2B;SvGwYxKPK7q9TUM/m/m9W6j6r03pT4Hc5&#x2B;N&#x2B;saJ4jZrAzFL2eE8SmimH6OrGfszLh1qL1MUVf/jqz7sb/AKxH5lEZ9zsPxh8OcPwz&#x2B;BXwhymPlKcLNZvqzA1HN7S6sejExFP/ANHkV&#x2B;0H3/lH5sphNPfCpt8j5c/SiaZltL8CekcplqFRl8n1blMKimlQqaVhYiX2R9QaZXVVp2Xrcy8Chu//ACo1ddcm9pbdye9VfxhKpzTD4p&#x2B;K&#x2B;l0ePeu&#x2B;Zf48F/L8Kg6Y6O8eumqeqMXTdJ6mxNM1XI5qvCVNeJ&#x2B;FU6qaommqbyd1/FxR5fHzWqXzTl3/APmaD5I8dfAHRslkdR8RNH1urLV0OrHzGBjuaa6m/wDC9022fF4saHUcZv2r9c0zNU8sx483d&#x2B;k6tZxjQ&#x2B;yej1GitU3KabdM3KapxmnkjpPl&#x2B;4l9ueGHxtdZ9OPDyHXmVp1fKKF&#x2B;sURRj0rvO1XzPoXw58c/DbxPwlT011Dh/rPlTqyeY/u8Wn5Pf5Sfya&#x2B;GnqfrfG0zVtR1XWMbMaVpmTbwsHHv/eJOqFU77L7o908OfiR6N6ozOFg1Z7E0rUPMvw1iYnlVVXHlrX8YO4t63jnCr1dqf69FGM9cxmM9evxiHktRwb2O9pdLZ1NP&#x2B;ju3s8sTjlq5ZxO3Tr0xNMz4P6wNRFipyfHHhl8YviX0PTh6f1BVTrmRpt5M1XGNSvSvn5pn0L4afEx4W&#x2B;JqoymR1pZDP1b5DUGsOtv/AJXtV8meg4f7QcO4himKuWrwnb8p6S8Nxz2H4/wPNddvntx96jePfHWPfGPN2DKgtiUuVKvOzFu0HePHkt8fcpJc/Mq9APz6uk9KzCj/AHNU/QlP7lKXZfkXV1/7rzH/AMmr8iUfuL2J95nP9uPWfkNMFiSOJKwW4C9EXy1dgIyPe5wV6vpVGqU6HXqeXWdrwni05R49P4roTh1eWZibTEHp&#x2B;H8QPh3jePeJ8N9GazH/AGjwtEWqYiqwksFYLqSVKqm9cOfLG1wPd57s8d1jiPC6S1WtOKqdNx2m3H&#x2B;7qOndf&#x2B;KnVunuu/FfNZ/ByT6V8MtAwK6q8OhrGzeoYmHViPCdbqhJRTQklvXvY69q&#x2B;FbrLxg8Ds74/wDi34u9UZfrjU9CxdV0zAyGq14OS0iirCeJhZanAS8rpVPlVbd3cD3f4EOqtC6F&#x2B;AnpbrXq/VKcpkMhpWbzWezeYqhU0LM41Tbb39O8o1098ceazviR030x1j4D9RdN6B1jmf1bpjqTVK8NU5vFa82GqsJXwvOohVOb7HROe1vqLKfo4vBPozpvR8HUsTqTqzI5LF0/M5n8HCzVNOYx8VYVeI7U01VYdKbfE7nd&#x2B;r/D38RvjxrPTer/ABA9f9OaLpfTev5bWMj010ppteK3j4LfkpxM1i1JtQ6k/LSlyB614lZvxp8e/i66r&#x2B;F3SPE7UdC6Uy2iZDPapm9OVFGNgYLo/awcGuJVeLXXTNTbimhpHf8A4l6Jp&#x2B;W8GNb0bFwqcfByvTmPTh/rSVd8PAq8tTnlQnPe51Z4MP8AE&#x2B;PrxjrqcqnQNAVNv/KxH&#x2B;Z3J4j6RqHUXh5r3T&#x2B;lUU15rPaLmsvlaK61SqsSvCqppTb2UtXA&#x2B;Qers1j6Z&#x2B;iC6XqwaK/1avJ6WtR/DTaWWeepeL5vSJk7m&#x2B;MjxH6ayfwtZ3pfpHN5fOZ/rjTaNG6T07KtVVZuvMqnDXkpX&#x2B;Gmip1N8JHsngh4EYHT/wAKugfD/wCLOmZTUKcv0/RkdZytFfnwcRuXVSqoUpN2dtpPzeDXwXeAHgVrOH1D0V0xmMXPZemqjI5rVs/iZqrJUVOXRgrEbpwl/wBKT7sD0fXPDrWemPiQ&#x2B;H/pjJ6dmszlulultTy&#x2B;czeFg1VYeD5clhYNLrqS8tM1KFMSfRsQ5RVU1ZWCA6h0f4PumMXrZdZ&#x2B;I3iJ1R1estqteoaXpGvaiq8hkcZ1OqmqjBpSVTpn9nzTEKx295Ul5Yt7AfMA7yAAAmOQLcAAmJvBJ9QLyESFFigII0UNASBBTVKW/wBwMvY7J6Uo8mgZRLnApdjratSn7HZ/TtPk0LJ0/wD5NR&#x2B;QH7PYoXb7gCNsOWIb3QQB72CuVdwAgAqAkchlhtEAfMMReQAXeSqeCF&#x2B;YAgEgLgnpuUBuCyQBIFwA5L6chx3JvdsABsNmBYIXa1/YP2AgL6/cXkCXDL7KwWwEK1CEwrEkC32DJPA&#x2B;YDgvqiekFtIEe1gX5kdwC3DsABN37ML3DtsF3AoJMblTAADkBNxsAADDgbgLNABoAhyHbkABADANDYe5E29wKAgAHuL9gAAAAtkT5iUlcCzck3krhkvIANJ8CY4G4DdWAccgCr1J7CfQSnyAAmQAlDkAAAL9wD9SN3HE2KgHqAAEALcoE2ADXDQAhSNdgP2rYkFtwItDNoRr0Gzkt&#x2B;QiZwMu7jsJjZFiFdx7CJ4Cpad/sGphos3gjtvAEc2Tn5hJO5XCd0GuEioiV4f0EWku/AiLwBIfCLVt/MXkOY/MKjJ6lahfyCTnYZ2BP0I23uVxDQi9mBGo3ETui2EIZEdhI2uBhAgXqWAuESh/kRwtpsjUO5OYSAR/mGr7CXPoG5tAyEvhCPUPYS0Aty9huv5CPQerAjU22sVd4gRAhTsEGhcvuS8WEKKOEHM2DkKQI&#x2B;4qamYLvZojlr/ICv25ERygixGxBPKnf8g1yWOQZZEhO/cib52LKfJHb/IgtnZbjb1Aa7MQELhBTEBqbC/AQ2AfYQFIvMMRaGNlcsoZEi8yLMiUWLKWy&#x2B;gF&#x2B;RGA5ScBBtJRIlPkJOLr5E2CrJfkSXwPmEWeULkvwg3xDCjf9SPQf0haYgCkl7QXm5EMAENpf1FuBkWz4EEUTtBRncAASETyoKHfcrcbkakqi9WRblW24mEBRzYjSn1G9mTIfMX7B9xsENx&#x2B;Yt9gMBHAvO4VhzYgO9pG/wBSgB6DYEvywCag&#x2B;Q/0yeT/ABfh00LOKmfwercK/bzZfGR9ebKHyfLf6XfJfrPwmrM&#x2B;VP8AV&#x2B;pcpXPaViU/xNjSTjU0ers&#x2B;C1cvFbM/ih/Lymq/5m9&#x2B;fucf8zVN3dHp931yJf1Y&#x2B;HnNrP8AgN0dnPMn&#x2B;J05k3K/&#x2B;VSeYp6B6Xw/EDE8UMLI1U6xi6TTpuLmfxHFeXpxHiU0&#x2B;WYtXVU5/wCZnqvwmZt5z4aeisbypRoODRC/5V5f4H4PiK&#x2B;J/TPh91Xp3Rn0DrHUWc6gzGMqclomEsTGwsDCpVWLjeTepUpq3Nzxt6MXqo85fGNXTy6q5HhVPxdidTdN6J1j0/nOlupdNws5kM/lq8DOZXHpmjFw6lDpaOrvBL4MfD3wR8RM34jaZ1LrurZmvIfqOl4etZ54603LNy8LCbUw3G94O2dNzuDqWRwc/gKryY&#x2B;DTiUKulqpKpSk09nD2OdTO5xNd8YdP&#x2B;FPVmLV475HNadj4C6Xyyw&#x2B;lasXDdKxKaM3j6phuhvdeerDplWt6HjNcwsn4p/Dz1D1hiYlS0zxC8cchh56p1r&#x2B;9yP4&#x2B;BgeV1f8M0R9Ufb&#x2B;bymV1DJ4uRzmBRXhZjDeHjUulft0tQ0/kdSdRfCl0/pHwsZ34ePDTOYuXWWw68xoOazdSqrwc3Tj/rODVU0ltiqlTGwHXPin4E9KeD/xT&#x2B;EHVHhlpuFpOj6j1FmMrqWlZSjy4LzSyWL&#x2B;HjpbKp0eemruqVvB7hgfG9o3/tTz/SmZ8NNbp6V0/XFouN1zh001ZLDz3mVHkrW6o87VPn2T3Oreq/ifzfi94n&#x2B;EPSGr&#x2B;G2s6Pruidd4P/amnUcjVhYWVzDy&#x2B;LhKjDxHbEprdVTUTalHi&#x2B;l8T4htA8L/ABJ6Ofhfler&#x2B;kc91Tr&#x2B;Tz&#x2B;nadUqdT07ErxsRrEVFT8uPTFdFaSirZoD7Zw8bCxa3h0Vp1U0qp0zeHsyZ3NZbT8pi5/OY9GFg4NDrxcXEqVNNFKu229kj4t1vqH4kOvOtPCbSPCvqX&#x2B;wOoepvC1rXc/qWC3Vl/wBWxsOquqrDa/edc03uvO/U7k&#x2B;PfrzP&#x2B;HXwc9SZjUMvm8XN6hpP9n4uPp2C6lgYuLRDxKoh04cpqePMgO3uk&#x2B;tOkuu9Ko13ovqXJarksRtUZrT8zTi4ba3U0tqV2PJ3Op/g76C8CujPCHJan4D4mTr0/VsvgY2exshm3iYeLmacGmiuppt&#x2B;WuVdWvwdrzwBRfkT3YAkdoKHewA6v&#x2B;Ib4qOhvhs1jpvK9fZTMrI69jY&#x2B;HiZ7Aw/MsqqKaWqnSr1JupJxdbwz5j&#x2B;GjJ9I&#x2B;P36RzqLxj6IyNVeg6ZRi53BzFeG0q8arDpwViQ9vNU66knc&#x2B;xvFnwi6B8bejsfobxE0SjO5HG/ap/adNeDXxXRUr01L/WTwHw7/AAweGPwz6NntK8PMvmaq9RzH4mbzedxVXi1pKKaPMkv2VeFHLO00&#x2B;q01jSVxTE/STGPLEz1&#x2B;TOJiKfN1N&#x2B;lbmn4fdGxZjy9Y5W87f3WMfSeiv/3NlGlC/VcO3/0o8H4s&#x2B;D/QHjd0lX0T4jaJ&#x2B;u5CrGpxaKVi1UVYeJTPlrpqpahqX6X5PYcllMPI5LByOFVU6MHCpw6XVvFKhfkaty9RXpKLcdaZn9cf4Y5jlw&#x2B;L/i/So8fNXcb4OXf/AOZpPkf4tuta8PAyXQen4v7eNUsfNU0u8bUU/WX8kfXvxj4dNPjzqLaaVWVy7f8A97S/gfJOd8Eertd8dF1Z1R&#x2B;Dj6ZVmHj0YmHVZU0x5KGndcfc&#x2B;VaedJZ9ob9&#x2B;/VERRNdUR4znaIfobXU8T1nsLotHoqJmb1NqiqY6U0zEZmfLtPll5vTOlF4c/Dznck8OMzXpWLjZlcvEro2&#x2B;ShfI6j8L&#x2B;iOjOu1ldKy/UGLktewcd4iwsfDnCx6aXKS7OEz6N656o0rozp6rWtXw/NlqMbCw8VRMU11qlv5TPyOoPiR0fQOn8fRPFDo94OBmMXMp/i5WFTjQvNTXbfs3zJy8F11&#x2B;/NdE5pqvVTMVx05oj7Mx4btT2t4PotHRZvUxTXb0tFNNVucxVyTVjnpmJ2qzHx9He9K8lKofCiTUtRUqoqV01uj1TrHrTP6d4UY3XGi1ULHp0/DzGD56JpTfld18z1Do74rumNVqyOndT6fi5PM478uZx8OmcHDq80J3vDV/STz9nhWu1Fiq7ao5opmYnHWMb9HudV7S8F0Gro02puxRNdMVUzPSYmcRv4&#x2B;vbd9QeGnxSeKfhvVRk/7T/tXIU75PUanU0v8Alr3p&#x2B;6Pofwz&#x2B;Ljwu6&#x2B;dGR1TN1aLn6lH4GfqSoqf/AC17P5wfGFGJh4iVVGInKlQ&#x2B;C2a2Nvh/tDxLh&#x2B;KYq5qfCrf8p6w6vjnsJ7P8czXNH0dyfvUbfnHSfyz5v6QYeJhY&#x2B;EsbBxKa6K1NNdDlNe5q3Y&#x2B;EfDf4gfE/wvxKKNC1&#x2B;vHydLvp&#x2B;cf4mE12Sd6fk0fXXgb4y6V40dHrX8rl1l85gV/hajk1X5vwsSJTTi9LV181we94T7QaTitX0cRy1&#x2B;E9/SXxP2m9h&#x2B;KezdH09Uxcs5xzR2z05o7Z98eb2vWJ/srMR/4NX5Cj9xeyJrMrScw5/wBzV&#x2B;RcN/3af/Kd73eNn&#x2B;3HrPyTHx8HLYVeYzONTh4dFLqrxK6oppSu23wjrfxi&#x2B;L34evAnK5XMeIPiHl8OvPYH42Ty2n0VZrExcOY/ESwlVFH/ADOF6nmPiLaXgB1vVUtuktR//wBbEOqv0f8A4J9GZL4WdA6k6j0rLarqXVOi0Y2qZzPYKxKq8Bry4WXXmX7OHRhpJUq0y&#x2B;SsHZur/EZ4Xaf4DZv4itM6goz/AE5l9MqzmHmctvjRZYaTuq3VFMPZs6E8SF8f2a8Hsx8TuQ8XMpoeNkso9Wy3h3ltFwqsOnJJKv8ADxcaqaq8T8O7TUK6VzqfPaTjdLfAF1/pehYOJi6BonjRi/g4eHU66KtNws3hKpKLOnzL2Ppj4ofiF6FxPhmzOW8O9dyesat1vpf9l9JaXkcanExc1jZmlYaiilylQq3VVNqfLDA9A1XrenVPiS8BPihwcmsrluvunMXRtQoj93FxML8bCTc3XmbSnhHq&#x2B;PnMxpPjDo3xp1100ZTUvGHN6JmsepQqdL/C/UMKp1LalYmDU&#x2B;zdUnZPj38NXX2T&#x2B;Dbo/oHwv0v&#x2B;0ur&#x2B;gsXSs1pOHh4lNP4uYwXTTipOppeWKqndq1Poe0574S8l1p8HuQ&#x2B;GvqLV69OzNOnZd42pYOFTi4mXztOIsWvFp2VT87qumt9wOo34d9TeKHwH&#x2B;LXWmh5CvM6r19r2oazlcGlOrExsvg5qlYVCUS3&#x2B;HgNUr1Xc9i0n41&#x2B;l/G3wEwfDrwJyGa1PrrUunXkcfSFp&#x2B;KqNKr/B8mLi49Tp8vkov5Um3W4SVz6H8MugtL8LvDzRfDnRsWrEyui6dhZTBxcSlKrEVFKTrqjmpy36s8jpfT&#x2B;g6I8R6NouUyjxq3XjPK5anD89TctvypT8wPnfw9&#x2B;ErH8UPgQ6L8F&#x2B;v8XUumtd0fLYWcyWbpw/LmNOzmHi110VOlu9nel9&#x2B;Gj3Hwo&#x2B;GrxO0PqTTOsPG34j9c6xzWjuqrTshh5enJZPDrdLp/Erow3ONVDd63C7bR3HBbP/ACA8VpnRHSGi9S6l1lpPTuVy&#x2B;q6wsJapqGHhJYuaWFT5cNV1btUqyWyPKpchrk48xmstk8J4&#x2B;azFGFRKXnxKlSpdkrgcl/8AIex6Z45&#x2B;JvU/hZ0vkdZ6P8N871RnM9reWyFOQyVfleFTi1NVY1dUPy0UpXccrY9h6p6u6X6G0DG6o616gyek5DL0zmM3n8zTh4eH71VOAPIg9X8L/Gzwm8aMhmdU8LOvdO1zAyeJ5MzVksaXh1ceZOGp4cQzoHI/Eb8VfxSdEajqvwz9PaP0vRo2ZzeDqOp6zX&#x2B;s/rWPhVVKjLZel0pS6VTVVXUoTrVK2bA&#x2B;pvUO51r8IXjBr/jx8PHTnif1XlcLC1PP4GLh5&#x2B;nAo8tLxsLFrwqqkuE3RMep2U7AS87BuGUcgLoegCdpAkpvcR2HdIvqAGwACABPIAtLjcnFhK7gWqWtuDtPScN4Wk5bDa2wKV9jqvezZ2xl0qMth0rjDX5AbTvdie&#x2B;4T4iwlRYBaP8AIKGVBtAFcBdxE7ACrtJOSpwwEXgQE7iJAkepXvuGlwF2QDjcQRFmVuBIBfn9xEXAkPYFaJxDAQXfhhRMMAT5ljgew&#x2B;QCVyQtnyIAgLFpIBV7hXZABbqyIVKb/wACc7AW&#x2B;8Ak9i7gSWAPkASuL7AekgABvwAd&#x2B;QAAAGwBxwwOJHIAIl3/AKFhsB8gRblXoAuHuLB3AkReSkhFVgAjkcj1AE2dykv3AvzBLyXfZgSVMSH3aKglwAhDa8hoAJA92ABN2WCbsCyHsAAuSbFdh6AF6j2HAAE2sXgkLfsAs0JT2EJoL&#x2B;rAV&#x2B;oAgBYC4AEi1yj5ASHvJfmEggAAuAE&#x2B;oYAe4lzMieQADspYuLvYD9lKapEWKlCj0FjZEi8CE9ysNNhUhj2LEciHIwiX4BXe7&#x2B;diASLyhG5XAAzDXzF3/Et94IrLcqo9oj2LvuInfsItcBd2QXeUNpsG0AvJNrllbz6kavt7EEKoRC&#x2B;q&#x2B;UFwHYiRXCshNoTAgC22AQIAkA5L6IW2AUZOSzYnOwFkkNf6B7wy2ZQSIlfkpN0oJ3DfkKdmOYY&#x2B;QEtt&#x2B;ZbO7EX5HrABu0T9iStyypJLVwLd3KZls0gHuPQMjhgN&#x2B;R7MMNeoD3EXDspn7COUEI9BDm4TEBTZSEr2D7h&#x2B;gQjgOVeIJuokrtwBObNzwJlSJbdxzEhROdvYrbmxJgQlYA3Vz&#x2B;YlvfkNt7MJuAD9EE43T&#x2B;gh9hdbfKAG/KF/vwNrQXbYBb/MTOwXAskBWRJ8hegcRIQsndjmA3eEG27E6haZG1pEb3L6oqjfqPYEl9iBHcDgOGygvoN9nYTfdDiSdEHbccOH7XDmR6sKNf5hja0BzNuQEj3J6SVxuwHqNnLfzDvcc2&#x2B;jIgoXBUoJMblAj2uH8vQvoRsCe7Z85/pVMk838G2t4qp/&#x2B;19TyOJ7f39NP/qPox9nT7HRP6SvJfr3wXdZLyy8LDyuKvSM1gs5tNONRR6w3uGVcvEbM/ip&#x2B;MP5Gq69zSncm7gqseqfXn9Nvgjzdef&#x2B;FrpHFxKnV5MjiYV1/wAGNiUrb0R1t8Tef8XegvjQ8Oeu&#x2B;k9Aw&#x2B;qclj6LqWWy3T9FVODj4EU0PMYlFbT8z8nlapf/AA1Lk93/AEfmaec&#x2B;FTp5uufw8XN0e0ZjEOfxxr/VfiY8Hc48Xy/i53WMs6fL&#x2B;95sk6t&#x2B;P3PnJ47UxjUVx5z8XyDiUcvEL0fiq&#x2B;MvftK8V/DTWer8z4e6b1xpmLr2SoVWa0inOUfrGGn3omeVNrHsX8Nz5B8M/h06c6x8DOq/GDR8jTl/ELL9X63qWn9SYdLeZwczls5irDwvNvVhunDVDo2aq2PcOvPjz0rw0yXQvVmsdN5rPaV1p0lVqGXymm5erEzbziqwf7uhTDXlxK25/wCDc4Gk&#x2B;jk7S2XdHpHixq/idqfhOuoPA7L4FWtYrymZymW1GhJYuC66KsTDcuKanhupTwz3TDdX4dLau6VKnZgeO6j6L6X6teUq6i0XBzVWQz&#x2B;FncnXWv2sLMYbboxE1eVLXs2dReJvR3jh4N&#x2B;JGqeMvw/9MZTqXIdQU4VfVfR&#x2B;PmvwMSvMYdPkWay1TXl87oSpqpe/lpaO8E9oI5TsgOidX1XUNR&#x2B;Lzwr1rP6Jiabi6j0DrDzGRx48&#x2B;XrdWUxKsNxzS7fI9r&#x2B;NHKfr3woeIGXSmel804iZihuPse/ZzpnQNR1zJ9S57SMDF1DTqcSnI5yvCX4uBTiJKummrdKpJStnC7I9Z&#x2B;I7p/VOrPALrLpnRMjiZrOZ7prO4OUy2EpqxcSrBqVNKXLbhFmR0D1LX4jaTqHhr8Pfwm6hpnR2L1NoNXUevalh5BYmGqacLCpb8kQ3XVvET6Tft/wI8Y&#x2B;rdWwOo&#x2B;gfGjCyuB1X0TXR/bOPkaGsvnMrXQ68HN4VLuqaqaak6eKqWrnoWWwH4e&#x2B;KPgZ4ga/gYmVyuo9G19LZn9Zw2lls1iYODjYNNTheWqqrBroh89jy3WuPk8n8cL0zTv2sbV/CLOUalTTTb&#x2B;7zNLwXU1/1YiXuQd1dM9UdP9YaHlOpumNWwc5kM9lqMfKZjCqtiYdaTpqU3SafJ5BQrpHy5&#x2B;jN8Dsx074Y6b47ax1vqee1HqDRf1OrIYuPOWwMthYvlwVTRFqqaaIn/mZ2R4xfGd4ReB3iZlPDPrejU/xsbI0ZvO57KZCvFwNPwa63RRXjVUp&#x2B;SltO/AHbbjv7CWrnDlM3ls7lcLPZLHoxcHGw6a8LFw6k6a6WpTTW6aODXtd03prQ851HrGP&#x2B;Fk8hlcTMZrFhvyYdFLqqqhXcJN2A/b5k3Ekl7NH4&#x2B;n9f0fqrQ8p1L09n8PNZHPZajMZPM4LmnFw66VVTUn2aaZ&#x2B;xP14Arh/mJlSmF7DsB8lfHL0ZqOmeJeB1lTlq3k9TydFCxVTZYuHZ0v1jys6RVU8n9Feoumen&#x2B;rdMr0bqTScHOZbE/ewsaiVPddn6o6G8Uvga0/OLF1Tww1R4GLPm/s7NuaH6U17r5yfP&#x2B;Oezerr1Nep031oq3mO&#x2B;e/r8X3H2M/iDwyxw&#x2B;1w/X5oqojlirrTMR0z3icbeHfL5L696LyHX/S&#x2B;Z6Z1HEqoox6f2cSh3oqTlP6nzt1D4BeLeS1PC6cq07GzuV/EjLY&#x2B;Fi&#x2B;bBpT5v&#x2B;780fXfWXh51n4f6jVpnVugZjJ4if7NWJR&#x2B;xX601bP5Hhp7s6Ph/GNdwaarUU7eFUdJ8Xs&#x2B;OeyvBfayKNRVXOcY5qJj61Oc4nrEx4eD0fxJ0mrQ/AbUNHrr87yujUYTq7ulUqfsdO57pDQa/hvyfVlGQop1DD1apVZlU/tVUuqqnyt8qy&#x2B;h9E9W9N5Xq/prOdM53Grw8LO4Dw668P96lPlHWXX3hZrXTXgHi9EaPTiani5fPrGpqwcL9p4fndU&#x2B;Xujf4LxCiiii3NeKpuxM9sxMYnydL7W8BvXrt2/Ta5rdOmrojvMVRMTTiOucdJh1/PiD4YYfTvijX1FiZjB1LDTeHVi1VfsJL&#x2B;7qTs06Nvb0O9etfGHorw9w8muo87iLEzuGq8HCy&#x2B;E635f8AicbLiTqjxhw8TD8AOjqMWh0VUvDpqorUOl/hOz9bH5fEnp&#x2B;rrHxs0XpvUM28HAzWn5TDpxEpdNHkbcesydpe0um4tVbuajaKfpczTtmKJjEe55zS8R4h7M279jQfWmv&#x2B;W5YrmZiK7tM807z3mHf2ha9pPUemYWr6NnsPHwMahVUV4dU/1s0fTH6PzGxXqHU&#x2B;X878n4OVqVPCc4in6H84sTpXXPBrxt0npvSeoMy8nm8zgVYNX4rp/Ewa8SHRUk4bmVteZP6Nfo&#x2B;knqvU0R/9rZW3/wBWKaXDeH29DxzTVWq&#x2B;aiuKpicYnGJ6u349xu/xj2N19vU2fo7tmaKaozmM81O8eXh5d5fSGtJ/2VmL/wC4q/Jlwv8AZ0/9KNa0n/ZWZlT/AHNX5Mzhf7Kn/pPovd8E&#x2B;5Hr/h6f8RMf&#x2B;wDrZvb/ALJ6hP8A/L1nzD8L/UfxwZr4WOmPDDoTwr0inL5zQ8NaP13m9ZpWHlMpiTFVWAv26sWiltJK1kz6o8aun9W6r8HequmNAyn4&#x2B;e1Dp3OZbJ4CrVP4mLXg1000zU0lLaV2keM&#x2B;GLojqPw1&#x2B;Hro3oDq7KU5fU9I6ey2Wz2BRi01qjFpoiqlVU2cPlFYJ4S/D50R4Y&#x2B;B&#x2B;U8DMzk8PVtNWUrw9UeewlV&#x2B;v4mK3VjYmJT3qqqb9Ldj8XhN8IXw4&#x2B;CGtvqTw08LcjkNRaqVGerrrxsTCpqmaaHiVVeRX2pg7Jqcsk&#x2B;rAskLueo4/jX0Dg&#x2B;M&#x2B;B4B06hjV9R4&#x2B;j1an&#x2B;rUZep4dGXpq8s1V7UtuYT3j2A9ti25nFxcHL4NeYzGLTh4eHS6q8SuqKaUt229kM1mctkcCvNZzMUYOFRTNeJi1qmmld23ZHq/jRh9Iav4L9TLq7MZivQ8Tp/NValiaZjJYtWWWFU63h1JpebypxeAPZNP1HIavksLU9KzuDmMtjU&#x2B;bBx8DEVdGJT3pqplNeqOfY6QyHjN0d4T/CP0n1D4QdMZnHwtVyGS07ofQ9TxoxcfFxopwaMWpeaIU11tTCpZ6vgddfE/4H/EP0L014x&#x2B;J&#x2B;mdTaP1/jY&#x2B;Rxchp&#x2B;j0Zb&#x2B;y83Th&#x2B;en8KG6qqNk6qt4bA7x8UfGPwz8F9Bp6j8TescppOWxMT8PA/Hqbrxq/&#x2B;GiilOqt&#x2B;iTPl34yPiWz3iz0b4ff&#x2B;xvw81vO6dqHiDp2JltY1SirT8pmMxh42JTTk6lWlX&#x2B;3VTU24ilUzvB2B4DaHkPHf4kPEPxz61wcPPLpLqGvpjpPJ5peejT6cvRQ8fGppdlXXXV&#x2B;&#x2B;rxKP0/HnXgYOX8J8vV5MOivxf0hvamlJfiv2VwODx58R/iB6D8N/DzNdXavpuk9Qa54oaZkNYwum66q8u8li4tbeAqsWnzOaKUqqkleYscur6RkPiN&#x2B;MrVehutMDDz3S3hpouTx/wCxMzT5sDN6pm/NXRi4lDtiLDwqISqsqqpg38dWLh5jE8JMvhV01fi&#x2B;MGkTFS2peJK&#x2B;p4jxA6Q&#x2B;I/wT&#x2B;KzWfGvwX8L6OtdE610nLZbVtKp1bDymJlc1gLy0YjqxFCp8vN92BekehOmvDj9ItquX8PdMwdPyOseGP67rWRyNFOHgrMU5pYeFX5KUlS3Sqn6wzyX6PRYOW&#x2B;DnKZ&#x2B;jCooqxtQ1nGxaqVHmf65j39bJL2R7T8Pfg51zoOq9Q&#x2B;L/AI05vK4nWfVv4dGbwdPfmwNLyeHS1g5PCqf7ypbqqdX&#x2B;Js9s8F/B3pbwN8NMl4WdL4&#x2B;ZzWn5J4zVeoV0114jxcSrEr80JL96t2jYDrv9HJQ6fg76SrdMPEeexI/6s7jv&#x2B;J3gjg0zS9M0XIYWlaNpuXymVwKfLg5fK4NOHRQuyppSSOcBAEyG&#x2B;wEexbAb2AfMDbcAA55G4d&#x2B;QAYDAl&#x2B;30ZON/exXMbk9ZA1gU&#x2B;fGpo/4qkjtnDTWHSk9qUdVaevPqGBT3xqVHzO1qV&#x2B;ylIXsNqPYsvsRXUlatdsIbFhEW1igAm1cABvYAQAUclUdghbaQDUELe5PkAKmTYLsBV2j6hNLgcSPT6oB8xu5/iFdWYb5QD0THH&#x2B;YQlICFfqRuC83APeYDtyJ5HH8wD2uGI9AvYCRLsW64CmZYm4BtkK&#x2B;9ifIAi&#x2B;hAgLN7ib3C7wH9QJYvsHDYgCMCwfoA2AAB7EnuUl52&#x2B;YBdioi7QUBAcFj0I/UAEAAG4ABwHuPRE2YFmATdQyyAAEgLwLAAJQHA9AHqTbkNvsE&#x2B;HuA9CgAIUgABYME&#x2B;QFDU7hAAAAFuREcBjgALAAAAAAT4ZAKPkRexQAAAC/AfqPcA54JveSwRqwBWsik5C3AqF/6QC3QH7knEyL7ilyt&#x2B;A5e7g2VJe6UEStsWYUzv6lpvxsERrsSbl34&#x2B;oTm7QVGmrJDewb5QtvIBqLELC5D9PmEZiOR7lewLIl42JDjgsMOAqNPZCZ5K&#x2B;3BP&#x2B;odkRLuWGLxv7hqLrYKkIepXO0Eh9uQEJ887j0TtyN3JWoc9gJD7Ea5KLO7IJCbIywpkQuxcgvVDYARIja5D7D0EvsAtFvmwhFwv6uA33Fu4tuG13AcyJlj2Qvsx2MmzF1x8g05kkSoEC/1EBQ3MEdtluVNDGwQuw9C&#x2B;6J6Ne43B35HpJG72LNpkQHMjf&#x2B;Abav8AQR6lD1TDh2DiJSDe5BSTPrYjclvuAfqyPfncqc7okpuIALsxaYj7BTtYNw9gHzFojkkW&#x2B;e8hwAbUiXG&#x2B;4vsVNbR8ihImXsSeGW8wn8yIS0rsXXHyCXoGo3aGIUvPISUX&#x2B;4UvYrcqZAMNW&#x2B;W42sxFwEdiO0P8ypQ/4j3QEcNCbRU/kE5HHYCpRsJnfkf02E7WCL6kTXAlrdBSrDCnp/AbqQ52j6C7QB&#x2B;/1D335G7j6izumRB7XEWJ7lUNAL/0iQv3nYRd3D3h2CluwmHEDf27CYvI3B72&#x2B;oe0L5BtxE&#x2B;w4lBBexdlHoRtCOwF4EJ2Y2G12iCOH/E6i&#x2B;PPIf2h8H/XuC7&#x2B;TQ6sSP8Aoqpq/wDSdvW2aOuPi9yf6/8AC91/lUpnpLPNKO2DU/4HJZnF2mfOGxpKuXV258Ko&#x2B;L&#x2B;LycU7e5VHJl1/tRFpKnOx6x9iip/RP9G/nnmvhhyGVaS/VtVzeGmuf7zzf&#x2B;o7Q688KdJ696t6V6yzmo5jAzXSeqYucyVOFDoxniYNeDXRWmtormVDTR07&#x2B;jDzDxvh5zOXdU/g9Q5ilLtNGFV/H7n0W0lujyGsjGqr9Xybi8Y4pe/5S&#x2B;afEbxM1H4MtX60y2q9FaxqXTHVOYxtV6bzuj5J49GW1DGo8uNlMZJf3aqxV&#x2B;JTVt&#x2B;20eB8KOg9S6U6l&#x2B;GzSutNLpoz&#x2B;V6Z1n8XL42HLwcWvAw8RU3/AHaqU4&#x2B;TPrLFwsPGw3hYuHTXS91UrHqnWfhRk&#x2B;rvEbpDxFWq4mXzHSmZzWJh4CoVVGYox8B4VVL5TX7LTXbY1o6uuetfGhrGrdM/DB1Z1B09qWNks3p&#x2B;Sw8fLZnLYrorw3RjYbmlq6PUvEr40sDwR8WqugOq&#x2B;lNU1rKY3S&#x2B;R1TJ06Hp7x8xRTVVi05iutJ3w6Fh01TvNTXY9s&#x2B;NjLLNfCh19h1Utx01mK0lvNK8y/I9T6Cryua&#x2B;MLR87XhUYn674KZXEodalws0p&#x2B;1Zew98678SurOrPA3L&#x2B;J/w3ZfLa5mM3XlM1kMLFX7OZyzxaPxaVLXlr/D8&#x2B;&#x2B;zR2DhV/iYdNbphum67Pk&#x2B;ScfWNb8O/hX8W9H6J1vM6a&#x2B;kPErMYekYmTxqqKsrg1ZvLZj8Ol2in&#x2B;&#x2B;qTW0VNbHaXih8aHR3hX4jYfh5neieoNWWV0vBzvUGp6Pkfx8HScHE/crxkrw4lxsrkHcyd9xujg0jVdO13S8vrWkZ3DzGUzeBTjZbMYNaqoxMOpJ01JrdNNM5&#x2B;7A9e8VPC/pLxh6JznQfWuReNks3Sn5sOvy4mDiUuaMXDqV6K6Wk1UtmjrbwJ&#x2B;D/J&#x2B;CnV2v&#x2B;ImueJms9XazqumrT8tntbqpeJl8pTLWCmt7xLttsd03iA0qrQB0/8AAVk85p3wqdMaZn8piYGPlXnMLGwcah01UVU5vGTpaezR4T4hKsbwP8Y8t8RWpdOLVOkNa0XD0DruhYSreRwVi1VYOb8sftYaeJXTWuKWnwd9000q6pVPsjor4ss78SWi5PWcPw98N8t1t0vr3TteQzOj4WMsPN5HMVKuh41KdsXDqVamndOlPYDxXxCdbeOfUXjL0j8Onww9WZDp2jG6dxNaz&#x2B;s4uUpx8OjK0VLDwcKlNOzcbcNXPLdOeKnW3Xfg54h&#x2B;GPi1pmXyvWnS&#x2B;iZrL6tTkU/wM5hYmWxHg5vCTuqMRJ24aaPU/DXpvqPwW8YPBrPeJDdGY1fwyq6WzeLiN/3WfwXh4&#x2B;FhN7eaqn8Sne7oZ5TxUzWBkPjC1XTNMoorr1nwWzy1HBpcTVg4z/CdfyrrSfqB2H8H&#x2B;M8x8LfQGKk//wClMmvphJHZCtVCPk3w96z6n6c8G/hiWi6/j5TL6pqGXyGpYODiNU5nBqyeJ&#x2B;xWtmvNTS/faDv7rLxv6Z6F8U9G8MtfyeYor1rSM9qGDqFMPCwaMrTTViKvn91yonb1A91T9dywdT/C54/Zzx60Tq/qPCzGn5zJ6R1hndP0fMaZVNGYyuGqKsKuW4bqVW&#x2B;x7L4A&#x2B;MWB46&#x2B;G2X8QMLpvN6RiYmbzGVzWm51P8TAxcHFqw605SlTTKcAe6QgAB&#x2B;LX&#x2B;m9A6p0&#x2B;vSuotHy&#x2B;dy9airCzGEql99n6nRXij8DmiaksTU/DHVP1LGab/s/N1OrCqfamren5yfQRGaGt4ZouIU4v0RPn3j3u64R7Q8X4Fd59HdmmO8daZ9Ynb5&#x2B;b&#x2B;fXXHhp1x4dZ95DrDp7HylU/sYlVM0V&#x2B;tNSszwU3uf0X1nQtH6hyFema7pmBm8viKKsHHw1Un9djo/xR&#x2B;B7pzWvxNV8NtT/s7MOWsjmJqwan2T3p&#x2B;54fiPsjqbGa9LPPHh0n/E/o&#x2B;x8C/ilw/V4tcSp&#x2B;iq//AGjM0z86f1jzfHXX3h1074jaMtG1/DxPLRifiYOJgV&#x2B;WrDrhqV3s&#x2B;Trvx96KrzuNped6J1GmvXtCwMOMnRUlj4mAn&#x2B;xiUrepp0vaeT6C698K&#x2B;vfDTPfqXV/T&#x2B;PlU21h4/l82Fif9NaszpL4gPDPXuoqcn110W61q&#x2B;kuaaMKfPi0JyvL6pzbmYOt4Vfv6bX0Wr1U0RTnEVdImY6TE9p6T&#x2B;b0XtLpNFxHgl7VaS3F2a4pzNE/WmmmcxNMxnNVPWI3zjHd1Ph9XdZdaeLPTmr9aZZ4WNRncvhYSeA8P9hYt7Pe83P6W/o&#x2B;ao1jqZR/&#x2B;65X/AOyxD&#x2B;b3T&#x2B;u9ZeK/jRomZ6lyXkzWTxsOnEpowHR5KcNuttp7S5fzP6Qfo/E1rfUytH6rlp/&#x2B;6xD1FyIo47oqOWKZimraN4jMT0fObE1XfYvi17nqriqujFVcYqqxNGcxmfi&#x2B;ltWaelZi3&#x2B;5q/Ixh/wCzp/6UXV3Gl5j/AOTV&#x2B;Rmj/Z0z2R7Du&#x2B;Uz/bj1/wALKSv9z0TQPiS8KOq/FrMeC/Sur5nUtYyVOL/aGJk8jiV5XK14aTqw68ePJ57x5U253gz8TPivofgv4H9Rdcaz1Fl9NxMPS8xhaZjZiqPxM3VhVvCw6bOanUrL0OmfgT8cPDXor4TVq2a6R13Sch01oFOp9RdR6ppX4GBqWbxPNXi/g4jc5iqYXm5mhLdFYPqOex&#x2B;fUNY0nR1hf2tquWyv49fkwf1jGpo/Eq/4aZd36I&#x2B;WfELxS&#x2B;PvOeFGN8TnSOL01ouhZXLPU8v0Tjaa8fOZjT1FXmxsZylW8P8Aa8tHliNzx/xda1T8R3SXgBrmg53E02nrLqbCmvDxIqwMPMZVrFpVS2apddKfcD6f8O/FLoHxY03N6z4d9TZfVsnkdQxMlmM3lVU8NY&#x2B;HHnppqaSrjzK9Mr1PSNP8T8XM/Gnn/CHD6R0qijLdA4ep4muU4D/XcR1ZpUU4Lr/8NXcd2ux2B0L0B0Z4ZdNZbo/oHpvKaVpuVoVODlcngqinZLzON6nClu75OlemqVV&#x2B;ky6lrW1PhXlE/nm0B154F&#x2B;FHVPxvaT1Zi/EV1vrGc6X0frLUsloml5XUKsL8XEpxX/eYjpjzU4dPkoop2tU3uc/w1PVdH&#x2B;Azxa6I1LXMbPZfpbOdS6Vp&#x2B;LmK3VVTl8LBq8qbfq2/ST3n9G4lieDnUmPSnGJ4ja1Vf/5yPVunOluqvCH4JvGnM&#x2B;I/T2PpWNqmrdRZzL4eZVPmxcDMU&#x2B;TCxLN2qmycO22wHovijTVgeAnwu42r9Z57pvR6cbLYeoa/kaqKa8jXVk6acLEVVadNO9S8zVk5O7PDTwp&#x2B;DPo3xa0jI6T1Lh9WdeY2HXmsjqWr67iapncNU0&#x2B;arGbdTowJTlNKmZse0eFXg50j1r8JvR/hX4r9J5fU8nT0vkKM1ks7hWVdODRD701LunKPZfC7wH8HfBTK15Pwp8OdL0NYqjHxcnl0sXFXarEc11Kb3YHRek&#x2B;F3xj/AA/&#x2B;NvWWY8COkenOpOlettaq1eh65qlWWenZrEX95KpmqpTvCbaS2Ox&#x2B;s/hpx/iA8EMh4b/Ev1D&#x2B;vaphags/j6h05/3VYGMq63TThNpvy001OiWpaU7nbUFA9U6L8FfDrobo3ROhdN0GnN5Lp3EeLpNeqv8AWsbBxm6qnjKvEl/iTXV&#x2B;1upse1iVwAAgElJ78AB5krEdSU&#x2B;xh1rYDfmW6Ql7JScfnW7OgPDb41emdT8fOvfDbxL6w0bScLR&#x2B;o8rovSunrE/7znsSuVVUlvW3XVSrKKV7yB9CcRHsVmaXJUwKyJ&#x2B;heNiWaAqsUm8AB6BxvA9hvyA3MpQrfI0l6hXA59HSq1jKrvmaF/8AhI7UavDR1j05hrF17KUf&#x2B;fS/o5Ozm/2m/oF7C9ArMPtI23bCHN&#x2B;wVrgtwAXYJ3kAPZCCuJsIbVkATQ25Cn&#x2B;YvFvmBB6C/AAD1A2AqcbieQncTaGgExwJe0jgPeQIxIE9gDnYAtuwEUFbkgi24Aqd5IAKm&#x2B;4UJ3JYJ/UCveV8hbgjLfYCbuw5FwBZS4Eol&#x2B;Q2AYmeQAHsAxIDe0AIT3AMkOdyka5AJepfcXHAFe0EAfcAAPSACT7FtuRABcnpBedyIC/InqWzAARI9wADvYDnYCNBKNmVINRuBLwX5AfMB7CfUfIO10gJ/SCcPYS1v&#x2B;YgA7bib2EdiyAHI2AAQpHuAA9hckdgKRuC/MjV5ATOxediTfcNSrALzAY53LvugJHco9hPAABsXASCNd2OLgUe4d&#x2B;bBdmBEto2G5QAm8BCRvs&#x2B;AP3JQvkW7/0Cj6oqRsqnug3aIktiWShsAlb&#x2B;ZI5W5XP8xflAS3cK73LDe33JbvPcBFt&#x2B;SfL6lduBu0rMCNEgsdx8gIGXYkCBG3P&#x2B;ZGluzRGl2AjjYQ4LFpIrIoKIllSS43Hq&#x2B;xLJeUdROXASasncr9hZ/wAwI77EdzT&#x2B;5IIJAW0wVw77CyAgSLYiAe4cbATBQuiNlAQ9g9hzuTjYKSUlwiA13C9vkItAU/e5ewXW9wtiRLsvqWeP4gPYKG5j5iycC3cdgiLv6kbfmLtySXwBZvAbkj3DbAPa0jzORN9iQwixLF1YjT9EV2vEgF/qPdCIcNpiYtAUW0yGm9gqXwOX9wJtdBWvJXStpHN/oAUpzAUbQJG4DZN9yTe3JbEUOykCzeGI5XAcbk43A1eJJd2ZI5gTGwF9WUy97TJVVaR2Fs/qG4u2yKp82EuNyYCVx&#x2B;QV1b7kae5Uu8lBDdCewbQFb5gf0yWm5ZWzYB2W4lTAcv2HFibAn3&#x2B;yI/dDe4cSoKiygobkia55F5lckXZd3sRtcFnyq5Goe4Qcv5ib3I43Yt/mBVCu19g7vuXeSO1kICV/qJSspDbSHFkBW/6RLu33JNT2IQaURdbHp3xCZP8AtHwK6yyET&#x2B;N0tn6UvfL4h7hseI8QMlTqfQWuae6Z/H0jM4b9fNhVIyonFUM7c8tymfOH8LEru5qltLclSfndLWzaC9T2D7FEvvT9FjnPx/BbXMpM/g9SVOI/4sDC/kfTbd4Pk/8ARR5rzdB9WZJt/savgV&#x2B;n7WE1/wCk7k&#x2B;LLxR6q8G/CZdedIPB/WcvrmnYOKsfD81NWDi5qjCxFH/TW/bc8jxCMayv99ny/jkY4rd9flDsxwlcQkRVvEpVdKiSwohmm6p&#x2B;XW9F0jqLSczoWvafg5zJZzAqwc1lczhqvDxcOpRVTUnZpp7HqWB4K6Pp/jFpnizpWdqy/wDZnSleg4Wm0Ya/DeA8WjEoqVW6dPliLqGe7NbShMu&#x2B;wHyd4w9M9QaB4A/EdTrGk5nLYea6n/tHT8bHw2qcxhVYGTarof8Aip81DUrtBx5LqPxt6J&#x2B;JHxA6h6E8PNO6q0nO6JomZ1fRasz&#x2B;FnsXL1ZN0LEy7adOJT5qMROl7tWZ2V8d2L4l6x4LY3hl4aeG2b17G6tqemZrMZWpRp9Fbp/vq0/8MeZTwc/ir4V&#x2B;KHTWc0Hxj8Csvks11NomiUaXqmh57G/DwdYySir8Pzz&#x2B;ziUVp1UVNx&#x2B;1UnuB0h0P42eN&#x2B;P4MdGeCfgjl8TQtd1jrbVtLyeN1BkqlXpmnZaurGoproc/tLCrw6ef3T3Hx/wDHL4jPBL4W&#x2B;ocbxZ0vydRZXNYOU0vqnpXBdWXxKGlWsziUVOcFfs1UVbqWrQzyviF1zrOPm/Cv4jet/DzN9KUaX1ZmdO6i07Uak68nRm6KsvRj1VUqHT&#x2B;JThftdq/me8/GzhYOe&#x2B;Ejr9Nqql9MZiqVdNJeZfkBt&#x2B;KPW3WWW8POsPBPE07qLpzV86sLqrN5fGpreBgVYNsShyodOJ&#x2B;8rtTEHaFN6ZqV3ufO/UuUwPBrpzwcp8KVTomT6i64yK1vLZD9nCzf6xka/wATzU7RU6KXChSp3ued6p&#x2B;PPwQ6O8YM54Q63VqtNWnY&#x2B;Hl9T1vC0&#x2B;rEyOSzFceXDxcWn9zdKWoTE7DuuXyW62ZjBxsLHw6cfBxFVRXSqqaqXKa4aNXVwPVfGXwg6V8bOiMbonqh4&#x2B;CnjUZjI6hksTyZjI5mhzh4&#x2B;FXH7FdL57Nrk6s8KfhA1Twk1HrHxM678WtU626h1np/F07LZ/UMBUV4GUpobpwklVVNTcS7TGx3844MuI/yA&#x2B;NdEozGk/C58N/VOqYVeXwtF6003Cz34qaeEsT8bAXm5p/adKvtMHbXjPg4GN8afhJh42FRiYeNo&#x2B;v4WLh1qVVS8DDs1ynB2T4ueE3SvjJ4b6n4Y9T4NWHktSwkvxMulTXgYiqVdGLR2qprSqT7o6E6N&#x2B;Fvx&#x2B;6G&#x2B;I3w/wDEXr/xXzvW&#x2B;V0mvP6e81Vl6cJZHKVZSpYVWIt6q6sSFVVfgDh&#x2B;DDwG6b0Tx08SPEHpTVc9pK0jr/UdPr0PI4vkyOYyzw6HQnhL9lVUVVSmu0HbPw5&#x2B;OeH4geC2Z8TOvKtM0inJa1qOVzuPQ/wcBU4GZrwlivzt&#x2B;V1KlNy92etfCrnsno/jX4z9DahmqMLUv&#x2B;3P9o4eUxK4rry2PlsJ0YlK3dMpqe6Pn/E0jF69&#x2B;GrpnwmzWYxcPTOpfiCzunaysCp0vEy365j4lVDa7wvovcsj7o6a6r6Z6y0nD17pLqDJanksX/Z5vI5mnFw6vTzUto8gfOGe8Nel/gx8ZekNa8KclVpvSHW2rU6F1FolOO6svhZyuhvK5rDpqb8tXmodFUbqpco83qnx9eC3QXiP1L4b&#x2B;Lmt4WiZnRdeoyGVxaKMXFWPhVZfCxlj1qmj&#x2B;7pTxPI3dSpmCDvQlzh0rVNP1vTMvrOk5zDzGVzWDTi5bMYNfmoxKKlNNVLVmmmn8znAkIj27ln1EAfn1PSNM1vI16brGn4Oay&#x2B;LTGJg5jDVdNXumdJeKHwQ9JdQfiap4d6h/ZGacv8AU8aa8vU&#x2B;y/xUfdHewTi5pa3h2i4hRy36Inz7x6T1dvwnjvFuCXfpNHdmnxjrTPrE7S/n9194Ldb&#x2B;F2pVvqnpWrL&#x2B;b9mnPYeEqsPEXpiJfZncv6P2iv8AtvqbEppflWWyy80WnzVn0vn9O0/VcnXkNUyOFmMDFXlxMHGw1VTUuzTPH9J9CdHdC5bGynR/TuW07Cx8T8TGpy&#x2B;HHnq7s6DR&#x2B;zH8jxSjUW7maIztPXpMenwe34r/ABFnjPs5d0F&#x2B;xi7Xj61M/V2qiZnE7xO3m/ZrU/2TmWt/wKvyGGv7ul90XW0/7HzL/wDIq/ImH/s6V/yo9X3fNJ&#x2B;xHrPydf8AxVaTpeq/Dn1t/aem5fM/q/S&#x2B;fxsv&#x2B;PgU1/hYiy2IlXTKtUpcNXufOvjVmM3p36Jvo/HwvNVlqdK0B6kqKpTy34uE61VHGyZ9ReOPS&#x2B;s9beDPVfR/TuWpxs/qnTucyuSwqsRUKvFxMGqmlNuyUtXZ4Pwh8GsPTvhj6f8AA3xX0bJ52nL9MYGm61km1i4OI6aFTUk4UqVZ91PqVg9e&#x2B;Kjxh6O0H4XtQ/7MZ3LZ/MdV6N/ZXSun5StVV57GzOH&#x2B;Hh0YdNN7U1S&#x2B;Elc9G638Eur&#x2B;ktO&#x2B;GvoHS&#x2B;n85n30lr&#x2B;W/tjHyuXqrw8tThZWK8SupSqKfO4Te/B2L4O/BD8Ofgb1Bh9VdE9HY2JqGXdX6jmdUz&#x2B;JmXk6XaMFVt04drSlPqdtzaIANQ2n3PU8h4N9I6f4yah454VWaq1zUdFwtKxvPjL8KnL4dfnSpoj951btt9j2y3C9wrOAPw9O9L9NdI5CrS&#x2B;lOn8lpuWrxq8WrAyOVowqKsSpzVW1SknU3dvdnpPjT8P&#x2B;B46a7oeH1Z1jncPpjS8f9Y1DpfL0KnB1THpqVWE8aufM6KWpdG1Vp2OxNuCSwJh4dGFQsKilU00qKaUoSXYpfRoMCCSNi037gNtw6lEwSyp8zt7nrOd8afCjI9M651lide6Ziab03VXTrebwMyq6MpXRT5qqKmv8UNfsq90gPZ59ZMYuLRh0OuutUqlTU24R0N4ffEx8RXjP1lpOoeHPw416f0Fm83S8bqXqXO/g5jHyrb/vsLLqGk1tM7p7HjfFjFxviY8d9Y8EtX6vx9I8P&#x2B;h8hl8brHEyec/V6tSz2OnVhZWvFlOjDpoXmqh3bSYH0DkdY0nWMOrE0fVctmqKK3RXXlsamtU1LeluluGfP2f&#x2B;NXqLxLzmp&#x2B;HPw2eHT1Pq7I65mtPx8PW8dUZXJYOXdFNecxqqKrUVV1OmihPzVeVviDrf4c8t4S&#x2B;Evx7Zrw8&#x2B;GfqzC1Do/XOka8TVMlp2frzWXyWdwqrTiN1KWk3u3&#x2B;1B7V&#x2B;jk0vT/P4r9W15bDWdz3ibqGHmMZXbow6ppp7wnXU/dsC&#x2B;BXjx41&#x2B;IHin1Z8H3xXaLkchrOLoGJmMjqXT1Tw6MbLYi8lfkql3Srmlq68rm6PDfo/PA3wr0Pxc8WsXL9LZTO19P9cPI6NntRw1mMfL0UU1NpYlab80xNUy2j2PTsnl&#x2B;uP0l2c1vR8NVYPR3h9TldUzWHdPNY&#x2B;K6qMOpxusOqY/5T074R/HzpHw1&#x2B;JjxO8FuqtM1Va91N4l42NptGXyTrw/w6/MvPXV/gpSvL3TsB9n0uXubTm38DiolHLS2wKu4iNhAAR6jYcifQB8wLgCpEbRW&#x2B;xAPI9IUqvqbJ0xP943/APgtnZS7t/I636IXn6pyi4VdX/2FR2OlNwKl63DUlHzAE&#x2B;ZfUAASX3KgLMqB8/qF7iE3CAL3JbsXe&#x2B;wbnkCANQAC9QCgQWLBHHAFb4IwADsE2wAHI&#x2B;YkAW3Ym5Q4VgJKmCSUQpkCeyKGuRL7AC3VyIALbi83CAEaHNiiAInO5SR2DAq2E3YAD1A&#x2B;QQBAL2AAATPIAbobBuAABHdWAqASQADfYMnNgKgAAYCgQA9wi&#x2B;kDiJAbBrkP0DmY9QHsSPQvHqJ5XYCNB7WKQCOxY4DuIAkXKAA5sR2LyGgJv9RebIRGyHIFjuByAAkAA3BEUJdwEgAB8gHYbICXRSeyKgI99hF7lABIAMAAAAe0EiQ/4AeRSlfIqQSDXLNkSAaiduSW7EEgkXk0o3I7FhUaQ2&#x2B;vId2N92ERxM/cOKbv5B2&#x2B;ghzMXID9ER&#x2B;nzK0o/Il4KpzcSHd/yHzCC2ZGuzK7WknAEat6Di6LEEa59SqepN9y3TJutryQXddiVXVi8BqbBEae8EvyVzyG&#x2B;/cuYVGp/gLbj3Hq9hkQCJAAciBzsEBbcl5uy3HcBYMjXzjgqqRdpHpuJaZihce4myfoOC4VLzAad2w4iykeifyAPsxK5Dh7cCZewCby/oHzBL9tyy&#x2B;4E2UMvO0hTMKREWa5AS0Im7JD2b&#x2B;pf5BBRYJNOIDaiPoR9kxC4V3RF&#x2B;9dC7Ls&#x2B;QG95uHeHIlvjYS24KF&#x2B;25G00HbZhzGxEJ7hVcySUt2E4YFn0Dd7Emdg3IhSJKpSkWkJoBLaiQmLrdBlFlXncktOSOOA3G8ERUwoW69ycgdVX3ERfsLv1KlKsAfs/UOHabcE4DYF242I36CeULWJ3RU1F9gnPBJXCLPrwA/eW/sLf4SXncTO5QmXBZ7MjtwJtAVXEkhK8/cqsogmyt9SAo2CU2HAlICtudw/QfPckyAbnYTJPZjkiK/Ymxd1sLLgAlOyODU8L9Y03M4DUqvArpjvNLOe7sTESdFVPelr7BY6v4O6xgfqer5rKPfDzNdH0qaOFHlvEXKPTvELXchDTwNZzWHHti1I8Om0exjM0xL6/bqzRD7Q/RPZtvTetcn5rU42SrSb704yf5I7W/SG4FOL8JXU&#x2B;YqV8tXksdPs6M3hOfQ6X/RO5upa71pklHlqymSr&#x2B;aqxV/E7x&#x2B;PvLVZv4PevKaaW3h6P&#x2B;LC3/YxKKp&#x2B;UHlOJRjWVe74PnHH4xxa57vhDsHT/ABH6Tx&#x2B;tqfDFakv7bWi4epvKOh3y1Vbo86ez/aTTW913PYbu58&#x2B;aJmaV8cvSOqOuadV8GqkquKnRmsOvfm1f39T2Hpfxn1nTviS8T&#x2B;j&#x2B;stcow&#x2B;nemtA0zVMr&#x2B;LQl&#x2B;rUV4WJ&#x2B;M/Nu6f7tOHN5NJ0zuLdwpt6ktFj0PwN&#x2B;Jfwd&#x2B;IvTc1qXhV1Zh5/9SrVObwKsOrDxcNP92p0VpPyuLPY97m0rZkBNrZx8wnsl&#x2B;RCprsB43rPovpvxC6Vz/RnV2l4Wd07Usu8HN5fEVq6X&#x2B;TThp8NSdUYXwudU9PeC/XPhHgeK&#x2B;sdQ6br2iY2U6fymuYirxNNnCxKVhLF3rpfmoU1XXlO603G4TvKA&#x2B;SNb8Tst4jeDvg/ivRs9pup9MeKei6Rr2Q1DKvDry&#x2B;awsKrDxEuHTdNVKzT&#x2B;R7t8L3Q3S/UGU8Y&#x2B;kurdEwM1iZ/xI1LA1XCzGGqniYFVGHVhSnx&#x2B;HWnS/dq53J1x4bdG&#x2B;IeVyeV6p0dY60/VcvqWUqpxKqKsPNYNXmw8SaWvNHZymuDqXxf0jxa8B/E/VPHXwX8PMTqzT&#x2B;oslg4XU/TeUxacPMU5nBpqpws3hTaqaWqK6buEn3L2HXOH4&#x2B;df&#x2B;EPwq6DntKzWbz2odHeJi6Xz2WTVeJqOVwsfFwaMFuqZdWG8JTZypT79x&#x2B;AXxG9SeIvVGpeFvi14b4vSPV&#x2B;mZTDzq0yvMrGws3k63Cx8KtJSlV&#x2B;zUuHHy6IznQXXvRvwmaR1H4qaQ8lrvUPjRp&#x2B;v57IVOHlqsxqFEYdXZqmJ7Sdx&#x2B;L9f9j/GX4SaplavJi6nput6fmalZ4uFTg4WMqX3Srpn3&#x2B;ZB3ZadoDSV4K09gBl&#x2B;w2K72QSUb3A9T1fwR8Ndb8U9N8as30&#x2B;qOptJy&#x2B;Jl8vqWBiVUVYmDVS6Xh4iTiulS2pUp7HSvVfwudedDfDlrGl9NZvL6pr&#x2B;heION1l01Rl6ak8drMfjrAae1dVDxMO0qWu8H0unPyELdgfJPxK/E54V&#x2B;PfSHhr0d4YdSYOb17XOvtJzH9l0J/rOQ/AxViY34lDh4boc0uVe57T4J&#x2B;H/RnVnxV&#x2B;PdHVHTOTz36xnNLy2L&#x2B;s4Krbwa8kvNTfZN3&#x2B;XodvZH4fPBXTfER&#x2B;LGn&#x2B;Gej4HUdSfm1XCydNOK296pX&#x2B;J81bs9f8KPCrq3oz4hPE3r/Vsrg06X1VjaZjaXjYeMnVV&#x2B;DlvwsSmqnelqpJ9mqkB4L4Cc5nMl4Saz4b4&#x2B;Zqx8HorrPVNDyOLXiOqr9WwsZ1YVLnby0VqlelKO7mdGfBAvw6vFXCdMR4taq496cFneb9gJad/cqcknlCQKBxuALsEgpYvwB&#x2B;fWVOkZlf8Ak1fkZw1&#x2B;xTfhXLrEvScyl/4Ff5DDX7FKS/wondlP2I/fgLuX0kJBIrE2bgJTdMTwFeyAqXme/wBSNOSzK2&#x2B;xN7QBLsJScWPqOnZXMYeTzWewMPFxnGDhYmKlViOG/wBlNy9uD07x38cNK8DumMvq2L0zqeu6lqOcWT0bQ9Hy7xMfO5l01VKhWilRS26nsgPd3e8HTXxBfE3mfBnxs8OfDPFp0zLaX1ZmM3XrGr6ljeSnK4GBRS4pbqSpbdS/aqso2uek9F/Gh47ad8QHTvhH8QXgBg9J5DrGmtdP5nB1H9YxacSmWqMV/uzw1CabVmegfEz8OXRuufpA/DfJ9e6vqfUmR6vx9SzOc0nVs3VVlsrRhYdLowcGlNeSibtLdoD6u1Txt8MNL8LM34019X5TG6aymXxMarVMtiefDxKaKnS1Q/8AE/MnSkt2fPfiH8cPxM9BaPlvGnV/hgw8h4a15vBWLmc7qManTlsStU049eEn/dzKapatKl3Hx/5zJ&#x2B;G2k&#x2B;E3gr4d&#x2B;G/65pWf6ypx/wDsppLpwFnaMrGJTl1wlViYiqbfabnlOt/Dj43fix6QznQniJhdKeHPSuq4X4Wc0/AwnqWoY2DMql1trDw3ZXpSaYHhvj21zrHqLxM8E9L8KepMbI5nqjO5/LZfOUYlVNOHhZjAwqPxvLKTqooxaqqZunsfj8dvBPw58OOp/B/4PuhtJxMtoPVPVmJqXUlNeK66tSpytFNT/Fqql1OptN8W9jy3jz0tgdF/E18M/h/l89Xj4Wj157L0Y&#x2B;Kv2sRYWWwaFU42b8v3PZPjx&#x2B;H/AMXfEx9H&#x2B;LngFiYNXV3QuqV5rIZXGxqaFmMOvyeelOqKZ/YVm1KbQH0Hg4OFl8OjLZXCpw8KilU4eHRTCpSsklwj4L6E8Ofhu6y&#x2B;Lvxg0X4ntdqy2cweqXm9O0vU9XqyuSzWVqpbpxKqfNSsSpU&#x2B;Xd7Ox374Saj8dniN1TpOt&#x2B;L2gdO9D6DkMb8XP6ZkMd5rN6k/I15G1U1hUS5iZsu1/bvFb4TPh58aupMLq/xN8LdN1XUsGimhZvFVdFddK2prdFS86XrPYDw/gH4h/DTr2uan0D8O&#x2B;lae8voeWo/XM9o&#x2B;mqjKqqqppYVOLC/Eq/ZlpNnzB8H/AIV/E/q&#x2B;n9adVeAvjFpeh5DU&#x2B;udRy&#x2B;p5PV9NeP8AhV0YlsfCs4qaqhray7H3D0x0T0l0FotHTvRPTOR0rI4S/uspp&#x2B;VpwsNWiYpSv6nWfwdeBfVvgN4b6l011nmcniZ3UupM7qbpyWJVXThU41SdNDqaU1JK8KCjzfw8eAmi&#x2B;A3SuY0/D1jM6vrOrZyrO9Qa/n4ePqGZq3rqfFK2pp4R75l9D0bB1TE1rB0nK0ZzHpVONm6cvSsXES2TqiWvmctFDk/Rh0enyIOTDWyOWlJKIMURa5ulQgNKe5NwGwKie4LMOwEBYfJADcE32HqhuwPM&#x2B;H2H5upsGr/hpqf2Ow0ouz0Lw3oVXUT/AOXL1NfWk9&#x2B;SARYIF9gJuxBbvclgEAN&#x2B;oAcbFsQAWVEQHvcK9hbf8gDmQ1YPfYMBZbF39CMXYCF/TI/YrutyTO4AC0CQA9mBC7AS/JfcKewAF34JcAJDDABAP0ImBQAp2AewA5AB7C5G0BXHJJ9Ckb9QG3JZM3X1K57AUcEdnsUB7jYEvsA&#x2B;Q4D3EevACfUL1Cfb/UT3ARcffsT/ABXRVLWwFduR8gNrASezGy2FTcSg2twDfaA24uRbWRfXuBfUETtsXcC7bj1JPYrvwAaScfxHyI2GBZaW0&#x2B;rAE9gJ6gBbAOQAADAAkXkq9AiIC&#x2B;g5Q5AAShySZVgKCbepQJ3LyNgAmdgG4AAPuHYAB8hPcAAX3IAAm5HsBfkAvYqAhKpV0V3JVHIHk3ZlaTV3YNqZjkiVo&#x2B;xsBdIJpkmRzdgL9iMrX0RGuxVSIUC&#x2B;5YfI9mRAnoV9oJF9mVUd7ib32L/IjUMCTaAXm5Pf5MiHFvmQsh7FVHtuR&#x2B;5W44JvdMIltoRV6Ml4hP7Fh7NgPZlZLP8AxCbW27jCpC2uT0RrglW38wJdqOwagR&#x2B;YEIQSxfkSwABMLcqjQ2Ekc8oiDfqJDTbkR6Fyq&#x2B;skbW7I9yrbzJARNvgNzZoNrYXSnkBfdh9n2DURIiOOQFkiXdpks/8ACvcS1eQJ6ib7Bzzz6COZAvOw5m5E&#x2B;F3K3AE2KnC9ESXMiZ3CK3azJNpDu5gjCqnAW8MJxcJqIL0Fc3/ZDl39CCfUBFpgnAbDII/mW3I&#x2B;RLMIs9kGSVwFuVVXuWYckVuABXfkjEzuRuxIOiks9xvZhFRYgXAvJIFVriVuRgC7ckDE8BVt2IJHuEJgskdhwFUTYi7F/qAC9RdOGE45&#x2B;iHyIh8xzKC3n7kfoBX6Mj3EpWCc7gWZRN7l9SegUaL6EcLZl9iIJxccXC7ie6AP1RKgRviJA/iJ8QeS/s3x660yCUfhdV6hSl7Zis9QiNzsb4v8o8h8UvX&#x2B;VVMJdV52pfPFqf8AE65R7G1ObdM&#x2B;UPrGmr5tPRPlHwfVn6KXNeTxJ6oyUuMTRMKv0/Zxf/8Ao&#x2B;q/iZ6C1zxR8AervD/prDpxNQ1bQsxl8lh11qlVYjp/ZTb2lwj5C/RZ5t4XjlrGUl/33TeI2vbGwv5n3qkjzHFYxrJ9IeD9ooxxSqfKPg&#x2B;butZ8IfHHwT8TuuMPDyOUxemMbpfV8fGfloymaxMHDxMJV1bJOvDrpu4ln5Mzpmj&#x2B;K3xfeL/h3pOsYNS1nwqymRxsTCqTWHiVvGoTbXKWJS/md&#x2B;eKPhZ0P4y9E5zw&#x2B;8QtDws/pmdpjEwa7OipbV01b01J3VSujqPwy&#x2B;D/AE74Y/ELU/EDwWydeby2N0VjZN5LP5uqvHzOeoxvxcJ1VOzpa/Y4iEda6Nw/Bdp/hjrGnYTq6NwNC8QeiNLXTvVOSwsJYVb8ip8uI0rYlFfkVdFfapnXXhH&#x2B;kK6w6d0LGyfXvhh1DrejdPa3nMh1L1rl8BVYeTVOarpw3XTSv2lTh&#x2B;TzVfxP2dHfEd0H4p/G50NqHQGlajpPUWo6FqGneIGjZzJVYWJgLCw/xMGnFlJVVUYiqSqW6cHu/wADWi6Hqvht4i9Hahk8LGwX4k67lc7l66U1VRXiXpqURemrYDvvStV0/XNMy2s6TnKMfK5vApxstj4dSdOJh1LzU1J8pppn6FUu58y&#x2B;AGj&#x2B;JvVnws6n4QeGviS9B17o7q7O6Lk9Xx8BYypwMvmXVRh1UvdPBqpp9IR7j4CeN3iHkNV6i8H/AIklksLqfpPT6dRr1XT0/wADU9OcxmaaeHS6Wqqe7VgO60ypuZSOnvg&#x2B;8etQ&#x2B;IDQOrddzOrZTPZbSuss3kNKzWSw/LTiZSmmirDfrap35O4Fe0gKneGGk7O/yHMi4Hrfip4YdO&#x2B;LnS1HSXU1eYoy&#x2B;HqGVzuFiZbEVNdGNl8anGw3dNR5qFKi6k9N8Z&#x2B;heq9c8f8Awo620PRsTNafoeoaktWxsKqn/u1ONlHRRVUm5adSi20o7W3cN3EwrdgCaV5L/Vg43gfsx&#x2B;QBenPAXvIa4EX7ANuNtx6eUN3LeIkCr0LL4ZKVCAHjtB6Q6Y6WzOoZvp3Q8tksTVc685qNWWw1T&#x2B;Pjumml4lSVnU1TTL5i55F7huQBH2TCnlDd3&#x2B;oSh2QBe5U&#x2B;CWlWkJcgX3Lz/mSbl32A/NrD/wDdOZaX&#x2B;4qt8hhw8KmF/hQ1qFpGZqn/AHNU/QYbmimXwTuzn7Eev&#x2B;H5tb1bK6Bo&#x2B;b13Pqr9XyeWxMfG8il&#x2B;Sil1OF3hHrPgP41dMfEJ4ZZLxX6NyGcy&#x2B;m6hiYtOWw8/RTTitYeJVQ6mqW0pdMq55HxXpVXhb1LS4c9P5397b/YV7ny/8LXi/qXgJ&#x2B;izy3i1pGi4GfzOi5fM4uDlc1iVU4eK6s46bum8LzfYrB9fxU2oQVeG/MvOv2P377e/Y9f8M&#x2B;qs71x4VaB1vqGFhYeY1fQctncejATVFNeLg01tUy20pdrnzL8DGD1x1j8G/iZlOndRxMxr2odS67hadjY&#x2B;M3XVjVYNFNCdVT3mFLdrdgOx9U&#x2B;PToPNeJNHhz4ZeHXVHV/4erYeQ1HXdEyCq0/J4tVaoc40/teVu8KLO7PB/G18QnjL4O&#x2B;K3hn0p4VKjMvqrM53KV6XXgUtZjMeSijAdVbTqpoprxVVUqYbVD3Oqfhc&#x2B;OrR/hr6Q6b&#x2B;Hfxz8Bdf6RxMnWsji61XgN4OYx6q3ONWqqU5bctp1fQ95&#x2B;OLqrQOmPi1&#x2B;H7XOotTwctkcLWs7ViZvGxFTh0&#x2B;dYFNLbdkpav6ger/ABUfADhaL4J6148YPir1PqXiNoOV/tXMa5jaj5cPFrwkqsWmjDSSwqEk3TDleVTNztLR/ixWg/Ct4e&#x2B;IurdNYnUPWfVWQy&#x2B;X6f0PBS/G1DPOh01VqqH5KYTqqriyccn6Pj88XNO0nwTzvg90hqOHnerevVTo2haVk8WmvFxFjNU4mI0nbDVDqlvudeeN3w9/EL4W6/4LdYeAHRGX6rXh5otenZzSsXNUYNNeJVh00vFbqqUJzV&#x2B;0rpr1A9X8ZNB&#x2B;IzA&#x2B;KLwL6j&#x2B;ITrfR8bG1Dq3EqyPTei5FU4elpfhtp4v72M3KTbsvLbk9v&#x2B;MzxA6T8Kvjj8GPEDxD1NZDQslkNTpzOfxKW6MKuqny0txfd0yewZT4TvGbxe8XOjPiS8dOtcjpmu9Paj&#x2B;NT01pmC8fK5TK0p&#x2B;XAor837WJVU6qq8RzwkrHenXvhR4Z&#x2B;KVGUwvEboXS9bpyGP8Ai5OnUspTirBr7rzL0UrZwuwHTHxQeGOu/Ft4adGeNvwzdXZZa105qb1bpfNZtVYeFm6H&#x2B;zVS/Mppl0UtSlMcScPTPRX6QHxfxsplvGXrfp7oTRsHGoqz&#x2B;V6Tp/FzueVLlr8SrzU4SqhJw5jg&#x2B;ichkMjpmUwtP03J4WXy&#x2B;DQqMHBwcNU0UUrZKlWSXY5kp9QPWupvCHoHrDr/AEHxN6i0P9Z1jpmjGp0XMV41apyzxUlXV5U0qqmqUpacHsrTViqHaTPAGap33MVo5Gm2Yqpn/MDgro/4TH4ak56qeAqOV9QOOjDUyctNMcCmiHDSORUqLAKUok1bgiXoZ/HwFmFlXjU/i1UOunDdX7TpTSbjtLV/UDkagkXgt&#x2B;BC2YALu9hd7IOUAnuZZpoywCvuFCQW9gwPY/DKmddxa2tsu/8A7JHvbTW6PSPC6jzajmcSrjBSX1PdpAsXuNiDkBLQ9wLgAgEAgqUuJJfcbcAUNxK/MJwhAB&#x2B;4tN39hFgu4BzuJcQHaw&#x2B;YDmJJuCr8wIOS7EaYEcwL8Ivow7AAPQJ&#x2B;oCI3QDHzABzG1wRtQAam7gcSH6oPuBdwQvzABuB8yQtgCXMhQ79xsUCXF4KybW&#x2B;gCHwLBxx9g44WwDYsom&#x2B;443AvImIlk4lj5&#x2B;wDiYDEuZDfP2AiYa7oSu24s918oAq33DffuX1I7AUQTZFAkkb4TkrfKI7raAEv&#x2B;RbTv9SRCgJLvYCqIhFv3J8hfl7gUTykR92JnZgUTeCX4sW4AN2E3DAEm5SbOwFkEs7FTQCLiGG/UAGhfsAAXsAAAZJKAuBHoEAAvwAADAB7AR3QAfIAAH7EbauhN4E24AbBX2EXsUAPcAAyVe5SR2QHlW5bI1IUFiLI2BmIlPkL0K0iOZmACh2Yaa5K39hVAGIBd&#x2B;ZDXoBkWUsoiSqiibB77fQQk9hE/IiM/vbWFmX&#x2B;AczZlVP6kOOA7chuFcCMk8lYCI72D9SkcbwAe8MSxDbn&#x2B;JG3wiwqxeSX2gQu32DU/IiHqt5JxZC653D7SFQO9hD3AQtJOdyxI&#x2B;QVN&#x2B;R7oNw9h7lBxs0H3D&#x2B;ZG25AKJ3K7KSNwnIvvH2Ii2agNcNEbWxX7FVLxwSGVqfUTa6Al9p5FuwbasTgZRfkJsG7CYUBT95i3JJ/IAF7laInyhLIgLsBOCqFIAAYlEmdhApGxeLoOPKA9mHMWC7iY3CD2Ui0zIi5IaCqoexfQidobuLAJF3yPKt4F4/kMh72v2EQrom9vUN3KLJZi0kUVLsRPnnuQWUGTiUWezIF4LM7GZiyXPAko0vcWZJjYWW7AvyIvVE5jzF5uhhFkTeCNTIj1uFUqdoRm5U0ybB8gWVJOBuhbYnyKS3IFgT6Echp87AJK2Ta35Cdr/QgsiSQu3JLpwgKxeb7BX9ire4H8cPj3yFWnfGF19l3THm1x4qlf8eHRX/6jqHzXud8fpL8n&#x2B;p/Gl1kohYteUxPecpgnQ7hqzPYaeebT0T5R8H1DQV50Vqfwx8H0T&#x2B;jGzjwviRrwFV/tun8zT9KsN/wP6EL1P5y/o4c3iZT4otMopaSx9OzdFS7r8J1fnSj&#x2B;jK9DzvGIxq/c8d7SR/6jn8MfNpOSty7ySQo2OpdA8dh9G9I4HUdfWGD01kaNUxMP8OvUKMpSsaqns60pa&#x2B;Z8ZeE/iB4m/Dt1l4t&#x2B;J/THQWe6q6cx/EnUsvrekaZfM5PGUV4WYop5oardNfKiln29LR1/wCDPgrX4S9R9c6r/bVOby3VvU9esYOC8PyvLPEwqKa6H3/apbT7NWA&#x2B;Wemte8fugPhNXVWlfidL9SeKfi3NONmcD9vIYOcxP2anTVs/2Err/Ee0dEdG&#x2B;Onh38cHR3T/AI4eIen9VYOsdF6rlMrn8PIrCxcXBpqw8SrCxlEVw7r0qPonx38H9L8bvDDUPDvOZ6vJYmP5MbIahgr9vJ5rDrVeDjU&#x2B;tNdKf1Pn7QOgPis0n4uPDXrP4gtT0zU8rlsDU9Lyeb0TK104dLqy/mWLjWimrEiErfu/IDg&#x2B;DTwDyOifEJ4jdd9G9VahouU0DxDzuSzHTuUxEshm8rVgU1U0vDUeWqmqtVKpcKPU7L6F/SA&#x2B;BnXHiZjeHGXo1XJ0f2lXp&#x2B;R17OZLyafnczTV5XhUY0wqm5hOJPE/Drlc1pfil8QPTVFVVOdr6oWcy&#x2B;D5kq/LjZGl0Vpdm1CfodFeD3i30/pHwbYHgt4&#x2B;&#x2B;F&#x2B;a0XSNXyOaeg9a4GD&#x2B;JlHmvxMSrDxMWumXgYtOLSruLpAffspuzsXZWPkTqf42&#x2B;puhfCLwX8ZswsxncDqLTM3l9X0nK0&#x2B;d6hmqMCmnDppcSqnjU2a4qe59CeDPjLg&#x2B;JPhRpXiR1boVfS&#x2B;Pn/PRjaXq2KqMTAxKa6qHQ/Mqf&#x2B;GVbkD3Zb2X3F1wKa6a6ViYVSqTunS5TK78AErSkE&#x2B;b3KleEhACHuybldu5H2AKJ9iqe4V1Ei8AWQ&#x2B;xI55DnsBQRMoBL1AkQAA9x7ACq7JFizbcD8&#x2B;sS9JzL/8AJqn6Ewv3F7IazfSMzP8A4FX5Ewo8lN/8KJ3ZT9iPWfk8F4swvCzqbzTbp7OzH/yKz4w6d81P6FXOwn/8PxeP/wC4/wAj7O8WVU/Crqfyb/8AZ7Ox/wDeK&#x2B;1zoP4N/BvB8UP0cWl&#x2B;EHXGUzen4Wt6bnMHHWNgOjFwlVmMSqjEVNSXampd7FYu2vB7qrprpz4WemOrNX1jAwdNyHRGTxsznKq/2KaKMrT5nL9mdE/o4PEXQ&#x2B;gvg16s8UNbyuaeRyHVmqZ7FwcvgOvGqoSw35VTu6uIPI&#x2B;BH6PnxK6QyundJ&#x2B;N/xGah1N0loeYpxdK6QytFWHlavJV5sP8AGqqbdVCd/wAPb14O/vCnwa6D8FtAzvTXQWm4uDlNQ1PG1DN04&#x2B;PVivEx8Vp11ftWUtKySVgPmvxO67zv6RxaB4X&#x2B;F3hfrmQ6SynUGBqHUHWHUOn/AKtTTh4Ll4OXUt111TD7c9z9Hx1&#x2B;H/SXiL8VfgZ4cdYaTTndIz&#x2B;JqeBmsm8R0&#x2B;bD/DwounKiFdObH1rRT5aFRQkqUrJKEj0fr3wC6O8RfFrpLxi1/NZxah0asx/ZWBgYlNOFXXjKlVVYiabcKmyTW4HhfBP4M/h/8ANYr6l6E6QxK9Wrw3hrVtVzleazGHQ/8NFWI35FFv2UrdztJenyEyxD7/UCRAFgBQoiCRyXYCp3MjYcAHuZ8qbixp&#x2B;5L7QBh0qYLB6v4n&#x2B;K&#x2B;h&#x2B;GGL09kdTwasTM9TdR5bSNOwqOcTEbdVTfCpopqfq0lye1JLgCQlEMvNkej/EP4lde&#x2B;FHhvi9WeG/hhm&#x2B;rdTozmDh06TlG03h1Vft1tq8Kmdk7tW3PctLzGdzemZbNalkllcxiZeivMZZYnnWFW6U6qPNCmHKnmAOeeDpDpLXNfzP6QPrDQ8/ncWrIZXw806rTsCp/sYaqzFbra9XVvG8eh7fmvib8HMn485f4b8XqaeqcxknmFlVg1Oih&#x2B;XzrDqr2VbompU9leJU&#x2B;oZzU&#x2B;l&#x2B;iPjc1vqzqnqLI6ZlcbwwyaxMzn8zRgYdPlz2KodVTSn7gd3UY2Di1V4eFi01VYVXlxFTUppqhOH2cNP2aPXfDfxX6N8U6tbo6R1H8erp/XMbStRpj9zMYUeb5XUM&#x2B;Reifja0Pws&#x2B;ITxU0/orJdQeKOV6g1fLahoGH0vlnj4eHi/gqjGw3iXVNFKVFKqpTTVJ3D8GvSvWXSua668VvE/onLdEf9vOoqNR0/pvG1CmvEwKacFKqutqKVXXU3U6d1eQPdPHLx6z/AIM9ddCaJj9H42c0fqrXHpmpavRU/Lp&#x2B;JXSlgSlM&#x2B;etxeFCfJ2TupavyjojqfxS034ivHvSfBPw2zGFqOh9Jahg6x1rrWA6cTAw8bBqdWWyVFas63ipVVRtTQ1yd7zGwC/LJHYsOCMCNMkRyaaUbEi4HtfhYn&#x2B;Nnau1FH5s9ylHqHhbTFOcxId3QvpP8z22GnZhZaQm0BOdhMOwQ9gHbgbgPYsEmdy8T3AP2IWZRAHBfREKrcgJSsPZiz3Gz225AXdv4j0gWvZ&#x2B;gW8AN2FHH3EB&#x2B;8gJJui8Ec9gDsZasaZIYBW2KiSu4XaAKB7CQHuSzWz&#x2B;Y9xzMAHEhv0Et8fcJ&#x2B;0gJ9BPZyFG4cgG7i7iREckULZgW7foG4E8oRIBz8w7ETe0BxvAFEevBPNOwTWyAe69gnawfryhblgJvP9IO6kQm7EnsgLPv9CSnd7Fjj6jfb6gW3YL3JZbBS7xAFlciX2JtyE3EwBU3G3JPmN3shteALLvcnHbuEr779wpe4BJdipMd7h&#x2B;aNoAjfYKHYencJS4fYCxefUKZtsN&#x2B;BFtrAIUbbDbf5BpsRAFBE&#x2B;&#x2B;5QBHsUesAR2uE5LHcl&#x2B;wFT7CbkXuW&#x2B;4D0DnkABMsSB8gHuET2L6wAAQ9QF2GNyruwIEitdiSwLbuHPyCuH6oCPexL8lYAm2xUSGUB7ACUAlbSAAEFj1RNrlTW0AeTibq4j1NdriLGwM1Up7kexp73JFwMviz9wmleSv2EwBPn9A0Ntn9hPbuBPZB&#x2B;5bJb3Dh8AZZH7FaDAzzx6h29Cwp2D9ijLUckfuWOF2EMZEjgseoSj1K7WSII4kgAEfZCzK53ROzZRHPI9oQalyLdgJEcB73&#x2B;pdtyP1&#x2B;QUatsCtuNyVdgBCt9yACRSXcJFEvMpEdL9CxuEoasREhwv4EqspksNqZJ8iqu7mdwrXHEdhYIu1iNN2/IQlaCW5RBHcFbe7&#x2B;ZJKpIkk3iPoOJAoUbkXaSpJbBAjtco2CpJSbKzkTeBApH6FkktfUBDa2DnkKWxL29ADZHbgT37Bx3gCzFvQL0exmE9y390BWiNytvoG1uvsJe4gVPsiJcyE57l3ct&#x2B;w6Ij9CbWK5&#x2B;xHPLHZS/AUpf5kVxMIbjXeXYl9uBNg3ZJCBb8INpr2JKCjkQLM7IqfozKbTlBNTZBFbjZfULbf6CYUkl7pBVmbRA5svoTbkKeALz7DmN/cm939izZQ0Bdt3sHtKIna0Fm0P7EQVQ80qUSU/cJtLYCyo49mFdfwJMqwTQVZTWwc7CWrNciUtyIm&#x2B;ysOBPd2ERdfQBF&#x2B;wcq38A2/8AUWnbkAnLlrgvt9zPu7Fd3Mcgfyh/Ss5L9T&#x2B;MvWsTytLMaZkcRf8A3imn/wBJ85Wjc&#x2B;pf0vmU/Vviww8wlH6z0vk657xXi0/wPlpO8Qeu0m&#x2B;lo9IfSuGTzcPtf8Ydy/AHmqsr8VfTNKbjFeZw36zl8T&#x2B;R/Sql9z&#x2B;YXwVZn9V&#x2B;KXo3ETd9Tqof/wBWFXT/ABP6fw/MdDxqP9RTPl85eX9pYxraZ/D85EuEW9rkUIsWOnedItEhqPmV9p&#x2B;RIXFwMtJh0zFtnK9Cwyx6AdYdW/Djh6n49aT4/dG9ZZrRNRwcOnLdR5LBp82BrWVplU0YtM/vUy4qOtOl&#x2B;s&#x2B;hPhc6q1v4cvH/ACWUwOjNb1TMah0dq&#x2B;qYKqyeJh49f4mLk8R1JqmqjErqid1Uj6aSPE9b9AdE&#x2B;JGg4vTHXnS&#x2B;S1bIYv7&#x2B;Wz2Aq6Z7qdn6q4Hzr48dEeHPTXV/w&#x2B;6T4dZDKYfTlHXmLiafhZLE8&#x2B;BGJgYmInQ5c0uq6i0W7H4fid8JKfil&#x2B;NLQPAfq7X89lOmdH6JxNbzOWyGYeHVj41eYeCnK2ahX9PU7Q8Wfhxx9V/8AZhlfC/AyeR0/oDqvL5z9RxK6klk6cOrDqw8N3ulUoThQo7HgvHDN4PhB8Wnh/wCNetVrB0XXNLzPSurZ5yqcti4lax8q63xS66a6ZdpZZHm/CXozOfB54c9SPxH8V8zq3R2keXNaLmNVbrzOn5dUft4Ndf8AjSqS8sd4PM&#x2B;AXxYeDHxJYeYw/DbqDErzeUpVeY0/O5erAx6aG4WIqav3qH/xKUekfpK8bUMb4TtRo0vTq86sfWtNw8fKYdUfj4bzeHNEztU4pn1OrfEb4lfBb8LpjxM0TpzG6N696E1nJ5fUumtTyyy2ZxNNxa6cDMYKcKnHw1TWq004mlVEH2kivufNvir8duleAfxCdQeHnX2UzWf0ynQ9Pzmg5TSci8TN14uI61ipJfvUqmlVXiL7zbujwb8aPD3x46JwOvfDjXKc7kcWt4eI3Q6MTAxV&#x2B;9h4lFV6KlKlMD2mL2Huet9AeLHRXiZntd03pLUa8bH6b1fE0zVsOvBdDwsxQk3TfdQ05Vj2RMBF9hNoKiLsAiwmXEi/A/pgN90UicqS/IARJCeH8x6gVAbiEALHoRSNwPz60v8A3Rml/wCRX&#x2B;QwVOHSu6RdYf8A7ozKa/3FX5GcJf3dKf8Awk7s5&#x2B;xHrPyaqopxKXRXQqk0001ZoqXlslbhehF7ln1KwQN3t8ireyuSewBe435Ert8g7/wAO7bgN3HoHvcA7bEsHHAAvBGjxPW3XvRPhtoOJ1T1/wBV6fo2nYVXlrzmo5qnCoThtUp1NS7Oyu4PnbxR/So&#x2B;CfS2mZvPeFvSPUPW1OTapx8/pun14OQw6m1TSqsfEXNTSUUueAPp92Pw6t1L05oOYy2T1zX8lk8bOY1OFlMHNZqnDrx624VNCbmptuIR0t8Wnih4j6Z8NegZ/pjUMz0x1H1drGj6csfJNV4uQrzVdLxaaXUrumnzUzCc9j9HhR8Angt4cdXZXxN6k1HXur&#x2B;qsrjLGwde6n1bExq8PFX&#x2B;OihNUp9pTgDu&#x2B;bbD1DcuWeMzvVemZLqzIdG1KurOZ/KY&#x2B;Zo8tM00YeE8Omp1dpeJSl3v2A6m&#x2B;MHAdHU/hFqirpX6v4pZKh&#x2B;bZ&#x2B;fCxl9bWPeOtPHLpLobxd6R8Hta89Gf6vwc5Vp&#x2B;LK8iqwKaavK/WqWl60nX3x8dQYvR3h/0f1vldCzmq5jSPEbS8xltK0&#x2B;jzY&#x2B;crTxF&#x2B;FhrmqpNpHp2l4HxK/E34y9HeJniZ4IZDw86S6F1PG1LDxtXz34mpZj&#x2B;6qpdMJJYdD/ZblKPLuwPpjqzMdQZXpTUsz0nk8PM6nRkMWrTsvi1&#x2B;WnEx1Q/w6W3snVB6P8ACl4qdX&#x2B;MPglpnVviFov9n9QYONmMjreUWG6VRmsvjVYOJCe0umY4k9X8cPja8MeiensLRPCfqHI9XdY63/3fpjQ9GzFOZeLj1WprxXhtqjDpbTqbcwnCPwZjQPio&#x2B;Hnwz6ewPCXpjS&#x2B;us4sniPqfT85nFl8WvUcbFqxsXN4eI4VVLxK6qXQ4hKlrkDo3xP8ACf4tNf8Aie0noXBy3TfTWYznWur6z0z11l8KnMZ&#x2B;nLfh1N/iUzLopoqw8P8AapSVTpXB2brnwD&#x2B;APSmjZ/xm&#x2B;LDxA6j8QM3pOnYmPqOq9Q6jiLCwsKhOp00YWG5VKbcUeZ3e1zsP4cPCPxWyeu6h46fEbqOVx&#x2B;tNZy6yuBp2QqTy2iZGmrzLL4bTaqqqqiquvlpKbHbOoabp2s5HF0rV9Pwc1lcxQ6MfLZnCVeHiUvemqlppr0YHQ2c8ZMv0B4W9GYvwafD5/wBoNL6sWLh5DEyWVeSy2Sih/h4uM3RMOvd1RKpf7Wx7XpnhRnviM8CNJ0T4vfD7TVrdc4udyOn41VKymJLSdGJRW3TU6YmKovB2bpGk6ToGl5fQtB0zAyWSymEsLK5TK4VOHh4VCUKmmlJJJdkfo9gPV/Cbwb8NvA3pSjorwv6WwNK0&#x2B;it11YeE3VXiVvequupuqt&#x2B;rbPZ25DCjuAHqE&#x2B;zABmYWzZr5EvEge5eF9MafmsTvjpfZHtNO0nrPhnRGj49XfMv/AOxR7MvNAWWhYXJMK4RedybD0Qj&#x2B;mBfQLYe452AADfcBMgSALyE&#x2B;69yWiUVw&#x2B;QE2CIE5Ato2JITkAGPYD1YC5OLlJM2sA9WxMIWG26AL0D2hl9BfgCd01uHv/mNwBG01A5DfqItdAJey7FUbokqblajYCWiUw2FHH2EypkAr3DibrgR3Ca2/pAG1uRRBVMO5Jaf7wFUO6EuYgbOUhNwED1cwHdP&#x2B;BFwwDu7fmW7e5Hd7fIq7QA3qQdrL6hTaEHeyQCE7chP8yTHJZb2QEbfK2F3dlfZoygNJrgR3RN7hXtIBqLOxYV/4kv8AQsboA/6YvzwH/Vhz6gHsJ9QrWkTe4FT&#x2B;QTvEkbsJ2lgXfYc7CewAFlEnnsE5AsyVuTKfoWeAHJNlYpL8AEUlp2L6IBsALgA/cMewEh9wnIvP8ArgF7lTTCACQNggEcguzDl8AT5ie4hlhzLAjDVy3T7B/QCQPUCwAL1CL5Y3YEcAsdyOwABiZ3A8vaI9CNR7GtiXNgZe0iJWxpSvoROPS4GYvYNIvCuRqHAGUr7lVnD&#x2B;ofa2wSXYCNBxMyWA0BlJkfeDcQzLSQGWouGp5K0I4QGYe6&#x2B;4S7o0SbSAjsSeyLaZI78ARiL7h7iAI7Blac3I16lEe/yDXJYgnyCpHCIX0JPoEN7iLSWHs9yS4hsA55I13HAjkKcyAo4EwA2I/QX7i8BDdwZSez/Ivmm33Hm/yG6m4/gFPIbSukBNhL37huLQGVEm8QRr0L8w95GVTb&#x2B;AXqIKRAD3InyFUm6sGxeORCHIlTDI29osNlKKK7LckuWmw9/cRaEFFLux7O79QuwmePqJkJs4ZG3sIvZCOBARCE2JfsX2AS3dl2JdBtsGyxTsh8vsSXwVv1&#x2B;pERwRuHb5Bty5Qb4KqTFiyiW5QvNpAsl9zM3grcECfQXJD7hFyi&#x2B;4mDLVtvuVObwToL5rWEkn1CfdFVZtIuROShDi5fUiKk2tyAlbuW5LxzcJtO5VHH9It2pJde3oJSVkQwT3Et8laSuR9wip2CfYUzuJvdkBudvoN93Ehyg053AbOwhx8gl87dxbaQJ77GpfBFtEBdp&#x2B;gH80P0zeS/B&#x2B;IvQc&#x2B;kox&#x2B;k8JSv8AlzGN/M&#x2B;QE2nKPtb9Ndk3heKvReoeX/a6Bj0N/wDTjT/6j4om8dj1mgnOjofQ&#x2B;EVZ4db9Pm7D&#x2B;FPOrI/Ef0XmHU1/&#x2B;MGXo/Zf/FV5f4n9U4P5M/D7mnkvHTo7Mr/D1Lkvn/fUKD&#x2B;syho6bjkf1qJ8nQ&#x2B;0v&#x2B;4tz5fMV7Dcg&#x2B;Z0jzSz2v8AIOWE3wJnj2ASG5Ce9w2ATLCcJEipFvFgCfoeB8TvDXo/xe6Iz/h911pFGc03UcHyY2HVvS96a6X/AIaqXDTWzR560Qw3eEvkB8&#x2B;ZH4MutNK8Fet/BfUvGrUeotM1nIUUdK061T5sTSMTC81eH&#x2B;3L868/4bmE/wBg/B0nT8Onxp&#x2B;H&#x2B;X6E8dem8jl&#x2B;uNDopyWt6dmall9QyWbw1DrwqrVVUVNealqaWnsfSSc7nXXij8Kngh4vdWaf191Z0lTRrumZjCxsrrGQxHgZicOpVUqqqlrzpNbVSB1tpvTWkU/pNcbEzmSoxcTK&#x2B;EmD&#x2B;p4mN&#x2B;1VQ1m/I6k3z5W0cuS0D/2T/Gfrnh10fnFpOleJ3RuPqWBRlqIoymrZepYdePRTZTVRXTU0t3QemfEN1f1X4XfpC9L8TOnNJzGpZTS/DN43UGm5LB8&#x2B;Pj5H9bqoxa8Onmqh1UYkcqhrk5NA8eOh/ie/SB9Daj4O6hVqeldK9KajjanqNOBVRRRXjryKh&#x2B;ZJpr9nfll7j174HPELxa8JfHPrzwp8QOj8/wBT4Op9f1ZfUut9LwksLBzv4VMPGw/8FFdKT83Dqi59tJubqPc&#x2B;fPg9VOH48&#x2B;POVu0uusHEU7ftZdevofQa333IKkosTdzJVZQLATfcvsABHCuXbZDmIC2AiuoLFiJIoCBDQLHEgRLgrf8ASIH6Afn1hr&#x2B;ycz/8ir8hhQsKl&#x2B;nYmrtPS8xf/c1fkXDthpNcE7s5&#x2B;xHrPya93AtMIczDDffsVgcd/kR7W4E9nuHHbcA1G5C&#x2B;hKmkpf2ATxJ6X40&#x2B;NWgeDOn6Li6rh/i5vqDqHKaRpmW80efFxsRUupvtTT5qn3hLk8X4C&#x2B;JvjN4h611XlPFPwdr6Vyek6t&#x2B;BoOPi47qq1HAbqaxIiFFKolptTU1aD0n9IBpdOa6V8PtWWHOJkfFPRqqKuyrxXQ/zQHf897E2sej&#x2B;PnjZlvA3o2jXcDpLUeodVz2a/VdF0DSqZzGex3TVX5VZxSqaaqqqocJD4dPHLR/iH8LMn4kaZo&#x2B;PpuLi42LltQ0vNOcTJ5nCrdFeHVZTDXZWYHmPETwp8OvFvTsppHiV0jk9aymRztOby&#x2B;Vz2H58JY1NNVKqdO1UKqqzlXOkPiT0PRuufGnwz&#x2B;EnpPRcnk9H/XX1J1Nk8plKcPCWTyjX4OE1Skkq8XdR/hXs/o6qqmih111JKlS29kj59&#x2B;EBV&#x2B;LXi14j/FHnGsTLapq/9g9L1tTGn5Nul1UzxXiN1fID2f4tPh/68&#x2B;IPSultA6H6&#x2B;wumqdG6go1PM6k8u8XEoqwqGsL8OiUnUqqpTbSUHRuY6Z&#x2B;I74RPii8OcnqXxE6v1roHXmsV6bqWU1lNOiuE3UqfNUlHmTTUOzTsfQXjt8Xfgf8ADlqmS0PxQ6izOXzmo5arHyeVymn4mYrxKaavLZUJw3VZTvD7HXvhdpXXPxWePGlfEf1t0bnunukOkMvjUdC6Tq2D5M1nsxjU&#x2B;WvO4uHP7FKpSVC9nwB9HtXg&#x2B;dvis8UPFHwD8cumvFjpDwc1XrLSc305mdIz2U0jDqqxcDHeNh4uHV&#x2B;zTU1MRdRE8o&#x2B;iLIO92B8w9IaJ8U3jNq2L8SHjL4d0aXT0vk8zmfDzw2px4rxc88OqnDzGadTjzw3Sk/LHmbSR7r8OWrfGL1Z1bmeq/H7QdD0Pp3PaHhPKdO5RfiZjL5vzRX56ndJpOp0t1L9tJOzO6XfcbgeodJeAHgn0H1bmuvOjfC3RNN1jOur9Y1HKafRRi1eb95JpfszzESe4WXHHBAA3AAF9xK7E3dw2AsAPkATkehJtYTLgA1aBFt7h32Fu/wBQPevDfDqWg11VNQ8xU6Y7QkewK/8AA8L4f0&#x2B;XprDat5sSt/c82p3BJMXTX1C2lkh88lWwFn1CqXBJS/1ClykwLCkOJgTuyKziAKo2KSVIArcE3sBtsBZ4DImuCt8SBPfYXiJF0Rud/oBdrSLhbbCZ4APuUjcKY5CccgX2RHL4L8iN8gOfUT2ERdB95APf8y&#x2B;wmNyJ9wDRHazfJb9wpXP3AjTG&#x2B;2xbv37BzaAI43Qm92W83&#x2B;hItdWSAcyT3QScOQ3uAtEBdkN&#x2B;Qkm9wF3b0LKbgJxsxCW7uBHHIm8sWbs2I4gCNyXYhVMgFL2LM/6ks0LpsCtwvne4cyNnt8yO7hMBs1YhXD2FtgF0N7wPUk3swLZOw2CgQ0wFhbzAegFmboWmPsG&#x2B;WJhyBJnjgrs13knoVe0gHE/zG9ri&#x2B;3cbXYBJbjvP5C7lQIAT/hYTcWDiN5F0pQFTfuI9SJ23&#x2B;w5&#x2B;QFlN2E&#x2B;gTvAunsAvuRuOCuG7v2Ir9oAqjhhKBdMb7sC&#x2B;5IvcsIjAjabuiw4G4e38gLcEuW8bAS8lUom/FypQA&#x2B;ZfVEsAK3eQ0GxN5t6AGluQrUWkkgFuFvsBIFjsE0nd/Qbe4W4BruOCCQAakIAeZqXJl2OSpcvsYavEGwJD5X3JF1L2NNTsSHIEjvZSTyvk0lxCD2dSQGI5QZX2uRpSAhJEuv8AM1bZkacgRv1I72fygsJO5Jh2AjvcRzHyK9rkttIEaJfuahkYVA7bAQoiPuESOzJNrNlvz9SO/wCVwDhWD3uPRlfZgZfaQysy12Ko7okqLlcpzGxJTVwg7cexGV2siVXdgJtyJuNtwA2I9ysjkgNxx7AXn5h9yiP2&#x2B;oV9n8itKYMzHIgJbK7kUbCzCjtv&#x2B;ZPYu1ySggu8AEnt8yqpJl7FbhSSZ43CE8yLvixPN3YlxvcgqjYi7&#x2B;u4bcyJW8/Yqjbncjh/wK9w33/MA3aIDbZOLfQN33&#x2B;oRX6bkV7vbkTyEMKSl3&#x2B;of5D5ElIC7qSSJEqYASGw57EdxHUJKnfcyV2dmAl7lJMXkS4CDs9/Yk9yuNmhfgQpZe44lIilOGw7qEgg21sHtPfkgvuguVT4lifXdEn6hN39R1FmNmE3sEg97ICw07LYsmVtZimW9gdWl3Kp4ZJ5E&#x2B;hEOS&#x2B;64IJvuBV2ZfSxLoK1kQWUH6BWsLp7/MCJ8SUjabDfovQAr7MqaTIrXKm5/jAFs1tDI019SyLyBGmJUCZuhZgfz/8A02&#x2B;T8uqeH2oqm1WX1DCb9qsB/wAT4PP6D/ptck6ulegNR8s&#x2B;TUM9hz/1YeE//Sfz4uryeq4bOdHT7/i95wWrPDqPf8Zee8Ls3VkfE3p3O0b4Ou5StfLGpZ/XimfLPofx36ZxVg9RZDGf&#x2B;DO4VTh9q0f2GwMSnHy2Fi0u1WHS19Dq&#x2B;OR9aifX5Oq9pN67c&#x2B;vyaF4gNRuPU6F5gUsqbRF6oAWQm&#x2B;5C7cgBK2IWXNwFtoG/A7DaGBW4smIhkbvcsOJT47AdRa14VdX4vxraV4w4OmYeNoP/AGAzOk5rHWJTNGYeZpxaaaqXd0umb7Se&#x2B;9I&#x2B;Ffhr0Dqed1nonobS9KzWpV&#x2B;bPY&#x2B;QyVGHVjuW/wBp0q&#x2B;&#x2B;x7Bs00Lq6f1A&#x2B;ctP1rVPhx&#x2B;M/qDL6/0znMbp3xazOQr0nWMpgurCymo4WH&#x2B;DVg4sKKfOoqTb4Po5qHE2MYuXwcZJY2FTWk00qlMNOzNRG3yAszsHsGmnMhAN7lcRciad0L7AXcgW&#x2B;xYfcACb82gXAqmNyuOWRe42AvBH6FewgD8usf8AwrMf/Jq/I1hv&#x2B;6T9DOtQtKzE/wDg1fkaw/3FHYndlP2I9/yWFvJPSCw&#x2B;SXV5KxNtxv8AUOCbgDxXXPWGleH3R2pdca3Ri1ZXS8niZnGowaHVXWqVPlpS3qbsly2jyp6L8RfV&#x2B;v8AS/htiab0Xg4Vev6/nMHSNB/Fh04eZx6vKsZpu6w6fNitf&#x2B;WB8p/CP&#x2B;kc8ZPG/wCKDOdK&#x2B;Ir0DQek8PJ5nFxMnnVTgYmT8kKhfiV1J1VttJp&#x2B;tlB7l8c3xd&#x2B;AuudCZPoDw&#x2B;60w&#x2B;qOpMPqbTc9ltK6cwqs1iNZfM0YtX7dCdNDilrdu8Rue7P9Gl8KurdN6XpHVnRFWpZ/Ip15zWnm8TCzOoY1VXmxK8aqhrzeaptxwnCO0fDPwE8F/BnKLJ&#x2B;GHhppGjJKHjZTJ0rGrX/NiOa6vm2B846n0z8b/wAWmv6b41dK5mjwlwtA8&#x2B;D0/pWtYNWNmM5TipfjY&#x2B;LT5YplKmmlNTHm2m/e/wAM3gv1H4KdC5zSutescPXtc1jWcfVNa1PByiwMPEzGL5U/JQrJRSu0uXFzsS0z33G2wHp/j/p/iFrXg9r&#x2B;geFOVwsTqDUtPrymm14&#x2B;YpwqMCvF/YeK6nsqKanVaW/LCTk14DeFmQ8E/B3p7wt06qmtaPpmHg42LSo/FxonEr/&#x2B;qt1P5ntwA/Lm9D0XP53C1LPaPlMfMYCjBzGLl6aq8Nf8tTUr5H65YlcDiADZBAAOJQAAAHhNd8QOnen&#x2B;r9E6Hz2Zf9o6/XjrI4FMT5MHDeJiVvtSl5V71L1A82GDrKjxI8ftV8bH0XpfgzhZTpLI5&#x2B;rB1DqTUs&#x2B;lXmcJ5dV04mXw1dxiTQ57r1A7NB6T48&#x2B;PXRXw8dE/9uet8HPY&#x2B;BVmacHDy2nZb8XGrbTdVSp/4aaU6qnwkdafFh46dXdOaBk9Z8NvHjovo7KfqtGZw8xrqWax9TxK4dODh4NMuilUw3VDbdSVobYfQO7hHrmseKPR&#x2B;k6nk9F/tKnHzWe1evTMHBy780ZqjL1ZirDqatS1h0tv3SPnbwV&#x2B;Lb41PGforL4XTXwsZbA1F1PDxOp9YzuJlNLxaZj8WjCrpWLUnvFMo8l03&#x2B;j86i6n094HxDePOr6xhrVczqOX0zpv/wB35ejHzFVdWPVVUvNiYjq87p3UU2A/J4zfGv011L4RaHp&#x2B;h67rml6l1I//AMYaekcp&#x2B;vajoGUXnVVTVKaw66q1Rhpu/wC1U0rHdXwzan1pq3gP01n/ABCw84tXqyHlzOJqWA8LMY1NNVVOHi4tDSdFdeGqKqqWpTqaP3eFHgX4SeB&#x2B;l4uj&#x2B;FfQmR0fCzHleZry2H/eY7Ss663NVT33fJ7Zuo/MC/INW2IofJeJbA7D6DpjpbLuea3/APhM8v3l/c8X0bSqOmsrSnvQ2/mzyb9SR0CfX5Fl9zM&#x2B;pZKK2/tsiSxKnb6iQLIvFyJ3lhR2AtlZfYqaMzaBPIGk&#x2B;YDTMz3HmA1IVm/zMupbhPsvoBr5e5LxKCcKEG&#x2B;9wG/yKrr&#x2B;ZlONypuYQF9Z5EqSLuxLAsuf3vsR3UfYKOwlSATvv8g3y0LcckhICpuZgqabn8zMxs4L7JgL7yLbSxZ3b3Dn7AFO65Au&#x2B;BHq/wCQF42JPrwJv79w1NwDT78kdnYsLefckcAIEKbC65GygC/0iX5X2EytySBX3Y9wptBPmBdyFIgKoj&#x2B;IbFu/sHK5ANuSCQAm&#x2B;42sLABvcbMBeoF5G/JNgAL6kTb4LzuAUQPuE7Qit8MCK1wl6F9USf8AIC&#x2B;sQHPKJZ7sqfL7gPt2G1puJmEX7gRq8wSPUrSiy&#x2B;aH8wHq1yE53YXr9hcC7X7Bw1diz339hzcCb2DT9RfaSzUAUK7DnYPuhwBfkT1gFAj/AKsHHPcP0DdwF&#x2B;BspiCkYB2KoFnaRK7gB8gPUC2Ybl7kKnaAIPkEEA2An1ChgBN5CuAEuAAAGwG23cDzlXqZe8mqp5MtXtt2NgZYn0NNRwR24AOGiFnmQ5amQMNTu37Bp99zTUojS5f3Ay0oDT3ZYh7OERq0gZq9A1K7GnvJI7gZc&#x2B;4a5fcrV5gjSSYEdrEbgrS4JAC5N7ldhAGXDj8g&#x2B;y/MO6vBWnH&#x2B;YGbK3YQuGWOZI44AQZZqCfMCNXsyQvuaZGry2BHZ3q&#x2B;xG5fYu10SF9wAfoLINIu6o53kbbBruL9iIloETuxd9htdgKkoiDPq/uamFMEdroom432&#x2B;4gW3AgKoXIixBNt2SWUjTKpzDI3e74LHakWV2vuO6Jf2FlZhu8jnYA3Fv4BPj8xDme5Jau39wpsg94Dd7KBHoATbtInsTYrXoVCXO5JExuRNf5hR7iXcWgkzzyEakibiYj3IufuLNSFXdBzGxJ4f3JU&#x2B;wwYW03&#x2B;4&#x2B;YV3P2gTNn8xkOdiX7l3iSN8yRC2y&#x2B;pW5siesCXyyrlZm2xL2/ixtYJykoGQczYjAe4FVmJbu18yCwRpKLP5D6GU7yiqeApMOYK42kROwm12DYnvuVNtw0S3&#x2B;ZJl3QGk0WYMqdki83qIitxspL5m9yShIFVuBL5JMCSCp8/QEksTdgLi02HyF2AtMovuRW5&#x2B;4T4AriZ&#x2B;g7pjmP4BTv8AkB8Xfpqsj&#x2B;L4MdJaiqb4PU9dE9vNlq3/AOk/m/KP6c/plsj&#x2B;P8M2kZxU/wCw6twG/TzYGOj&#x2B;Ysnp&#x2B;FTnSR6y9rwOr/QR6y5Mvi1YeZw8amzprpafrJ/Ynp/MLM6Hk8zS5WJlcOpP0dKZ/HKZj35P6/eG&#x2B;PVmPD3QcxiVJvE0bK1Nra&#x2B;FSaXHY&#x2B;rRPr8mn7R702p9fk8200hbdiO4jlHnXliO4foIi/5FaSAkR6E2LLdyOzAFT9CF3QB73DVrieZF57gPdFkli7KwDZ/wF4CfZlurL5gPZfMRaLi&#x2B;65Cn&#x2B;dwI01t9BKXP0LPLkQA9GwF7j&#x2B;mAvIshHZhgLzuIeyEvcRzIF9BI9hIFlK5UocmU1sWQPza5H9k5i/8Auarz6Fwo/DpfoZ1u&#x2B;kZj/wCTV&#x2B;TLh2wqV6E7sp&#x2B;xHv8Ak1LYuHLUvgO7mJKxR32Y9Z&#x2B;pX6smwB73Z0X8dfWXWfhR0x0l409L9L42tZXpLqujN6xp2BR5qqstXgY2C8RdnT&#x2B;JZ8OpHeaFdNOJQ8LEoVVNVMVU1KU12A&#x2B;ZOgfje8UPik1XB6Y&#x2B;HPwR1XS8piVpan1j1Th005bIURfyYVM/i4nZeaO6PpbTsriZHIYOTx83iZmvCwaacTMYsefFqSSdVUJJNu7i0m8vlstlKPwsrl8PCob/AHcOhUr7G7MBtdE4LzEEADjYsOdglOwE4L7EHsgDBYi8BWYHh&#x2B;ruueneicTSsDXs28PE1nVsLTtOw6aZqxcetVNKOyppqbfCR5iJe51T8TuV/G1vwxzcXwfEvJbv/iwcwv69zxHjX8WeoeF3iRg6FpXSmRzvT2jZnKYfXWs4&#x2B;p04demrNVRhfh4bvieVOmut7Kmqnl2DuPUNa0XSK8GjVtXy2VeYxFh5dZnMU4bxa3tTT5mvM/RHVni7p1NfxVeEuqtfu4Ou4LfvlcNr8mfNPxb6Rqnxi&#x2B;Mehdd/DNl&#x2B;oOuMn0hmsCvUMHLYlOU0mmmjEVVWHgY&#x2B;JH4mPW4mqmVTTT6H0N4a9M/E94i&#x2B;J2h&#x2B;JvjxoPTfTWmaBRmatM6f0rM1ZrNVYuNh/h&#x2B;fFxv3ElS3&#x2B;ypuB3Nms/k8liYGDmszRh1ZnG/CwKanfEr8rq8q9YpqfyZ8s/FD1N4lZD4vei87kdE6sw9M0fVtMpymeyUUaTiYWZxKsPNLHqbXmxX5qKaaeEn3bO3fiZ6j686Ey3THiH0V4b6h1Xh6JrleLqWj6TH6zVh4mVx8FYlE7&#x2B;V4l16&#x2B;h4Tw00Lxo8c&#x2B;tMl4reOfS/8A2V0TSMR4nTXQ7zCxsavHdLp/XM5Ukk66U35MNWpb8zukB4P47OntM8SOjdAwekPF3N6Zr2dxMfI9O6fomJhYlWs/rlCw6sOqZ/ulSnVVWrKlN7we5&#x2B;DvwafD14M5TLY/T/h1kczqmFl6aMbWdUpeazOJUkparxZdKlbUwkeU6D&#x2B;F/wACvDLrzOeJXRfQGWyms51VKvNuuuv8KmpzVThU1N04SfKpSPfwCUQkrAABuRqdyhgRKCr2CCQHZHS37PT2UoX/AINNvkeQk/HodH4elZajtgU/kfruwHzE9gnygrL1Aq9RN4I9txxuBUwmphk3Yt2A1JJ9SbOZsFKsBZcbgO5JQFT5kqd9yQAKvcbqIJMXEgJKnG7InyAKncONiTyJA1d7ElxuRvhhv0AstX5Ew4ImWdkAl7Cz5IG7gVTK/iWO5FsJfMgXid/UKlO/fshfZPngf1cA2&#x2B;bFlTJJcp&#x2B;hF2kC2mImBck8oRcBu9&#x2B;BabEAAKe4ewALaxUm3H1C7iLQ2AsuSFf2IBYF49yMAFPKK0RuwnuAiQAAS5AAAnP8S37DmQAIne4TndAVOCpuCegnuBX2QsQNcgXiAv6km5fQCtxYKErkW0hNxuBZtEwG1zKJHEB3APsWeysSPUXQFTXuL/vIilXZdrwASSs0VS/3kS2yX1CAq3ui8hWExuAIyhv0YEvFiojU8FABgj5AON2FG42UhQrz7gWbSEJHICeRMkTKATCe4ADfcTIidwgCCjkJMIC2YaasLJ/wFuF6ARzyJ2lciGWJ5A83duGILCvPcQpUM2Bl09yeWbSba9CO4GHMJC8FdKa2J6pfcCPYkOZRqLSSPQDO9kHPYrttyT5XAlyNcsrie/oGBIJxYr9iegEe/axONiu9/wCAal3W4GWhYsJW9O4dt2BlwmIiEykj7gSEuRv7ssT/ADI&#x2B;0AJSc9yNXK55J6P6sCexGoVmXbYNSBmbuVYnMmr8kSn5gSEWHywmqmHdeoEahEdrlqVpIAkk8vsW5H3&#x2B;oE32YcXkr24Hm&#x2B;oE&#x2B;XI2kOyhL5h3Xe4CFwQrXJHMbFCXBmLyX1gMKkWF0xEcBXUQBG/RB3DjsHAQcrj6ki9lYNhuQpvsG&#x2B;zI7W/gGggAAEknkVWG4VJfF&#x2B;4b5kROxLb/AGKFlKncTawYu3awQldvkJ&#x2B;Y5hMgFl7SFHJAybKvHuR&#x2B;hWQIcF4gjkBVTaJIAQ2dx8w3u5AUAvywoV5GcBbuXgTZ3ERdoILe7K43Xci9R7tCJCXI/pQOdwon/IZVbTvI9PKHKcEb7KwRU4Viy&#x2B;SS0W7Vh3Bz2L8ibIWCqgk1eQ7hSiIvrHsIIy73gBEXGwbfcgFpsW20khh&#x2B;gHy9&#x2B;l4yX618ImNmY/8AtbqLJVz7uun/ANR/K/3P6zfpVci858FvUVdNM/gZ3I4nt/3nDp/9R/Jk9LwjfSz6z8nsOA1R/JTH4p&#x2B;EI/c/rb4C5hZzwQ6QzVKX7fTeStTt/sadj&#x2B;Se&#x2B;yP6t/Crmv1z4buicduf/wAXcsm/ahL&#x2B;Brccj&#x2B;lRPm4faGM2aJ85&#x2B;D3662ERyejeIvxJ&#x2B;C3hP1lpfQXiF1zldM1LWKU8lg5jzQ6XV5U6nEUp1WTbPeMPFwcfCpx8vi04mHXSqqMSipNVJqUzzbyrSv8A5E9IKu7JfmQDRCzyNgIJEACylsN1twLPcOIAeob4kW7/ADCnkBPcqlb7k3uFOy/ICuN9g9t7Ebb3RfRcLcCprZkSS3Da7k&#x2B;gGk&#x2B;JuLkmxb7SAcyJTuw4nckxsAmzhlT&#x2B;5F7lSU7gE/UrfqTb24sL8gOdwu0ksnM/Mt&#x2B;APz6ym9KzEf8Ag1fkawlGHT7ImqqdMzH/AMmr8i4d8OmY2J3ZT9iP34DnhDe7Csr9w5fcrEmFASe9w13JxuBU12FpuwlcO62AbCycoOFweP1/qjp7pfRc/wBQ69q&#x2B;BlsnpeXqx9Qx8TEUYFFNPmbq7Wv6geQt3ESrHFk81g57K4WeytTqw8bDpxMNtRNLUr8z8fV2PnMt0pqePkMSqjHo07HqwK6N6a1h1NNfOAPI01UYlKqoqTT5TPWvGbrvH8L/AAn6j8Rcrp/61i6Jo2YzmHlv/EqoodST9JSn0k9e&#x2B;ErWc1rHwx9E6zq&#x2B;fqxsbE6cwHmcxi1Xqqppiqqpvmzl/M8f1B4t&#x2B;F/xE&#x2B;APiAvDXq3B1HK5TStS0zO5mih004eMsvXP70Socp7MD37w91rPdR9AaH1DqdSeZz2j5bMZmqmjyp114VNVULi7djzCa/wo&#x2B;OvErxz6K1rwi6L6YynxX53prHy/S2T8uk9D4H67q2dzrwaV5cRUT5aKbfsKHU6nLXlRzeAXUX6ULrTpT/s/n8houl5CnEqpyPVvWeQqwtRrwdqanlaKnNUX/bS9X3Du6r4nNM/9vWV8G6eh9Ven5rHxclh9WOhLJValh4bxasnS4mqpUJy9vMmt0z2nxV66r6E0fTM3g14VFepdQ5DTaMXG/dp/Gx6aanvv5fMl6tHXvhT8EPQvhl1xlPEXNeIXVet6jlc1iZ79X1LV28m89i0V042ZWCkkqqnXW42XmOwPGTwe6L8dugs14cde4OYqyGaror/EyeO8LGwcSipVUYmHWv3ak1KYHW3xVarheJvUHS3gP4Xdc0ZPrN9QYOq05rJ4FOZq0fK4FNfnzOLTtT&#x2B;8qKVVDdVaiybObpz4Afh4y2ewOqfEPp3F6w6jb/E1PXNezWJiVahjTP4mLhef8NxsqfK0kkuD3HwN&#x2B;G3wo&#x2B;HjTszkvDvRMWnM52pPUNVz&#x2B;Yqx83m2tvxMWq7S7Kx72B&#x2B;bSNF0fp7TsLSNB0rLZLKYNPlwstlMGnDw6F2VNKSR&#x2B;lditR/qS7AsksgAESPcAAG/UEbAs3JyPaRebsBK3CuJWwpiUkB2jkKfw8jg09sKlfY5ls04sceXSWXoX/Il9jWwGuG0wvSTKZVG7Ar23LupTMt&#x2B;hb7NICr3&#x2B;wb7ktEscXARHMexZSe5mZV39hKiJgDc2FjNplBuNmBZLMbszMCXLT&#x2B;wFkSRNxJPVcbAaC9GRCW7gWd0JI9939Am2BZm8EbvyRORVuBZf2K9jDuV1AaW/wDMJ3gkxAb9AKnJZsRObiZtHuBZLJmYsg21wBW3ZCSS/wCYT4As3gSRNOxQE9wx6yJsAESPZgAVrldyFWwEdwVrkgAC4j1Aj3KLgAPUDcAvQBlhqwEI0vUoAkKbCHNixeRHqBElNkUQUA4IwGALvwyF9gDdoQaS4Ktroj3AX2Rb8fkRP1LbYCe7LdiJctsR&#x2B;ewB9v4h7b&#x2B;4i0fUPa1&#x2B;4CJvO5ZvEEdX3K/WQCZZ4RLj3ApAp7ieEAs/4jYK90xPACXwIbW4iFsPkA5uEuPzEPcK1gKiR2ZUI7gT0Y&#x2B;YsryErAVAL1KBB7lsPUCfMbAAWbDfkhXsgD7QEAnAHnXuEo&#x2B;YjeStP&#x2B;mbAjun6mWpNcwvqRgZgRHJfkAMOHswzTS2MtPZARpkcxsa3RHTFoAjTXqZe8m4J8voBmLGdtjT7ojQEvMkabfyNEatAEa4klXaTTnuRzvAGWoYaW5qfWII04mAI0Ze0waaHuBn0Jtt9Uah7JSZh8q4Eci2zK04kgEe9gtu0l5IrbsCbOWkHzJb7fQjcW9OGBLP&#x2B;ZCwR73AE5L7Ee88AR34gqUbIN8JBOVf7gIUWJ9Su8t8MjAlU7Da8B&#x2B;rHoFQj7la4Y9yiWmGGy8kZEN7&#x2B;pG/T7FcNwyevoBIaYluxZ&#x2B;pIuAU9yOS3bv8yO2xQIyv1C9CCOeEIcjmwjhlUa5TI1f&#x2B;ElX0HMFyMu4hzcqSW33Jd8W9iZFj0j5kaEdkWOeAI7bIW7FbndEW8qQhzDDQdrIQMKl1sCtdiQEAItICgCdoEgXYj9y77kYBsE2v6BubDqKHV3ZHtb7AIvmRfmZkqYFsLCyHmtYKNPc0nwSY&#x2B;fqFO/YiK42UBS9yRG7Km9oArEcBTIkBu9wmCX7gUSAAAJbkDo79JLknn/gs62w0peHlcviL08uawX/A/kAmf2Y&#x2B;OnIU6n8IXiDlmp8vTmNiR/0RX/6T&#x2B;Mv7W87no&#x2B;DT/Qqjz&#x2B;UPVcBmP5aqPP5Q2r7H9Sfgtzled&#x2B;F3o3FxF&#x2B;7pf4avxTiV0r7I/lnS5Z/Tn4Bc4s18KXStUv8AYozNG/bM4pjxyP8ATUz5/KWXH99LTPn8peJ8Xuj/AA8yvxU6bqfiv0/lc7onXHSj6fy2NnsFPDwc7h4tWKsJ1P8AcqxaK6lS01LojeDuTonpbR&#x2B;gOltO6F0bOY&#x2B;LltOy34OTebzDxMV4VNknU71QoU&#x2B;x4Dxc6W8OvGLSM/4JdU57C/Xs1kKc5lcOnF8uYyzVbWHmsJymqqMSlNNbNJPc6X6D8R&#x2B;pOrvEzwaxeps9VXq&#x2B;n57qTp7Xq6a/2cxmMthKh1tK37f4VNcceY8s8m&#x2B;mM9nsjpuUrz&#x2B;pZzDwMHDS8&#x2B;NjVqmmmXF29rnI73TlcM6J&#x2B;JrxHxurfC3xr8Lv7PWBi9LdMYWYws1TiS8ajGwKsVOI/Zaqw6l9HY7l6PzKznSOlZr8Rt4mnYFVUu8uhO4HkfSCepWov&#x2B;aI3N2AdwC7WALYew&#x2B;YcTYBLJedwPmBX2ExyPkJtsAur8C8TP3DciFF2AUBTwI7le8R8gIi8cCLx6BpRb6gKmt5LaybI03ytxuvUA72ksxZ9ibv&#x2B;Je4EUNFaXIczLABK92F2GzkqnsB&#x2B;fVp/szMR/4NX5DDadFKXZDV2v7KzDf/AINX5DDS/DpjaCd2U/Yj9&#x2B;DVk5EWtzwJW8/IbclYjXq7fYju4gvEeWxx4Oay2Zrroy2Zw8R4VXlxFRiJuirs42YG1LcL5l3sfOXxpUdOaF1NpOteLHxMa/0x0xqv4GRy3TfT2F5MXHzdGOsRY7xFNXkScVuEknTe52X42eP&#x2B;g&#x2B;BmjZPFp6Q13qXO5vDdeV0npzIvM5h4NC/axqltTQpS8z3bSLgdgumVt9j5P6v0/qHqjwI&#x2B;JvSNbz&#x2B;NmcXB6kzryrxa58mHh5LLYuHRTGyVKpSXH1Oxei/0hfwqdW9M43UOo&#x2B;JWX0DHylXlz2ka/S8vnMvXMeV4bl1bf4Z4Oo9P8WeufFLUfFXQPh08Bdc6h0zr7NRleptSp/UdOw1VkcPLYtbqxknXFVLaVMyotuQfWPQOcWo9EaNnlR5VjaVl6/L5vNE4VL359zk0rqDSerem3rmk1/i5PMYeKsOuqiFiU01VU&#x2B;a&#x2B;9LhtPlNMz0XoWN070XpXTeaxKKsXI6Xg5fErw/3XVRhqlteko&#x2B;bulPB745&#x2B;oOn8LwD6t1/ROmei9O8&#x2B;TxupNJxvxdS1TIqpqnDoV1gVVUNUup3Xvco9/&#x2B;H7pzP8AVPwQaT0fomsU5TN53pPMZLK5&#x2B;pN04NdX4uHTiPyuYTvZnTXw4fCFmvGLM9U9ReK/irms1pH9srTcTTuiH/Zml6u8thUYVWLVThpVVRUqsNtNKryM7t8QPhC6c6vwNP0rpnxL6u6T0vLZHCyOd0nprV3gZfO5bDp8tFNaammqP2XVQ02nebNdmdH9IdOdAdMZLo7pHScHI6bp&#x2B;AsHJ5TBpinDpX5tu7e7bbIPCeGfgP4OeDmUpynhj4caTo8UeV4uUylKxalz5sRzXVst2e2QXbZBsA&#x2B;xF6or/qAgIEAgLbZIQtwPdAQAAA2BYAR7FI/RAGLfbcifcvFgD9jeXwvxcxRhNx5qknCl3sYbXCOfS6fNqOBTP&#x2B;&#x2B;p3/6gR1dmYVsOldkaMLbsamXZgJVKKn6kbcxKJ5l85A15uZG10zLqScTYrcxdAVu1xJlt8lm3YCyWZsZ808hv&#x2B;mBWw6vX2Mz6r5lmdwNWEpbGZhSJ7AWew80OxPMkRN7fYDU9yzJmW7IT3&#x2B;4GpS2bEyoJsSXMAangNpkABv8AqBMXJK7lAfIs9zMrdlnb1Aq3gsvsZkKqNgNT5XdF802MTwXncDTfYJ3In2E89gK5W4l7MkwNwLL7XG/ckqboTKj6AVMqMpR/kVVPlAVOCyoszMt7FldwLM8EC2sgoAF2J8yr0QEA90VAQrXqFa4vx9IAJMbboX4DXcAo5DVxxsIgBHp8hFrhN9w24sAvCIVd0hZgQWLDVytJcAT2CttP0LHr8gkt2BEoe4bYi7lFbsBN7MsP7k2cyJte4F3t6BR9PUJp3YfC2AriLE3C9dgneyAN2mRM/u2QuxEKfQC3&#x2B;YbtI9YI2nYDSc3RJ5i4T4/IL2AsL6kb5Ku7JMAE&#x2B;UH3FouLxICOZCL6kXsBQQoDkJQAAVhA9iy&#x2B;WAi&#x2B;4XsEpLK7SBkQytkAqh7/AGEN7Jhb2YaW/qAaa3I7clZlgefVK3RqLbilWt2LtKk2BmHvJHfmexp&#x2B;hH39bgRzu/zJC/kaie5HMygM1Lgy03d7Gn6kaQEu7pCIktl/Elvt3AjuiQaj0sRpvcDDVoJBpJcfUcyvmBmLEaNNWn8yOXu/sBl0x7kai7ZqGAJCckSv/IsJ/wAx7IDLXdokSpNX5JtdfmBI4JDnc1d2ZAMwlMEai8/c016mYiWBBElah2&#x2B;QtEsDO3JHe7NMjU8gZfYNdzULgkNuJjuBkXLuiAQRG7DD7QAqdt/mSIfqVytiOYkA&#x2B;yRCtcIlncAyF3sGgMw0Jg1BAJwyPsWJ3&#x2B;5HvMAH39RPqIjfaSS4uwDTW4d2yuGtiROwEnsCw9yAS8iCxAAm/JfQQW4GYsIvBRCmYAzHHHISNRaxIdgHGxP6ZX2fISWxRGl3I7uPQ0ktvyEKN/sBGoUkSW6Nb7kSSdyA1Yj3LDW0GblDjYe5bcog6gL9gHtcKlojsJvyVqQREe3cRDKCiOz2CSV92LK0hxxuFVWEmZUxNyq/sQaT9ApgiL7hFLKV&#x2B;DN1BW2rgW28yJ9Zgi3tBW43AX&#x2B;oW8hS&#x2B;RzcCiYIt&#x2B;4fqBW/Uy0tiu/&#x2B;QhJWA6/&#x2B;KzJf2l8MnX&#x2B;SifP0hqEJemBW/wCB/E1LhM/uP45ZT&#x2B;0PBbq7T/LP4/TOeoj3wKz&#x2B;HCqn/U9DwXe3XHnD0vAZ/p1x5wjsf0l/RxZv9Z&#x2B;FfR6FVLwc/nKKvT&#x2B;/qf5NH820pifkf0T/AEZGZrx/hlpwK/8Ac6/mqaYfD8tX5tmfGo/0fvj5tjje&#x2B;jj1j5uyfHDwC0jxky2U1PIdRZ7p7qPS1X/Y/Umk4nkzGWVS/aw3xXh1c0vtKh3Oota8EcL4TekfD/rvU&#x2B;q81rWF0z1zmc91XrWaw2qnh6hh14ONj1JT5aaa68OpvhJuVc&#x2B;nKX2RxanpWma3puPo2s5DCzWUzWFVh5jL5jDVVGJQ1DpadmjybyT5d6s6m6U686q&#x2B;I&#x2B;rpXXcrqOXxvDTIuvM5PFpxKHWspnV&#x2B;8rNxB&#x2B;vwe0Lrv4btE8PevtR8TdV1/p/rLCyeR6lymr4/4lORzeZwk8vmMB/4KPxPLhOjaK0&#x2B;D37OfCf0L0HoXWuL4Q6Bgaf/ANo&#x2B;i8bSno2Vw1Rh4mKlj1UVy3&#x2B;83july4hI6S8TPGLB0/4Xun/hq65pxsp4jZDUdDyNGlYmFVTiY7w8xg14eZwmlDp8lN2n&#x2B;zUqlwUfWuN4g9C4PVS6HxertOo1mujz06ZXnKFj1U8NUT5n9Dy1Shwz5f8ADb4afDbxr8TPFnqzr7J49fUGV64eV0zV8HMVYeZ0zDw8vg14Lwak/wBmHX5uz5O3PDTxE6j1nxl658LtZxsLFy3TODpleRx/JGJWsfLuqvzcP9qiduX6EHYnsW56jqvjf4a6V0zkesauosPG03UNZwtLwM1l6XWlmq8X8FUVJXpjEXlc7Pc9tTfcBwAwwAJuVWAcyW&#x2B;7IAKmuRzYTaAt7gF6Cb2C7fmVWkAoLC4RmyuOIb9gLD7lZElElScTP0YEStKsVLuOLIoD3DteA1PBLAW4TIigfm1l/wDurMN/&#x2B;DV&#x2B;TNYSfkpf/KjGsudJzL/8mr8mbwf9lTfhE7sp&#x2B;xH78FmXLDd/kIWwaTt2KxSYv5o7ydRdbY/hH8FPSHVPjbTo&#x2B;pY2H1B1DgZnXsT9ZrxmsTFxKcN4k1N&#x2B;TDoVVVUbcco8n8U3iPoPhp0LpWpdW6xVp2jZ7qjIZTWM/wDteXByzxfPX52v3aavIqG&#x2B;1bOv&#x2B;t/iA6S&#x2B;LlYvgD4DaLi9SaXn8bDo6p6oxMnUtN07KKtVV001VR&#x2B;LjVKmKaUolzNgOn/iG8aOvfiX8WczonwodGYHXuhap0nXo&#x2B;qY&#x2B;f0mvDwMlUsaqt42Fma1TTS3&#x2B;zs7uim1kdwaV4SfG54o4GG/EHxY0Lw8095ejB/s/o/ILNah&#x2B;DSrYdWaxbUve9KqUs&#x2B;g9O03T9HyVGnaVkMDK5fCUYeBlsJUUUriElCOdW4A6i8Lfga&#x2B;HPwt1KvqXC6KWva5jYqxMxr3U2J&#x2B;u5rEr/4prXlpf/TSvyO3MPBwcHDpwMHDpoopUU0U0wqV6I07bCey3AL25Iu/qXfYl43AS4I47ASAKRsAJACnuAC9RcJtAILdbE9BKAbDfgnO/sFK3YFG42skR2ctgLwG4Ht9REsByBAtZAVbbH6dIp82q5ZLnMUL/wDCR&#x2B;ZSfs6epdeuZSmf9&#x2B;nH3Cx1dhptLcs&#x2B;pmb2fsVPlBFm0FkzL5YnsBWyzaDPmtcNvuBqUrfcrc7GPM1uhPcDafaxG3tJmbSG3IFbLLiGZbdxebAbbSUETfckruJ5VwNS5hEm6fYy2JQGnUhNoMtpCb7ganv9izMx8zCaLNoA03zPIVST3J5mnZknuBpPsVtJ3Zhu5ZsBfNNh5klZElQVObuQLaJ4E9iStoDiLAVR2Fm9yKZnYJvebAaTclW25mewmyuBr3EtIifohMgWeAiJ3AGlF2E23uRKxXvb7gJtD/IT2fyJtK/gWVMNQBU09ipmZaLxAFDAAfMq9iFXYCq0&#x2B;qDstrElMKNgDfYTYW4X1F2wF43Fu433EAIUCFumVw7iIswJD3&#x2B;4m24ae8h35AttoHqRMQ1Z/KAK1wSOZXyL8xHezAiRbx/Ml1csOYXzAjvYb8i7W3AVvoAlbyE4/mOBfuAKrymiJTz9CgLL2H9MrjZWHFkBNuPmJcB3XyG8fxAX5ZZe6CVrjj8wEvuOBxAutwClKPpcXb&#x2B;Qu3b8xxsATXcqvyTbbgRDsBUBtaQA24LuTkICq/uItuJZEBbTZhvsJ9SbAVuSexSfICrsN&#x2B;w&#x2B;pL9wLdE3&#x2B;ogJX/zA9hSUKOwW3z5EQpETwbAkORBY7MkegEfoR&#x2B;q9zRHZyBHE3MvuaqsSHMoDLU2EQrmmiOwEbRnytcGvL9ieiW4GY5BXN5D33AxzYOVYsQRzs0BIkNWmCw&#x2B;xLq6YBrsZq9zT9DMeoEqfH1I2Woju7gF2YUcoe5AIzMXubZPuBIgnoyulQ3BHHcBZki5fkQCNTuNntyXkjd9wJ7pmSu9x7sCB7bAfMCMVbFHsBl9kmRpmoiYJbZ7gTe7G24aQjuwFncNRwXb/ADI7sCE9ii24EUPgcFItwEXuTeyYac3LKkCNbuSNQrl3fqFuBIWy3CXBXMzA3AlhEl33X2HP&#x2B;YEc7SF3&#x2B;obbHqnsAdyFm8wGgJAiBHJUrlVIsTY0yPbciI4uGntBYvb5k3AjXqITdypRsF6ASIe3yDhl9BfZgZhCCpWUJfQPa8QBmF3BWoJdgLpEhbwXjYWgCQmoHoUiQCLljkKBHMARepfcILfcCrewngKW2HLW3yAKQn6v6huNg1a4Gk5ezEElJbFTAbbhpkcclulCdwD9xNon6DiGtiW/1A8Z1pkVqPR&#x2B;rZGpysbTcehr3w6l/E/hBjUPCxa8OP3amj&#x2B;9uew3jZLGwmrV4VSj3R/BzqHLVZLX89k6lDws5i0fStr&#x2B;B33BJ&#x2B;3Hp83oOBT/AHI9Pm/KqnvB9/8A6LHOvG8BdWyrrl4PU2LC7J4OE/5n8/pi7fB93/onsz&#x2B;J4V9TZRNzha/RW&#x2B;0VYFK/9JtcYjOhn1hu8XzOin1h9XJypbNpo46VPJtHj3klb5nY8VrPQ3RfUOt5LqXXulNPzuo6fV5sjnczlKK8XAf/ACVNTT8jysqJbJPzvyB0l4l6prXw1&#x2B;Lmo&#x2B;NmX6Yzuq9IdUZTAw&#x2B;qMLS8F4uY07O4K8mHmlhq9eHXhtUVxdOilmfCLVsjnPi8661LK5ip5fqPozQtT0zz4bpeLgpY&#x2B;G6knezdMzdSd3VU01U&#x2B;WqlNPdNSjrTx18CNf6/1TSuv/CvrmrpXq3RcHEy2U1SnKrFwsbK4jTrwMXDdqqJSqX/C1IHy/wCJHRWtar8JmS6o6e6izWU1TpzxlzmHkaK8RvL4tWLrbpp/GoX7yprdNXEQ&#x2B;59S5Dx50joPTemunPiH13SenuqdcwsSlZenHf6tjYlFfkf4eJVZTNDhuf20jovqnwt6y8J/gt6p6Y6xxsbHzOk&#x2B;ItGp4mqY9FNP63gPUcvjvNQnCpaqqcTaHOx2T8UPjV4K6Nmch4UeIvhrqfVdWt6TjZqrC0jS1m68rlJVLx7XpXmiHT29AO8Ka1XT5qXZoXaPmLwy&#x2B;LTK9B/Cf0j4k67qFWe03L9WV9Pannc3TX&#x2B;O8rh4uPhYeLEeZ4nlowm01eWne53b4L&#x2B;Onh5489OYvUfh/qeJi0ZXMfgZ3K5rL1YOYyuJE&#x2B;XEw6r0ymmns1sB7hb6heos4E8PgCgi9yoBzcuwVt0EmwF&#x2B;EWE93ISnd/cifdAWe0e0E9Su2xHe6&#x2B;oFULm5dkZXo/eCxb3As2CbJJX63AXYQhLYq7gSF9BtyIbFkB&#x2B;bWbaTmX/5NW3sbw5/DpX/ACo49ZUaTmf/AJNX5HJhpeSm0/sondlP2I/fg1wTjf2EQnLbE8&#x2B;hWL8HU/S3TfWei43TnV&#x2B;g5PU9PzCSx8ln8CnFwsSGmppqTTukydN9LdNdG6Th6D0noOT0zJYX&#x2B;zymRy1OFh0&#x2B;1NKSPIJTyS6c/mA9go7WE3sWPUCKVCTLG7CsNgI0Pdh9n9xEgRoFi9iJAI7Ar7EABWAAQA&#x2B;49wBIsX1I7uAEcACACU2kNcoB&#x2B;qAXjsPYW2E3sAEcoWiC8AR&#x2B;x5DpNefqHKr/AMx/kzrnxU6p6g0DrnoHSNKxnRlNY6kxcDUkv8eHTksziU0z/wBdFL9fKdkdHKeosvK2dT&#x2B;zA97T7MvmbcmV/AS&#x2B;/wBQNWmzF95RlXYTuBtOVDInwSYZG4A1MbBtzuZbfYPcDSfYSkZ83b5iZsBpsKYsZnlCe7A3MjzepjzepU13A02pkk3IJjYDTcu72JNpRA3ywNJ2uJhbkT4HuwL5ml&#x2B;ZZtMmfM3yJ7rgDW&#x2B;4TfKIoX8RzAGk/Us&#x2B;piYuqTSuBZjZ/MehGJ7gW4TuRPsW75AS0VVPZElRDF0/yA07zcNqxJS3HMtzAF&#x2B;ZURcQF/TArLPDIthvsBfmLsDZ3&#x2B;YFpXb5MJ9/kSG/9CqJlgX3Ek&#x2B;X1LNwL7BASALJPkALPcKVfkTeWAEsqqS2XBFvYsNpgPSA4&#x2B;w2/wBBDctoBs7ke9xedtyp7ARpzEFi4Uiy7gGvLcbXkS1wEuwCHNxdbFUJcL3JD329wF94ERYRaws3AEupgsRdoXXqN1sBPRmr90TZ/mXgB6Nkid0VXsEn3AjbVmiqldgpiXYL3AJIeqKp5I3F/wAwDXA9Rx6hyBfmLMBAAAAADcgACoCFAvMgB6yWJ/mRwAi2/wBhMBuf4CLgIUw0HE22EvuH2gA5CVthK3EQ7oD2FJ7QIfm22NCGbAz5YUQIcGnTDgkdgMuxH6I01w2Ze4EhzsiXg1BGuAJU3zBmLWNxwZn1Az6BSttivuyQwC3uZfZGoaTf1I/N2Aw09mIfcsSpYfYDLneRVDuX14HGwGbckasWIu0IQGWp&#x2B;hFKcR7GmiP2Az5eAVrs/clvsBCNGmo4IwJuyNNuINEa3uBnkNKeS&#x2B;WOPqRvswIR7GotMkAzuRrj8zURsGmBl&#x2B;xHc1FL4JAEDuIfYARpPgWW6Uj3EKZAkJ7IOxokNvcCdo/MjUblhq6YdNwMu92WOBZO7FwJECPUrtyGn3Ay5JDn8y7WRfkBFsLyvuGnNhEL&#x2B;YB9grciJ3DuA3JZbc9izaVBN7L6sBzME9l8zXEkj&#x2B;mBE1dsJ2hGko53JZOEwCVpSDS7i8yvuO9gEK1iWieRH3CUbgQQtmXsxFrKwEStZAvNnJdt0BmGt0ErQWJ3E90BCOZNQRrhoDLnffsErliFHrYc3QGV8g05NN2gjlWYGY&#x2B;/YRBVDRfkBnYQVqXEEhtSgHuVT24AsrNfNAXa6gPePuLxAdrgSLhRt9TVWxH7TcC34Qcq4kJp3lgJfZR3EWlCLXROJ/iAe5H3ksypZHGwEc1Utd1c/hZ4s5R6f4pdSaf5Y/A17OYcdox60f3Ung/iB8SWTWnfEN1zkVRH4XV2opf/AMzWd3wSf6lceUO84JVi5XHlD0uH/mfb36JPNqrpbrTJRDpz&#x2B;Urmd5orX8D4hTV2mfZX6JHN1U5zrfIXvhZHE&#x2B;&#x2B;MjsOLRnQV&#x2B;74w7Lim&#x2B;hq93xh9pq6hoJzcJzeSK&#x2B;54x5FqStmf6Ym8AWbQCewn1A/D1L01onV2gZ3pfqLT8PNZDUMtXgZzL4qmnEw6qXS0/kzo3qfwZ6z&#x2B;HrVumfErwd0PUessPQdNzWkajo2dz1NWcxchj41ONhvDxK0vM8KumId3Q/ST6Au0I5/gB8T6L/aer/DliYvV3TK07Nf/AKxWDi5/ScWqmr9VqxNQw6nhPhx&#x2B;Itu/Y7v1OrS/D7428ljaXl8PLYXV3QmaxNZ8lljYuSxsP8LEqSt5lRi10&#x2B;beI7HvXin4OdOeJ3S9XT2L/wBwqetZPVP1nKYVKqqzGXxqMSiqru3&#x2B;GqW945PTPFnpPW9V&#x2B;Krw&#x2B;17K6ZjV5Cnp3XMlnM3RhN0YVeJhYToVVWyb8tUT2ZZHhvCT4yuoeuNaymo9Z&#x2B;EuY0TpHqDVMTI9K9TPN04mHmcWmuqiinFphPC/EdL8lTs3bdo77hu8nwt010h8Tmh/B7nelej6cDrXTMo8xkq9FroWFqXT&#x2B;oZTM1Q8J7Y1Crw6a/JVFSTs4OxcbxR&#x2B;LjxV8bdcyPgxquk5HS&#x2B;i9G07Ez&#x2B;javkm/wC1M3j4CxqsF12eG4/ZlbNX3IPqS0RYI9R8KfGDpzxP8OtO6/w3/Z6zdby&#x2B;ZyecqVNeUzdNbw8TLVz/AI6a06Y5g9up2lAa&#x2B;RYlbexFVCgsWsuADUue/JIcQaS7EfYCWj2LKm/JJQUAWePXuJjhBOFM27BJpREgJTW4XcbOIEW9YAqt8y7Ee937E5aQGn7kurj2ZQPzayp0rML/AMmr8i4bihS3sNWhaZmL/wC6q/Jlovh094J95l9yP34LtdfccWLE7r3IysTddiKBO6LMcx7ASVBeFP1kes/QTDloBt6wN/kSRvs7APQNSLbMe4BtdrjgOfmQB6JgMAB7hXAAMAAPYl&#x2B;5X7ACSUlnvYBZqBPckojqpTSqqSlwlO4HFqGp6fpOVrzuqZ/By2DQprxsfEVFNK9W7I8H0v19lup&#x2B;ruo&#x2B;msDJuinp/Hy&#x2B;DXj1VWxasXApxpUWhKqlfU64&#x2B;IzqDwb6t6U6qzfVfTmX1nO&#x2B;HNP460rU85VgYGNj4mXWJQo8ypxZpcKU/wBpOFJ4XWOqfEXSutettB6L8DNd1d9X5PI4uRz2HmcPJ5LAoqyFOFV58etzRVS1tSnVsUd6631NoPTeTWe1rVcHAw6sPErw3VX&#x2B;&#x2B;qKKsSp0pXcUU1VP0R6llvGnB6q6P6r17ofRM1m8fQMv/wB1wfw5qzeJVlMPMUKmlO7/ALymmN5TOu&#x2B;k/hN8SusdA6eyPxBeK&#x2B;PiYOgaUslgaN0vXVl8LGwnh00VrHx3OJiVVKlKp0uhQ2krs9zz3w953pnpjJdDeA/Wq6K0lfiU6ph5XTqcxjZhVxOJRiV1TRjQoVb8ySi1kIwOvPhy6n8efHfC6U17rzpWujTOm9cz&#x2B;aq6k1N0ZbMajUlmMvh0UZSiXheVYkVOpx&#x2B;xaZPqfoejzdQU1/8ADhVP8j1fpbprSujuncl0vomFVRlchlqMDBVdXmqdNKjzVPmp7t8ttntXQanW6mltl6vzRJHuTJ6Pcs8NEAvzCmYgnN2Vt8gVtu2xPN/mT2ZG&#x2B;7A15uSJ33ZJ9QnYCuCTexG/XgKqXa4FbS5L5vUy9vQN/QDfmcRuTzNXnczNip2A1Lan8xPcyFVzAGk4UlTvZmJL5u35ganhFMpzcst8AWXMoSzLq5L5l34A0m9v4BXTsRO5fNFlYCzF19wnG3vsZLP0A1NxKJPHqXZS0AXYqcmZUTFip32AszwXiCTcAVu10WOPuSf6gqb5Av0LaSK3JVMARuCpkuUBsWbz6EQn1Au6uyuWtjPoXdK4F5hFUpESktm5AX7FXYltmhFrbgVvsJRJsXgAAwBfkWbmY5KttwHoH6sq329kLO4Etygv6sXizFk7gVQ3DI5mwVuRC&#x2B;gFlNRBJYd7MNXswF/5F3fqT080lfowCnlk2e5Ve7&#x2B;Qvstu4ET7c7DZQE7Qn9ixNwI1JYf3EW2uNtwHuiLm832LLCVryAiyh&#x2B;wvw/oN9vzG3ADdB&#x2B;o24HEMBe8hTEQLpBK8yBZewAAJsBX2AAeoHzAb7ssOJRFdlXpIBsXd4K7bok9gDVg205kbsekMByFcRKF4hgVzwRNzYtu5ErQmBdrojciIHETYD2TmAl9BF4b2CTv&#x2B;ZsBxuT1L6sO7Az6Iy0&#x2B;xpolULYCJBWhlkRyrgZaJUpsad7kqUXYGGmlDHlcGo/Pky1yBGrGYe0m4cbe5JTsBmHMw/oR0mmuSNXj&#x2B;IGY9CeVcGmuBAGXZWJtY01wzLiL7ARqOfsRqStQg7pv7AYfsHvsmVzwGpAy12/INQ4K18xCd38wMhpovqR7gR2&#x2B;fYjv&#x2B;0t&#x2B;xr5E4sBIS5kjXZFhNBqFAGXtJIT4NR3D3sBl22JHp7JmmR9/oBHteCeqRWiRwgJ6BK8wXgICcE5gvuPcCbu4gMNSBGuZG15LF9g5&#x2B;4Eum0iP0NbPckd18wI0ErbBr02K&#x2B;XPsBmOxYVi25ZNwI9oQK7EaiwE5sElEF2LDAhPc01HBGmuAI94QiHCKRICO1v4iIZY9RHcCTF5EJX/gVTN2RwkBHG0FXM7CGhF9uADXoSSpNWSuAE2akRO/JfVonMoBBI3k1F7skTsBlqA1c06R5XwwM&#x2B;4a9C1exHtdgRUrZciE9ywIbAy6YV2HKtwajuRw1sBElEsJDZ&#x2B;hUkuQC9A57hr1EvYArrbkNbwip9hu4AiXoLFlMASLXQiJbZUmPmBl&#x2B;3Atu4K0yNdvsBmFsfxZ&#x2B;NHT/AOzviw8Qctt/&#x2B;NObrj/qrdX8T&#x2B;09nbufxz/SI5H&#x2B;zvjP68wVTHn1TDxf/u8DCq/id1wSY/mKo8vm7jg04v1R5fN0sqnTyfXX6JfO1Udb9X5FNxXpWWraSt&#x2B;zi1Kf/wAI&#x2B;RZlH1L&#x2B;igzNOF409QZRtf3vTbq3vbHw/wCZ2nE6f9DX&#x2B;&#x2B;7t&#x2B;I76Kv8AfeH3ymgm&#x2B;3zImmh6HiXkFlMLdzSEpUEAsrlkl8L2LKnawc7AG4Yt3&#x2B;xIn/Qc3YF9J2DSampfOBfewt9AOnfEDwb8W&#x2B;kvEHN&#x2B;LXw4dS6flsfV66KupOmdZoreT1DEpSpWYoqpc4OL5KVS2lFSSnYx0rVgeGfxd9RaZrcYGB4haLks/pmNVVFGJm8pRVg4&#x2B;BS/&#x2B;L8N4dccpONmdyOy3PVPGDwa6L8belf&#x2B;y3WmWxvLh4yxslncpjvCzGTxkmliYWIr01KWuzTumB8s&#x2B;Ieq4P8A2P8AGTp/S8xS8jpfjLo&#x2B;bwMTDqXloxMXFyleKlxatVN&#x2B;rZ9LeJ3jFmPDnxD6E6LWlUZjA6x1fHyGJj1YvleXqoy9WLTUv&#x2B;KXT5Y9TrTr74RdD8M/hG6u8NfCqjO6nqGZxf7YePqWM8XM57N4WLh437VSSdVTWF5V7nifFHxy8OvFbrjwC1/ovqjK5rFzvWLxasrh4q/GwU8ni0V010fvUOmqrytNK4H0lpXUnT2s5zM6dpOt5TM5jJYnkzmBgZimuvAq/wCGtJzS/Rn703PPofLHw5eDHR3THxEdU5TNa3ndK6&#x2B;03qnNapmcanMNU69o2aqdeGnRU2q6KXV5W0poro3ufSfV/W3S/QWk0671drOFkMnVmsLLLM47ilYmLWqKE3xNVSU&#x2B;oHlb7BLlilypQ59wM327Cz/zNNvsRJzbsAexE&#x2B;FcTePuxuBW0/4i&#x2B;0fQkREFV1cC2gPcismywncApj8xzuW7RJkD8&#x2B;sONLzD/wDKq/IuG4wqf&#x2B;lQces1NaVmP/k1fkbwr4dP/STuyn7EfvwafYsdpQfdfYN&#x2B;pWIt4uRei5K&#x2B;GyJRu&#x2B;QK57P5iLwhZcW9ycb34ANtlhO8&#x2B;4l8DdT&#x2B;YBtN3JZorvaOSOJAkXsFfctgrgRgRbccSAQdiyH2AgjuW7UwQBAjk4HqenrUlo/67hLNvBeMst515/w5jzxvE2nueoeLWqaXrujah0llPFtdJZrI0ZfNalqmHVgqvAy9VdU0zi/s0&#x2B;ZUVLzRbcsRke54uLhYGHVj42JTRRRS6q66qoVKW7foeH1Dr7pXTeqtK6Mzmp0057W8pmMzp1Cc04uHgqh1udtsSlrvc6AyviB4ndXZDUvDrwG0fG606QxensLSMLq3qXVP1fKrMzi0Y&#x2B;P&#x2B;PDxM3NNdH&#x2B;zUTTCaPyeGXgx0d4u9S5Pw68V/HzNdX6j0Hpyyr0bp7LYmRyWT8sYFdOJjUft4tb8kVUutSv8ACkTYeydffGbkdV1XF6D8G8GrVNVzNWfymXxdPy9WbqwszhV0YeE61hp04dFdbxH5q3Cpw/NszyvxTdU6Hq2j6N0XovXmNpvUGV1CjWP1/TK1i/2ZlsqnVmM1jYalVYapdVCoq/errpS5jtPo3w/6I8PtM/sbofpLT9Jysy8DIZSjCpb2l&#x2B;VKX6s4emPDDw86L1HUNY6V6M03T8zquJ59Rx8tlaaasw/&#x2B;dxf29S7DqTwJ8BvArxHw34za3kNb6v1evOOha51xlqlXiVYdliYWXdNOHRRd&#x2B;RqhQuTuPrTonRevtDp6d1&#x2B;vNLK05rBx/LlM3Xg1OrDrVdKboabplKadmrM8rTSqKVRQoS2S2RbvdEFsklwlCI2tpE90SyUXAj7yee8P6Z1TGqjbA/ijwL5/kew&#x2B;H1M5zMVvjCpX3YHtbckm/YAC33IL9gAmCNwy3knquQEiXu0S62&#x2B;YqstwLL2MzePyLxBN7SAm2xZS&#x2B;pHHD4Ey4AOpWKnNoI42RN7gbm4dUK5lVXE3lAa9V2sVPgymm5CbkDUrZibWMy2VN8oDUuI4E3loifYSBU7u5pP0Mbmt1Z7AWdrll7mU9mWW7p&#x2B;wGky3hPYyipWlAW1uPmVW9exmbQXcDUBdyKN5KAZU167CLCb2As3u7BRKM&#x2B;jKnYDSakqc8GVy39Sp8gUET7jiWwLMcFUQT0CfIGldWC3kTKgcT6gX1Q2YCnkA&#x2B;zHG49fuLOyYD5lAiNwBf62IE/QCzJZc7EW0SVtzE2ANPf15F2rhvsUCeWeRteCkU7P6gLh2W&#x2B;43u&#x2B;/0DaVv4gXe8/Ilkp3Ze7JCaugKvRSFcDnYBD7hdyhXAEZR/UAR&#x2B;wHuWLASYD7bl&#x2B;ZGuwD3L/EiuWABLSagkT8wI4dpLKmwAAq2Jtcvv9ADW7kXmwV7QGrAOdxfuHbd7DZe4BP1EXs/cvy&#x2B;RE3uBXCiSQ/qVP8ApCIaYCOBHI9RHYApXzJsW8DkCTbYXizgX5&#x2B;pVxKQHsjcR25BX27hzwjYGdm5EepZlwkg5X8gI73M1Urc077slScAZjhi75jsV92gktwI5iXHyI1Brgj2kDDnZBlF0Bl&#x2B;ZN3I0&#x2B;xpz3&#x2B;hIiwGXZbEtuatwRpAZhu31DTkrUcB9mwMuOxGitKQ1aQMu6uRr/M0/YjjYDDp7k5NtLfuRq9gMwk5ZIaUGmiPYCVb7fUj7ldrtEvv6ASJI0v5GvaxAI7XsSE1K2K1Ng5nf5gZtMz/AJD2K295ENAZZLmvKos7kjkCbktsn6GnSuUThgSGgomd/kX1JaJa&#x2B;YEj0EehYm4ahJAZI0&#x2B;DUWkNRwBm0hpP6FYAz&#x2B;7cRHIj87SITYCbT2FhD2ksenuBJ7NCHNkVQ1fkNf5AZh7tcC7G9r&#x2B;hXN7bgSGrhXf5F43gRPIEZHcrdxDQEFytcBvsAi0ka4kobfAEa7iChKLMCeVxHoRrsagNcgZ3DuVLsIAkSrhd4LwAC7kjiSgBHcjXoUAZa5JedzTV7Ejt3AivYQouVKGHTHAGfdk9TTlkakCWkOY3LEPZACXKBIAnJQwEWK/YijllU8IBZhrkTfcl&#x2B;AD&#x2B;ZmJRr0ZHsBmbqeD&#x2B;RX6UPI/qnxq9Wvyx&#x2B;NRksRW75TCX8D&#x2B;u0Sz&#x2B;UH6WzJLKfGVqWNEfrOiZHE//ADbp/wDSdvwWcaufSfk7ThM41M&#x2B;nzh8zzeEz6S/RbZ79X&#x2B;IvOZfztLH6azCS7tYuC/4M&#x2B;bKvQ&#x2B;gP0Z&#x2B;cqy3xRZTAWJ5VmNHzeG6f&#x2B;L9lVR/&#x2B;DPyO94hGdFc9Jd1rd9JX6P6PJzf8yyuSLYQ&#x2B;x4N5Eb9RKDtuNwBZbtJAgLHfuLv&#x2B;RU3E2J6pAGr2&#x2B;Qe1mPQO&#x2B;7Aj9QVPlkkA&#x2B;0nVPUXwf&#x2B;D&#x2B;a690jxN6N6U07Qtb03qLB1PM5zIZKmmrNqmmumvCcR5VV5221ylMnazG&#x2B;4Hyj4z&#x2B;MOu5fx06H0XXvDbU9M660vrzDymnapkslViZPVNFx6qqMR/jJRH4dVNVVD/drok7N&#x2B;PlUP4bs9i4rSpwdc0rEqb2SWfwJO4KsDAxMSjGxcCiqrDf7FVVKbp9j0f4ofDvV/FjwD6m6G0BUvUc3pzxNOVUftZnCqpxcKm9lNdCU&#x2B;oH5fHbxW6k8NerPDjTNCowKsv1P1fRpWpUY1Df9zXgYlSqpfFSqppfbdHtWT8V/DbUOuMz4aZHrfTcXX8phqvMaTTmqfx6KYmfLu7Ne0ny/wCIfxTeHPjX1F4KaBpmcxsv1PlfEHJ4muaFmcCqnH07EowcXDxKcRRC/bcJ87&#x2B;3sD8HPC/RPi21vQfETIYmR1vqnXMDqLobqnK4rwsarEwsOinHyKxFs1&#x2B;G26HaqjFcXTA&#x2B;oH7EifTudI9bfG1090V4t6t4fPw61/UtK6dWEupeptNyyxcvpdeJSql&#x2B;Il&#x2B;1FKc1NS0uDujTtRyOr6fgarpebw8fLZrBpxcvj4VU04lFSTVSfKaaYHLfYKEGr3EreIAQtoLPdieLfMnMAWYe4XoveRxD47je7As&#x2B;gsSfcNzCgD82sr/3XmFP&#x2B;5q/I1hv&#x2B;7ptwhqy/wDdmY2/2VW/sTD/AHF7E7sp&#x2B;xH78G029y72iIIOCsS7FolMSSwFV7Mvo2SWiAW6RZX3InyS0AVNzsHBA77MACSzx/VvU&#x2B;l9F9Lal1hreJXTk9KyGNm808OnzVLDw6HXVC5cJgeR4B6P0l4wrq7xLweisro9eDlsXovK67Tj4r/abzGLVRTh2snSqG3vPmXY9g6n8QOh&#x2B;i8/pul9W9WZDTszrGa/VtKwc5maaKs1ixPkoT3f813A8xK5Z4WjVeta&#x2B;v6tK/7NZanp2nS1i06w87/e15t4jX4Kwkv3VR&#x2B;15293EHXvxReN3T3hnoWmajl/EHKZTO6f1XkFndIwq3iZnO4Drp/FwacKia6n&#x2B;HiLEhJ2pXc6p6p6O&#x2B;Jvxs8Q8Lr/AMC9a636R82f8&#x2B;JrPV&#x2B;oU5bIfqsuMHB0tU1V1Qo/axPK25fNg7g1inA6M&#x2B;IbTNX618WtfxqNewc7ToWhRRhaZlKMLAw6sRYkKa64pddNVbs/NEHX/W3xia115nM/0j4A9ParruNhZzUMhi5nQcn&#x2B;N&#x2B;G1l3Rl8Z4tflwqKXjuqr95vy4SfMHteS&#x2B;EHTusM9lde&#x2B;I/xC1Pr/PZNurK5XO0rK5DLt0xV5MthNUttWbqblW2sdt6PoejdPZCjS9B0nLZLLYdKpowMrgLDopSUKFTHBR1F4MdPeK3VPi1l/E3xa0/Q9Gzmj9KvSsPSNP1V5vOYqxcTDreNmalFNKnCbpppTh11ftM9z6y&#x2B;HTwT8ROtMDr/rnw607VdUy&#x2B;CsPDx89hfiU&#x2B;Wlt0&#x2B;ah/s1NS4bTiT9fhv4LeG/hPi5/M9C9NYeUx9TxfxM/mqsWvExsxV5qql56626mk63CmyPal7kHhOpvDro3rDp/A6V13RMPE07LZjBx8HJ4TeFRTXhVKrDtQ1ZNJxtZWPJado&#x2B;laTTiU6XpmXyyxsWrFxf1fBpo89dTmqpwrtvd8n6Ul3D9QJaNh/LuWI4I42kA2pkq7fkSHHYWe6gCqXuHG/qRTtATXIBpbT9T2Tw8X95mqvShfmetq/B7N4e0pYOZxO9SQV7JuC87iHyESbQGxsAD2/kZs&#x2B;foaJC2aAjtdB3f5FtukSraQJN9hPYW7cjj5gLQSYDcsNd0AbgjmA1xASjcC8SJgitaSyAlbCXtJHvMhOP4AaT4ZU&#x2B;WjKZpAWbwkVuFLM0tR2LfYClRAk9gNWgqRPkVQrIClkk8iQKm4F5uLO/2Da3TYFTNKTM3ll9GBRJJ7soFtG4EFS9AEwob&#x2B;gv3kRx9yRy2BpWVuNx6oiVoW/sVNtXQF3uVO8SRepYtIC&#x2B;4hp2cBpdyzGzAJ8lMymoZpNt&#x2B;gDYqJEbbcACoqXLZCyBAGLd&#x2B;ACKm&#x2B;5Pcu1wKu249EJt&#x2B;Y5lAVNESchNt7ABvwHK/mImzCV5SAsNcku&#x2B;ApV32L6gNmFtZCUtx8gE3sXiSTJfQBcjkRHJdtkBNuSiOZHrIDYDnYQAAAFu3cNj1fzFtgEEccM1HcjUKWwHsOAvkHe6AWiIgOUogOOA9v4gFPYeoQUzcCxGwbTuIsGmrwBF7F/qSRcvy9gL8iL1HEDfgA72QuxL2m4jlLkB7onrHuWIYhpQn7AezQu4NNehLM58jLTd0SbRBtr0IwMuFf1I/Y0979iNSUZG9kWPQgEiHZEamy7GmnJKnH8bgZa4SDSWxWvQkJ2/ICRaUyJONzTRI7gZhKxKkk7GojkkSBkONpDEASpcrgzE2NRf8AgRtbgZI1v6mnPP1I4AkJbIzZ7fc216mWo3AyyTKt&#x2B;Zp33IBHK2C7Fgjh7gZfqH3bNNKGtiP2j5AZaDSdixJIAjVxE8QVpOxGgI1Lv8xEWLdORspAz6SRpGm5VzIEa7oSkp47lYj0Ajn/AEJHBYvPcegESXKJMXSK1fkk/wBSBGCtQGgMsJIsdxAEiNg5Ssi7EngCT3UBSrWjkr7scbgRtTMF5sLzEDe/5ARWvAtuVvuvcP0QEajeA0&#x2B;X9ipX5EObw/YCRL9ERL1NJRcNRx9gM7vcQ5hIsf1Ic7ygJ6JC97j7XJ8gLHECEAAXqH6iO4sgJyAG&#x2B;3yAINwLhACPsW4n6gNtyPuV23YkCPaF&#x2B;YaT4LBLJSwMuVMsev5lcKxKtwA4klu&#x2B;5ZYEZN1BWZc8gWVMrsVNPYzMcfQsxZMCuNhKJPb5QhPqBZfLkETlwNwK3BFFW6E9yOEr8gLn8uP0yGSWW&#x2B;KzJZxUqMz0nlW33jFxqf4H9R3VFz&#x2B;Z36afJ/g&#x2B;P3TGd8v&#x2B;26V8sxv5cxi//pHZ8InGtj0l2HDJxqo9JfHDhqEzu/8AR15z9V&#x2B;K/p&#x2B;lP/bYGbw/f/u9b/gdHydufAlnqcj8VnSNVVTSxM3i4bXfzYGIl92j0msjOkuR5T8HfanfT1x5S/qHsCXankPaDwDyI36h&#x2B;rD7iyUgN1LGygQolr6iJ/mBV6lm0GUWeQAVmJEgVPuLMk8AAECruwKrrY1S4uYW8tmgPT&#x2B;u/Ajw96&#x2B;1PT&#x2B;oM5ouBlNT07XMrqmHqGUy9FONi4uBVNNNdUTVS02mv5HQfxq9deLGn4WN0FqvhLqWp5x9TZLUPDrqrQMq66MtXTjUP8PHe&#x2B;FXT&#x2B;3S3dVU1e6Pq1VPgr8tTTqUwwPkfozU/Hzw28cPFvUOlujNO6n0fF6iwM3r/SiXk1CvBx8nhunHy9binETVNdLw6rTQ4e52b8AvWGP1N4ArTcTJZvLYeha9n9NyeX1DLvCxsLLUYzqwKK6H&#x2B;66cKuimP&#x2B;U8n42eGPiLp/WeW8ePAWnK19R5bKU5LWNFzuN&#x2B;Fl9ayabqpoqrSbpxaG26KvVrk8j0/wCPOiaJ0x0zqfit0rjdHat1frDyGDpObpVdSzsVKmmquhQ/MqP2anEygOx79vkJvf5hvhyJvICe6HpHI35E8sAttvoLbORPfgbW&#x2B;rAtlsy8TdQRd2x7tAcOrtrS8d/&#x2B;VV&#x2B;RMOXh0v0GsONJzNv9zV&#x2B;TLhx&#x2B;FT7E7svuQstqFsG&#x2B;BDm4cuxWKP0HBXHYJ2AhdndD3&#x2B;ZNuQHsLg9I6U8cdI6z8StQ8OdC6P16qjS3jYed1vH02rCyVOPh1Up4VOJVHnqfnTXlTTSd7Ae7nhPEPqzP9E9KZnqPS&#x2B;kNQ17MYDoWFpelqn8bGdVapledqlJT5m27JM5eudF6i6i6Sz2idJ9V16HqOawHRlNWw8rTjVZWp/41RU0qmr7nRvxP/Ev07ovQ3Uvgn0tqWb1frnIPJZSvRKMDFozOrUYn4OJi/hvBpbpprwqq6XiLyql1OGmiwO2tA8UsLK&#x2B;GOV8RfF3B0/pL8ShvN4OZ1bDxMLLt1umlfjKKam0k4XeLn5/EvqTobrHwM6jz&#x2B;Q6y0vG0vP8ATubw1qOHn8N4DVeDVTPnTdPPqdFeGPhF8R3VvhNo3hnmvBjpbo7StLx81XkcXqzNVaxi5PDxsTEqppwsqoodVFFfkpqxanCTteH7j4Q/o7vh98M8D9Y17TMfqnOV5p5nEq1pp5WnFbbmjK0RhUJPZeVwQY&#x2B;GTrTpnxJ8QtO6h6E1DFz&#x2B;Q0nwzyGl6lqGDlsSnLvNrEVX4VOJUlTiVUrzT5Zjnc/F4vfD7onxW&#x2B;O2tdMdf9R53I6V0plNN/CyWn4eHTjZr8T8TG/EWPUnXhU&#x2B;ZeVqiG3hpt7H0JksllNOy1GRyGVwsDBw1GHg4OGqaaV2SVkeNynRWj5HrnUPEDBVSzupablslmL28mDXjV0uO84zXyQHidD8CfCPpzrfF8SNJ6GyVOu42XwsCrVcWh4mMqMPDWHSlVU35X5KUpUNwe2NKJpLZ2aEXvICO5LzZld1KYm4Djs4CliyX8gnKAPaQE77hx/ICN2lDfaQ6rWFuOwCzdr2G7v2sgp4QduNgDXDY2UtBuJv9CT2AqT5PaugqUsjjNrfG/gj1WPU9s6EX/uyup/&#x2B;M/yQHnU0WTKb/maAReCpkKm4gBd3ZC77IRygI1KJV/VjTXckAZ8sr5EjhfmbgkOdwJD3mxNkWLTPrAhREXAzHYP1NR/qR8XAy7cF4uWHyhC5AhFCsjTUCIdwIVenASuGuwCWrSaTXJmOQgNKJsyoibYXowNL0LTGyZF7lSm7AqnlFmCLafzKo2Ablt33CsVpzYBDT3CcxIbl2&#x2B;QcevYCq5V7ENe4FtF&#x2B;wb4ck4clTn2AvH5BKLvYQt0EoAexfQkcFsgLN7ITFgiqOwDffYNPf7lRldkAcOY7lW&#x2B;/sS0lW8gVBTuRK8lXqBRMBK4ANj3G2xOYYFQAA1Cbuxbt7SSYLzKQCUnC&#x2B;Y53QtsV2e4CY5JtxcrhkhNRPAFUz8xsroNNsewCO6EBssANxAKBAAALYhXZ3&#x2B;wCZEMeX1DjYB8iR6FHqwC/j3Ey5kcbFW8dgHux6ciwcP8AiBHKcQHtPJd3sN7gRpTYMu&#x2B;6gXtCgCJW22LaN/uIgKADhKY&#x2B;qDfpwEoVyxNwIpe/csL0EcSF6gIUXRFsUNKPmASW/wBxzCQvt9BsrsC&#x2B;xGkXiwYHs7V9iKz8qL5bXDX5nPkZaixPWDbsp/MlUcu5BlqbEaT3RpqCF6DNU2sRqFc3zMEfDkDDViNG2lNoJHAGIT5Q/pGmvUQBiHsRpTPqaf8AwwR0oDLUkaNPfYjT237lGWRr1NW2gQ02BmN5I95g07Xm5KknaAMvbuS8Sac9iNKffa4GWlFyRe5pwQDLSS9iNLZm/LO5I7gZi/8AEjXcrlXgeoGdw94fyKR7&#x2B;wE3tJIc7Fs7hTO4GY9A1e/BYb9yNXAjZIT35NNLgjU2Ajhy0R34NbfxI0voBHTexC7WYgCCEtix2ZIAkSZab2ZqNv4hPsgMtNOEGixHA/JARq4fp8yw5uytcQBhr5iI4NRMLuSJ4AyvYqRUuA7cgZj0D2ujUWJEgTbkojuIXYBAG24bjkBzI42Epkn1&#x2B;4DlwiNW5LK329yPe31AjvcOYLxCZJi6AekDiCFkBE3G5JvMAAIAAQ5AEgBbdAANiSNtmLMAneEh7CN1&#x2B;Qfv9wI/sSxW/wBq1yerQE4G4bDXYCXulI4hIRvAaSQB&#x2B;xHdQ9xU/X6kbf8AkBV2h&#x2B;glpRMkbmxJhAaXuG&#x2B;fzMp&#x2B;gArbfJG7BkfdMCz2P50/pusgsPxA6D1aL4uj5zCb/wCnFof/AKz&#x2B;inmjk&#x2B;Af03&#x2B;U/vPDzUPLxqOHPzy7Ox4VONfR7/hLd4fONXT7/g&#x2B;Bp5Oyvg5ziyfxQdFY1VEp65h0RP8AxJ0/xOtG7WPePhlzX6j8Q3RWadbXl6lyctON8WlfxPVainNiuPKfg9DdnNmqPKX9aE12E3EXlCx88eRJT5EqLAJpsCr1&#x2B;ZfmSeYC9AKCezKwBHe3oE&#x2B;IG8ywE9/mPQO9wnfYCgktqSyBZi5ZT/iZm/8AIoFTc7l35ZLJyg3/AFIFR4Trrw36K8S8tkMp1roeHnqdL1TA1HT3XU08DM4VXmoxKWmnKfycnmtros2kClTMpyUCqwm8kUTcssA7uIHovyFm9itvsAiHtwIY3&#x2B;Qae6A/NrEPScx/8mrb2OTCvhUwrwjj1af7LzEb/hP8jkwr4dKnhE7sp&#x2B;xH78F2fYK3JXJ4bRuuun9f6t1jovS8xVi53QaMu9RXlinDeNTVXRTPL8qTfpUisXmHvEXPw5vqLQ8lnsnpma1TBpx8/ma8DKYXnXmxMWmirEqpS7qmlt9oP2v03PmHoPC1bA8TOis1qeZzOMsr4vdXZXz48uqMXBzFeGuFHlXPZxyUfTeazODk8tiZvN41OHhYVDrxMSupKmmlXbbdkkuTwfSnif4e9c4WNjdH9ZadqNOXz9WSxXlM3TWlj00&#x2B;d4crdqn9q3Fz1j4gPGvonwpem6B4jdN5/P6N1Fls3l8x&#x2B;o6TjZzz1000KnAqw8Klv&#x2B;8VdSU2/Zg65yfh/wCJfjYtFyvh70HieD/THT2cea0vO5jJYP8AamYqeC8H9jLKaMCl4dVS82L5qvRQNh5zq748/Cbw76rw9H8ROmOp9D0jNY9WDp3VWf0apZDOVqZeHUm6nTZxU6bq6tc5&#x2B;kfGDOeNnj5oWteFH/aLE6S0vSc/ha5ns5pNeV0/M4tf4TwfwniqmvFxFVS7ql0pTDvfzXRnwl&#x2B;EvTGt09YdR5fP9Xa/TWq6dc6uzlWdxsOrj8Omv&#x2B;7wkuFRSoOzaaaaKVTRSkqVCSUJL0IOrPGfxN678N/EvR8zo3g51H1blMxpGNhZLC0DDoeHh5yvFoT/AB6q6lTh0&#x2B;RKK3ZTWeb8Heh&#x2B;p9LzGreI3iRkdOwepepMbDxM5l8glXRkcDDw1RhZZYu&#x2B;K6VLqrsnVU4UJHvMuIknpACZU/xF2g0HYAnFpF2L8heoF3RH2Kflxta0jLangaPmNUy&#x2B;Hm8yqnlstXjUrExfLery0zLjmNgP0PaX35JU1TduL2YbOsvHHWdbyPin4W6VkdSrwcnnuqsxRnsChwsbyZHHroT9FUpjvHYDs1&#x2B;v0KpTlJe0nWHjX8XPgx4Da1g6B1zqeoVZvEw6cXMYem6Xi5lZTCqdq8Z0JqhOHE3cOEed8H/H7wm8etMzGreFHV2Fq2BlHRTmq8LCrp/CqqTapq8yUOFMAft8N&#x2B;seq&#x2B;ssDVMfqjw/zWgfqerY2WyNGbxqa6s3gUP9nHSX7qq3Sueyv5HWfRub6nfxQdYafg9Y1ahov9gafi16dC8ml5p1YlP4aae9dFPna3vTO6OzLq8AJaUIQ4sS6XIU8WAqbmwu1aCfUr2t82BG39xKeyHuHe0AVKGpSPbuiaHTo3nf&#x2B;LFqf8D1FOP5nuXSFP8A7gwG&#x2B;aq//smB5VPtuaVUswok1bZAalBNdyJi6swNJyoYV2RMtp/iAd9mHtP8B8/sGvQA12IyvuGuQMxIat/IsPdCAI0ndNEhTMGmuxLNAZaW&#x2B;wVrtFe0rgP3AP0Ukc7FiRFgDfcKUtg3csWSQEah2RN7o1FhCmWBI/qCza3yEFAKS09wrcBAVOCppqYIlb8i8gaQjdBFW&#x2B;9wEKb/AHYkW78CLw&#x2B;wFXYpFtD/ACKgKtpLTC3Ir2EXkC7KY&#x2B;hbbbETSLdbANnD&#x2B;RZJfuWwBMr9CFU8AVNr/NiOERfxK3aGAiNkN/5l5lheqAWTKTa8FAIQEV3Agi8jgQA9ytS5Il6lvwAKvULe6DAK4iw2VmVpbfwAjVu4u3bdbhWtJfWAG43QVrBKwCPUvuTYSuAKBfkAAPmABX2gekCHPuBPUFuQC7bCby6d9yexb/ICpw4ZN9&#x2B;4i8sKN&#x2B;wFiHdBTuGrQFERS7gGnytkIb&#x2B;Qu&#x2B;NyraZ&#x2B;YE25&#x2B;UBRuXfYTadgJD4HqVQnCEgROHKRVPcKGpn3F9wEdh7gJNKACgsXAAEa7FEdgJ6yJlSglxI2cyB7U1YkcmosrcEfqc2RH7k8rauy/IPvIGWu5GafaNu5G01LYEuR9ireWGpWwGWldsRBdiQkBm8SmRxwalRa5HfZlGX2F&#x2B;CmbIZEd3Zkg01N5JHoMjLXKSD3K&#x2B;0h2uBnbZkal3Zp94ZGlN0BkjS&#x2B;5q83I0wMv2JD4K6bzIiE7FGYI7K6Ne3JH3AythZv&#x2B;BVAa7dwMtehHc0&#x2B;0/UjQGXHC29Cc8mouZiFEAHLsTdwrGv6uRpQBlqA1wXyxZiE9gJ6EhPjnkrDQGX2gO73K4&#x2B;od1H3Ay0t2I7GoS4JEOWwMu3IhyVqXKCAkEiDUMy1IDdiW16hrv8AMQmwJdcwOYj6li8i8SBGrQmOS&#x2B;z&#x2B;RKu6/MA1aYJ6yOJT&#x2B;4bATGxC/MgBxySVyw2luSqPYA9/cvMJEl3hhd0gG/uW75JxJHO8/MCpzx8ie4lvbcm2wAAPcA57CQ/QbXAShNiSHC7gUkhcXHoA&#x2B;oli7ZJgC/xD234E8MjiL78gH6iURtbNCfUBIs9mSUxIBgSR3AbMjs/5F9EyON4AjZG&#x2B;4bI7c/YA3CDbMtcSizyn8gKmo7CbwRVTZokubAabXcjZG1MkbAVP&#x2B;kfC36bvKOvojoLUVT/s9VzmG3/1YeG//Sfc9TUbnxh&#x2B;mryLxfAvpbUIvg9VeTb/AIsvif8A6JvcNnGuo9fk2tFONVS/mwqux7P4MZtZDxf6Vz13&#x2B;F1HkqneNseix6sm9zyvROb/AFLrLSM4kn&#x2B;FqmBXD2tiUv8AgexrjNuYeiqnNEw/sdTdTG5XL5M4dU4dLtdIrjhHzh5NXfb5jeyRl3LPKe4Fb5Q83/CjImNwNNzsipPedzKcOR5gLPrBeY&#x2B;5mX3E8r7gamXb6kfN&#x2B;LwJgJ2UgXfYTeSXiUhPKA1PoWZM07FXqBpuPUKQlwJXcAtp4FnbsItcO1wEpc/IqZFvMfQsrsBU5Kn/AKGaWtioCx&#x2B;zuVq1ySwnAC94LE7EXqFLW4H59XqjS8xPGDUcmD&#x2B;7S/Q49XaWmZh3/wBlV&#x2B;RvDbeGrOfKTuyn7EfvweueKniVkvCzQcn1DqWnYuPl8zrWTyGNXhK2XWPjU4X4tT4pTqX1R1B154g6H4M&#x2B;K/idqWe8R9E6ez2s6foWLkM3q7eL5KnRj4NWJRl6X58epLDlUU7uJhXfsHi74MeOvjV1RqnROteJOQ0bw7zlWDW8LS8r5tUx1TTQ6sH8StOnCp/EpdXmpTq/atEW8/0P8L/hP4Z5fN6l0b07h4vUGPhV&#x2B;XqTXqqs/nPxWn5a6sTFbqaTh&#x2B;VOlWKxdM&#x2B;C/ir8ffVWs5/S&#x2B;nunNK13p&#x2B;U9M6y600PG0V1pp3WVof4mJTtFqZ7qZO7fDDwbzvTmm5PP&#x2B;IWuZfWNdwdfzes4mayWVeBl8PNZiirDqWFhuqpqimiuqlS27yz2boLSOqNA6QyGkda9TrWtVwMuqc/qlOVpwFmMTmpUU2pXEX2PLtWAeWmppulNpym1sHvuPb5ACNSIuI7AAHGwI5kA5gRcskSsBK66MOma2km4u4KomTqj4seodY6d03obG0rPYmDhZjxH0nBz2Hh2WPg1YlX7FX/L5lS/kexeOvjv0V8PnRn/AG162WbxMB49OFh5fT8u8XFrbvVUqVtTTSnU6nZJAe7K8WOhuiukfAzS/jJ1LJaHg4ur9WYem5nV9R1PO6jXjvTKsavBw/1XCp/dw06W6vLEpVU90d25HVcDWtEwda0THoxMPN5SnGymI3&#x2B;zUqqfNS36XR8t9I/DF8a/RHU2U6x6e8SOh8vqGLg53KZ/F/srExPLh4&#x2B;LRjPMVVP9rMYzrpX70U0pJQ1sHuPjV8deT8GNQzGqZzwR6p1HpXJZp5bOdV5fDw6Mt&#x2B;KqvK1h01NPESqmnzWVnEn5Ou/Enq7x26N8PfiA8BPC3VNXWk9V4mPhaTqdVGSxcbBqy2NgVYrdcqmhOve7a2Tk5Oh/BLwk1jxcxujfGbxD1TxG620jJYepYuX1zDf6hp9FdUUvBy9CWDQ5iE5qiGfQODg4OXwqcvlsOmjDopVNFFKhUpbJLgD51znhX4m&#x2B;KmtUdOfEt4oaL0pgdS4n4tHRHRuLTh5jU/w6UqqcbNYi/ExYpSTWGqbJXg7C1HwR1vw&#x2B;8Pct0L8K2e0HoyjCqf4v6zo7zNOImkvO2q1U61H71Tqk90z/AEL0hqnVuR671Lp3K42r6bg14Wn6jiYSeLgUVqKqaXwnyeW2UsD1Lwa8JNM8H&#x2B;l69GwtXzOq6hnczVm9a1rPNPHz&#x2B;ZqjzYlcbWSSpVqUkke3bptL7hdkGwIlaWPeStzyZnsBr58k3cpC/Au3wAXoy7XaIpvH1K1GzAjfLPdemKXRoOWpf/C39WelM936eTWi5ZT/ALpAfvTtMFThzyZlpwVQ1IGk33Ku6ImiqZAuylFnkzKTUsragCyW/eTKfZlAtmxbj8xd7ssU&#x2B;gE2FtxaJfzKu0gRpRI8tpFmr8sJP7AZa7IQk1BppB0rgDKS7C3Y15RAGYW5UryXy2Kkp/mBkr7ljhINWmEBliDTXAiIYESsas9&#x2B;SReWIbe3vcB6Lgqv/kXiSwAUrjcLbb6BW7e4ShXAqhlUbom1y72QD5lVtiRyygX3RUkRL7FW1nIDmH&#x2B;Reb/Il/cqUcAUNEvEclAMAbgWX3KnG/cl3zI9QLEFs4Y/ecl2uwHuBeAASHAEW2AsXEXj8hD4CT5AXWzKk0549ybclV1ZAE5u0VrlEVlLK7O4Ee8NC0bCXEPj1L9wJPYfzLE8i6AR3KkkI9RACCXkqQAQAH7gB7AQBXZhEgR3AtosHO0QKd4hFbUewEi&#x2B;whR&#x2B;ZfQJemwCHH8CpWl/MftbhbAH6kana5X2gT3AbEhP3K/Vhd4Am37UyVpRHoIj&#x2B;RUBFSFP8pLC7EgBC5Y9mWByA2IlyWILEcgSPQAQAsBEblhQBGSLmo3kJAe0tcLgOFwaancjU8HLkZfpJJsVq0kcjIm9xEraQ4HqiiNqYngjjdI1Gy4I1wSJGWRpM04QcbQUYfZcEiTTUhpgZ&#x2B;RnyudzcTFiTxwBmI2&#x2B;hHZ/wNPfYjuBlrdkcmnDcruTZRJRGZ9DTMtPj5AHKcfwI0g7uZQf3AkKCRzJY9AxsMsjVzbtcy12AzAhPcrXZi63KMv2MvtBtszVIEa9ZI5XBWruxIa3AR3JFi&#x2B;xLzvuBGv6kRaEvmI7r3EQr/QZEtwTcru7iO9gIItcD3QEaRHH&#x2B;Zb&#x2B;gu9wJUlN2SE3Zle8WRJsAhMjfJbwL8gTnckb/kVgCejYewsnuHC9wDut16E9W7htJkfaAEwrMgbfYAJuSZ4F&#x2B;4XZgGk9iWdmOfYOd4ANKPzDcWJeNxd8AV77EnsONyMCy1sR2YsGAkOZlGXHLLMAWfQjte4bTcDdb/QAmSbbcWD9ENlPrcCz6sJrgk7wyTG6Arl2UEEyt4EtgG/USm7kbhyw3NwD7AjaDd4ASJJO4nuBWJbs&#x2B;STF3uLALqLke4XZBvewEe5N7C62Q9AI09jLbdzTiZM1QgHmi0E8yiWyOIuSd22BXV/Ukm95I23uR1d2Bpten0Pkn9Mnkqcz8LmnZzy//a/VuWqnsng49P8AE&#x2B;s/NLhHzF&#x2B;lxydWc&#x2B;DvP41NM/q2uZHEb7J4jp/9RtaGcay36w59NONRT6v5Uex&#x2B;jScd4GrZXMJx5MxRVPtUj86do8wpbpqVXZo9zMRVD0kTl/ZvSsejNaXls1Q5pxMvRVS/R0pnO&#x2B;54noXOU5/ofRs9TMY2lZetSod8OlnlOYPm1UYqmHlZ2lZ7l5Mz3LK2b&#x2B;pigxF5CY&#x2B;QFXYSRewl9gKncJyABV6Fm3uTm7LtyAn0LxMk/MW5&#x2B;wF3UlVzKidi&#x2B;sAXd7Gk4vHBm5ZAvr9xF4kid5CjlgVPhMJyLdxPqA3dnYL0RL7N3NO74Ao4IpShsqXcCz6/UbOYE&#x2B;g&#x2B;YH59Vl6Zjqf91VD&#x2B;RrC/2avwjGrT/ZeYXH4VX5G8L/ZU34RO7KfsR&#x2B;/Bv1kkvf7De8jaSsR&#x2B;rFg3L/IgFUBu8kU7IXAsXJxJZXKIBKnCnsda&#x2B;G/xQdE&#x2B;LXiJmehOg9A1vOZbKYGO8z1DVptWHkKcXCxPw6sFYlceeqYf7Kaaa9Tsquqmih1VuElLc8Hy90T4w&#x2B;PWi/ENkdQWZ0HUvD3r7U8y9G07LY1CzuQwsHBraxvJTdqtYXndnDxFLTZR9AdQ&#x2B;JfT3TXXegeH2pYjpz3UdOZenr/C/wACimutN94f2OpPHX44c14L5vNall/AjqLWum9NzDwNR6my&#x2B;Jh4WXWInFSwlU/NieVym4SbThuGeqa/4j&#x2B;NHxd630xnvAvwuzPTK6a1L9exuserctVRhYWN&#x2B;FXhYmBgYNq8dNVuXal&#x2B;VfPsHpb4POn89qeD1X4/dZ6j4g6vgYn4mXo1lqjIZSv/AMnKURhrfepVMg8NqPXuX&#x2B;MXwl6b606D6Q1fJZTLdeabmaK9YyywX&#x2B;DgYixMXHSm&#x2B;GqfMvNy1Y/P8dXTGm&#x2B;I3Teg5HpjxZzuma7msTGyWiaXoteHiVar&#x2B;s0KmqmpN2w1SvNVWlalVdz6CwsnlMtk1kMrl8PCwaMNUUYVGGlTTSlCSStHoek9DfDX4I&#x2B;GvWeZ8QejOgcplNWzVNdNWc89dbwqanNVOGqqmsJPlUpFyPaelNCw&#x2B;lultM6Yw8V10adkMHLU1vepUUKmX9DyK2DukSeGyDjpyWUws1XnMPK4dONiUqnExlhrzVJbJvdpXOV24I4HuBYlfyHJL7jsAiBxuG&#x2B;OBNgFoJzYN8kb9QNLeAt7GXBZ9ANe4bW6RlMTAB25PetEUaTll/5NP5Hoknv2l0/h6dgYb/w4VK&#x2B;wH6FdWKpW8hNQFEe3YDSadypzuzC9Cp&#x2B;oG01sJXcyVPuwNbOWoEwlciqasxNmBpMs8SZdSW5ZT2YFngbuETzTZhegGtt/qEkmRP7Fh7oApKpdwkVewGWrwkWO5eR5VwwJHf6CF2LCSkscJAZi5UvQsL5lSSewGfLLuiumLFheoS5X2Ay1cJM003cXjcDMXgvG3yKl3RUo2AkXgNWsWIVkVKNgMpehbw4L5ewSb4AJPkexVM2K0&#x2B;wEtwWErR9Qodh6P5gVe4&#x2B;YlzKUiIcwA53KtthyAC2uypd2QqXcAyq73FlwIc7gW/8AkOJn6jmIL7gLgAAVRvIQT9AKp377CVMfmS8QyxwATvcQ5/MWX8hzCe4BhS1ASn&#x2B;ZZ4AivzYq9rhWn0G&#x2B;wBNvgvoRbQkUCwP6uFIANdx8/lBN92X3ANAWatuL7AIEf1Is1uI7gElMhyIX9Is3mAJt8i3Vx8i2dgHJItH3CXEF/qwDcR6hbSXkCW9rD5e5dgu0AQQUAI7AD5gLF35IVRswGxCq/IUTLAW4Ef1Ah7wGmAiCF4uw0wEWiS/LfYm1luVWAjVypevNhvb6hJ8ID2ppzBL9zUXt2ENHKMQ91YNQpRal6Ed3yQZjkQ2V3c/QnuURen3I03MmmpW5I9QI1OzI16l9L7Bzs/kBmpXgXLtyRp7iBHCsTZTBWk9xEvkDLuZaW/5G2uYMuCjLtMCEVww5/wAxkZ9SNI04vJGoAxf7kiLm9lBI5YGVtZhpTZlj52uFtElyMsnzRX6BqQI7KTLb5Zpprb7kaW6AyyObQV&#x2B;hP6uBHZ7EcO0s01HJGp5AyIi5X2&#x2B;gsn2Az6wGuIKRy7CZE53I4blmnfYkTsIEqXM2I0V3cslyiX2QduA0NuSCPfzMOU7lngiVv5lEvs&#x2B;RtyNnYbuPuBGoJ6IsgCcw2SUVw1d/QzF5SArfJHuG25ZABNykfeQD5FmoYhP&#x2B;JG7JtgPN6htd/oSXtH1JyBZS4E2vUT5hu4FlbElEZJbcuALPqGkLoQoAlW8SLcFd3YzzdAL7MT6jiGSQK/WBYkyJ4kCtp8EkN9yJ2tIFnsG7SS3YkzZ/mBZngnqvsJu2hPqA9vnYVN9x6QSr0ASrsSpmCNruSUtgNSvkSSSH2UgJ7BO0yRO0/wAAn33AsqbCYUu5mbcCQLNrGXG481tyNruAe5iqVubb7d9zFV9kBmWlcy6uWWqFY422lD4A06oR89/pRsp&#x2B;ufBZ1VUlP4OLksT6ZvC/mz6Ada4Okf0jGV/Xvgw65oSnyZDBxF/9OYwn/A59LONTRPnHxclmcXqfWH8fpi8hVJ29DM/sok&#x2B;Xdnu42ejiX9f/AAazlOe8Iels7RUqqcXp7J1prlPBpZ7LMs9E&#x2B;GjOPO/D10TmfNPm6YyUSuFg0r&#x2B;B7yqk9j51ejlvVR5y81XtXLTbkrcW9bmZl3LM7nExaUsSpMpxdcFTtt8gLLiRKJMbbC8e&#x2B;4FsmWZIuyEyBpejChQ2QcAWfX6Fm3qZLNwKr3L8zPErgs9&#x2B;4FT4ks9jN&#x2B;OxVKhbAWWXgyvRlAqcDjyktGwA1xzbkvsZ9UVVPf6gaXuF7kXuWQGwFhPoBwar&#x2B;1pmOo/3VX5G8OPwqXtYxqyX9mZif/Bq/I3guMKm/CJ3ZT9iP34L/MSGH6FYnsRjgAFYIkvsUBPAY24HyAziU04lFWHVtVTD9mdc&#x2B;EPwn&#x2B;BXgdr2a6p8P&#x2B;jKMDUs15087mMevGxMKiuqaqMN1t/h0udqY4Ox5G4EVNFFMUpJdkg5s2GvUX5YFcbE29g36WJZAJuLO4twGAvN&#x2B;XwG72E3kgFe3b5i62DdoD2AjsBJJSsBbkbunAfeSS5aaAXexU3sSahL3At0Ljf&#x2B;QSkA77HYOWXlwKKY/wAC/I6/opdVSXLcHYGHPkpS/wCFfkByKZsWP6Rml9zU&#x2B;oFUq5U5I7O9/YTD9ALtdlkid7ssgVibyiSANTPImbyRb&#x2B;5aVeJAvMeb3KkSyvHyKogCp9zShGaf6sai8JgVNMquzLdzSsAV7NBKQr2G9vMBUkErWUCNoLDmwEhzsIk0qe0iPQCJcehYCpgqQGfL2/IQ3uagKewGUlwaSXYRb91&#x2B;pYXIEai5XbYsRMv5khpxNgJDCU/zkrVrhJp/5gWY5I5mYLbdfMAEhEvbgKexQIu5YCHIAoSvcJdwHuPZQFNoZYTQDe9vYrcchJbsR2YBW4KQtwCLDmIHIS4YBegtvIlMReEA25LKHomLtzADfgL1QUCUluAXZ8hKHMFvP8BDANMR/wAQ9ZEcgUq3lESLABWQUTMDjYNLdIA7C83HsLTHADe7CiLiFYK7Atm7oqs/ci7QWe4ESgK82KuZHMgFdXfzC3gic2g0BPQX9ixaBCSAm3qVjcbbgAiepQAAADgexQDExxAXYb2X5APZFt2EQ4SEPkBC4Jxx7mt7p7k3UATiz&#x2B;4izuVT9REKYAi9ytt7fYRyLN7gLW/iEry1sNrplVnuB7XF4XAjluwpUXCXzucgkQZaubac3&#x2B;xlgRojUrc0SPQDLVvbuSPU016SPKpsBlpbsk3NNJIy53KJPP5E5LEPYNeV/wAAMwhAG5BGRzsmaJUmyjD3hEieDVSh3IBInngjUuU/qaj0JCGRlriQ0VwtmPUDMQZaS2NOCVAZa4jYnzNeqRGBGpUSRrsVke8lyI16kaS/iaahzJGlYZGNhaYVvkVxwPkN8DLS3knql9TTUoloAjI2uWWE2QojiSVJ8FczsTa6X0II57DfgNTsw4LE7CCASb2KI1eR7IvpySZsiCPckle8MjfqUHfYm7mSjfZkEqXYjluPoHKE91fgojUbh9xbkgAnuH77ibgL7ojSK&#x2B;6JfaQI&#x2B;0EZWmnsR3AfMjfZjYONtwDMzO7sX2I4V4ANl9IJN/8AMifqBXN7sLYkifUACTfcTyA59CTa6EKZZF62ArbHmvO3oSWSbAVOFYT6wR1Plkm0ga92SVFmZlbsspKQKmmg3CM&#x2B;YNz3QFnt2I2os0G3F2zPmgCuruPNG0SSfsRtS/uBZTY83czMok8yBuexl1NP8iefgzPEgb80RcnmTUWMySXDkDbqUXJU1x9zLq7GXVf/ADAVxMnFW1c3VUtpOLEdr2AzVWk&#x2B;Dqr43cktT&#x2B;EnxByrUx0zmcRJ96KfP/6TtHErU2Ovvijy6z/w49d5Hf8AF6S1ClL/APx6zkszi7TPnDO3tXE&#x2B;b&#x2B;KvmlsJ8M4qanCZumqXue9zh6CJf1U&#x2B;DjOvOfDB0ViupuNEw6Jf/K3T/A4/iC8dOvvBTXOn9S0/w5wdU6YzuewMnrWpPPLDxcpiY2PRg4floafmU1p/Jqx4/wCBTOrOfCr0jX5l/d5TFw//ALnHxF/A5vjYpdXw&#x2B;Z/NUtKrLaxpWNTU/wDD5dQwHP0Pn&#x2B;qjGqrjzn4vP3Yxcq9XbyfM77Gp7s/Dqet6Z0/o&#x2B;NrusZ2jL5TLYDxczmMRxTh0JS6n2SV5P05XNZfO5fDzeUzFGLh4tCrw8SiqaaqWpTTVmoNZg5k/rJe0M46cSmqnzU1Jrumaltz&#x2B;YGla6YlEmC/szEgLtQVuFcluZFokCpt8Cy2CfAXcCz6BMm&#x2B;xdgLPIT/alECAvuVevcifDKrOwFll9iLuNwKNt0BYCx2&#x2B;xU/UlhK5&#x2B;wGkWYUszeW1aS78AUvzIrltx3A/NrNX/urMOYjBq/I5ML/Z0qeEY1hr&#x2B;ycylaMCq/yNYc/h0/8ATaCd2U/ZhSx67C3YhWI32EeoI5mwCbiVsPSQ3CAvE7mW1yi33bJMgVVXsRtbchP9qzDf/EAlRPqRbQNrobxYA4VgoC9iboA7CQ16kAoIxPIFngWaJPYSA2dg5jYluLFm0tAJT3I9mvUq3DXMgTv5pC8yWxd7wZlcLfcDSd9tgmzKbmxU0By5enz5jDoT/exEvue90bL2ueiZNzncD/51Nvme80VJJBezmTUbFTfJxquOTSqbc/kEamSzPJifYvmmwG04d2WYf8ZMKp8MsvuBtNv6FMpzv9S0tbICxbcsfciuFfcDTS4Kl3RJmwTA2vcvuuTKh7Gkr2Aqvcq3Iu7ZpLuAW6k0r3&#x2B;5EipICpFSkUlSgCJN/wChXT&#x2B;ZYL7gZVMKC&#x2B;WeDUJO7&#x2B;RXS3/EDHlXNIVKSg3HqvRCJfAGFSlsVXNRAaSX8QMv0BfYkXgBEBKC78C0gTYGmm3YkcLhgTgsRZl8vZDfZ3YEW0QIa9ypdu4hJ2/MBzf6hrZBK1rli0AGu5IUz3NQSHFwF2VIeXsEgEBFsJT4&#x2B;4Bei2AldwoSkCqeQt9xeL9i8d&#x2B;zAjTiBOzK0Rrv3AqhW/piIdhCnYqnkBfZEcMvoPmA3CQUbl23/MAv9ArbfmEk1JbL&#x2B;YD2YstpDXrI5/iBONpKknv2Cc8blav6ASEwku/0Ckt&#x2B;wD2/IJOZQqXAh7fQCTDuipy7Bz2HsAV1uUAAAI7oAPdBqHuPkAFwvRFVnYBHqSPQsLugBPdlDUPcPtAAqaRI57lW9vmAs7QN5ExeAmkmkAdoF1sN&#x2B;QrcgEo3mxUo2Q&#x2B;XzCjgA0xHA53KBm5Ur/5h33YTUynuB7ZFrCODTXMkaUQcgzCi4d1sWysyPa6AkEiDUTsRpAZDK12ZGlP5gZjt9A0pNRe5L7MDLUWRlzwzbp5MtLeAMud2LvgsTJHfkCEmCwyRw0BlkNQlYQgMgsTsQCPa7I1N/wAzRG090Bl2ZDTTjsRqC5GP6gjnk00&#x2B;Cej5AywVz3IwI1PP2I1Ln8itTaAOwy1axH7ld&#x2B;PoH6gR23I4SDJMKz9iiPn&#x2B;ZGrS0VwuCO9wM3iysNlv7FdrIkMA3FySVzMEmwEbhwzL3LVBJ4S&#x2B;RRbtRyTd2D9FwGnEcgSr3&#x2B;xHtsVw0RxFwDUkTft3sUj7ASW7B9xPDgRIEm8Nk&#x2B;ZdnP5kKJdD0gMjnhgOYiyDUk34HEgJ4IRuQ36gJnZEbSUovHyI23YA29jL2K2&#x2B;WRgR&#x2B;gm0huCN/s2fIDzLkszeYZPN6Emd2BpuN2SeSN8R9RMbAKmmRwGyezArcXMzDuriVF6vcjq/0kCzHIm/mRl1JzMib7gWWRv0EzczN2oA1LQmxJfdEmLyBpsjZHVYjqlgV2v2I6o5J5oUkcAV1dyOqeSOq0GXU0Bp1QR1uNzLqW5HXHAGvNBFWY80onn5A26zDr9TNVd7HHVXw&#x2B;4VyVVvc48Svj8jFeJPJx4ldgYMaq0wj1Dxqyy1Dwm6myMSsXQM5RHvgVo9pxMVu8/I8J1rla8/0pqmUoo834unY1KSV3NDRyURiqJZRtL&#x2B;Gaqi0clVTmxnNU1YOaxMKtQ6a3S0/RmFWz3kO8icv6Y/o7dQ/XPhU0Kib4GZzeHv2x638tz2r4uOmta6z&#x2B;Hbqbp7pzSsXPZ7Ey2Fi5bKYFHmrxHh42HiRSlu4pbS9Dr39GhnfxvhhymA4/utYzdO/wDzJ/xPoXDrTiVPujwevjl1lz1l0t7&#x2B;9V6uHO6Xl&#x2B;pOk8XQ9SwZwc/p9WDmMOpb010eVp/JnSHh346614f&#x2B;Efhf0XltNwc/q2e6lfSudwcSt0uinKPFwcXFmJTVODTXG145k78w8RPe5819LeHvU7&#x2B;PLM6VqOlY1HTuh053qXS8zXQ1h15nP4eDg4lNLiG6aqMV2mPOajidv/D9lem9P6c1nTulOs8zrOWwOqtRpxFnG/xMji/jN15W9/LRU6o/5XSe&#x2B;qrls&#x2B;dfC/p7qTqDpzxO0PpLxKq6T1HLeLOdxstqtODh4lKbpwq/w6qK7VU1eaGtzk8T/FrrbX/hb6uWu5nC0zq/pDV8rlNXxtJxKqMN4mHmsviUY2FL8yw8XCqVST/4mnsMD6I2cMW5Zw5LF/FyuHjNy6qFU2/VHKnwyDUrcK3JEPkBpPgJvgif&#x2B;pZT3UALblTTVyKNl9wruALxsFLYlRCG/AFXuVN8GU777byaTgDSV/5F5Mq7vwObOANSFCMpxZ/cvo3IFXqWbQvoQJgaV12KrPYnEfxCtb&#x2B;AFlSUkytyyBwar&#x2B;1pmYSW&#x2B;DV&#x2B;RrD/AHKZ7GNUvpuOv/Kq/I5KP9mr8IndlP2I/fgSOQJKxT3YV1Z7lI57gHvE/Ij9tvQXVl8gwJK5uJfYNrcTFgF&#x2B;4nkeg9wIA0AFgPcT3AR3I7CeZHzAJsXJd7orccgN3sG4I4ZFPIFT4DcWC2s&#x2B;SOHsBZFnZP3JNoDa3TArcPcjYm25ABVP0J8hcDmyLf6/l03/AL&#x2B;j80e7UVPuemaNTTiatl6K6U155h&#x2B;h7hTU1wF7OelqdzaqXBw01y7wa8xUck3gT3Mqp7kkg5FUu5ql&#x2B;n0ONOFZmqKo9gORNPk0nOxxqp8pFVSYHJK/0Ev/ADZlP0LSBulvgqd9&#x2B;DKdrM0m4sBqk0vf6GUapVgNJTcqkKxVtPYC0s1TYylFipegFUN3NLbYia3aKmBSrb5k25GwGlt7scXZJsVf8SAqXoNvYJrlBPuAS9BFygDKSuRLlM3HYkRz9QJDY8qLHZCAIrcBJdrcl5mRupAWYSfLL6yLsCKU7i0lgJNsAkWNwkmGufuAS5gkFFt4AnogtzUWn1IvVcXAcK4j/Q1urbEjhgSHGzKrXdo9BFnb6jiQLbYpPcqARGxJScFJUluwFuCwTZT9SsB7AIsLZgEu6Cuy/u3a&#x2B;wXaQJ&#x2B;65LPYsJMkbXAS&#x2B;V/mXj&#x2B;ZElaGWAHeUNkRSnt9ix3&#x2B;gC62C3CvZyX2QEQV0UQA3AEAC&#x2B;xPcseu4CF3D77j1VhERf7gNiQWyvA5ARwFHIjhr2Hf8gKoVnuE5u&#x2B;wlT/EU9wDSdwknaREDd3YDfdbcBR6C63XsL8ceoBWfYeuwvMhebj7gE&#x2B;IFls7exbrYkVdwEpbFV9mHtYnKuBdxuIS3CjhgHd27lTbaaDQtNwPbmoqhGXY20lsZfpycgzE7pC8FagNJ7gZdt&#x2B;wajnkuzmBfZu4GX7kLfZ/kHPKAylGw3uw7XDSfAEt6IjXYvt8zLfbgCNTuRq2xWLxsBmG7QT1NRaWRqAMxe/cjVpNQNgMxKlEfq7lc8pEcTCAjfqRtbyWrYl&#x2B;F8gI0m5ZKi2VkyQBGvQkPtBW1yyMCOGRrsX5exG/8wI/Qj79i37kfr9AI7OzMu2zNOeTL3goja5Ik1xYvNyRN2uSiQ3uiNmolyjLneCQI2GvsHdbEt2AS3v8rElclbUWj3I7u35lEZl7/Y0yQnYCOHaSN/0yvtxBHzYCesBtgARtq0fcjbvJXG5LCBN/YOOA9pI4RQI54K3BG5lIAZdxDvIavADbf7kYI2NwhLgia3YbYmVcdAqc2SI3FrB2e5G0tyg2RuEl3I44TDjf8wHFyB1OIIwEwhtuSbwSUwNSRtC7Rlvn&#x2B;IFb9RMO9rGXdiZA15tzLYb4kiafICV35JL4Dc8kbj2ArqfBJb2e5HUG55As8t3JJHO7RmUBpty5I6o5JJPNwFadTXy9SNmZhSx5u3zCDcEb9Amk5Mt3Cq65/wBDFVQdTgy2BW43MOv1FVXBiqtbgwtVZxV1wtxXXK3OLFxYcpBcLXi23OHEx5lM48fHi/8AE/Fmc1W3&#x2B;zU7djOIZdHNm9QpwqX&#x2B;1eDwWrazmceirCw6oVVnHKOXOYtdfL92fhxcJ1O7LCdXyh8W36PLpbxXxc3154U04GjdRVzXj5WPLlc/V6pf7Ot/8SUPlcnwT1r0P1d4cdR5jpLrbQcxp2oZaqMXL5nDhx/xJ7VUvhqzP7O4uVUzB1x4/fDJ4a/EH05Vo3Wujr9Yw6H&#x2B;o6ngJU5jK1d6auV3pdmdro&#x2B;J12MUXN6f1ht2tTNO1W8Omf0Xmf8Axvh7zmVqqn8DqLMJX2Tw8Jn0rh4nJ0v8Ifw8dYfDT03r3RXUucws7lcbWXmdL1DLu2LhPDoU1U70VJ0w19zt&#x2B;jGudVr66K9XXVTOYmWtemJuzMPIUYr4OZVU1fteVeaITZ&#x2B;DDxXtJz4eJxJpuJ84fEJ8P66f6S13qDqjP4uf6Y1DxOyvUWv5PJ&#x2B;ejEwtPqwqMHHVXkctYbSxLf4U3wegrKdDaZ4ceP8A014W9b4&#x2B;u6JltK0rN5HNZnUHmvwow5eHTiS3VTSqElO0JcH2lUqMXDqwsShVU1UumqmpSmnumjqTxO&#x2B;GPpmnw98QcDwp6ey&#x2B;T1Lqzph5JabgKjBy9ePh04jwq0kkqKnVXDezhdnIdtdP5j9Z0LJZiI/EymHUlM70pn7aW&#x2B;WeK6Rw83luldMy&#x2B;oZerCx8PT8GnGwqt6K1Qk18nKPJpgbTm8hNt7Emdip&#x2B;sgUJkn1&#x2B;pUBeYKnSRRAXuBdn/kVOUZUtQkXiALtyJ7E4lFtxYDSaHmn5GUiwBZ&#x2B;2xXb/AFIrMqaauBd7plViKz3KrAWmxU3yRP0C3t8gK7LcszsRN7FV90BwapP9nY99sKr8jeG/7un2RjVGnpmYaf8AuqvyN4T/ALun/pRO7KfsKF6ASisR2Jt7htT7Ecb/AGATeUJS2RJvIbnYA/YT3Yc7EgC3XoTgrJ8gHrJPcTI9mAbjcW7jfcn3ANrcJ7KSXmCzwAdrL6QG/wAyX7&#x2B;4mVL4APstvQWFkxMtQgDfYjAewATARNuQE9hIkN2ATtyG&#x2B;JI4QuB&#x2B;vQp/tjAf/M/yZ7dS1B6l0/TOsYLfEv7HtafCYjI5VUu0GlVeH7nFTV2NKq8yUcvmDq5ONN8Gpf3A2n2aNJuTjT7/ACNUuSDlVTKn6GKW&#x2B;5qm&#x2B;yA2p3auaS5Mr8jVMyBulmk7wYT5RumdgNLc2pa&#x2B;Zmm/BqmeX9UBpOCr0ZlKreDSdXeQKp/mVEX3KBVBZ&#x2B;Zlb7lTfAGvMwRO5U7gWeSq6hsiKtu3qBpe/wAglw0Tb0LPZAVOF7hESexUwLZvYQuWBC&#x2B;YBKeBFpC9UVXukBPLaSR6Gko27jZxIGYjgROxpORFoX0AykVpTYrVnHyD22ARe6G2whr9lMbboA0tkhE7liL8kiwCLQWO6HIhNRwBEoUsb8lccob7IBz6D5ljsiR3AK1pHoWBHqAAgAL8CI5KkEpTgAvmIa3LFhEdgCXz&#x2B;RSerXuVeoD0&#x2B;gXYWHZgOI3Flsh6F9ZAivwXcQIcwAAakQkwJdblTHIAF9CXLAEKlA&#x2B;QhrcCptWn7Bu0sltuCtpu3YBD5/0CVr2Ch2VmVNR/mBI7tiIe5YTuv9REbfICNWDdo&#x2B;oid3JUo337gFvYJPkLcNKb9gETeSJpMqhbIbOACT&#x2B;QEMoE8oa7FHMARq35CLQigCeW5YAfoACV7MRYsAe4VJTZGWu5puSNHIMtPuRq9zXM2I5f&#x2B;QGYJzCNO/JIAzZXgjhuxrdXfJGnKAy95I7Wjm5qO/2IwMz7kdzTUOSW5AzHYlSfY01ykGBlxeNyOdn9ivuSHtawE3uZvO1jTh3RHPAGZae3uHPBbkSi7QGX6k23NOE7uSP0QGXvchp24MtQ9gJ6klLYpG1O4EfqiOxZa3fzI0p&#x2B;YEb5ZH6cmnYy1/mBGrX&#x2B;ZluTT7wZagCONv4EtG&#x2B;xXtf8yNPllDdWIyvvJAMtpciY5QfuZfcCzC7&#x2B;5H6hy&#x2B;A2BH6E9Ckb7wBGlzJHLuVtk4&#x2B;YEb7klcspG4u2UG&#x2B;SPfcrt8zMLugFiOBZEb5EA7ckd3tsVuFK4MsCuGpRHe8CbGXDuxAvozLlPeCuUR7QrAJ42I9huR9pKDuRuHuGRwAmCN7XEkm2wCbQTzIOeER1f5iAlSnuSbRYNzuuCMoraSIyN8ehG3uBW5ImuHuRuLQG1wgHmDfBCXAs3sRu0ySraRZRcA6rcke0bhuYSJNoAs&#x2B;pHUg33MymgDqlWRJU/wABJJArqbVyTFhPJmp&#x2B;gFbmURtO6I3FyNpBSY2M1NzK4I6vUxVXwBaq&#x2B;Djrr4RHXNzjxKlFgsGJicI/Pi4vEmsSvdHBiOdywsOLHrbTg/JitzE7n6sSnzLZHBiYUmUSr8deE6rtHFVgy7rk/bVg32MvBTvBcph&#x2B;GrLTfymXkvNweQWDLsjeFlk6tzCZV&#x2B;PC0ujEoeHXhqql/vJnhNb6KzGCqs3ps1U3bwuV7HueXwElak5K8BRDRw1Swl1Wq68Ory10tNPZn6MHFvdnuXUPR&#x2B;U1Wn8fD/usZK2IqbP3PTc9p2d0jMvLZ3CdD4fDXdMwR&#x2B;jDxF3j3OWmu25&#x2B;HCxeT9GHibN&#x2B;wH6lUnDN01KT81FfqclFa7AfoTT4Krr&#x2B;BxU1StzdNfqBtuHNMFTMqp7FTf8ATA0L7CfUJoCvuJXBBwBr2gK/qhJf5cAWBsSLQFsBV6lkiCfYDa3CjYifBbzLApU7QSAoYGp7FUK0md/oaURd7gfn1ZP&#x2B;y8xH/g1fkbwnOFT7GNVb/s3Hj/wqvyNYLnDp9kTuy&#x2B;403HzDbSuxLVpI2o3KxOZ83Ae3cQlz9haJQCVFiPsmHtMWDugJIT5DGwCSNq9&#x2B;A/6kjc79gD/IS&#x2B;Wx7ok/UCtuLsjdvmHtBGAbLyQIBL7iY5JIlNbAWXIlTEiUR3sBZI9iN2bQhubICzeBL7E3dg6o9QLxuSzd1ySb3YlW/gBXtLI2RwR1NqAPI9Mf/FqW1P7DPZ03yesdLOdVnthO/wBD2RVFjoOVVfU0qvU4VVHJumq0oDkTas/kapa2aOJVbuTdM7MDkRqlmaHybpa2SINUtLc3Sn9TKSbsbpTmQNUtbG0uDMGlPAGkoNJObrkyoRqmANJ8m1PK4MJpblTfAG0yq/7Rn/EVOANJ8epb3kiiJm493sBpNgT7bACz&#x2B;Vip8bEW09kX2&#x2B;wGk/Qq3MqUVMDSutyv35MptbFctqEBV/VykUyVAOCoQEAhpSXy8ERVdtQBflf3IoSsvuW2y5ErdASFZxPyL8/YW7BbgIuN1P8AENWlrYLiwCO6EcyVeoQCAVbwSGASBVuEBICSixYtISkCNAt&#x2B;fuXey&#x2B;QGYKlyI7lS5gCROyDUFhvn5BL/ADAjUXX3Klw/qPcc3YBWvIScXQS9CpRb&#x2B;ABqArbCPUsICCz2L8wlACwFthNoAbcFgJxyPYCWEFa5mQubgQu9lAS4gWT/AJAH3gbKSruLdvqAi8Ej/lZpNCZ590BHGzYif3UI59RxsBUvQu3BPT8wAtuLyNryFvuAiX6BWcIsrYj&#x2B;4CyQcyP6kS52ATL22LFyNzsh6AVAIe4DbcidijezAIBFXsBFexY9CFidgEMJS4E32Lt3A9vmNiMK6kfM5BHZwRpO35lqiJYvNwJUlHt3MtRc1HCIwJyR3cFaTRI9AJC7X9w0kWOCNcsDLRHH9I1a8zBH3Ay45JtuV7kce4EdyNQUgEcEV99i1LkkOIfcCQ9yO1u5pqNiNWiAMOSOyNNxsvmZqbAjT4MxaTT2sRp9wMw9oJBWRpzYCTDkNp7PYRbfYOwEqV9zL9TTjgy5AmxmDTXpsZe&#x2B;wAnrsG4I&#x2B;zYEaXYj9C1XZPYCNrlk2asWbwSOfqUQhb8EfYCS&#x2B;CNxdIu9miO6/iBHEb/INyHHBG/QA24sRw92mHZbkcuwEu92T5la9Ce4yI/cSJ5fyI7c3KDc8GW1yVv0I/RARt8DbcT6BvZMCONyNsO/8SMBPcjdg2iNqYUepRW/6RmSt9oMz6kB7bkbtYs&#x2B;plqJc8FB2t6ElpQWeP4EbQEbhEmQ3fcjcraShU3Nl9iSJaW5HYA2G7SiP0I55ATEwRthueSN3iQHzEkbU7kq8wGm4uRvhfIl5abFU8gHayIG1BJlROwCbEiNmJj&#x2B;Zmpx/ECvazM1OL&#x2B;hHU0jNVVrMC1VQYqq5glVTfJh1LuFaqri6Rx1VkdXcxXVcKVYl45MVVdyVVXszLcXAziOVJx19oOSq90YqiJA4qqZMVUPg5nSmieRhcuCrDi5HhQfo/DRHh2sgZcKw&#x2B;&#x2B;xyYeH3RpULdHJh0RsSehLkwKFa1jmeHJMGn1OdUSjjlg/NXhzupPw6rouT1LLvL5zAVdPFrp90&#x2B;DytWH6HHXhTLMB1xrvSWf0SqrMYKeLl0/30r0&#x2B;6PHYeL6naWNgU10OmulNNQ1B6p1F0Gm6s5otMVb1YD2ft/ID16jETixy0Vpcn5WsbBxKsDGodNVLh01KGjdFa2kD9dNfCOSmu0n5aK7bnLTX3A/Sqp2NL2OCmrmTlpYHImuCpcSYVUo0mBRJF7Bz2A0nwwnd3&#x2B;hNlcbsDSluGg5m6&#x2B;wQ25gCyzVPojJUBrnuG43InYrTYFSbuOZ&#x2B;pE0&#x2B;Cv1QGqSqbSZTUbGk1ExyB&#x2B;bV3Gm48/8AhVb&#x2B;xyYLX4VMf8Jxaz/8KzFo/uavyOTBj8Gm/CJ3Zfcbi95JC9PmJe/YOOWViRHoJh7bh2UNszYCtEYbI72kAyJuBtdoesgPdbdw/T8ye4swDiRPKDafBG0AbfJJnYN2kjvwgK4i4bJU5RJAsqRtsiTIlSBpO0z9CSuxJI2BXHcT6mW72fyI2nu/kBpNXSDZnzXmR5rzAGpfYja2kz5m&#x2B;YI2lYDVVRl1NGaqrWZl1dwPL9KOc9XV2wz2Gmpu6PXuk2vxcerlUU/mzztFTXJew5lU9lf1NpubHFRU9p5OShPZActPf8zkpU9jGHS2c1ND3ggtFKe5uhcx7kppg3TTDuBaV2ZyUriPqZS4N023YGku6KlF5M&#x2B;smovNIFXY1Pp9TKNJxv7AVWRaX&#x2B;1sRRvPsVQBtNOHI9yJzz8iqWBqVtJfdoyapaiGgKp2KjMyipruBpPlIqamZMp&#x2B;pV2ncCrumanuROHe3oX1QCWVNkksLsBpP19hsiW7hNxM7AaEkT7FAq&#x2B;pe/oRTNqS3T3&#x2B;YFlLdh/6DYdgDUoLa6ki/LeCq1wL7iAAACl8BRyBVf8A1F4mQpmNxtyAhyNtuS&#x2B;sWHNwIkp2n5hX3RVbdblmP5AZVt&#x2B;fUvovkLqL&#x2B;wurAEHtFyza4t32AkdmW87CV/kIuAj7B3vIs7jnYAtrhegavJV2AKBIAF&#x2B;WxBxuIAQNtytBK8gFA5lCJ5ESpAq/pkmf9Q1Fl&#x2B;Q9QHKsVN8/mTYq2uAXcsRySICiNgKPT0uJvt8xfaADU3f5Duk1It3ESAfqPZjbcMB3YU8wFe8BPsA&#x2B;ggKXcvoA9iTcoAkepYXYC4ACCwBAXiBxIEL/AFsL7CAJ7oqmLh90VXu0gIuPcrmLl4&#x2B;ZKvQD26lOFbgrmbsKlxt8w1ByCNeghLZlaspI0A9yNWsUic2uBlxwQtu4cxcCNEcl&#x2B;ZHfcCNPhyRq1ytpkajkDLRF6o01YjVpYGX7EaK47kYEae4UTCQfz&#x2B;hGougJxb5kbK7WI57AZ/afMmX3NO0ufuZAl&#x2B;VI&#x2B;/oX3Mt8JXAjV2mkRornkjAjXoZaSvJqpSjL3gCNrgjfMlfYjiUBG7WW5lo029zLAm8yR889hCqfccwgJU0ZK3JGA42Jsrirvb0JK9gDcmW&#x2B;6K&#x2B;yM1PuwHzDgrfKWxmXF17WAPcy77Gqn6bGXCcsBPdkb5n7CZV/oRzO24EZJfNJbyRtp2Am/AlS/wCRLqF6Bt8lDiCOOQ7El8AH5UtyQvoIvP8AAb8/IojfoRxMltEGW4W47hy5tbuRsOVxuS3cQDck33Qb7k33IDaYQcKOCOVxtyWMCP2I1IJzYoWTI17C72G6/mQRv0I7FbMVbFBu8yRtPYOrsw/coy3CI33&#x2B;pWpkm&#x2B;4Em25eZTRG&#x2B;xJgCy&#x2B;GRtbwJh7kqccAPMRvhMy6os2ZdXbt3A06ofyMt&#x2B;pJ7mKm1aQK6uzMursZqqJVUu4Cp9zDqbcJlqbmf4GamFSp&#x2B;pmqpcBuHPBhghHVHBHV2DbmYsIalAZe1ib2k07ktvAGY4TLEKPQQuxYAkKIY8kWSNQ&#x2B;Pmaj/QLljyfc1h0Rsi&#x2B;RM3RReIMahyYVNro5km1CRx4dPeTlppa5gwliiXYy6N7HL5Zd19COidjAcNWH6HDXhTaD9dVMyYxKL&#x2B;wHr&#x2B;v9KZLWqHVVT&#x2B;HjL93GpV/n3PStV0jUdEzH4OdwmlP7GIv3avZnZ&#x2B;JRNj8mf03LahgVZfN4FNdFS/da/qAOtaMVO5yUYk8weR6g6Ozek&#x2B;bNZKcXASl/8VN/ueHpxP6YH7aa7Szloqm0H46MU5qMRdwP1qpNmvN68HBRW43N04k8gcs2/wAyzcwn6l35A1uv8wvQK&#x2B;zL8wElngk8hPgDSfNzU2kyody0tsDScDZX5IEBpWU/mE21/InoyqpRcDSa4LC22MzLsy0tPYDg1hN6Zj0qb4VS&#x2B;xvBthUzvBjV3Gm40v8A3dU/Q3h/7Klp8Lcn3mf3Peu7v9Rw7BvlSLQVgkhk9yS2BWw29pI32FoaAjb7yG&#x2B;JDdyNyAdlIJPqSZUSBZcbokrntYN3kjYFTa&#x2B;hmYDfEEbfAFbjckp3I6nww3PsBZEvYz5rfxI2Bp1RsHVJlVcEbA15ryyOqHEmXVDMuviQN&#x2B;ZbjzHG642I61FwOR122I6mcbxEt2ZqxLbgbqr7MxViJLc46sT1MVYn2A890k3/AH9cu/lX5/zPPYbb2R4Do2asHGqb/wAaX2PYMCmqqyRRzYUvY/Rh0N3ZnBwWt17s/TRhqEBaKWctNK2JSlujStZkBWd/ujVME43dyrezA2nL/wAzSMJ3NIDV1v35NKEpMo0tgKi3cshpR/iAJd2aT5Mpzc0omANLuVQlZGVvKNJLuBVcJ3Cs9wrMC&#x2B;ZlT7ESmwS5A0jSizZEWmd4Aq3sVXsyb7oTEubAaKtySE&#x2B;WBXbcsyptHqFEymLdgKvcqc8EV7wVQBUy7K6&#x2B;pE1AmFv8wL5lw4EraCLeSradwKrCXvBN/wCZdv8AUCrcerJKQUQBVBbzJPYAWHEoqnaYI7cFlvafmAmU/uHMSxE7sOVZ/YBa9pDadhd3EQokCRHy9SpLZMXWy&#x2B;hXwvyAmykv5hbtIbuUwEpOIG/HIX&#x2B;guA90F/TEQ5XzKlAACJ3HsACsC7IB7BhqHBWgJbkKVdcC0TBXP9IBZdhdXgJDdRHsASkFv2vwIkBE8B78h&#x2B;o3tDAPtAiVdfUW5EIAHFuRuAJuVXuhCb2&#x2B;gQBFSa5IigIDLPoNgIhHYTAbkAHHAuLgVdxCW4StsEpWwCOZEQrlXuSGrvgAnaBFrMJRuFICJEW2C7SEuWAX5lVmWbsS&#x2B;AG97bEasxvugr03A9xhx3ERb1NQ3/kRnIMtXSJ8yvsTlwwI5diMoaAzdPb5Bx9StWI1PNgMsj9zT9dyO4Eh8pEatt9y3nYy0uwDZbGWlwjTT3MvewEb&#x2B;RCxz9yQBH7kcOyZWpW5I3QGXYy4i5tzvwzL7AZ4I1HBXbgVerAy5XBLxtBXEkcwBNtiNM1E3SMtdgMv3Mvbb3NPszLU3AjJu9ivtJlpcL3Ajfb5kqTmxby0hEbgYi0hcoscEiPT0YGWlJH6moUTJkCONpI24gt5gjAjvuZd7v7GmSz537AZs9g2xZKWgwI2t4I&#x2B;72KyNT8gI&#x2B;8exlv1NVWWxl92BHVy2H6IS4sRzyvdARoOOGG&#x2B;H9zLu4AO/PsR22fIq2mCNgBPBL8CblBtGXaVBW4I33&#x2B;oyI/UgDsgD7mU1tG5edjLtYA54fIbU2JMGXcDTfqTezZl9pe9yz7FEcwlHAbm4bt8yVVLeBkRwyN8JBxuyN2iBAkhvlgjq9OREiNv7bkYqqTRlwt2UHUlcz5luKqpMurs/oBqqozVVzBJtDgzVVLKFVS7kdT2klVSexlt/wCoGnUntclVU7mXVz24J5gDqUEbuSqqHdEmXsAf7SMNt7ldtjNTWzXAEb5m5lzwVvhE2CpxcjiLcFbi7De7AzE3CXcsPgqtaQdWfVDdpI15fUc3CJD5uaSCgtKvdBYkStJy0UveTCV5OWizMZJbw6YtBy0qNzFHucqXa5hKIqWyulw5NKlK0FdLjYwHG1MmKqVVbuctVLiyMulLcDhroSVkcNeG2fqdMoxXRvK&#x2B;gH48XBprUVI9Y6k6Hw8eqrN6XSqK96sPir&#x2B;R7fVh8NHFXRKA6pxsPMZTFeXzOFVRXS701K5ujFnepHvmv9L5LWsH&#x2B;9p8uJT&#x2B;5i0q6/mek6vouf0LH/CzVE0N/sYi2YCjEmHJzUYimGfhw8aTnw8XlMD9dNS5fByU1W3Py04nLZy04m0gc88egdU2&#x2B;pimpbI15m7SBr1LJmVv69ip/wCYG9rQObMilKUVO3aQLeL3KogzdOPuVON2BeCp8wQAaniSpmVEmlIHDqinTcdT/uqvyN4af4dPP7KManbTcdL/AMKr8jWHH4VN/wDCid2X3Gn6kbgNk/ncrEtSoJKQnlIjhPcCp&#x2B;r3I3FiT2YbAjYb/MNKZn2Mue&#x2B;wFbl2J8yN2JK7gVvuyO1yTa6&#x2B;obtDAstuGjMpie5G&#x2B;ALYjZHVa6I3FgK6rWMuuFuR1GXWBp1v7kdcWOPz8pkda/4gN1YlpZl4iOOrFi0mK8SAOV1vuZ/EOCrFXDM1YsOZA/Q8V8sxViycDxlEzwZeMu/3A5qsRxuYqrTbuZwMPM5zF/ByuDVXV2pR57R&#x2B;g83mmsTP4nkT2oo3&#x2B;oH6&#x2B;g8GrMZTF8tMxiw49ke15bIrCSqqXyMaPpWV0XKLK5TCpppd6vV933P1prh/YBRRSrpL5GqU&#x2B;AtzST22Aekmk27GWpvJUBq&#x2B;9zS2MqeDVKvHqBVK2&#x2B;RpXIlFzSAqNQ0oM07lmFDYGkaVt5MqEXYDShqGuCpEUO5pRNwCT4KrKAlGxZvDATChlQgtuwC/BYfqOynct5kCpFhcsigt4l/ICy1xuI97EmLNFvsA5mTSbM3myKgNL1RfciYutlYDXrPuVOxnayd/Uq3hAVNIckvN0XcCpwX0Ir8COALPZi3NxDm7gbq4F3hsW3TsI9Q0tgG7LPBPYJeoGlfdib3&#x2B;xLF2uBdrhW2QtwxvMgN9txxcqT7iZt9wIr3bHuiruErOADtshuLRKKBN9xveSyRMBxDgvqT3CjbsBRfYAAt7FT9Qh2QDsizD&#x2B;RFfZhOALxuHbkbMcRAC0y39Anbb3EbwLL1Aszb8hKHErkk99gK2HwyK6LtZgSeU9kVOSKN&#x2B;xVC5AtpG5Cra4Eu&#x2B;S2Y3YAQBuX5AFvKFluA94f1Ag&#x2B;YkbgPmVkK5QCC3iPzMrsW6s/oBVI3fcfMez4Ad7hbw2OGGnF0Aibr5BKBfksdgJHYrmYaDUlYGWm99ipXsX1SHsB7k4ujLNNuY7EfscgxVKsTZWX3NOeSQBn1QLEMPgCNXI3fYvBG&#x2B;6kDMNK6EFb4ZLdwI1a5GnyW0Ee&#x2B;wGX3I4K1tH5EAji7TMuFsba4Zhx35AOODL23NMy7AR/Uy4NPa7MsCOFczK9zcWM1TyBI9SB7kn0&#x2B;wBuFLJUpdyupqzRG4s9wMtSoRh7bm6nCszLSVwM1bSSFBWuGiONgM2iwZWlDUXI4SAj9jL2uV7ckdru4GXuZbvK&#x2B;5ojXIGWp2a&#x2B;pHcu0IVRFkBlkbXHyK7XMtOZgA2TfYRcnp33ArgjU2/MNtBsCVNbIyVw7kdgJtYj9i3jYy&#x2B;8AHO8mfWSv0MvaEvoActbmS32f5kAEsVwzLadoAVdiPtPI9I5sRuwBv1In3DdrEbUw2UPNJG5uuwbXCIwI2uUR3UsrfZmWuSBJJK7EZQbsZbtcNtcQRuShMEmbhzwR1LuQRvgjq4QbvYy3bYu4My3aAm4iTLfCAjnhEbTuG2vkZbtYou&#x2B;xmV6kbtH1I6gFVXcy97/kKmtjM8AVskySZ3I1Lgosr&#x2B;ZltTIb4TI/cA73I&#x2B;zDbmE0Zqa2/gAbIxdPaRyBGptHuUWHoBEvUsFUC0EzIkSIZWrwgt9wC9ipRYQ24LSoCrSvQ5KU3wZpUnJSnBjI5KFeUc1N7vc4qFF0zlpSSuSUaU8FgUU&#x2B;pqVEHGM1JzsYafb2OWJZHRvKA4vKuxl0OLo5nR6bEdHoB&#x2B;eqiOJ&#x2B;RxV0JKf4H6qsPtwcdeHxAH5K6D8ue07LZ3Bqy&#x2B;Zwqa6alelo8jXhPdI4q8Lj7AdfdR9F5rS283pqqxcHmlXqo/mjw1GK04bv6nateEnY9c6j6Gy&#x2B;fTzel0rCxlLdH&#x2B;Gv&#x2B;QHqdGNG6&#x2B;5zUYiiEfmzGXzWQx3ls5l6sOun/AA1KC0YnCA/ZTiPucqrfHJ&#x2B;SjElbnNTiX3A/QquZKqpuzhprtv8AU3TUleQOVPsaTscaq80OTVLncDa7fccEs2FAGk7TI3J87lVuQKjSbhWMqZsaXZAcOrONMzDcwsGr8jeH/s6f&#x2B;lHHq9tLzD/8mqfoaw21hpRFkTuz&#x2B;572n7mfVss8NEbfJWCAjcE/wgWeNiNrvAmVuRsBK4I77sjsiNtX9AK2p3I3K3Mt33Dbm4FdUmW53I3w2zLqA032QdT5MOqHcjrSuBp1RuzLrRiquDFWLFgOR1pzc46sRTJirE4OOrFibgcjxEnuZeJZ0rY4a8Vdzjrx3FmBzV4rXJxV43qcNeNDOKvGXOwH6Hj3MV5hK8/U3p&#x2B;jatq1UZTK1eV/72u1J7JpPh/lcFrF1DFePVv5YilfzA9cyWTz&#x2B;pYn4WSy1Vb5aVl8z2HSPD&#x2B;qqMXVMfzP/wAPDdvqey5PTcLAoWHg4NNNK2VNMI/dgZWLeUD8mmaHksnhrCwMCmilcUo8phZfyKyN4GAktjmWG4b7AcFS4/gYunc5sSmbL8jjqXIFpqTVzaqW6f0ONJpwzSbQG4NJWt3Mpybp3AX4NUhKNglGwGqVN/yNJWMqee/Y0gLT7mkos0Re25UvQCq1iprcJXCSmZA0k/saVzKVyqQNRy2WCKCpWgCrYsdySXazXsBV6MqjgnBV2TQFKt1BAgLtya9mZUbSW75AqmShAAVPlv7jgL1AK5VP9Mi3kqaa/wAgLCdl&#x2B;RV7El82KBUrSFvEhBWV0BVO7/MenIEqfTuBXa0hJIk9/uW8RPIDgo53EoBPoEPkALM/IqfCRkvoBq8OCP8AMbj1/iAcrngKW/NIbXAnj6QBZi4sufqFf1G/EgSYe5fRBLnkluwFLbYitsUBAAgBuVTuSfQAVtP/ADHoLTdBXqsBYSkfT0I&#x2B;xYncBMWCmIgKlzcqcbIBcX2j7hWUEcf0wKg/cRxcb3TAj9/sVS9yPYKW/wAgLbdIu6JLTKBHKvI9ykdgKmJC2AFHrI2e4bvZAHwhEIehAKmlwF7CfQegCGkWYUNkVMzItxYBbZfUt3ZoJWmOA167dgE&#x2B;hV7bEhf4V6F4v9wHJSJWsUAXnuQACTBrckID3NwuDLiTTiIRlnII77IjS3ZdhxAGWp43EcMsbSRr1Ay0&#x2B;xHEXNPsZauBOI&#x2B;xJl7lcfukm0QBJjkj7FJ7ICLv9COHcrV52HuBl3MuXaTTI/UDNVJlqxuqEjMAZatH3gm3BpqefsZdrgRkqteSsnOwGWnMQZdjTfKRGgMv2Ju&#x2B;xaqfUjV7AR3UMzEPn5FZP3nMfYCODNW25pmWBHbZNEqS2NWdl84MuwGW4I13NP2JuBhkm5XBlu0pgRzuRWLvzcjAMy&#x2B;3e&#x2B;xpmYTAzA2L6EbgDLbgnsWJ3RHHDAkpckngtiL3kCPn&#x2B;JG&#x2B;JK9kzLsBKnF4I24hle8uCXkCSR9yuZJUBGZbclatCUEfaADckbDI3NgI&#x2B;xG2V&#x2B;pHV6ASqqOSTcc3I&#x2B;/1AN33I2HGyI3xIEfsRu8OxX3Rl1diiNkdXAfsSp3EA6iNqCTwRpsA2nMEcTvsHd3XsZYEvsRu/p6ip8mW1MlBsy3fcesmWAdSSgxU3MSabsZqcosCVN8sy3G6FStYkt7sQLsyN8Mj3uR1KdwK6uCOqdyeblETjdgG3yS7Ezcib5AotuTkTMXLkUEUbIpO4L3LyQtPogLZhduB/ELff7E6ipGku8GUbpTTGRqlRujdK4gzRO8G6Y3gkq5KIsmctCXNjjovZnLQ/wDIiNU22&#x2B;5pLgi9SrucYqVtypBR2NJKbAY8qDpng3EPceVf6gcVWGzjqovLR&#x2B;h0zcw6d5&#x2B;4H56qDirw/wDlP1VU2ZxujiPcD8leGjirw21t7n7K8NHFVh9gPD61oGQ1rA/CzmGlUl&#x2B;xiJftUnpGudOahoGLOOvPgt/sY1Ks/fsdlV4a3g4MxlcHM4VWBj4SroqUOlqUwOsMPFnY5aMSHuea6k6ExcrOe0WmqvD3qwN3T7dz12nFafkcprdMD9tOJfc5acSIcn4sPF9TmoxFIH6qa77nJTU9j81Fc8nLRWn/ABYHOmu5U&#x2B;xx01X/AIGk13A0r2RqX9TCNQncDScbM0n6&#x2B;5kqluQODVmv7JzH/wAmr8jWHV/dr2Maz/8ACswv/Jq29jWG/wC7pf8Ayondn9z3tNzuRhsja7lYEzZ/Iy3wxU1vJG&#x2B;wFb9TNTI3aSebgCtpmG1MSR1JuTNTXewFdRHVxJh1PeYI62luBp1KLmaqmlsYqxEYqxI9gOR1masTiTjrxUlucVeMBy1Yk7s46sVRucVeKu5xV4qA5qsaGcdeM&#x2B;5w1435nG8Sqp&#x2B;SlNt8JXA5cTG9fucNeYvC3eyR5XTOjdX1FqvHSwMN81/vNex7NpHR&#x2B;k6ZFdGB&#x2B;JiL/eYqlgep6b0trOqxXRgvCw3/AI8W0&#x2B;yPZdJ6F0zJVLEzNP49a5r2XyPPUZeUlEeh&#x2B;jDy3KQH58DK00pKmlJKySWx&#x2B;nCy1O6X1OfCyylSjnowPT5gcWFl0z9OFgKJN4eCkznowkt0BnDw5UwadLSucqw2la5KlHAH5q6eO5xVUH6cSmWcVScyBwunv8wqexvyjy3kCU3OShMxBqlMDkptcqhq7Mps3S0/5gN9zST4REaSkCrvBUr2CRVOyAeVbPc1FmmS7XuVJ7MCq&#x2B;xUk0SDTgAvVFShBT3j0KtgCNPt92RIvH8EA43L6MJPcq9gAiALsCqzhFUEiFJVGzgC&#x2B;xSJzdFXdMBaSpcQGlFkIurAXf6Cz2&#x2B;giC72gAnayKTZWsE5s2BdrFuiKWVXAqVwonck8IqcWAqa7jmWiN3iCzcBK7lM8xPJpXAAABwX3RCoBK7ssS7kRVbkBHqxMoLeHwFaWtgCb2dy8kt5rsS5/ICr3FmBbYA1a7EC8fzCdgKCfMKOPqBdxMkW1xbgCotrEkRyALZ&#x2B;gew22fIBbW5Kml6E&#x2B;dwm&#x2B;7&#x2B;oFlTDQm1mJ5UEvH8ALC3FrpWJ6pFu/cBPL3Exu/sHCuRX4ArnhclmFsRKBxsBVFvsN&#x2B;CJ&#x2B;hbAPZlVgix2AK&#x2B;7C9wmoETsAe1xxsLCbgN7JCJXyF&#x2B;Sp2ugG3&#x2B;ojdonsyxwBVO8Ei&#x2B;5XsOLALbyIW0l2uSI2&#x2B;QD5lAS7ABsVwIQEXct39eQo7IqV1C5A9xi3LsZe0o27Gap2OQZ5uLzc1/Sgy0&#x2B;wByZal2&#x2B;Zoj7bASfn7EasWFZT7kfaAMvtJl3VjZGp9wMtE2sWPQjAjvwZq9zVXaDNTlxAEZGuxWRqbJARw7TwZZp7Q0ZAj23I78mmuGR73AxUlOxlv1&#x2B;hupXhGXLewEcbSTcrsS4GWu5l72NwZqtCgDFXqzLvdP1Nv0MteoGXG5OLGnJHtZAZckd7NFai0fcjQEbSuRlfsZq7sCVPsYavBtqODNW8sDLhEdjX0I7gZb4gnD4K0p2JtaUBO0p3ZlvuzUS7GWkn8gM7uGw13L8yW3AkKSNJFdyO&#x2B;7Ay47mW43NWmIIwMuWpRG5vJXPqyNt9gIyTOzG6sH6oCTK3I77lvsZbm4EbsHD2YqM37XAMjZW7GW2rMCMja47lbaVkjO4BuCO4fsZ4uAbac/cy2VszVv&#x2B;0AmOfuRtvkbu5G1MARu8EqZan2M1bzBQe8GanC4&#x2B;YZlv3ATd3Mtw/wCBXVJl1SwDZlh1dw3Gw6COYujFfqV7T3I4V4LkZblbmWbbt&#x2B;8YYjAkvYy24hGrOyRhvkA2CNhP&#x2B;kAHMETlxb3DbT3KENOWVEbhtCU2yBKXJVDuZlvgqs9yDSbKttjM3iQnZMQNz62Lb2MrsmXZx3AqSk2jMclU3CuSh2mbHJS1ypOKmNpN0v8A5SI5qIRy01KFc4KGctD5QkctMRsapmXz8zFLnZmqbWZhI2okqjYifBVMkFRYW8ERr2AjT&#x2B;hl023Nw90RpNgcToc2MOnho5nSpiTNVPcDgqojY46qIP0um0u5iqi7bA/JXh7tI4qsPmD9lWHe5xVYd5W4H468OHMHguo&#x2B;jMlrFNWZyyWDmYtXTtV7nsteHOxw14Se4HVWdyOe0nM/qufwKsOtbSrNd0xTiHY2q6NkdXy7y2fwFVTH7NXNPqj0fXuldR0Ct4tKeNl&#x2B;MWlbe4H58LEsc1Fbjc/FRi8yc1GLawH7KakclNSPy0Yk2/M5KMSeQP0Ko1JxU1SbpqvEgck8yzSfY40&#x2B;TaaVpA4dXb/snM3/ANzV&#x2B;QwX/c0W/wAKJq99KzCnfBq/JjAb/Aof/Kid2X3G3UkZbfewcGfNwViOq25G0uwbTMVVRsgK6mjHmtDJVXGzMVV8MDVVcGKsSDNWJ6nHViQgNVYj5ZirETsmcdeMlycVWNPP0A5a8WEcdeLY4a8c468ZdwOarHf/ABHHVjTz9zgrxuGy5bAzefxFgZPL1YlT/wCGkC143&#x2B;ZMKjMZrEWFlsKqup7KlSee0roDHxWsXVsfyr/wsPf5s9m07Rsjp&#x2B;H&#x2B;Hk8rTQuWld&#x2B;7A9V0zoTPZprE1HF/Bp/4Kb1f5HsmldN6dpiSy2VSqS/fqvU/meTw8te6OejLKbr7AcGHl0nZHPh5f0j5HNRgRCg5qML/AEYHFRgXlI58PAXCOSjC2RzYeGlwBx4eClwc1GFybpojZHJTh8yBmjDU2Ry0UPsWmng2lHcDPlM1UycscyZrQH561JxV0zuj9FaZx1UgcXl49TPl7s5HS3JHS&#x2B;z&#x2B;gGPLLaCXHf0N&#x2B;RLgeVzsBFCNUwT2F1uBulraxumZ2ONPlm6WBteiKls2vYlLS3Kl9AKr2ZV3QSKvUBfff5FT/IJTwE42AqtsVIi7N3KlcCx3Fp2CXdFT7XAsLYqU7EVippgPcqUXZE4sVOOACXMI0kt5uRviyKu8AOfzKRFQFTvYqccEU9/uEwLHpzsWEuCW53Ch7/MCi3b2CKgCmLIvaxEitvkBPHqITsLvb8h7IC8SEp/aUiZDu3IC2yvYuybRL7F/iA3LuRXclAK&#x2B;xbO5Cq7APs2HZyN9xM8IApVp&#x2B;hZI7qwUcAX5fcNpuy&#x2B;pON/sWyYD5F3/ANSU&#x2B;6E2gCsP1JLdlHpYJ83AsvzQkE3MEV3/AJlsBG7Sr3Kp5CfCDt3AoAAAAC3Sgf1YiHIF5gQJuEwK44F3YibVp&#x2B;Qd77AV90SVEthuRZuGBZXcTD3EW2f0L/SAn722xZ7khvYseoFBJuUAoLu5J7j0gCwp3CjkQu4m24CX3gtmtyRwh2Asrt7hKdltyN4kNWkCzw0Sy72LxFp7C7m4CE&#x2B;dwvVhTyyrawAFC9fmAd3f5CIQs7zyJT4QBN7tmlvciUq/yKu8ge41JKeTLk0/UzVfdfY5BJ/yD5T&#x2B;obl2&#x2B;gm&#x2B;4EdyNehWZdufe4BzEszE7mn7e5IYEJdlagAZanj&#x2B;JlzNzUN3gjmYkDLi6fYy22zTXYk&#x2B;v0AnGxCvfj5EaTAy4lz&#x2B;RGWpSTYA0ZZdiPcCVb3MtRsae8xySVcDNStCMuIjsbqhcmGl34AjmLIzUnt6Gnaxltvb8wMtehG3HyNP1M8/5gZcR&#x2B;RNjTTdzLS2AkJXRNy7KGRw5n5AZZHE7FczuZqtzyBHtuZ5mPmafsZe1gJ9w0n/ABFruB7bASqOxhrk07XZmXNwJyZcblfvJnvYA0u&#x2B;3cjK1O5JQEbgzPZmm7yZlNXYEcJxBH6IT3I2twI12JNoK2pMt&#x2B;gEc8Il38i8QRuLtfYCNzuiO9pDZG&#x2B;wEqfJG5EWnZkdgI3AblT9CNvaCeZzZgWpIy77CSO7AjXEk4LVKe5mr3&#x2B;YBvuYcO5am5JU4AhGyvsZbANxsZb7sNx7Gat4akA3wjLc2D9CPeJAm94Mvc03Jlsojjgc7wG3sjLjdAGRj3I/cZEqu2SpzMovrcy/Uoy7p/YyzVStJhqbDITPBJS/ig36QR9wE8CSPaCcbkyKCN8piY4&#x2B;wGpKrL/MynNwgNOdyy2rGXHcKOANqxpX3ZintBpNgaW5qlrsYTjY1S/Ug2m3ujkpfp8jipZuiq&#x2B;wHLSzlo2OKiTaqne4HLS/Tk3Tc46Ym7N0tO5hI5Kd9zStu4MJt8mlV3ZBrd/wKmjE2RpOXZga3&#x2B;YixE3wyuJ2ARJl0zc1PIAxVTFzFVPBzVK5lqQOCqkxXRLs7s56qbe5muhNbAfmqoXucNeG&#x2B;Vyfrqw&#x2B;IOOrDkD8deH6HBj4GHiUvDxKE6alDVSsz92JR2OOvDkD0nqPoJ4fnzuhra9WXf8AD&#x2B;R6x5qsOt4eLQ6ak/2k1DR2vXhen0PC9R9I5HWqXjUpYWYj9nFS391yB6RRiwtzmw8T1k4dS0zP6PmHl89hOlp/s1f4al3TMYeJIH7qMSeTkprT5PyYeM4SmTmw8SdmB&#x2B;mlrk2naDgprtJyU1oDOqRVpmYpe34NX5EwbYNKn/CjGqV/&#x2B;7Me8f3NX5Fwn/c0X/wondl9xtv79zLq5kjqUmKqysWq6lscddcGa8SDirxlswN1YnqcdWJezOOvEg4q8Vd&#x2B;AOWrEg4cTFtEnFiY6TdzhxMwuX9QOWvH5k4a8dbTycOJmHNmfq0vp3WdZaqy2WdND/3mJZL&#x2B;YH5qseOTlyGmalq2J5Mjla6lN64ile7PadJ8P9Pynlxc/U8xiLh2pT9j2HLZHDwaFh4eGqaUrU0qEB6vpPh9g0xi6rjPEf8A4dFkvnyeyZLTMtlMP8LLZemilcUUwftwsqlutzmw8uoiAPz4WVe6OejL00xY58PAtEHLTgSBw0YHp9jlowLnNThehyLC5S9wOGjBtZHLRhehyU4RunD4AxRh9l7nJThm6aIsbpogCU4fdG6aJ5&#x2B;xqmng3TSoAzTSaVK7GlRc15e4HG0kjNSRytIxWBwVoxUpcqTmrXJh0yBxOndJEdKjaxtriSNAY8siIN&#x2B;V/UkLn6AcbT5Ecyb8rgeWLAZSa4NKFeR5byIUbAaplOyNqpzLZhNcFTYHInNyzPJlP1NJ9kAS9S&#x2B;yCe8IqdpgCq&#x2B;wCkqlgJi7vc1ynJlX35NWVkAuluPZi72C9UBSqGiXKkpuBYkqXoRNzBUwKrgiSRQHsVSiF&#x2B;YFU&#x2B;xV6fQiV5ExZ9wKtti&#x2B;4ShAAAALDXGxYlQuSLsNroCqIuxC25HLkcwk/mAa7B8r&#x2B;IaCdgKmVehFtsWyAvzJPcTIAAAAt4KneSD2AsyXayIIlSgLMbsS1siN/wBMJwtwKo7ewnvFiOHJdgEymyTP0CuF7SBqXMPaRK4RlSrT9CsCpvdibzJObq4VgKt5gpJWy4KAmSOZKyOd5AsifQjvedgrbgUSAALDIrFSWwFVv4ja4m0CzQCfX5iQrOLCYuBbtx/EJtWgRyvuN3f5AVORKJZ8fYoFCuybF334AexVPD&#x2B;UEkJr3A0pkjsr/YuzgX7fUCJLn7FSvAZFvAFUKxV6kScRJUwGxSTbcAW/cu9&#x2B;SLt3KpbQFXb0Gz9yTcqTbuB7goaF4sipWEdzkGWk7pDdWsywkyRKt8wI0ZaNWi/1I&#x2B;0AZa9YJLd4K97/ADCmYkCeskZr3Zl22AzLbiA03ZFZL&#x2B;aI9gMwR7Qa35I3eyAzVdSZag21zHJGm16oDD9UR09zTRm0WYEcN2MvukaacwZqAjnuZZW2ouRgR3tH0JVK3K052M7AQy1wtzUmWt5Ay44IzTgy0twI5mFsRqCwnsRgZb4I32ZX6oy2&#x2B;wEdzL97&#x2B;5puLmXC/ZAlV3cy3HJq0ka4YGXKJdu5WrQvyI7XYEZmr1f2K2oidzLc7ARmbJyzcTsZb9AJbt8jMwisy7v/ACANy4mDLs9ytzyR90BHezMt8yWpSSyuBNmySVoj2uBl&#x2B;31I2tkWoy0BG&#x2B;wveSkbm6Ay5gy3F2aqV9jL32Aj7GX7lcbph7fkBnmQ3fcfP6EqtFwJVu5JU27thxwSp2Al4a9SO92Kn&#x2B;RGwJu4&#x2B;pltrb6orsrL3MsCNmW52/I09rszMuQI1wR9kivuyOz&#x2B;QGWr7/Yj7JlcIlSfIEb7dzLdtjTibmX2YEfsZbi6NMjvZfcCO/8AW5l3K&#x2B;6I/eQMueOxlrubcp7GavYDDDTuXZ7mW1E&#x2B;tgJBObmmSEBl7&#x2B;o4mPYrV5ZIasgLPYs2M/Ln6FTUbAWezFyLYq9wNSuSpx6/IynyaW9vkBpNotLMrsaphK8Abpng3S329zFLXJul8gclLZyJreTipa7m6ap3A5abcm0zjo3NJ9jCRyU1GvNskjjVXf6m1VaxBpObGqXBiVwaT4gDasuxU0zFNSLS&#x2B;GBtOCtqF9jCfJZArfp9iOwlbtiUBGuzgy0n9OTV90N/puBx1USYqoaUHM1Jmqn1A/NXRvBx1YU8H6aqfUw6PQD8teFKOHEwLXP21YadoOKvCbswPE6npWU1PLVZTO4Kroq45T7o9J6h6Pz2hurN5b&#x2B;&#x2B;y/m4X7VC9TsbFwZODEwVtHuB1ZhYytDRz4WK3yex9S9A4WMnnNESw8WZqwm/2avbsz1Or8XL4tWBmKHRXS4qpqUNAeQwsWnk5aK7H4cLG4P0YeKuHNwNarVGlZj/AOTV&#x2B;QwqpwKIf&#x2B;FHFqtaWlZh/wDlVT9BRixgU/8AQid2X3HLVXG7OHExVNjNeLa9Rw4mNCtsVi3Xi8nDXjRycWJmLRJ&#x2B;fFzKl&#x2B;4HPXmEt2fnxc0k4VX3OF42Ji4n4eFS6m7JLk8rpXQ&#x2B;sai1iZpfq&#x2B;G9/Ov2voB4mvMupwpfoeR0rpLW9Xit4X4OG/8AHiWt6I9t0fo3SdMSxKMv&#x2B;JiL/HiKX/keYwsqlCiAPA6P0NpGnOnExcL9YxV/ixFZP0R53CyySVNKhbJI/Rh5ZLg5qMD0A/Ph5dbuk58PL90c9GAlwctODEWA4acCFEHJTg/1BzU4JyUYX09gOKnCOSnCOVYUXg0qIuBx04ccHJThudjdNFzSppAz&#x2B;HGyNKi5tUqxpU8fmBlUd2bpofcqpT2RtUxwBmmlJ3ZulehaaSql7QAVPP1DRryw7CLWAxUrSYrpW8HK73MNcAcNab3Riqk5a/YxUpUQBxNKLcEqhM21f/IjUbAZaW0EhbQae65kJRxIGfLK3&#x2B;ZHTJtLifkg02Bhr05H2NeUkdwJspKrCAgKmuxpP5mUaXYDSqexpO1kYpadzdLncCrsWNpRFHJpXfzAJNra494CXD/It4uwDKT3RQLASe8C6K12YC&#x2B;zKrcD2SG&#x2B;6AQVe5LMvIFQmLxwElA53AqngK3AfoIgDSbauCSUAELACreS&#x2B;qX2JtuFeIXuBeY9RZccBWvexLXcAV7SPZCVvJZ2kA7O6F&#x2B;STCuWeyAc&#x2B;hZkypS3K24swKCekfQTL9wLPYEZU5uAmQJW4m2wFn1HuRO4As8tBTwQqAKFyKd9hfYX4QBQuRPKHo/mFdgErQ39yzP&#x2B;ZN9i3hrcCplIrKFIb5ANyGhZ3EQoX3ANepVPJN1t8h7gUIBe4FsGyIttwG952KojckPeRcCpXHzH8SqePkAhTdhtTAsOYkAr/Qu12RqVt9Sr0YBdy2i5PkPkBWrSFM2E7WCj3&#x2B;QFSbGyDtf6BtT6dwCUQV&#x2B;liKXLLvEIBDCUCCrsAXsLplDU7MBPqNnLCSfcuwBWZU53REou3YtPeNwPcbbArXfuQzD2JN9mV9kRqH/mUZ/dI0XcnAEaalokLaDTRmHFwI9gxZ8wH/ACOZky0lf8zTjYy1O4E92R&#x2B;pb8kAjTdiP2K543I6m94Ay1yRvkrfLRly5lARqHDMuLorDAy1KjsZavc09pZlgSOTLj6mtuCOFswMmVMSjTI5Aj3afyMs1VtsRw9kBlyZajk2zNSneQMsw7Xk26TMJ8yBnfYm3BXYjXr7AZ5twZe5pprdfIywJ3iCO1myuykjU3AzUiOf8AMrngkxZgSDL9zRl&#x2B;oGW72sZavJp73UE&#x2B;YGd9ySV2TRG5cyBGTkrMu1osBJfcy3wisjf9MCO95uR3chtNbCeWBCWl/wAyt9jNTUgRvsZbX&#x2B;hW3Jmp8MBU&#x2B;5krib9zNTtvv3APuSp2K73ky3IGam4l7km14&#x2B;hXMTJLrcDLfLI97FcbGaneEgEWgzPYrb3glgJ7GW7bmtrGXtEAZ5Jb6o1Blt8oA1abWMtIr/IRLAy7bmXbnc3UrGXffuBl&#x2B;5Ldykc9gI1xBHJXZXXuSrtAGaomGZaNszCmAM1KXsZac/5m2u&#x2B;5GnsBiBFrGuZZKkt5&#x2B;wGSehp72J8gMyHt3Gz2uJa5AqfqVRwZm9p9ircDStdDeyYW&#x2B;xbbAVT/AKmqd9zKjc0u0gbRtLaUYpubUN7gbXc2mo5k46d4n3N0v1A5KX68m/MjisrM3T7GEjkpa5NUudzjVRumCDajdFT&#x2B;/cyjV5j6gVRwyzDIrbjfgDSa5E2IvcSwNX7&#x2B;wmODOxbAalLdIkpkkSwK5f8AC5HHAbe0EcsDMRyvUy0uTbfoSrbYDjqUu5iumeDk4uSJsBwV0WOLEwm&#x2B;D9NVLMVUKWB&#x2B;SvBnZHiOoelMjrmF/fUeXFpX7GLSrr37o8&#x2B;6OYMV4Xm4A6q1XRdR0LMfg5zD/Zf7mJSv2ajjwcW3Y7N1DS8tn8CrL5nBVdFSvTUj0jqLovN6RU81kFVi4G7X&#x2B;Kj&#x2B;aA8RqeJOlY8v/c1fkKMSMGj/AKUfn1HFnS8xL2wat/YixG8Chz/hVyd2X3GsTFg/NjZnyzc5MLL5zP434WTwKq6v&#x2B;VHmtJ8PMfGaxdVxYX/h4e/1Kxet0frObxVhZXCqrqe1NKk81pXQGfzbWJqmJ&#x2B;FS/wDBTep/yPcdN6cyenUfh5TK00LlpXfzPIYWRS/wgeG0npbTdLpTymTpVX/iVXq&#x2B;p5TDykQo3R&#x2B;2jLJW8vscmHl4VkB&#x2B;WjK8QcuHlvQ/Vh4CS2RunBXYDgowErpHJTgehzU4SibG6cOwHFThWj8zkpwn2N04fKN04ccgcawrG6cNKxyKiOblVHFpAyqOxryTuzSpNKkDKw4NKmxqlJ3KkBFSo9SqltyaStsWmmUBKaZvBtK0wEvUqS33uAjj6FShz6FhvcXAX2HuXcnqBGkuTFSNvsYqtuBx1Q7MxUuTkr7wYcPYDFS3Zl0zujTpvv7kacwBmOwhxDZdtg4mwEt3Fu5YvIakCL0ZGlsaRHuBmPQQohmoK0Bnmau5VxAj/QfMCqDScP09jJVKYG053RU45MJuJRVPIG6X3LKSmxmexU57AaKpJ7BAWLTJVvdyRXclTaUfYC7fwYEudhP9MCqRAXuVKQEJKZFIhNbhPiPuBVZtCmGpQgqcAFcTcNRyLbtgOdipks3IvsBZexZXK&#x2B;pE2rFbb3ABOH2EhMC8e/JdiTPL9Q3FgDdpdhfb&#x2B;BG2t0O1nAFmF&#x2B;RVvHqTYjbhoC7bhL9q7ChcjbgC7D52Foi4nn8gDYTsLc/mF6RAFU8gnOwvwBZsBugAkAAJHqABZ7l8smU4cliFIF23&#x2B;g3f5kTcx9Al6e4FKyXmPUvsBF6L2K2tkSHui&#x2B;gBOd7Fkkr3EcICpqfzKmmrIz8yoCzO5VvuZKuHIGko3diL179xTN7Fs1ABbbjaR6QUBAgCQLBYibkmNmFYA2u3zLezCjf6Em4Bz3K36CXyyWbA0pmWIckTcSkX&#x2B;IBIqbQC9gNS3ZdycXF&#x2B;wl8AFb/QtO1iT8vkWXEt7gE4T3C3dv8AIf1BUnMwB7k77EZZfAaMxlh1RNg/VkjYBxv9B&#x2B;Y9mPWLARoy7OTU&#x2B;hlpwNxJcuQ0&#x2B;BMXbJL7fQoNXky4e7KyNLuQSpWujLhGn6PgkTsijLV5RGlM&#x2B;pojUK/2Aw&#x2B;zI7K5py&#x2B;CPuBh3uzLU7s21Eka5kDLUmGlMG368Gao7AZvsRwuCv2ELn7gZfsRpyadkZbbYGWmnHBHZmqpMtvt8gINg7EfqwM1LsYqTTlG6nwZdwMMlThGn2MNcwBHfcy57Gn7Efp2Ay3&#x2B;RGV9iMDNTsZfvuaaZG03sBGzLlldyPb&#x2B;YGXOxl9zTTJUkwM1b3&#x2B;Rlu5pqXM&#x2B;xmp92BKroy03edzT3iTL233AzVMxwS8b/UtV&#x2B;SXdnsBGR72LPMkYEbh/mZqcotW5G5QGZvG9zLTdvTuVkW6ngCVTJLtF9iO2ykCNt2aI16C&#x2B;&#x2B;xGBPmSXyy1NmW2&#x2B;QJUvXgy6pVytxyR7bgZuR2K0R7wBH9SNcJFc8cBu8NbAZaUGapavsaZGk7sCVLsyOeS7rbcjsBKt4Zly1uaqS5Rnd3YGXPYja5K03cR2YEsrQzLSV/4GkRpu35gZhsMrVpIwMxxJHSbdtiOFsvsBhkav8zTVv4ka7gZi5HTaUjbUqCRcDDTRHLW3sbdKmxHTFwMqUpgQ5ujXlgR2&#x2B;YBLkqmPUyVJgapupn7mkSlT6mlZTEgap2mTSbVjKRtKyA3TEbmqLW3MUrk3Tw19wNJxK&#x2B;prkymphGlcxkbUrf7Gk1BhemxqnfcxG04ZpN8GFuaAqd9/qVP1Itp4LE7AVWf&#x2B;ZZIlfcsPuAuuQBADZ2BYsIuAfckM1D3Qj/IDEevzJV9zbTm5PKwONqbEjuciokfhvt9QOJ0y7GXRG5z/AIbX&#x2B;g/CqbtAH53QZdDbcUn6vwPQ1&#x2B;ry9gPwVYDbjkxi5GrE/Zqw2zy1GWUz5Tmpw6KVZcAdddW&#x2B;FOc1XKY&#x2B;NoGFRh42JhVL8PEtTU3&#x2B;R&#x2B;XT/CXMZWlPWa3W0lGHhv8AZXz5O0ZhQjFdKxKWql9h3XO2HpuR6dyuSoWFgZemimlWSR&#x2B;ynI0U7Ux8jzeNp9Lbqp&#x2B;5&#x2B;evJxMII/AstK2NU4K2jY/S8Cqm0BUdwOGnDUQ0bWGlsvkcn4fZFVN/4gZpo5cGqaFEmqaTSpSt6dwMqhf0iqlLk15YsmaVKWwGaaLQ0aVCj&#x2B;ZUuZNJARL0uVKOEVLsi0pcgEltBpLt3CXY0lIEVK7FSt&#x2B;ZaV2ENIC&#x2B;VdipBFSAKP9SpTdvgJdrFhgUWEWKrqAIxVa6YYAy7ptK5mrtBqp3hGWvUDDmTjqnsclSMNMDDW5Kkl8zTRLKyX2AzEqRf&#x2B;kV7bj1AjiYEKJktplIrSAzFpkWNRa6I0p/MCR9REOEIizYa9UAa5IV7z67EsASjgBIAVS3YqaRFbYqd7AaTXHBZvKZmYi5QNp9/qWWnYyruEaU8gXbdFmfYyVQkBpX&#x2B;oXZcEmxU&#x2B;4FRVexF6BXAquL7oS1dFVgF25dgnw0Jt3Qn0AJ8r7he7uJly2L72ANLgtt6V8xtuLzwBUJJvyVAJ9BwRzBZAsqLCSSALN5EvZkCApX7GZK7MC8SvqI9FckpF2u/sBbElOwm0/Qk9gKt77F2W/yI3aQ3EX&#x2B;cAWIlsNTcic7chQnuBSoi3si&#x2B;4AC4Ab7gk3goBFcEFwLefWRuN3cfMCuFb7hXJHuW4D3&#x2B;5UvX7ESv7FV1ZAL&#x2B;twp3EWsWUBGluVIWAFs1/kWZUskobMCp&#x2B;olNS92RcWK5mHsBfcWT3EyuB/EB8ykW0QOLgWXwCFAqfoF7BBXswKo427EcTCGykK6uBVD53KnEJE4ugpUNgWXtBbETuWbwBfl8xEOCT3LEgWyUokPZIsqYgbqzAqllSvcijndGlMfID3ClN7MegUtqEW0w0ZZGWvQj3NP0XsRlGXZe5G7QzTtb&#x2B;BGr/wCQEi0k5K7vbggEv/qRsrXuSJ3e/qBl7kccs09zNk/cbCJJbfUWV5K4iUR2XyAy3O5HvJp2UMy7qP4DIjuvnaDLRq72ZHYozVGxH6ldrx9yNX/mBm0mWnvBpk9UvoBhqXuRpdjTjsZccgRuFBl&#x2B;xp&#x2B;i&#x2B;hl&#x2B;wEmZTMuZhmmzNS5n6gZfsZdluba9TD7L7gRkb5gr2JtyBl3cyZexpqFYy02rbgR2Wxllaa5M87gTn94jK&#x2B;VJKvQDNUGXdyaqU2ZlqUoAjJKXBSOH2AkvhmS/IjlboDLiN/YjjgtTRHuBlsjv/qVxcjAy3czU2ae8yZqvyBHvdfQjccFffgy3aQJVK2RJnjctT7EfqBlzvJHb67Fccsl9m/qBlxG5mpWlmiOOWBiexKnH8CuziCP2Ajab3JVM3Zd&#x2B;dibgZasSHz9TTUrcjpkDNSMv3NMjAnG5lxO5rfcy7W&#x2B;oEajdEe&#x2B;xpwZewEcbiFsVpvdGfLG4EfoS2/1sV9iX7AZe&#x2B;wdjTpjYy3N5AmxH3K/cjS7ASIckjkql7u49GwMwR09zcP2JD7gYcq8E8raNxGwaAxDqbgjRuFM8kiXDQGYTWxHSlwaVM8/YNdwMulMR6GovA8vIGIb5&#x2B;pYbd4NQx5YAiXBulcR9iUrj6lV7gaiUa5MqP8jaAtPaDdNzNPl5RqlcEkapn27Gkp5MpNuYNrs0YyLTY0kxT/oWJ2RBV6o0vYlKk0lP&#x2B;gFW8wWkK6ktKngArblKkm5WxYQGUgty&#x2B;Xhsvk9AESPL&#x2B;ZrytwXytWX0AyqYRfLNkjUGqaVFgOPyXui/hxsjkVExJfw1FwOH8Mv4Sa2OZYc8GqcON0BwLC4LTg8Qc/kTvH0KqElLA4fwqZ2KsP0OWFEEavdgZ8t9yGmuYI1xF/cCNLkjXEfQ15bSieW8oDLpUQu5mrCVS2ORruIkD8uJl1BxVZdpn7nQmoMVYVtgPxfhegWH6M/VVg&#x2B;hl4Nrr6AcHkjZbk8qexzvCTcon4c2YHGqblVMqIN/hveAqOWgIlFoHyNKl8FVLXIGVCKuxYixUrXAJcFXuEiq2yYCmNk0aghV6gWLSWO1yLaDSv8AUAiruEktgAiWVb2EMRx9AJ6kd7JmnuZlARqz5MuxW3BGBmrv&#x2B;Zipcs29rGX3A4/kRpbs0zLjlgNvkT5rcrlfIP3ALt9glawS&#x2B;YtIFm9iR2XHYX7h7cgT5k9jUPYOOz3AzK7ja0Fa5aD7NQAi1hF7lXtwHKAkPYbXj7FjlEacbtAVJLgqJPsVAaXuVMyuCy27AaBG7bFQFW137l4u/uZk1MIDXzCsZTTZqQKnFmG27oidxK7AVzFy3JKEoB8i2giibiQK7/zE97km92VT/oBfQcQyTaEVSAa/qBfglg3eOQNE2uw0pFwF0rFIt7IIBN9ykhoscwA3LtaCACu6lsgGwGrMk&#x2B;pNwBfv3Kr2kyW6e8AX0CfrzcRb8wlz6gXdXQbi5LR7CwFSsPbYL&#x2B;oCfYC&#x2B;wIUCq7FghfnvcAonZFm9rWJzdmttwIu8C/NxsL7PuBZfcSnySY44Fo9wNWE3IndCUkBSz3IiqN2Au7FmOCK/I9wLZu4mLIk27uSpruAe&#x2B;xVAXeCT6gaA22C9gEOC78Et2Lxb6gVNu0ckvt&#x2B;QW9yzyAj&#x2B;kEp27D6lhz2&#x2B;QC0fkE5exFdwyr1AqiblU7EXZIsWuBWmv9Api9hHNQ9W7dgLPb6GqdzKc8p3CmVcD3KlvhF3lEvwrFtBlncRqxGacTcywJC7CIf&#x2B;RZI0&#x2B;QMtPmwgrjdL7kYEe25PRplcEfaYKMtW2&#x2B;ZH3K0okjAjiLkd1BatrmWm7sCO6I1OxXdEbSVxIcRSS7ewqvx8w7OwGX3Mvexp&#x2B;xN7AZfuZcRzY01HYy/6sBlxv9TLvafuaS7kYGWt4&#x2B;5Cvb3IyjLmbIjbUFe5G4cpAZc8GXtD3NOe5l7RHAEqX7Oxi1zbSMuAMtWiTL9zbS9jLAxUo2I1DNP5GWBl/wBehH3k1F7Eq7QBn0MReGzTUIy0&#x2B;QIyRyUjcq3yAj9O5ipd3sbdk3LMVKdgMuZ2I3BWo5I7AZd7k2WxXdNIlwI2myNNu4a5I7K35gRxyZfuzTMuwGfVLYjlvct&#x2B;3yJAGW&#x2B;V37kczc05S9TO6sBH6GWp5szTSky1b2Aj/pEatEFZAIyPcvZkcKwGXL5JH&#x2B;ZrnuZqQEe&#x2B;xlmmpuSO69wI0ZqVrGiMDLhWkjh&#x2B;pW7bEAi9BMlJCV5f1Ay&#x2B;5Dd&#x2B;5l2ewGWoX8yNS49DdSUWZGgMeV8A016EauBlpEcpWNNc2I01ugJ6wRJ7SaiQ9wMRb/INM01LkiVv5gZ8q3gkPuaa9B5WmBny&#x2B;o8vqa8trjyypAzHYNN7mo4TI1AEiVdMKWWErIqpbVgIlaIKkx5YNU0wroCUr1NIJcmkmmBUu25ry2FMGkn3JIq32NJWuRJ7G1tsYyCvv2NKbNESngtKc2ZBqlcLsaV3clK9TVKd5fIFNKOSKE9/mWlPv7gI4T9ypFpTZpU2AipuXyzwappS2cGlTKuBlUy7GlT2KqbQaS7XAyqJsapo5gsQ7s0ktgMqmDUWNJJbhLysCeWOPsaSUyIAE8qi4a7FaWwht7gZ/pE9jcepGn2AzF7kj0NulJDyp7IDDV9w6TXlES9gMeWY4LEI1CVh5bTHuBjy3DpRqFP5DyvsBh0TsZeH3OWOw8vMAcH4SWxHh&#x2B;hzOjsSqm4HC6LSkRUehzOiVBl09gOPyWsPLOxyeSwVL/mBx&#x2B;WOJDpmxt03iB5HEgZVMXCS7GvL3EASCrs/oVLuFC3AJrY0SJKAsC/MIAr8BxtBU5d0PRv3YEdzLZqYcL5GatgJfZ/mZcGm7OEZcRcDNTXC4MPextp7Iw1E/cDLl3JtdmmrxHzMvtIEfeNg72K0TbiAEcSIbKgBPQQuCj3Al4LAgASPUbKCwAJEFgNNOAAvyRJKxYb2EdwHyAiSgLbF224J6SNnsBe5bgAVOCokgDUzeb9wmlyRbFn3AvEwFdyZmOIKpV4Aq33G4TjdhAUBewAt&#x2B;42dyL1LMfwAt07fkG1u7kblf5jn27gVO8yNrNEW9n8y2SmbgWJakW9DMpbdi&#x2B;gF&#x2B;ZdyT9ewXuBVYntuJ7oTH1AbOCk5KAQSE&#x2B;g9wBY4JNxwBduA4jYXKAmNoIp5LzdwN9&#x2B;wC8TcsSv5ETc3&#x2B;4hMBdWncqZE3yuRMW4gDUdwRXe5QLwLxLD2DUAJXYTyie5dgLeLPYid4bAuBUt9g0OJDXcBCcKRfZchSluEnFmBofMmxQLYK8IK4AJ9xS77/MP1m4At4cqSpTz9iL0fzZU5X5gW82C9B6hAVK8SFCd3yPkFa7Aq7z7i0bBpq6C7gJX9MqVrC/qFvMAI4HqxurL2KATLdK1yLuX&#x2B;YFvF4D7E2/iWbgW6W4u3buFP&#x2B;gW87Ae6K92T9r2NNRwR&#x2B;xlkR9kjLbSNO6M/MCNSrhxF2HC4EoQJK7km23uWVDSIIEdyOVsH3DVMgSUuNzL9DTT5RH2Ay&#x2B;62JUl2LVtZEbl/1cCcQSHEJlavAi2xRnywR9jTSMvf22ESMkqcMr2Mtt2AjUbkfqVt8szUlO4Ebez7Gfc0/b7ke10Bmra2xmGae2xHMXQ6DLiTNouajhka9fqwM7KEzLSi5qJ4MtdgI2lZ/mYq9L/I04jcy5Ay95Iw2J5KM1GWzb9oMv3AzPbcjiHDNNSSGvUDjqTXBlqLbm6uDLS3j5gZZHbngrRIYEam0mWaajZGWBlp7GWmlY23zBl&#x2B;/wBQM1QZnsaujLibgZbI95XJWRz9wI7/AC3JYtyP6AZe0kcdzVt5I3FpAy9rGWrT9jbcmWp3YGGoZlzsbanjcy1fcDNW5GWLbgCNEai6RpkaXIGIcXX2I/Q049X2IkBlqdzPo/kbajYjS5YGWvUy7Gmu/wAiNAZabuTf&#x2B;RYs36CP6kCQiMtuPzDveQMxHqRzKZpkhO0gZcTt9CM15bbB0zsBm6siM097kAy0luHdmiONu4Ea9eCQkoZry&#x2B;nuH/UgZagz6Qbaa2RloCReR7MqQAjU8fcQ9oNb7IKl9gMNb2DW8m45kjpW/YDMOdjUKZRVSlwXy7SBlKLFUpXX2K1GxUnABLlGqVO4VNtipRYBSuDSXoKVaTVKaJILaX2NEpUKEzdM94MQSlbGqV6BJ7G6fYgKlSaSbVi00wap9gIqZlGlT2KqVO5qIAzSryzdKnZBKdkaSXYAqVt9SqnsipTsa8t/QCUpz6FSngsSxEbgEkuCqFeBF43LHYBDTmCxyRtJtsq9wLyIFN/9Rd8AL8MiX5GotMCLASCpdipTZ8bhLn7gZgOnhmkuUx5VL7ewGHAheppr0ENbgZavAaj3ZpqNyR6AZhLb7BptbcGo4EegGaaWVpMsWsWL7AYdNg6UbhsNdgOLy&#x2B;n1I6UcvlvcnkfYDidKgeVR2&#x2B;ZyeVdiOn5gcbpe5PKmcjRHS5kDCpDpk35LDypXA4/LFi&#x2B;Xl7G/LwyJAZSjgqRfL6FiGBmCq6mCx6BKFZQBHbcn2&#x2B;ZqJ/0EQBl2v9zNVjbd9zLVgMOOXJl2ubfvyZgDNXoZc7o04avYy&#x2B;4GanDI/wCpKyPe4Ej1EcFfZINegEiLDfYsRAtyBNixxAcvmw7OAFnafYR6FhubhLjcCRwBDC42AWSkOEVQ3BO8ANnvBYSugkpgAS3Av&#x2B;8WGv3RM8&#x2B;4Et3Kv3roi7osxzuA&#x2B;ZfRMciOwBNCezI4iHYqmQLKCIrF2AqafoW7uSWEpvIF2cvcsz/Ek32FLcAWSkm1voJcenqBfNwJgkqdxMgWSqCACtzwJT&#x2B;gC33ATOyQnkPuiAal7Bv&#x2B;oJebiOe27AT9Cze5Fdl5Avox5lyIh/5iUAfcNvsRw3KRZb4As3BE5Vi35AszuN1f8yFv3Aqh79iMMegBPuyzKIo7CfQBC7liHuERTMyBYh2NTbcz5X/SE8tgaHqRTyUAWXyQAWZkqaXD9zPyKmBfUR68kRZlx6AEmv4BUw9xD7F9IAqAgAVdxcbbMTPzAsTwF3Xcl1YPgCxbdQVbyRTuF9bgaL6ohU/zANzwOQ3efoJAt/uIUTAW1mOZgC02EWCvwLrdgOPcolbAC8BhPiAr8yBfUXbuxxawhpQgC5ZaXzASZV7Ae6O25G19hVU1eCT5l5osZQJ8iF3dhFX8iCO9yT3LfsT9qdiiOdpI7st3suCOORkZaEIvuyfs7DIkf6ke25ppUqG5Mza14QEaj5GXa6K20jLqpfABxNx6SR1qLyTzLcCszUy1OeTDqTgCVPgjl&#x2B;6K2Lc8gZbI2abT5Rl0tOSjLTl&#x2B;xPY1DbuSpPuBlmXf&#x2B;Bpzf7GXvLAy/QlXoiv1M&#x2B;dK4E2I9/5FqqS5MuqnuBG7XMVWNVVpbsjiYbGRxtXHqaapTgjUfQDNS7Ml044NOYM1TdIoy1czLnaStTaYJ5ZUpgZfsZqRu0/vKxGlywMRLiCNQzb8vL9zLa4Ay1yjLRpuTNSjgDNSTMtRwaqTI4pUyBlozff0NuImTLahAYa7fmZaRutzb6GKkgI7bEalXRVL2Q8rAy3e5ISSlGnS&#x2B;eDPEgRxBmqeEVuSVOFYDPGxH6FatMEcv6AZaT5JY15HdpGXS1wAdtmSZexG3vATlxABoloUdgquQ2uX7gRrvuRpbmm1MtkhPnkDLpMtcnI1vJGpA43PBINNdw1AGIW0hwnsadKvLI18wM&#x2B;WFJGjTTl2JeboDMdw94grvwSJuBIQu&#x2B;fmWH/MvlbtCAxbuIvBYblNcBJtzH3AzFw1NoNeWp8cdx5b7AYatDDpW5ppqzRHEAZdPfYlos9zcUpxKI0o39wMpwadnMhJp7fIqV4YEStsTy3/ACNqi1kXyPgDKo2hfYqVuSqlpzBpUS4gDCpmw8rb2OVYcsv4VwONUwaVMm/KkipRwBhU90aVK3j7GvLG6ELdkkRKyh89jVKfJKXeEjkpV/cxFg1Sk2Eoexq1N2QVI0nKgyoTg1S1OwGqTVKvJKYbhm0oAJSWIE0pbDzKWBpdyqGZVUu7NSAsVTwTzKYCrVpQGldzH1KkuOAnKlMsNXQEd9lyEWGt0WLwwIWHsOCvm23qA53JF5SsWaVZMWm1wEOkKHwG1TafoTzqZAqf&#x2B;EsTuRPz02Kr3QBqZsIhw1YqTkOm9wMQ5K0nwWzcJ/Yk3hK4CEv5jyvjuWy9BFNUXAkeo8vBppMQBleoiCqJs&#x2B;CqHsBEk1sSGahBwgMumLQTywa3vBYlqwHFVR2ew8vocrotLQ8qVmBw&#x2B;UKmzOV0Lgy6e4HH5WPLOxyOhhqFsBxxGw8vucnlcXRnbj3Ay042CSdzThegSpdpAzDiSNScnl/1I6HMAccPv8zLVjbV7oxUkt2Bloy0uF9zb2I1O3YDjqRh3sctVrQYa4gDjYa9H8jboe0bkdDSu7AZa9BsvmVJO8jy92Bm0yHM7RPoaVMdibboCXTsWXuxDvYRey&#x2B;oE4iCpOdmI/5SKJ3Aqu5hheg32XIbhXQBz9hZXEzwJngBvyE1MRcNNqICT4VmAv8AciT5NQ27/YkN3gCc2K1DDsw3L/ZAPb8mN7BrZpcET7gVew2uibruJgDVuGJ/0My4tYswrgaQIomCzTG4Fn7ieSSu5FUp3QG1HAsnZklb&#x2B;aSqqn09ACc2XcIUw7BSrAavwCKq8BVLcC3AV7BLloCw5sT5FQte4BMEbvZCW7QBbtqQm53EOYSkTaY&#x2B;oFUPgcbEnZRYvmX&#x2B;oBXcobP&#x2B;DCdPIURuAs9&#x2B;SpoRxIhq&#x2B;4F3K2&#x2B;5JfYN2sgEATG4UdwHzK/YcXQtutgF&#x2B;C7ojhOLbhNTEgVWuvoJ&#x2B;hJXYqV1PIF5hlCU2ZVTewEiAXyuYkroi4GblTW0D91ww36gFupKrbkmd2WKkwKnLgQkh6IJr7gVX5E9xFipPdMCIvqNt0Ve4D17oJuIexVD2L5bAZXuVzv9Cw0ySlYCpifQkzZIqc8AWQmuxFL4F&#x2B;ALduWXmzmeCNQtgomYAuy34L8yJzt9xZKbAaHuZTnZGkmwKpDZEXzuLoCq&#x2B;24phIz5m5NK6uwL7Iqu7ETtsPM1LjZXA//Z" />
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>